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Abstract 
 
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that catalyses the 
synthesis of ADP-ribose polymers from NAD+, in response to DNA strand breaks. 
PARP-1 is implicated in the pathogenesis of many diseases and plays a major role in 
controlling the repair of damaged DNA. Inhibitors of PARP-1 are of use in the treatment 
of cancer, as potentiators of radiotherapy and chemotherapy. 5-Aminoisoquinolin- 
-1(2H)-one hydrochloride (5-AIQ.HCl) is a potent, water-soluble PARP-1 inhibitor that 
exhibits outstanding activity in a wide range of disease models in vivo. The aim of this 
project is the design and synthesis of derivatives with substituents at the 4-position of 
5-AIQ. 
 
The modes of cyclisation of methyl 2-(substituted)alkynyl-3-nitrobenzoates with 
different electrophiles (ICl, PhSeCl, HgSO4) were studied. The exclusive formation of 
isocoumarins demonstrates the influence of the nitro group in directing electrophile-
driven cyclisations towards the 6-endo-dig mode. The crystal structure of 5-nitro-3-
phenyl-4-phenylselenylisocoumarin showed intermolecular and intramolecular pi-
stacking. Attempted synthesis of 4-benzyl-5-nitroisoquinolin-1-one by selective 
reduction of the nitrile of methyl 2-(1-cyano-2-phenylethyl)-3-nitrobenzamide failed; 
approach of DIBAL-H to the nitrile was sterically obstructed, leading to reduction of the 
ester to give 2-(2-formyl-6-nitrophenyl)-3-phenylpropanenitrile. Bromination of 5-nitro-
isoquinolin-1-one gave 4-bromo-5-nitroisoquinolin-1-one but Pd(0)-catalysed cross-
couplings (Stille, Sonogashira, Suzuki-Miyaura) of this and of 4-bromo-5-AIQ failed. An 
alternative approach was Pd-catalysed cyclisation of N-(2-alkenyl)-2-iodo-3-
nitrobenzamides. Reaction of N,N-diallyl-2-iodo-3-nitrobenzamide with Pd(PPh3)4 gave 
2-allyl-4-methyl-5-nitroisoquinolin-1-one and 2-allyl-4-methylene-5-nitro-3,4-dihydro-
isoquinolin-1-one. N-Benzhydryl-N-cinnamyl-2-iodo-3-nitrobenzamide gave 2-benz-
hydryl-4-benzyl-5-nitroisoquinolin-1-one and 2-benzhydryl-4-benzylidene-5-nitro-3,4-
dihydroisoquinolin-1-one. These products are not interconvertible. The secondary 
amides N-allyl-2-iodo-3-nitrobenzamide and N N-((substituted)-cinnamyl)-2-iodo-3-
nitrobenzamide gave good yields of the required 4-methyl- and 4-((substituted)-benzyl)-
5-nitroisoquinolin-1-ones, respectively, under optimised conditions (Pd(PPh3)4, Et3N, 
Bu4NCl, 150°C, rapid heating). Hydrogenation gave 4-methyl- and 4-benzyl-5-amino-
isoquinolin-1-ones. The 4-substituted 5-AIQs were evaluated for inhibition of 
recombinant human PARP-1 activity. Three were more potent than 5-AIQ; 5-amino-4-
methylisoquinolin-1-one (IC50 = 0.25 µM), 5-amino-4-benzylisoquinolin-1-one (IC50 = 
0.5 µM) and 5-amino-4-bromoisoquinolin-1-one (IC50 = 1.0 µM). 
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1. Introduction 
 
Advanced cancer is one of the leading causes of death in the Western world. 
Chemotherapy and radiotherapy are the two main treatment modalities currently 
available. However, lack of selectivity, treatment-related toxicity and the emergence of 
resistance limit their effectiveness. Efficient repair of DNA in the cancer cell is an 
important reason for therapeutic resistance and this repair of tumour cell DNA that has 
been damaged by radiation and chemotherapeutic agents has been identified as a 
major obstacle in the path of effective treatment of cancer. Targeting DNA repair 
pathways has been identified as one of the novel strategies for effective DNA repair 
inhibition in cancer therapy. Inhibition of DNA repair has the potential to enhance the 
effectiveness of currently available DNA damaging agents.1 
 
1.1 DNA repair 
 
The integrity and survival of a cell is critically dependent on the stability of the gene. 
Cellular DNA is repeatedly exposed to exogenous and endogenous toxins, such as 
oxygen free radicals, ionising radiation, UV light and various chemical agents. Cells 
have highly conserved DNA-damage sensor mechanisms in response to such cytotoxic 
exposures.2 These include: 
1. Initiation of DNA repair, removal of DNA damage and restoration of the 
continuity of the DNA duplex. 
2. Activation of the DNA-damage checkpoint, which stops cell cycle progression 
to allow for repair and prevention of the transmission of damaged 
chromosomes. 
3. Transcriptional responses cause changes in the transcriptional profile that are 
beneficial to the cell. 
4. Apoptosis to eliminate heavily damaged or seriously deregulated cells. 
5. Tolerance of damage 
 
These responses determine survival of the cell (with mutated gene) or initiation of 
programmed cell death. DNA repair is the most effective defence system and 
comprises six major DNA repair pathways. 
1. Base excision repair (BER) 
2. Nucleotide excision repair (NER) 
3. Mismatch repair (MMR) 
4. Double-strand break repair (DSBR) 
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5. Reversion repair (Direct repair) 
6. Cross-link repair 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. DNA damage responses in mammalian cells.1 
 
NER is the major repair system for removing bulky DNA lesions formed by exposure to 
UV radiation or chemicals, or by addition of protein to DNA. The damaged bases are 
removed by excision nuclease which makes dual incisions bracketing the lesion in the 
damaged strand.3 MMR removes nucleotides mispaired by DNA polymerases and 
insertion/deletion loops that result from slippage during replication or during 
recombination. The main targets of MMR are base mismatches such as G/T, C/G, A/C 
and C/C. The four principal steps in MMR are:  
1. Recognition of mismatch 
2. Recruitment of additional MMR factors 
3. Strand discrimination 
4. Resynthesis of excised strand 
 
Double-strand breaks are produced by reactive oxygen species, X-rays or ionising 
radiation and during replication of single strand breaks (SSB). DNA double-strand 
breaks are repaired either by homologous recombination (HR) or non-homologous end-
joining (NHEJ) mechanisms. When, after replication, a second identical DNA copy is 
available, homologous recombination is preferred; otherwise cells rely on end-joining, 
which is error-prone. 
 
Treatment of cells with alkylating agents gives rise to N-alkylated and O-alkylated 
purines and pyrimidines. One of the critical O-alkylated lesions is O6-alkylguanine. 
Some single repair proteins can directly revert these lesions. In human cells, removal 
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of the O6-methyl group from O6-methylguanine in DNA is accomplished by O6-
methylguanine DNA methyltransferase (MGMT). Another protein involved in the DNA 
damage reversion is photolyase which binds to DNA damage induced by UV light and 
causes photoreversal of UV-induced pyrimidine dimers.4 Many bifunctional agents such 
as cisplatin, nitrogen mustard, and mitomycin D induce interstrand DNA cross-links and 
DNA-protein cross-links. XPF-ERCC1 nuclease plays a special role in cross-link repair.  
 
Base excision repair is the main guardian against damage due to cellular metabolism, 
including that resulting from oxygen species, methylation, deamination and 
hydroxylation. BER is mainly responsible for removing damaged bases, which can be 
recognised by specific enzymes, the DNA glycosylases. Lesions removed from DNA by 
BER include N-alkylated purines (7-methylguanine, 3-methyladenine, 3-
methylguanine), 8-oxo-7,8-dihydroguanine (8-OxoG) and thymine glycol. The major 
oxidised purine, 8-OxoG is highly mutagenic because of mispairing with adenine. N-
Alkylpurines are hydrolysed at the N-glycosylic bond, giving rise to apurinic/apyrimidinic 
(AP) sites, which are one of the most frequent and potent lethal lesions. Both modified 
bases and AP sites are repaired by BER.4,5  Depending on the initial events in base 
removal, the repair patch may be single nucleotide (short patch) or 2-10 nucleotides 
(long patch). Short-patch BER involves removal of the incorrect or damaged base by a 
DNA glycosylase which generates an AP site, which in turn is cleaved by an AP 
endonuclease/3´phosphodiesterase leaving a single-strand break. Replacement of the 
damaged base and religation of the DNA involves binding of PARP-1 and / or PARP-2, 
followed by recruitment of a complex including DNA polymerase β, DNA ligase I or 
III/XRCC I (X-ray repair cross-complementing) protein. Long-patch repair is involved in 
the repair of oxidised or reduced AP sites.6 
 
In response to DNA damage, the progression of the cell cycle into S phase is delayed 
by the G1 cell cycle checkpoint control, whereas progression into M phase is halted by 
the G2 checkpoint. Prolongation of the G1 and G2 phases functions to permit more 
effective repair of DNA, and thus avoids DNA synthesis and mitosis in the presence of 
excessive DNA damage.  
 
Some DNA lesions often persist through replication of the genome, in which case cells 
have evolved damage tolerance systems to allow complete replication in the presence 
of DNA damage. This response tolerates, rather than removes, DNA damage and 
consists of two mechanisms: a) template switching and b) lesion bypass. Template 
switching involves synthesis of DNA on the undamaged template only. Lesion bypass 
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utilises the damaged template by nucleotide incorporation opposite the lesion, followed 
by extension of DNA synthesis.7 
 
1.2 DNA repair inhibition 
 
Use of pseudosubstrates of MGMT as DNA repair inhibitors is a promising strategy to 
increase the efficacy of therapies based on alkylating agents. O6-Benzylguanine (O6-
BG) is a non-toxic inhibitor of MGMT. It reacts with MGMT by covalent transfer of the 
benzyl group to the active site cysteine and, hence, leads to inactivation of MGMT. O6-
(4-bromothenyl)guanine (O6-BTG) is an orally bioavailable inhibitor of MGMT, which is 
ten-fold more potent than O6-BG. One strategy for disabling BER is to target the DNA 
repair enzyme APE I which processes the AP site. Methoxyamine is a small molecule 
which specifically targets BER by binding directly to AP sites and preventing their 
processing by APE I. This leads to an accumulation of these potentially cytotoxic sites.  
 
Human protein kinases ATM (ataxia-telangiectasia, mutated) and ATR (ATM-Rad3-
related) are potential sensors of DNA damage. ATM responds to the presence of DNA 
double-strand breaks (DSBs) and initiate signaling cascades leading to a DNA damage 
checkpoint. Wortmannin is an irreversible inhibitor of ATM. and hence rejoining of 
double strand breaks (DSBs). 3-Cyano-6-hydrazonomethyl-5-(4-pyridyl)pyrid-(1H)-2-
one (OK-1035) and NU7026 (2-(morpholin-4-yl)-benzo[h]chromen-4-one) are  potent 
and specific inhibitors of DNA-PK. KU-0055933 (2-morpholin-4-yl-6-thianthren-1-yl-
pyran-4-one) is a small-molecule ATP competitive inhibitor of ATM kinase. Use of small 
inhibitory RNA molecules (siRNAs) to inhibit specific protein expression has highlighted 
their potential as therapeutic agents. Peptide co-therapy is another strategy that can be 
used to specifically inhibit protein function. Pentamidine is a potent inhibitor of the 
enzyme endo-exonuclease which plays a role in double strand break repair and 
recombination. PARP-targeting inhibitors have structural similarity to the natural 
substrate NAD+, and thus act as competitive inhibitors.8 
 
1.3 Poly(ADP-ribose) polymerase-1 
 
NAD+ (1) is a versatile biomolecule, which functions as a coenzyme in many oxidation-
reduction reactions. Poly(ADP-ribosyl)ation is a post-translational modification of 
proteins catalysed by poly(ADP-ribose) polymerases (PARPs) and is involved in the 
regulation of DNA repair, gene transcription, cell-cycle progression, cell death, 
chromatin function, genomic stability and cell adhesion.9 Poly(ADP-ribose)polymerase-
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1 (PARP-1, EC 2.4.2.30) is the most abundant, founder member of the PARP family 
and has been the most extensively studied. PARP-1 is also known as poly(ADP-ribose) 
synthetase (PARS) and poly(ADP-ribose) transferase (PADPRT). It is a nuclear 
enzyme present in eukaryotes. PARP-1, upon activation by DNA damage, catalyses 
poly(ADP-ribosyl)ation by transferring ADP-ribose units from its substrate NAD+ to a 
variety of acceptor proteins. 
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                           Nicotinamide Adenine Dinucleotide (NAD+) (1) 
  
1.3.1 The PARP super family 
 
Recently identification of some novel putative PARP homologues increased the 
number of PARP family members to seventeen. The main members of the family are 
categorised into five groups.9 
• DNA-damage dependent PARPs consisting of  PARP-1 and PARP-2 
• Tankyrases consisting of tankyrase-1 and tankyrase-2 
• CCCH-type zinc finger PARPs consisting of tiPARP, PARP-12 and PARP-13 
• Macro-PARPS such as PARP-9, PARP-14, and PARP-15 
• Other PARPs including PARP-3, vPARP, PARP-10, PARP-6, PARP-8, PARP-
11 and PARP-16 
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Figure 2. Schematic representation of the domain structures of the PARP superfamily.9 
  1             181                                                                         1023    1088         1327 
24 ANK REPEATS 
 1     57                                                                      872      934             1166 
16 ANK REPEATS 
DNA 
dependent 1   FI        FII    202  231          385   463         524     662      859     908   1,014 
Automodification 
domain 
DNA-binding  
domain 
PARP 
domain 
1            75       218     412    461   570 
1      49       192     388   433      540 
1            243 261 332     401  462          657 
1         75                  200     276       368          502            701 
1       68 73               191               285    513  604        689  727        902 
1          161        255   319          446                   644         825   854 
1        820         938   1032     1149    1228   1347      1523       1601         1794  1801       
825   854 
1         88           191    259          437 444 
1   13   80                                               598-607 650-690          819            1025 
1  7        99    129          331  
1                162                               470       630 
1                                           404       630                 694       854 
1      93          273 322 
 1           94       246      433   438     570  607       735   877           1041   1562       1724 
RRM 
Macro 
domain 
NES 
WWE 
HPS 
vWA 
VIT 
SAM 
ANK 
MVP-BD 
NoLS 
Zn 
fingers 
DBD 
NLS 
BRCT 
WGR 
PARP domain 
UIM 
vPARP 
PARP-4 
Tankyrase-1 
PARP-5a 
Tankyrase-2 
PARP-5b 
PARP-3 
tiPARP 
PARP-7 
PARP-12 
PARP-13 
PARP-9 
PARP-1 
PARP-2 
vPARP 
PARP-14 
PARP-15 
PARP-10 
PARP-11 
PARP-6 
PARP-8 
PARP-16 
Macro 
PARPs 
Tankyrases 
CCCH-
PARPs 
BRCT Breast Cancer Susceptibility protein C terminus; NLS Nuclear Localisation Signal; DBD 
DNA-Binding Domain; NoLS Nucleolar Localisation Signal; MVP-BD Major Vault Protein Binding 
Domain; vWA von Willebrand factor type A domain; VIT Vault Inter-α-trypsin; SAM Sterile α-
motif; ANK Ankyrin; HPS Histidine-, proline-, serine-rich region; NES Nuclear Export Signal; UIM 
Ubiquitin Interacting Motif; RRM RNA Recognition Motif; WGR domain is defined by conserved 
Trp, Gly, and Arg residues. 
 7 
1.3.2 Modular organisation of PARP-1 
 
PARP-1 molecular sensor of DNA breaks, is a 113 KDa protein composed of 1014 
amino acid residues, predominantly localised in the cell nucleus. Three main functional 
elements were identified in the PARP molecule following partial proteolysis.10  
• The amino terminal fragment of 46 KDa contains the DNA-binding domain, 
which includes two zinc-finger motifs and a nuclear localisation signal (NLS).11 
Zinc fingers (FI and FII) are loops (residues 2-97 and 106-207) in the 
polypeptide chain formed as a result of a zinc-ion-coordinating cysteine and 
histidine residues.12 These zinc fingers of PARP-1 recognize single and double-
stranded DNA breaks and trigger activation of the enzyme. FII plays an 
important role in the binding of DNA containing single stranded breaks, whereas 
enzymatic activity is totally abolished in FI mutants, whatever the nature of the 
DNA breaks.13 Bipartite NLS ensures efficient translocation to the nucleus. 
• The central 22 KDa fragment, the automodification domain, contains 15 
conserved glutamate residues, which are presumed targets for auto-poly(ADP-
ribosyl)ation. Through the breast cancer susceptibility protein C terminus 
(BRCT) motif PARP-1 participates in various protein-protein interactions. A 
leucine zipper motif, characteristic of protein-protein associations, is also 
present in this domain. 
• The C-terminal catalytic domain (46 KDa) contains a block of 50 amino acids 
(residues 859-908) that are highly conserved among vertebrates and is known 
as the ‘PARP signature’.13 It catalyses NAD+ hydrolysis, initiation, elongation, 
branching and termination of ADP-ribose polymer synthesis. This also contains 
Glu988 which is directly involved in the catalysis of the ADP-ribose transfer 
reaction. The structure of catalytically competent PARP-CF (40 KDa 
polypeptide) has been reported by Ruf et al.14 
 
1.3.3 Other members 
 
PARP-2 is a 62 KDa protein of 570 amino acids. PARP-2 bears the strongest 
resemblance to PARP-1 and is also activated by DNA strand interruptions. PARP-2 
contributes to the residual PARP activity observed in PARP-1(-/-) cells after treatment 
with DNA damaging agents. DNA binding domain of PARP-2 is distinct from PARP-1 
and PARP-2 lacks the central automodification domain. Even though PARP-2 is devoid 
of zinc fingers, DNA binding is facilitated by the high ratio of basic amino acids in 
DBD.15 
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PARP-3 is a 67 KDa polypeptide comprising 540 amino acid residues. The N-terminal 
region is short (54 amino acid residues) and contains a targeting motif which localises 
the enzyme in the centrosome. PARP-3 functions in the maturation of the daughter 
centriole until the G1-S restriction point. hPARP-3 appears to be the first known marker 
of the daughter centriole.16 
 
PARP-4/vPARP is the catalytic component of vault particles, which are barrel-shaped 
ribonucleoprotein complexes involved in multidrug resistance of human tumours. As 
shown in Figure 2, vPARP contains a BRCT domain, a region homologous to the 
catalytic domain of PARP, a region similar to the inter-α-trypsin inhibitor protein, von 
Willebrand factor type A domain and major vault protein interacting domain. vPARP is 
involved in mitosis by ADP-ribosylation of the major vault protein.17 
 
Tankyrases were identified as components of the human telomeric complex. 
Telomeres are essential for chromosome maintenance and stability and are maintained 
by telomerase, a specialised reverse transcriptase. Besides the PARP catalytic 
domain, tankyrase-1 (PARP-5a) has a sterile α motif, ANK domain containing 24 
ankyrin repeats and histidine-, proline-, serine-rich region (HPS) that mediates protein-
protein interactions. Tankyrase-1 poly(ADP-ribosyl)ates telomere repeat binding factor 
1 (TRF1), thereby causing the latter to be released from telomeres, allowing access of 
telomerase, that restores telomeric sequences lost during cell division. In this way, 
Tankyrase-1 acts as a positive regulator for telomere length. Tankyrase-2 (PARP-5b) 
differs from tankyrase-1 in that it lacks the N-terminal HPS domain, but it probably 
shares some overlapping functions with tankyrase-1. Knocking down human tankyrase-
1 gene expression with small interfering RNA (siRNA) showed that it has an essential 
regulatory function in mitotic segregation.18,19 
 
The CCCH-type PARP subfamily contains tiPARP (PARP-7), PARP-12 and PARP-13. 
These members share a similar domain organisation comprising CX8CX5CX3-like zinc 
fingers, a WWE domain and a PARP catalytic domain. The WWE domain is a putative 
protein–protein interaction motif that contains two conserved Trp residues and one Glu 
residue. PARP-13, identified as ZAP, is a rat protein that confers resistance to retroviral 
infection.20 ZAP binds to viral RNA via the CCCH zinc fingers and inhibits the 
accumulation of viral RNA. 
 
PARP-9, PARP-14 and PARP-15 belong to the subfamily of macro-PARPs, which link 
1–3 macro domains to a PARP domain. All three are localised within the same 3q21 
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chromosomal region. PARP-9 was found to be overexpressed in aggressive diffuse 
large B-cell lymphomas (DLB-CL) and might promote the dissemination of malignant B 
cells in high-risk DLB-CL. Macro domains in macro PARPs have a phosphoesterase 
activity that functions on poly(ADP-ribose). Such macro-PARPs could generate 
polymer ends that could not be elongated by a PARP, which would provide a way for 
macro PARPs to control polymer size. 21,22  
 
PARP-10 contains an RNA recognition motif (RRM) and a Gly-rich domain. PARP-10 
shuttles between the cytoplasm and the nucleus and accumulates within the nucleolus 
where it acquires a CDK2-dependent phosphorylation during late-G1–S phase and 
during prometaphase to cytokinesis.23 PARP-10 is potent inhibitor of the cell 
transformation that is mediated by c-Myc in the presence of Ha-Ras.  
 
1.4 Mechanism of action of PARP-1 
 
Poly(ADP-ribosyl)ation occurs in almost all nucleated cells of mammals, plants and 
lower eukaryotes but is absent in yeast.24 The activation of PARP-1, followed by 
poly(ADP-ribosyl)ation, is one of the earliest cellular responses to DNA damage. In the 
absence of DNA damage, PARP-1 displays negligible activity. However, binding of 
PARP-1 to DNA breaks increases enzyme activity up to 500-fold.25 Poly(ADP-
ribosyl)ation comprises of very complex regulatory mechanisms and consists of three 
main reactions: initiation, elongation and branching. 
 
1.4.1 Initiation 
 
During initiation, substrate NAD+ binds to the catalytic site of PARP-1. Tight hydrogen 
bonding with Gly863 and Ser904 mechanically stretches and weakens the C-N 
glycosidic bond (nicotinamide-ribose). This cleavage results in generation of the 
intermediate cyclic oxonium ion and leaving of nicotinamide (2). This is followed by the 
transfer of the resulting ADP-ribosyl moiety (electrophile) to the nucleophilic centre of 
an appropriate protein acceptor. The protein acceptors may be nuclear proteins 
including histones (H1 and H2B), p53 and DNA ligases, DNA polymerases, DNA 
topoisomerases, high mobility group proteins (HMG) and DNA-dependent protein 
kinases. Poly(ADP-ribosyl)ation of these nuclear proteins is referred to as 
heteromodification. However, the main protein to be poly(ADP-ribosyl)ated is PARP-1 
itself in a process known as automodification. Glutamate, aspartate or carboxy terminal 
lysine (Glu, Asp, or COOH-Lys) residues of acceptor proteins are then covalently 
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modified by the addition of an ADP-ribose subunit, via formation of an ester bond 
between the protein and the ADP-ribose residue.26 
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Scheme 1. The proposed mechanism of NAD+ cleavage by PARP-1. 
 
1.4.2 Elongation 
 
Polymer elongation involves the formation of an α(1’’→2’) glycosidic bond between C-
1’’ of nicotinamide ribose and the 2’-OH of the adenine ribose. This results in formation 
of linear polyanionic polymers with chain lengths of up to 200 ADP-ribose units.27,28  
 
1.4.3 Branching 
 
Polymer branching occurs when the C-1 of the nicotinamide ribose is joined with the 2-
OH of the nicotinamide ribose of another ADP-ribose polymer via a 1’’’→2” glycosidic 
bond. Polymer branching occurs on average after 20 ADP-ribose units. 
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Figure 3. Formation of linear and branched poly(ADP-ribose) polymer. 
 
1.4.4 Termination  
 
The synthesis of long negatively charged polymers on histones causes an electrostatic 
repulsion of the nuclear protein from DNA. The strong affinity of histones for poly(ADP-
ribose) compared to DNA, results in temporary dissociation of histones from damaged 
DNA and their transient electrostatic binding to poly(ADP-ribose). This results in 
relaxation of the chromatin at the site of the nick allowing access of repair enzymes.29 
Reassembly of the histone-DNA complex is triggered by poly(ADP-
ribose)glycohydrolase (see below).30  
 
During automodification, PARP-1 acts as a catalytic dimer. The introduction of a SSB in 
the DNA duplex induces flexibility at the nicked site. PARP-1 binds specifically through 
the second zinc finger to the centre of the characteristic V-shape in the DNA molecule 
and the enzyme covers seven base-pairs symmetrically on each side of the break.13 
This, in turn, leads to the recruitment of a second PARP-1 molecule through the leucine 
zipper motif in the automodification domain.31 The second PARP-1 molecule serves as 
a polymer acceptor during subsequent ADP-ribose polymer synthesis by the first 
PARP-1 molecule.32 
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Figure 4. Mechanism of action of PARP-1.33 
 
1.4.5. Catabolism of ADP-ribose polymers 
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active PARG, which cleaves the ribose-ribose linkage in the linear (1’’→2’ glycosidic 
bond) and branched (1’’’→2” glycosidic bond) portions of the polymer to produce ADP-
ribose monomers.34 PARG is known to catalyse hydrolysis both of terminal ADP-ribose 
units from poly(ADP-ribose) polymers via exoglycosidic activity and to remove larger 
oligo(ADP-ribose) fragments through endoglycosidic cleavage.35 The Km value of 
PARG is lower for larger ADP-ribose polymers than for smaller ones, indicating that the 
enzyme probably removes and catabolises bigger fragments first, then switches to 
remove ADP-ribose units one by one. The proximal ADP-ribose moiety is removed 
from the acceptor proteins by ADP-ribosyl protein lyase.36 It was shown to liberate a 
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dehydrated form of ADP-ribose (5’-ADP-3”-deoxypent-2”-enofuranose) from the 
acceptor protein. The degradation of ADP-ribose polymers represents a major 
regulatory mechanism for PARP-1, resulting in the down regulation of the enzyme and 
frees the site for further polymer synthesis. 
 
1.5 PARP-1: Biological Roles 
 
1.5.1 PARP-1 and DNA repair 
 
PARP-1 has been implicated in DNA repair and the maintenance of genomic integrity. 
This ‘guardian angel’ function of PARP-1 is supported by delayed DNA base-excision 
repair (BER) and the high frequency of sister chromatid exchange in PARP-1-deficient 
cells after exposure to ionizing radiation or alkylating agents.37 PARP-1 interacts with 
multiple nuclear components of the single-strand break repair (SSBR) and BER 
pathways, including the nick sensor DNA ligase III, the adaptor factor XRCC1 and DNA 
repair enzymes such as DNA polymerase-β and DNA ligase III.38 The following steps 
are found to be involved in the process: 
• Identification of the DNA break 
• Translation and amplification of the damage signal, the poly(ADP-ribosyl)ation 
of PARP-1 itself and of histones H1 and H2B, the triggering of chromatin 
structure relaxation thereby increasing the access of DNA repair enzymes to 
the break 
• Recruitment of XRCC1 to the damaged site followed by the assembly of the 
SSBR complex 
• End processing, whereby polynucleotide kinase that is stimulated by XRCC1 
converts the DNA ends to 5′-phosphate and 3′-hydroxyl moieties 
• Gap filling by DNA polymerase  
• Ligation step catalysed by DNA ligase III. 
 
Another role of PARP-1 in DNA repair is regulation of the topological state of DNA, i.e. 
activity of DNA topoisomerase I. This enzyme plays an important role in controlling the 
level of DNA supercoiling and relieving the torsional stress that is generated during 
replication, transcription, recombination and chromatin remodelling. During this 
process, topoisomerase I can get trapped in a covalent complex with nicked DNA 
through the 3′-phosphate terminus, which inhibits its DNA-ligase activity. If unrepaired, 
this can lead to genomic instability or apoptosis. ADP-ribose polymers target specific 
domains of topoisomerase I and induce the enzyme to remove itself from cleaved DNA 
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and close the resulting gap.39 The poly(ADP-ribose)polymer can also serve as an 
emergency source of energy used by base-excision machinery to synthesise ATP.40 
 
1.5.2 PARP-1 in the regulation of gene expression  
 
PARP-1 regulates the expression of various proteins at the transcriptional level. Three 
principal mechanisms are found to be involved: first, the regulation of chromatin 
structure and function; second, the regulation of DNA methylation by PARP-1; and 
third, the participation of PARP-1 in enhancer/promoter-binding complexes. In the first, 
poly(ADP-ribosyl)ation confers negative charge to histones, resulting in electrostatic 
repulsion between DNA and histones. Loosening histone-DNA interactions renders 
various genes accessible to the transcriptional machinery. In the second mechanism, 
PARP-1 binds to DNA methyltransferase-1 (DNMT), which is a key enzyme in DNA 
methylation and a global regulator of gene expression, and thereby inhibits its catalytic 
function.41 Thirdly, regulation of transcription is associated with functional interactions 
of PARP-1 and various non-histone proteins. PARP-1 acts as a coactivator in nuclear 
factor-κB (NF-κB)-mediated transcription.42 NF-κB is a key transcription factor 
regulating the expression of several elements of inflammation such as cytokines, 
chemokines, adhesion molecules (ICAM-1), and inflammatory mediators like inducible 
nitric oxide synthase (iNOS) and inducible form of cyclooxygenase (COX-2). It has 
been shown that inhibition of PARP-1 activity (5-AIQ) reduces NF-κB-mediated 
transcription suggesting that catalytic activity of the enzyme is required.43-45 Studies 
have also showed that PARP-1 deficient cells were defective in NF-κB-dependent 
transcription activation in response to tumour necrosis factor (TNF). Treating mice with 
bacterial lipopolysaccharide (LPS), an endotoxin, resulted in the rapid activation of NF-
κB in macrophages from PARP-1 competent mice but not from PARP-1 knockout mice. 
In fact, PARP-1-deficient mice were extremely resistant to LPS-induced endotoxic 
shock.46 Although NF-κB-dependent transcriptional activation is promoted by PARP-1, 
sometimes expression of NF-κB-target genes is silenced by PARP-1.47 PARP-1 is also 
required for the activation of other inflammation-related transcription factors, such as 
activator protein-1 (AP1), AP2, transcription enhancer factor-1 (TEF-1), trans-acting 
transcription factor-1 (SP1), octamer-binding transcription factor-1 (Oct1), yin-yang-1 
(YY1) and signal transducer and activator of transcription-1 (STAT1).48 
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1.5.3 PARP-1 in DNA replication and cellular differentiation 
 
Poly(ADP-ribosyl)ation plays an active role during the process of DNA replication and 
differentiation. The involvement of PARP-1 in the regulation of replication is supported 
by observations that poly(ADP-ribose) metabolism is accelerated in the nuclei of 
proliferating cells. The fact that PARP-1 copurifies with DNA polymerase α and δ, DNA 
primase, DNA helicase, DNA ligase, topoisomerases I and II, and key components of 
the multiprotein replication complex (MRC) suggests that PARP-1 is part of the MRC. 
Poly(ADP-ribosylation) of histones was proposed to facilitate the assembly and 
deposition of histone complexes on DNA during replication. Various experimental 
models using PARP-1-knockout cells and pharmacological inhibition have 
demonstrated an inhibition of DNA replication and cell proliferation, thus suggesting a 
possible role of PARP-1 in regulating these two processes.28 
 
Replication and differentiation are closely coupled processes and this may provide a 
rationale for the differentiation-modifying effect of PARP-1. To function as specialised 
building blocks of tissues, cells need to undergo a series of proliferative steps during 
which they gain new functions and lose others. This process requires concerted gene 
activation and results in differentiation into specialised cells such as hepatocytes, 
neurons and renal tubular cells. The idea that PARP-1 interferes with differentiation is 
supported by the findings that PARP-1 inhibitors were found to inhibit differentiation of 
human granulocyte-macrophage progenitor cells to the macrophage lineage. 
Overexpression of PARP-1 also arrests NB4 cells and blocks all 
trans-retinoic acid-induced terminal neutrophilic differentiation.40 
 
1.5.4 PARP-1 in cell death  
 
Despite the ‘guardian angel’ functions of PARP-1, its over-activation has been 
proposed to represent a cell-elimination pathway through which severely damaged 
cells are removed from tissues. This suggests that the PARP-1-directed DNA repair 
process is a highly inefficient and energy-consuming process. 
 
1.5.4.1 Cellular energy dynamics 
 
PARP-1 is a very abundant enzyme with up to one PARP molecule for each 1000 bp of 
DNA. With the formation of each ADP-ribose polymer, PARP-1 consumes up to 200 
molecules of NAD+. In addition, the rate of turnover of nuclear NAD+ in a normal intact 
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cell is estimated to be at least 100-fold less than in the DNA-damaged poly(ADP 
ribosyl)ating cell.25 Over-activation of PARP-1 can affect cellular energy levels by 
depleting the cellular stores of substrate NAD+.  
 
NAD+ is an essential cofactor in energy metabolism. It is an important respiratory 
coenzyme that regulates an array of vital cellular processes, such as glycolysis and 
mitochondria respiration, thereby providing ATP for most cellular processes. NAD+ also 
serves as the precursor for nicotinamide adenine dinucleotide phosphate (NADP), 
which acts as a cofactor for the pentose shunt and for bioreductive synthetic pathways, 
and is involved in the maintenance of reduced glutathione pools.49 The level of 
poly(ADP-ribosyl)ation in cells is the most important factor for the maintenance of NAD+ 
levels. DNA-damage-induced NAD+ depletion results in ATP depletion because NAD+ 
resynthesis requires at least two molecules of ATP per molecule. The result of massive 
NAD+ usage is a decline in the rate of all vital processes, leading to cellular dysfunction 
and, ultimately, cell death. Moreover, under these precarious conditions, 
phosphoribosyl pyrophosphate synthetase and nicotinamide mononucleotide adenylyl 
transferase consume ATP in an effort to replenish the cellular NAD+ store, further 
worsening the energy shortage and leading to a pronounced reduction of energy-
dependent processes, such as DNA, RNA and protein synthesis.25  
 
1.5.4.2 The “suicide hypothesis” 
 
PARP-1 carries out two seemingly contradictory activities, DNA repair that enables the 
cell to survive and NAD+ depletion to kill the cell. Based on this observation, Berger50 
proposed a “suicide concept” postulating that the activation of PARP-1 by massive 
DNA damage is actually a suicide response, since it causes rapid depletion of NAD+ 
and ATP depletion and leads to cell death before there is an opportunity to repair the 
DNA. This cell death is presumably Nature’s way of preventing gravely damaged cells 
from attempting to repair themselves. Such a suicide mechanism limits the possibility 
that massively damaged cells will try to repair and survive with a high mutation 
frequency and a potentially malignant transformation. This activation of PARP-1 by 
DNA damage may provide a safety mechanism whereby massively damaged cells are 
removed from the population, thereby decreasing the likelihood of preserving cells with 
highly mutant phenotypes. When a cell is damaged, the partial energy depletion 
provided by PARP-1 activation may prevent the cell from overexerting itself until DNA 
repair is completed.  
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1.5.4.3 The “molecular switch hypothesis” 
 
The “suicide hypothesis” is controversial because it was never established whether an 
extensively damaged cell dies because of a depleted NAD+/ ATP pool or from the DNA 
damage itself. The two sides of the argument viewed PARP-1 either as an 
indispensable cellular survival factor or as an active mediator of cell death. However, it 
is currently accepted that PARP-1 has been implicated in both apoptosis and necrosis, 
the actual mode of cell death being determined chiefly by the level of NAD+ and ATP. It 
was therefore plausible to hypothesise that PARP-1 serves as a molecular switch 
between apoptosis and necrosis.51 Virág and Szabó40 proposed a unifying concept 
according to which, cells that are exposed to DNA-damaging agents can enter three 
pathways based on the intensity of the stimulus (severity of DNA damage) (FIG. 5).  
• PARP-1 activated by mild to moderate genotoxic stimuli facilitates DNA repair, 
by signalling cell-cycle arrest and by interacting with DNA-repair enzymes such 
as XRCC1 and DNA-dependent protein kinase (DNA-PK). As a result, DNA 
damage is repaired and cells survive without the risk of passing on mutated 
genes.  
• In the second pathway, more severe DNA damage induces apoptotic cell death, 
with caspases, the main executor enzymes (caspase 7 and caspase 3) of the 
apoptotic process, inactivating PARP-1 by cleaving it into two fragments (p89 
and p24) at the DEVD motif in the nuclear localization signal of PARP-1.52 
Cleavage at this site separates the DNA binding domain from the catalytic 
domain, which inactivates the enzyme. PARP-1 cleavage is viewed as a marker 
of apoptosis, rather than an executor of the process. This pathway allows cells 
with irreparable DNA damage to be eliminated in a safe way i.e. via ingestion by 
macrophages. In fact, PARP-1 cleavage prevents the overactivation and 
thereby maintains cellular energy for certain ATP-sensitive steps of apoptosis.53 
Cleavage of PARP-1 is believed to aim at promoting apoptosis by preventing 
DNA repair-induced survival and by blocking energy depletion-induced 
necrosis. 
• The third pathway, necrotic cell death, is induced by extensive DNA breakage 
caused by oxidative or nitrosative stress (hydroxyl radical, peroxynitrite, nitroxyl 
anion). The overactivation of PARP-1 depletes the cellular stores of its 
substrate NAD+ and, consequently, ATP level. The severely compromised 
cellular energetic state inhibits the apoptotic cell death process to proceed 
because many steps of apoptosis are known to depend on ATP. Under these 
conditions, pharmacological PARP inhibition or the absence of PARP in PARP-
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deficient mice preserves cellular ATP and NAD+ pools in oxidatively stressed 
cells and thereby allows them to either function normally or die by apoptosis 
instead of necrosis.40 In addition to numerous biochemical and morphological 
similarities and differences between apoptosis and necrosis, a distinctive 
feature of necrosis is the disintegration of the plasma membrane (as opposed to 
the compaction of apoptotic cells, which is followed by elimination). Consequent 
leakage of cellular content from necrotic cells into the surrounding tissue 
exacerbates the inflammatory responses. 
 
According to Figure 5, depending on the intensity of the stimulus, PARP-1 regulates 
three different pathways. In the case of mild DNA damage, poly(ADP-ribosyl)ation 
facilitates DNA repair and, therefore, survival (route 1). More severe genotoxic stimuli 
activate an apoptotic pathway that eliminates cells with damaged DNA (route 2). The 
most severe DNA damage can cause excessive PARP activation, which depletes 
cellular NAD+/ATP stores. NAD+/ATP depletion blocks apoptosis and results in necrosis 
(route 3). The inhibition of PARP-1 in cells entering route 1 suppresses repair and, 
therefore, diverts cells to route 2 (dashed arrow on the left). The inhibition of PARP in 
cells that are entering route 3 preserves ATP and cellular energy stores, and either 
prevents cell death or enables it to occur through apoptosis instead of necrosis 
(dashed arrow on the right). 
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Figure 5. Intensity of DNA-damaging stimuli determines the fate of cells: survival, apoptosis or 
necrosis.40 
 
A great variety of human diseases, such as cancer, ischaemia-reperfusion injury, 
inflammatory disorders and neurodegenerative diseases involve damage to DNA as a 
crucial element to their pathogenesis. Most of these damages are caused by oxidative 
stress where PARP-1 is very much involved as the final mediator of cellular injury and 
death. PARP-1 inhibition, therefore, is an attractive method for studying the 
significance of this enzyme in biological systems and may prove useful for the therapy 
of these diseases. PARP-1 has been extensively investigated as a target of novel 
compounds, capable of inhibiting its catalytic activity, which may be used in a broad 
spectrum of diseases to counteract PARP mediated cell death or to enhance the 
efficacy of chemotherapy and radiotherapy. 
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1.6 Therapeutic potential of PARP-1 inhibition 
 
1.6.1 PARP-1 inhibition in cancer therapy 
 
Radiotherapy and many chemotherapeutic approaches to cancer therapy act by 
inducing DNA damage. Since PARP-1 is a controlling enzyme in the repair of damage 
to DNA, it is unsurprising that the first proposed application of PARP-1 inhibition was in 
radiopotentiation and chemopotentiation. DNA repair processes mediated by PARP-1 
can lead to resistance to chemotherapy and radiotherapy. Therefore inhibition of DNA 
repair may be therapeutically beneficial in the treatment of cancer. The rationale for the 
use of PARP-1 inhibitors as chemo- and radio-sensitisers comes from the observation 
that PARP-1 is important for DNA base-excision repair and its inhibition caused a 
significant delay in the DNA repair processes. 
 
1.6.1.1 Chemopotentiation 
 
Co-administration of a PARP-1 inhibitor with cytotoxic drugs that cause single- and 
double-strand DNA breaks potentiates the activity of these agents and causes 
persistent DNA single-strand breaks. A potential role of PARP-1 inhibitors as 
resistance modifiers when used in combination with the methylating agent 
temozolomide (TMZ) were evaluated.54 The methylating agent temozolomide (TMZ) is 
used in the therapy of various central nervous system (CNS) tumours. TMZ resistance 
develops frequently and diminishes the clinical response. This phenomenon is often 
the result of the efficient repair of methyl adducts at the O6-position of guanine 
mediated by MGMT. The combination of PARP inhibitors with TMZ interferes with the 
repair of methylpurines. When PARP is inhibited, the recruitment-promoting functions 
of XRCC1 are impaired, which hampers strand rejoining; this leads to the generation of 
permanent single-strand breaks that trigger the apoptotic process. It is in combination 
with this cytotoxic agent that PARP-1 inhibitors were introduced into the clinic for 
cancer patients in 2003. Tentori et al.55 demonstrated that the antitumour activity of 
TMZ against brain lymphoma is enhanced by the use of an intracerebral injection of the 
PARP-1 inhibitor NU1025 (8-hydroxy-2-methylquinazolin-4(3H)-one). Systemic 
administration of GPI15427 enhanced the efficacy of TMZ against metastatic 
melanoma, glioblastoma multiforme and lymphoma growing in the brain. These drug 
combinations enhanced the survival of lymphoma-bearing mice with respect to 
treatment with TMZ only. AG14361 increased the activity of temozolomide and 
topotecan, and the activity of radiation therapy in vitro.56 AG014699 is a potent tricyclic 
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indole PARP inhibitor that has completed both Phase I and II studies in combination 
with temozolomide. Clinical trials are also in progress for INO-1001 in combination with 
temozolomide in patients with malignant glioma.6  
 
PARP inhibitors have also been shown to enhance the cytotoxicity of the camptothecin-
derived DNA topoisomerase I poisons irinotecan and topotecan.57 Camptothecins act 
through the stabilisation of topoisomerase I-cleavage complexes. Poly(ADP-
ribosyl)ated PARP-1 and PARP-2 counteract the action of camptothecin by facilitating 
the resealing of DNA-strand breaks. Therefore, it is conceivable that the enhancement 
of camptothecin cytotoxicity induced by PARP inhibitors may be due to the impairment 
of the strand break re-joining mediated by topoisomerase I itself.58 
 
Non-toxic concentrations of 5-methylnicotinamide dramatically potentiated the 
cytotoxicity of N-methyl-N-nitrosourea and of γ-radiation.59 The PARP inhibitor 4-amino-
1,8-naphthalimide has been shown to sensitize p53-deficient breast cancer cell lines to 
apoptosis induced by doxorubicin, an anticancer drug commonly used for adjuvant 
therapy of breast cancer. The combination of doxorubicin and PARP inhibitor PJ34 is 
effective in reducing cardiac toxicity induced by the former.60 Cisplatin and its analogue 
carboplatin, which generate platinum DNA adducts, are used for the treatment of germ 
cell tumours, gynaecologic cancers, lung, bladder and head/neck cancer, whereas 
oxaliplatin is used for the treatment of colon cancer. Oral administration of BGP-15 
shortly before cisplatin treatment prevented drug induced renal failure without reducing 
the antitumor efficacy of the chemotherapeutic agent.61  
 
1.6.1.2 Radiopotentiation 
 
An intriguing area of use of PARP-1 inhibitors is in the potentiation of radiotherapy. 
Treatment with ionising radiation is the most widely used anticancer intervention after 
surgery. Radiotherapy damages cells by causing both single- and double-strand breaks 
and inducing apoptotic cell death. DNA repair mechanisms within cancer cells attempt 
to minimise this damage and then resistance emerges. In vivo efficacy of PARP 
inhibition for radiosensitisation has been recently demonstrated by a preclinical study 
showing that intraperitoneal administration of the PARP inhibitor AG14361 significantly 
enhances sensitivity of colon carcinoma subcutaneous xenografts to radiation 
therapy.56 AG14361 also inhibited the recovery of growth-arrested cells from potentially 
lethal irradiation damage. This sensitisation of growth-arrested cells is important for 
tumour radiation therapy because experimental and clinical evidence indicate that the 
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growth-arrested cell fraction within a tumour is radiation-resistant and capable of re-
entering the cell proliferation cycle and thereby re-populating the tumour after radiation 
therapy. The PARP inhibitor INO-1001 has also demonstrated radiosensitising effects 
in vitro and in vivo. 6(5H)-Phenanthridinone, a PARP-1 inhibitor, also enhanced 
cytotoxicity induced by ionising radiation.62  
 
1.6.1.3 PARP-1 inhibitors as single agents in DNA repair-deficient tumours 
 
PARP inhibitors might be beneficial in cancer treatment as a single agent. This would 
certainly have an advantage in terms of toxicity, as one of the concerns of 
chemotherapy combination studies is systemic toxicity caused by the use of PARP 
inhibitors as enhancers of cancer therapy. BRCA1 and BRCA2 are essential for the 
repair of double strand DNA breaks (DSBs) by the process of homologous 
recombination (HR). BRCA1-deficient and BRCA2-deficient cells, when compared with 
matched wild-type cells, were profoundly sensitive to inhibitors of PARP-1 In some 
cases, BRCA-deficient cells were more than 1000 times more sensitive to nanomolar 
concentrations of PARP inhibitor, suggesting the possibility of a highly selective 
therapy.63 PARP-1 is crucial for the repair of single-strand DNA breaks (SSBs) and 
PARP inhibitors cause an increase in persistent SSBs by targeting the HR deficiency in 
BRCA-deficient cells. Germ-line mutations in BRCA1 and BRCA2 indicate high risk for 
breast, ovarian, and other malignancies. In these cells, PARP inhibition results in cell 
cycle arrest and apoptosis. This suggests a role for PARP inhibitors as single agents in 
cancers exhibiting BRCA1 and BRCA2 mutations. Evaluation of KU0058948 suggested 
that the sensitivity of BRCA1- and BRCA2-deficient cells to PARP inhibition seems to 
be dependent on the potency and/or specificity of the PARP inhibitor. A Phase I study 
is ongoing with the KuDOS orally available PARP-1 inhibitor (KU-00559436) as a 
single anti-cancer agent. In addition, a Phase II study of AG014699 in metastatic breast 
and ovarian cancer in proven carriers of a BRCA-1 or BRCA-2 mutation is in 
progress.,64 
 
1.6.2 PARP-1 inhibition in reperfusion injury 
 
Clinically, when there is a reduced blood supply to the tissues, the cells are said to be 
ischaemic. Ischaemia is a common condition during surgery and in many diseases, 
such as myocardial infarction, stroke and haemorrhage. Early reperfusion is an 
absolute prerequisite for the survival of ischaemic tissues. However, reperfusion has 
often been observed to exacerbate the injury sustained by the ischaemic tissues and 
lethally damage the organs (ischaemia-reperfusion injury). The damage, which occurs 
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during the early minutes of reperfusion, is far greater than would have occurred if the 
ischaemia had been maintained.65  
 
It is well established that oxygen-derived free radicals and oxidants play a role in the 
pathogenesis of ischaemia–reperfusion. Recent studies confirmed this “oxygen 
paradox” and suggested that reperfusion could trigger sudden metabolic and 
physiological changes, most notably, an outburst of oxidants and free radical 
production, in particular, hydrogen peroxide, hydroxyl radical, superoxide anion, nitric 
oxide and peroxynitrite.66-68 These are capable of exerting cytotoxic effects 
independently or synergistically, via a number of mechanisms; both hydroxyl radical 
and peroxynitrite (a highly reactive oxidant produced from the reaction between nitric 
oxide and superoxide) can also trigger massive DNA single strand break, leading to 
PARP-1 over-activation.66 In stroke, heart attack and other forms of reperfusion injury, 
the main steps of the process are as follows.48 
• The occlusion of a blood vessel prevents blood flow to the organ. 
• Restoration of the blood flow (spontaneously or in conjunction with a medical 
intervention, such as thrombolysis or angioplasty) triggers the generation of 
various oxidants and free radicals. 
• These species (hydrogen peroxide, hydroxyl radical and peroxynitrite) induce a 
range of oxidative and nitrosative injuries to the cells, including protein and lipid 
modifications, mitochondrial dysfunction and DNA damage (base modifications 
and DNA-strand breakage). 
• PARP-1 senses the DNA breaks and becomes activated. 
• This process leads to the consumption of NAD+, initially mainly from the 
cytosolic pool. 
• The cell attempts to regenerate NAD+ from nicotinamide, which is converted to 
nicotinamide mononucleotide by phosphoribosyl transferase using 
phosphoribosyl pyrophosphate obtained from ATP.  
• PARP-activation-induced depletion of the cellular pyridine nucleotide pool 
impairs important NAD+-dependent cellular pathways, including glycolysis and 
mitochondrial respiration. NAD+ deficiency allows only the ATP-consuming part 
of anaerobic glycolysis to take place, thereby decreasing the synthesis of 
pyruvate and the mitochondrial formation of NADH. NADH-deficient 
mitochondria undergo depolarisation, which converts the ATP synthase into an 
ATPase. 
• Finally, the ensuing cellular energetic starvation leads to the shutdown of 
energy-requiring processes which leads to a breakdown of membrane potential 
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and leakage of the membrane. These events promote futile cycles that, 
ultimately, lead to cell death through the necrotic route.  
 
It has been proposed that inhibition of PARP-1 should alleviate depletion of NAD+ and 
protect organs from damage following ischaemia and reperfusion. Table 1 summarises 
some of the diseases in which PARP inhibition or deficiency provides therapeutic 
benefit in vivo. Two organs in which PARP-mediated reperfusion injury has been 
intensively investigated are the brain and heart. Pharmacological inhibition of PARP-1 
with 3-aminobenzamide (3-AB) significantly improved the outcome of myocardial 
dysfunction, as evidenced by a reduction in creatine phosphokinase levels, reduced 
infarct size, and preserved ATP pools.69-72 5-Aminoisoquinolin-1-one (5-AIQ) also 
proved to be a potent inhibitor of poly(ADP-ribose)polymerase activity in cardiac 
myoblasts and reduces myocardial infarct size in vivo.73 Neuronal damage following 
stroke and other neurodegenerative processes is thought to stem from over-excitation 
attributable to a massive release of the excitatory neurotransmitter glutamate acting on 
the N-methyl-D-aspartate (NMDA) receptor and other subtype receptors.74 Stimulation 
of NMDA activates the production of nitric oxide by neuronal nitric oxide synthase 
(nNOS), which ultimately accounts for reperfusion injury in the central nervous system. 
In PARP-1 knockout mice, a markedly reduced infarct volume is observed after 
transient middle cerebral artery occlusion.75 Several PARP-1 inhibitors have also been 
shown to reduce infarct size and improve neurological status in cerebral ischaemia-
reperfusion.75-77 
 
Table 1. PARP inhibition in animal models of inflammation, reperfusion, degenerative 
and vascular diseases.48 
 
3-AB, 3-aminobenzamide; ISQ, 5-hydroxyisoquinolin-1-one; DPQ, 3,4-dihydro-5-[4-1(1-
piperidinyl)butoxy]1(2H)-isoquinolinone; G-PH, aza-5[H]-phenanthridin-6-one 
derivative; PHT, 6(5H)-phenanthridinone; INH2B, 5-iodo-6-amino-1,2-benzopyrone; 
GPI-6150, 1,11b-dihydro-[2H]benzopyrano[4,3,2-de]isoquinolin-3-one; PJ-34, N-(6-
oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide; INO-1001, Inotek’s 
indenoisoquinolinone derivative; 5-AIQ, 5-aminoisoquinolin-one; ONO-1924H, N-[3-(4-
Oxo-3,4-dihydro-phthalazin-1-yl)phenyl]-4-(morpholin-4-yl)butanamide 
methanesulfonate monohydrate; DR2313, 2-methyl-3,5,7,8-tetrahydrothipyrano[4,3-
d]pyrimidine-4-one; AIF, apoptosis-inducing factor; F-Q, 2,8-disubstituted quinazolin-
4(3H)-one (43d); NA, nicotinamide; 4-OHQ, 4-hydroxyquinazoline; I/R, 
ischaemia/reperfusion; NMDA, N-methyl-D-aspartate.  
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Organ/Disease model PARP inhibitors Effects of PARP-1 inhibition 
Brain   
Stroke 3-AB, ISQ, DPQ, G-PH, 
PHT, INH2BP, GPI-
6150, PJ-3476, INO-
1001, ONO-1924H,  
Reduction in necrosis of the neurons, 
improvement in neurological status, 
protection against white-matter damage 
and AIF translocation 
Traumatic brain injury 3-AB44, GPI-6150, PJ-
34, INO-1001 
Improved neurological status 
Hypoglycaemia ISQ Improved survival and behavioural status 
Meningitis 3-AB Improved survival, neurological status 
and reduced inflammatory mediator 
production 
Parkinson’s disease GPI-6150, ISQ, F-Q Improved neurological outcome and 
dopamine loss 
Heart   
Myocardial infarction 3-AB,71,72 NA, ISQ, 5-
AIQ,73 PJ-34, INO-1001, 
GPI-6150 
Reduced myocardial necrosis, reduced 
infarct size, improved myocardial 
contractility, and reduced neutrophil 
infiltration 
Transplantation 3-AB84, PJ-34, INO-
1001 
Improved myocardial contractility, 
reduced inflammatory mediator 
production, extension of transplant 
survival 
Ischaemic 
cardiomyopathy 
PJ-34, INO-1001 Improved myocardial contractility, 
improved survival 
Diabetic 
cardiomyopathy 
PJ-34, INO-1001 Improved myocardial contractility 
Ageing-associated heart 
failure 
PJ-34, INO-1001 Prevention or reversal of diabetic 
endothelial dysfunction 
Vasculature   
Diabetic endothelial 
dysfunction 
PJ-34, INO-1001 Prevention or reversal of diabetic 
endothelial dysfunction 
Ageing, Hypertension PJ-34, INO-1001 Protection against the development of 
endothelial dysfunction 
Lung   
Acute respiratory 
distress syndrome 
Benzamide, PJ-34, 5-
AIQ95 
PARP inhibition suppresses endotoxin 
induced pulmonary damage, reduces 
inflammatory mediator production and 
NMDA mediator production and lung 
oedema formation 
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Organ/Disease model PARP inhibitors Effects of PARP-1 inhibition 
Ovalbumin-induced 
asthma 
3-AB, 5-AIQ, PJ-34 Reduced inflammatory mediator 
production and improved pulmonary 
function 
Endocrine/pancreas   
Diabetes NA, 3-AB, INH2BP Protection against necrosis of islets and 
reduction in the degree of 
hyperglycaemia 
Joint/Arthritis NA, 3-AB, PJ-34 Reduced arthritis severity and incidence 
Skeletal muscle I/R 3-AB70 Reduction in reperfusion injury necrosis 
markers 
Liver   
I/R injury PJ-34, 5-AIQ80,81 Improved survival, reduced hepatic 
necrosis and protection against hepatic 
leukostasis 
Kidney I/R Benzamide, 3-AB, 5-
AIQ,82 PJ-34 
PARP inhibitors accelerate the recovery 
of normal renal function after I/R injury 
Transplantation PJ-34 No effect on the function of the 
transplanted kidney 
GI tract   
Colitis 3-AB78, NA, INH2B, PJ-
34, 5-AIQ92, GPI-6150,79 
INO-1001, ISQ 
Improved survival, protection against gut 
shortening, lipid peroxidation, nitrosative 
damage and ICAM1 expression 
Mesenteric I/R injury 3-AB, NA, GPI-6150, Protection against histological damage, 
neutrophil infiltration and mucosal barrier 
failure 
Eye   
Uveitis PJ-34 Protection from leukocyte migration 
Diabetic retinopathy PJ-34 Inhibition of the development of acellular 
capillaries and reduced leukostasis 
Retinal I/R 3-AB83 Reduced I/R damage to the retina 
Ear   
Cochlear I/R injury 3-AB Improvement of cochlear function 
Skin   
Sulphur mustard 
induced vesication 
3-AB, NA Protection against NAD+ depletion and 
microvesicle formation 
Peripheral nerve   
Diabetic neuropathy ISQ, PJ-34 Protection against loss of motor and 
sensory nerve conductance 
Cavernous nerve injury INO-1001 Improved erectile function 
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Organ/Disease model PARP inhibitors Effects of PARP-1 inhibition 
Many organs   
Haemorrhagic, 
endotoxic and septic 
shock 
3-AB, NA, PJ-34, 
INH2BP, GPI-6150, 4-
OHQ, 5-AIQ86 
Protection against haemodynamic 
decompensation, improved survival, 
protection against gut hyperpermeability 
and myocardial, vascular, hepatic and 
renal failure 
Thoracoabdominal I/R PJ-34 Improved survival and neurological status 
HIV Benzamides, 
benzopyrones, INH2BP 
PARP deficiency reduces viral replication 
and integration 
 
Protection against organ damage by PARP-1 inhibitors are also reported in reperfused 
organs such as gut,78,79 skeletal muscle,70 liver,80,81 kidney82 and retina.83 It also 
improves the outcome of heart transplantation84 and protects against multiple organ 
damage secondary to haemorrhagic shock.85-87 
 
1.6.3 PARP-1 inhibition in inflammatory diseases 
 
Over-activation of PARP-1 also induces the expression of a number of genes that are 
essential for inflammatory responses (overviewed in section 1.5.2). PARP-1 acts as co 
activator of NF-κB resulting in expression of NF-κB-dependent inflammatory elements, 
such as cytokines, chemokines, iNOS, ICAM-1 and TNF. Both cytokines and 
chemokines can trigger free-radical formation through many different pathways, for 
example by stimulating xanthine oxidase activity and by recruiting activated 
neutrophils. In addition, the level of production of nitric oxide is increased due to de 
novo iNOS expression. These events further worsen the oxidant stress, producing 
even greater PARP-1 activation and cell dysfunction. The earliest implication of PARP-
1 in the pathophysiology of inflammatory diseases was related to pancreatic islet cell 
injury and diabetes. In streptozotocin-induced pancreatic islet cell injury and diabetes, 
inhibition of PARP-1 with 3-AB prevented NAD+ depletion and the suppression of 
proinsulin synthesis without modifying the extent of DNA damage. Subsequent 
experiments in vivo demonstrated that such inhibition delays the onset of 
streptozotocin- and alloxan-induced diabetes.88,89  
 
The role of PARP-1 activation and the protective effects of PARP inhibitors have also 
been demonstrated in various experimental models of inflammation, including acute 
inflammatory diseases (such as endotoxic shock), as well as chronic inflammation of 
the gut, joints and various other organs. (Table 1) For instance, PARP inhibitors and/or 
PARP deficiency is effective in arthritis,90 colitis,91,92 and pulmonary inflammation.93-95 
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Systemic inflammatory diseases (circulatory shock) are associated with a reduced 
responsiveness of blood vessels to vasoconstrictor agents (a result of nitric oxide and 
peroxynitrite production), myocardial dysfunction and impaired intracellular energetic 
processes, culminating in multiple organ failure. The severity of these inflammatory 
diseases is suppressed by PARP inhibitors and the production of multiple pro-
inflammatory mediators is down-regulated. It was also demonstrated that treatment of 
mice for tissue injury associated with stroke and neurotrauma with PARP inhibitors 3-
AB and 5-AIQ reduced the degree of spinal cord inflammation, tissue injury, neutrophil 
infiltration and apotopsis.96 
 
1.6.4 PARP-1 inhibition in cardiovascular diseases 
 
PARP-1 activation also has a pathogenic role in hypertension, atherosclerosis and 
diabetic cardiovascular complications. In these diseases, the dysfunction of the 
vascular endothelium (that is, a reduction in the ability of the endothelial cell to produce 
nitric oxide and other cytoprotective mediators) is diminished. The oxidant-mediated 
endothelial cell injury is dependent on PARP-1 and can be attenuated by 
pharmacological inhibitors or genetic PARP-1 deficiency.97 For instance elevated 
extracellular glucose levels (as in diabetes) trigger PARP-1 activation through the 
mitochondrial release of oxidants, which is followed by DNA-strand breakage. In 
hypertension, angiotensin II acts on its endothelial receptors and up regulates NADPH 
oxidases. The subsequent generation of superoxide and peroxynitrite triggers DNA-
strand breakage and PARP activation.98 In vivo studies show that PARP-1 inhibition 
improves endothelium-dependent relaxations in hypertensive and diabetic animals.99 
PARP-1 activation is also involved in the early functional changes that are associated 
with atherosclerosis and vascular injury. The preservation of vascular function might 
underlie the protective effect of PARP inhibitors against diabetic neuropathy and 
retinopathy.100,101  
 
1.6.5 PARP-1 inhibition in HIV-1 infection 
 
There is an increasing body of evidence suggesting the involvement of PARP-1 in HIV-
1 infection. During the life cycle of the HIV-1 virus within the infected cell, the RNA 
genome of the virus is reverse-transcribed into double-stranded DNA by reverse 
transcriptase.102 The proviral DNA, in turn, enters the nucleus, where the 
virion-associated viral enzyme, integrase, catalyses the integration of the viral 
double-stranded DNA into the host genome. This process requires nicking of both DNA 
strands and may therefore lead to PARP-1 activation. At present, it seems that PARP-1 
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regulates HIV infection at two levels: integration and transcription and PARP-1 
inhibition may be a viable strategy in controlling HIV-1 infection. Studies show that 
benzopyrone derivatives, benzamides and nicotinamide possess potent antiviral effects 
in HIV-infected cells.103 
 
1.6.6 Other diseases 
 
A large number of studies have been published providing experimental evidence that 
suggests other clinical indications of PARP-1 inhibitors. PARP-1 inhibitors provided 
beneficial effects in a variety of disease conditions including Parkinson's disease,104 
Alzheimer's disease,105 acetaminophen-induced hepatotoxicity106 and UV radiation-
induced dermal necrosis.107 PARP-1 inhibition by 5-AIQ prevents experimental asthma-
like conditions in guinea pigs108 and PJ34 protects against allergic encephalomyelitis in 
an animal model.109 Malfunction of the immune systems often follows profound stress 
and this immunocompromise is alleviated by inhibition of PARP-1 activity.110 
 
1.7 Development of PARP-1 inhibitors 
 
Intensive research over the last decade has yielded multiple classes of PARP-1 
inhibitors, the vast majority of which bind to the nicotinamide-binding domain of the 
enzyme and act as competitive, reversible inhibitors with respect to NAD+, the natural 
substrate for PARP-1. 
 
1.7.1 Classical PARP inhibitors 
 
Nicotinamide (2) and its 5-methyl derivative (3) were shown to be competitive inhibitors 
of PARP-1, at millimolar concentrations (IC50 210 µM). Being a natural compound, 
nicotinamide also acts as a substrate for NAD+ biosynthesis.111 Although reasonably 
soluble, it is a weak inhibitor of the enzyme and lacks specificity. Moreover, 
nicotinamide administered to cells is not always inhibitory but is often stimulatory to 
ADP-ribosylation. It has also been shown to act as a radical scavenger in certain 
experimental models. Benzamide (4) (IC50 22 µM), a close structural analogue of 
nicotinamide first shown by Shall111 to be an effective inhibitor, lacks the ring nitrogen 
and cannot undergo metabolism by NAD-biosynthetic enzymes analogously to 
nicotinamide. However, this compound had limited solubility in water, given the 
hydrophobic nature of its structure. In an attempt to improve the aqueous solubility of 
benzamide, Purnell and Whish112 introduced polar substituents on the 3-position of the 
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aromatic ring of benzamide. 3-Amino- (5), 3-hydroxy- (6) and 3-methoxy-benzamide (7) 
were found to maintain inhibitory activity with improved water solubility. They were 
found to be competitive inhibitors and two of them, 3-amino- and 3-methoxy 
benzamide, (Ki < 2 µM) have become the benchmark PARP inhibitors against which 
novel compounds have been compared.  
 
1.7.2 Structure-activity relationships of PARP-1 inhibitors 
 
The emergence of 3-substituted benzamides as prototype PARP-1 inhibitors has 
stimulated considerable interest in the structure-activity relationship (SAR) of this class 
of compounds and a number of very detailed investigations by research groups 
working independently have been undertaken. Sims et al113 provided new information 
concerning SARs for nicotinamide analogues. The presence of an unsubstituted 
carbamoyl group was found to be essentially a prerequisite for significant activity. 
Picolinamide (8) and isonicotinamide (9) both exhibited activity comparable to 
nicotinamide. Introduction of additional ring nitrogens was also tolerated and 
pyrazinamide (10) was only marginally less potent than nicotinamide. Upon alkylation 
of the ring nitrogen (11) or reduction of the aromatic ring (12) activity was abolished, or 
markedly lowered.  
 
Sestili and coworkers investigated the enzyme-inhibitory activity and in vitro 
potentiation of alkylating agent cytotoxiclty of a series of benzamide analogues 
modified with respect to the nature of the aromatic ring, the carboxamide function and 
aryl substituents.114,115 Replacement of amide group with a carboxylate (13), alkylamide 
(14), sulphonamide (15) and thioamide (16) resulted in dramatic loss of activity. 
Reduction of the aryl ring to furnish cyclohexanecarboxamide (17) abolished activity. 
Replacement of the benzene ring with a thiophene ring in thiophene-3-carboxamide 
(18a) reduced the activity. In contrast to earlier reports which showed that replacement 
of the benzene ring with a thiophene ring in thiophene-3-carboxamide reduced the 
inhibitory potency, an investigation by Shinkwin et al116 demonstrated that the isomeric 
thiophene-2-carboxamide (18b) displayed good PARP-1 inhibition, with potency of the 
same order of magnitude as benzamide. This confirmed that the heterocyclic thiophene 
ring can substitute for the benzene ring in simple PARP inhibitors without significant 
loss in potency. Alkylation of the amino group of 3-aminobenzamide had little effect, 
acylation of this substituent significantly enhanced potency, with 3-acetamido- and 3-
propanamidobenzamide (19) and (20) proving to be potent PARP-1 inhibitors.  
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Figure 6: SARs for nicotinamide and benzamide analogues. 
 
Banasik et al117 conducted one of the most comprehensive investigations to date, 
where they evaluated more than 170 compounds of diverse structures for their ability to 
inhibit PARP-1 and mono(ADP-ribosyl)transferases using standardised assay methods. 
These wide ranges of compounds led to the identification of new templates for the 
design of novel PARP inhibitors. All highly potent inhibitors were polyaromatic 
heterocycles. The studies showed that the compounds that had the carboxamide group 
incorporated within the ring system displayed very potent PARP-1 inhibitory activity. 
The strategy of cyclising an open benzamide structure or creating a further ring system 
on the existing cyclic amide was one of the best approaches to designing new PARP-1 
inhibitors. The compounds include the 1,8-naphthalimide derivatives (21) and (22), 5-
hydroxyisoquinolin-1-one (23), phenanthridinone (24) and the quinazolinone (25). 
Compound (23) was over 100-fold more potent than benzamide and 3-
aminobenzamide. 
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Figure 7: Potent polyaromatic heterocyclic inhibitors according to Banasik’s study.117 
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On the basis of the above structural requirements Griffin et al29 proposed a hypothesis 
for the interaction of inhibitors with the enzyme active-site. According to this 
hypothesis: 
• Benzamides occupy the nicotinamide binding site of PARP-1, with the 3-
substituent accommodated within the ribose nucleoside-binding domain. In 
contrast to the substrate NAD+, inhibitors were incapable of undergoing C-N 
bond cleavage and instead serve as competitive inhibitors.  
• The orientation and electronic properties of the carboxamide group were 
important factors in the binding of inhibitors.  
• Molecular orbital calculations of benzamide derivatives indicated that the ability 
of the carbonyl oxygen to donate pi electrons correlates positively with inhibitory 
activity. Hence the carbonyl substituent should be a good hydrogen-bond donor 
to a putative amino acid acceptor within the NAD+-binding domain.  
• Conjugation to an electron-rich aromatic ring improves the donor properties of 
the carbonyl group.  
• The fact that PARP-1 inhibition is good in compounds with an unsubstituted 
carboxamide in the benzamide series explored the possibility of important 
hydrogen-bond interactions this group can have with amino acid donor in the 
enzyme active site. 
 
The preferred conformation of the carboxamide group of NAD+ within the active site of 
the enzyme also has important implications for inhibitor design. Ab initio energy 
calculations performed on the nicotinamide ring of NAD+ indicate that when enzyme 
bound the cofactor adopts the anti-orientation (i.e. carbonyl anti to the 1,2-bond of the 
ring).  
 
Suto et al designed a series of rigid benzamide analogues, the 5-substituted 
dihydroisoquinolin-1-ones and isoquinolin-1-ones, by closing the amide nitrogen upon 
the benzene ring with an ethane bridge to constrain the orientation of the carboxamide 
group into either the anti- or syn-conformation.118 This was achieved via two strategies. 
The first was cyclising an open benzamide structure which gave two compounds, 
depending on the direction of closure: 1) 7-substituted 3,4-dihydroisoquinolin-1-ones 
and 2) 5-substituted 3,4-dihydroisoquinolin-1-ones. The second approach involved 
inserting substituents at the 2-position of 3-hydroxybenzamides, providing a series of 
2,3-disubstituted benzamides. The 5-substituted 3,4-dihydroisoquinolin-1-ones (25a-d), 
where the carboxamide is in the biologically-active anti-orientation, were 50-to 75-fold 
more potent than the 7-substituted syn-analogues (26a-d). The positioning of the 
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substituents on the benzene ring was also found to be critical for optimal activity. When 
the substituent in 5-substituted 3,4-dihydroisoquinolin-1-ones was moved to the -6, -7 
or -8 position (which corresponds to position 4, 5 and 6 of benzamides respectively), 
activity was decreased. It was believed that substituents at the 5-position (or 3-position 
of benzamides) were accommodated within the ribose-nucleoside binding domain. In 
contrast to the substrate NAD+, these compounds are incapable of undergoing C-N 
bond cleavage, thus serving as competitive inhibitors. 
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Figure 8. Schematic representation of the anti- or syn- conformation of the carboxamide group. 
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Table 2. PARP-1 inhibitory activity of conformationally restricted dihydroisoquinolinones and 
benzamide PARP-1 inhibitors.29,118 
Code R IC50 (µM) 
25a NO2  3.2 
26a NO2 13 
25b OMe 0.42 
26b OMe 120 
25c NH2 0.41 
26c NH2 8.0 
25d OH 0.10 
26d OH 9.5 
R IC50 (µM) 
5-OH  
(25d) 
0.10 
6-OH 2.0 
7-OH 9.5 
8-OH 11 
5-OMe 
(25b) 
0.42 
6-OMe 39 
7-OMe 120 
7
6
5
8
N
O
H
1R
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Interestingly, the 2,3-disubstituted benzamide analogues were almost completely 
devoid of activity except for 3-hydroxy-2-methylbenzamide which has only very weak 
activity (IC50 590 µM). Energy calculations revealed that the presence of a 2-substituent 
restricts the rotation of the amides, causing them to exist predominantly in the less 
hindered, inactive syn-conformation.  
 
Structures of representative classes of PARP-1 inhibitors derived from the classical 
PARP scaffolds (benzamide or cyclic lactams) have the benzamide pharmacophore in 
all core structures (Figure 8). This constrained arylamide motif was identified as a 
consensus pharmacophore. In this amide the N-H is held cis to the amide carbonyl 
either by incorporation into a covalent five-membered ring (isoindolones), in covalent 
six-membered rings (isoquinolin-1-ones, 3,4-dihydro-isoquinolin-1-ones, quinazolin-4-
ones, phthalazin-1-ones, thienoisoquinolinones, phenanthridinones, and 
naphthalimides) and covalent seven-membered rings (tricyclic inhibitors of the 
Newcastle group). Intramolecular hydrogen bonds have also been used by this group 
to maintain the required planar benzamide conformation in their potent benzoxazole-4-
carboxamides and benzimidazole-4-carboxamides.119 General understanding of the 
SARs of these benzamide pharmacophore-based PARP inhibitors has led to the 
synthesis of highly potent novel inhibitors.  
 
From the above referenced studies, it became apparent that the following features are 
essential for the competitive inhibition of PARP-1. (Figure 9) 
1. An unsubstituted aromatic or polyaromatic ring system  
2. A carboxamide group restricted into the anti-conformation  
3. At least one proton on the amide nitrogen.  
4. A non-cleavable bond in the 3-position relative to the carboxamide group.  
 
 
 
 
 
 
 
 
 
Figure 9. The consensus pharmacophore for PARP-1 inhibition.  
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Figure 10. Structures of examples of potent inhibitors of PARP activity.  
 
1.7.3 PARP-1 enzyme inhibitor interaction studies 
 
X-ray crystallographic structures of the catalytic fragment of chicken PARP-1 and those 
crystallised with competitive inhibitors, such as PD128763 (25e), NU1025 (41d), 3-
methoxybenzamide (7) and 4-amino-1,8-naphthalimide (22) have helped to confirm the 
above SAR scheme.14,120 Costantino et al have discussed the modelling of PARP-1 
inhibitors bound to the enzyme and the consequent SARs.121 It was found that, in all 
the above PARP-1-inhibitor crystal structures, the position of binding is similar i.e. in 
the nicotinamide sub-site of the NAD+-binding domain of PARP-1. Analysis of the co-
crystal structure for PD128763 (Figure 11) showed that the carboxamide group 
invariably forms three important hydrogen bonds. The carbonyl oxygen of the inhibitor 
accepts two hydrogen bonds, one from the side-chain OH of Ser904, the other from 
Gly863 polypeptide amide NH. The third hydrogen bond is formed between the 
carboxamide NH and Gly863 carbonyl oxygen. The carboxamide must be in an anti 
conformation in order for these interactions to occur with the active site. This supports 
the fact that compounds, in which the amide is constrained in this conformation, are 
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significantly more potent than those with a free amide group. The presence of a planar 
electron-rich aromatic ring is needed to enhance the ability of the carbonyl group to 
participate in hydrogen bonding within the active site. The aromatic ring presumably 
interacts through pi-pi interactions with Tyr907 and, to some degree, Tyr896, which lines 
the other face of the pocket and provides further binding energy forming a “pi-electron 
sandwich”. This contributes to the increased potency for the larger, planar fused ring 
molecule. 
                                 
Figure 11. Enzyme-inhibitor (conserved) interactions between PARP-1 catalytic fragment and 
PD128763 (25e)14 
 
‘Non-conserved interactions’ are strictly dependent on the structural diversity of docked 
inhibitors. For instance, the carboxylate group of Glu-988 is at a distance of only 4 Å to 
the C9 atom of PD128763 (25e) that is structurally equivalent to the anomeric C1N 
atom of the nicotinamide ribose of NAD+14. At this location, Glu-988 could either 
function as a general base activating the acceptor protein for nucleophilic attack at the 
C-1 of the nicotinamide ribose or by stabilising the intermediate oxocarbenium ion 
formed from the cleavage of the ribose-nicotinamide bond of NAD+. DPQ (25f) forms a 
salt-bridge interaction with Asp766, the amino group of 4-amino-1,8-naphthalimide (22) 
forms additional hydrogen bonds with Glu988, and the nitro group of 8-methyl-2-(4-
nitrophenyl)quinazolin-4-one (42i) forms hydrogen bonds with the side chain of 
Asn767.121 
 
In some cases, inhibitors induce structural changes to the active site of human PARP-
1. Fujisawa published the crystal structure of the catalytic domain of human 
recombinant PARP-1 complexed with the inhibitor FR257517 (43e).122 The 
quinazolinone part of the compound binds tightly to the nicotinamide–ribose binding 
site. The hydrophobic 4-fluorophenyl ring of the inhibitor induces a significant 
conformational change in the active site of PARP-1 by displacing the side chain of 
Arg878, which forms the bottom of the active site. X-ray crystallography and molecular 
modelling results for the quinazolinedione-based PARP-1 inhibitor (44)123 also showed 
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that the nitrogen atom of the tetrahydropyridine ring directly binds to the COOH of 
Asp766 and, similar to FR257517, the tetrahydropyridine moiety of this compound 
induces a conformational change. The terminal phenyl ring lies in a deep pocket and 
interacts via van der Waals interactions with the protein.  
 
Modelling studies of 5-AIQ docked into the nicotinamide-binding site of PARP-1 
(chicken) also showed putative water-mediated hydrogen-bond interactions between 
Glu988 of the active site and the amino group similar to 4-amino-1,8-naphthalimide 
(22) (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Molecular modelling study of 5-AIQ docked into PARP-1 binding site. A: View 
showing hydrogen bonds from secondary amide to Gly863 and Ser904. B: View showing the pi-
electron sandwich with 5-AIQ between Tyr896 and Tyr907. C: View showing proximity of 5-NH2 
group of 5-AIQ to the Glu988 carboxylate.  
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B
 38 
N
O
H
R
(25)
1.7.4 New PARP-1 inhibitors 
 
During the past decade, structure-based drug design and an increased understanding 
of the molecular details of the active site of PARP-1 have facilitated the discovery of 
highly potent new PARP inhibitors. 
 
1.7.4.1 Dihydroisoquinolinones and isoquinolinones 
 
On the basis of Suto’s studies, numerous structural modifications have been made to 
the parent dihydroisoquinolinone and isoquinolinone, giving rise to a great number of 
highly potent and selective PARP-1 inhibitors. 5-hydroxy-3,4-dihydroisoquinolin-1-one 
(25d) was shown to be a potent neuroprotective agent against NMDA-NO mediated 
neurotoxicity in brain cortical cultures.124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. PARP-1 inhibitory activity of various 5-substituted dihydroisoquinolinones and 
isoquinolinones.118 
 
PD128763 (3,4-dihydro-5-methyl-1(2H)-isoquinolinone, (25e) as a chemopotentiating 
agent, sensitises cells to ionising radiation and reduces DNA repair.125 PD128763 was 
found to be 60-fold more potent a PARP-1 inhibitor than 3-AB. DPQ (25f) (3,4-dihydro-
5-(4-(1-piperidinyl)butoxyl)-1(2H)-isoquinolinone) patented by Guilford 
Pharmaceuticals, has been shown to exert neuroprotective effects in cultured cells in 
vitro and stroke models in vivo. It was believed that the structurally flexible 
butoxypiperidine side chain at the 5-position of DPQ favours its insertion into the 
Code R IC50 (µM) 
25(d) OH 0.10 
25(e) 
(PD128763) 
Me 0.14 
25(f) 
(DPQ) 
N
O
 
0.04 
Code R IC50 (µM) 
29(a)  H 6.2 
29(b) NO2 3.2 
29(c) OMe 0.58 
29(d) 
 (5-AIQ) 
NH2 0.24 
29(e)  
ISQ 
OH 0.14 
N
O
H
R
(29)
 39 
hydrophobic pocket within the active site, thereby increasing its potency tremendously. 
The effectiveness of 5-substituted isoquinolinones was comparable to that of the 
corresponding 3,4-dihydro series. 5-Hydroxyisoquinolin-1-one (ISQ, 29e) was found to 
exert PARP inhibitory and cardioprotective effects in ischemic reperfused heart 
preparations in vitro.70 5-AIQ (29d) was found to exhibit tremendous therapeutic 
benefits in a wide range of disease models in vivo, including animal models of 
myocardial infarction, ischaemia-reperfusion of the liver and kidney and acute lung 
inflammation.73,80,81,82,86,92,95,96 
 
1.7.4.2 Isoquinolin-1-one-related compounds 
 
The isoquinolin-1-one core is also present in various tricyclic compounds. 1,8-
Naphthalimide (21) (IC50 = 1.4µM) exerts protective effects in oxidatively stressed 
endothelial cells in vitro. The 4-amino derivative (22) (IC50 = 0.18µM) has been found to 
reduce ischaemia-reperfusion injury in the heart, liver and skeletal muscle.70 It also 
exerts radio- and chemo-sensitising effects in vitro. The benzopyrano(4,3,2-
de)isoquinolinones are a related class of tetracyclic lactams of which GPI-6150 (30) 
(1,11b-dihydro-(2H)benzopyrano(4,3,2-de)isoquinolin-3-one) has been studied 
intensively. GPI-6150 is cytoprotective in vitro and exerts significant protective effects 
in experimental models of stroke, traumatic brain injury, neurodegeneration, circulatory 
shock, diabetes mellitus and various inflammatory conditions (including colitis and 
gouty arthritis).79,126  
 
6(5H)-Phenanthridinone (24) was first identified as a potent PARP inhibitor in vitro by 
Banasik et al.118 This compound, insoluble in water and commonly dissolved in DMSO, 
enhances the cytotoxicity of nitrogen mustards and ionising radiation on lymphoma 
cells in culture. Substituents at the 2- or 3- and 8- positions of the core skeleton were 
preferred attachment points for good PARP-1 inhibition. By incorporation of suitable 
acidic or basic residues onto the ring system, water solubility and improvements of 
potency in vitro were observed. Compound (24e) was found to have 52-fold greater 
inhibition activity as compared to (24) (Table 4). The electron-withdrawing 2-nitro 
compound (24b) and electron-donating 2-amino (24c) and 2,3-diamino (24g) 
compounds showed values of IC50 at ca. 0.17 µM and about 3-fold better than (24).
127 
The phenanthridinone derivative PJ-34 (24h) is cytoprotective in vitro and suppresses 
pro-inflammatory cytokine and chemokine production in immunostimulated 
macrophages.128 In in vivo models, PJ-34 improves the functional outcome in stroke, 
myocardial infarction and reperfusion injury, circulatory shock, diabetes and its vascular 
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complications, colitis, arthritis and uveitis. PJ-34 also protects in chronic heart failure 
and improves the endothelium dependent vascular relaxant function in various disease 
models.60,76,94,109, 
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Table 4. PARP-1 inhibitory activity of isoquinolin-1-one-related compounds. 
 
Guilford reported a new series of compounds that contain aza-5(H)-phenanthridin-6-
one and partially saturated aza-5(H)phenanthridin 6-one scaffolds.129,130 Two such 
compounds (31) and (32) were evaluated in the transient and permanent stroke models 
Code X R IC50(µM) 
24 H H 0.52 
24(a) H 3-COOMe 0.18 
24(b) H 2-NO2 0.15 
24(c) H 2-NH2 0.18 
24(d) F 3-COOMe 0.04 
24(e) F 3-SO3H 0.01 
24(f) Cl 3-Cl 0.24 
24(g) H 2- NH2 & 3-NH2 0.18 
24(h) 
(PJ34) 
H 
2- HN
O
NMe2
 
0.04 
 
Code R IC50(µM) 
33(a) H 0.30 
33(b) OMe 0.30 
33(c) OH 0.10 
33(d) NH2 0.05 
34(a) Me 9.7 
34(b) Ph 9.9 
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and provided a 30–40% reduction in infarct volume. SmithKline Beecham reported 
thieno(2,3-c)isoquinolin-1-ones (33), in which the thieno ring is fused to the 
isoquinolinone scaffold, the most potent being (33d). (33a) was neuroprotective in 
models of brain ischaemia.131,132 Shinkwin et al116 reported the synthesis of 
thienopyridinones (34) inhibiting PARP-1 activity at ca.10 µM. 
 
1.7.4.3 Benzoxazoles and benzimidazoles 
 
Researchers at the University of Newcastle-upon-Tyne designed a series of 
benzoxazole-4-carboxamides119 (35) and benzimidazole-4-carboxamides133 (36) that 
elegantly favoured the active anti-conformation by means of an intramolecular 
hydrogen bond between the amide proton and the cyclic nitrogen. The benzimidazole 
analogues are a few times more potent than the corresponding benzoxazoles. These 
compounds exhibit potencies superior to those usually shown by monocyclic 
carboxamides. Compounds with substituted phenyl groups at the 2-position, such as 
(37b), (37d) and (37g) are the most potent examples in these classes of inhibitors. 
NU1085 (37d) has been adopted as a benchmark inhibitor of PARP-1 due to its 
potency and good solubility in water. It increased the potency of the cytotoxic agents 
topotecan and temozolomide by up to 3-fold.133 
 
 
 
 
 
 
 
Table 5. PARP-1 inhibitory activity of benzoxazole-4-carboxamides and benzimidazole-4-
carboxamides. 
Code R IC50 (µM) 
35(a) Me 9.5 
35(b) Ph 2.1 
Code R Ki (nM) 
36(a) H 95 
36(b) 
[NU1064] 
Me 
99 
 
36(c) Ph 15 
37(a) OMe 6.8 
37(b) CF3 1.2 
Code R Ki (nM) 
37(c) NO2 8 
37(d) 
[NU1085] 
OH 
6 
 
37(e) CN 4 
37(f) Cl 3 
37(g) CH2OH 1.6 
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1.7.4.4 Benzimidazole-related compounds 
 
A natural extension of the benzimidazole class of compounds is to replace the 
hydrogen bond that encourages the molecule to adopt the anti-conformation with a 
covalent bond. Skalitzky et al134 synthesised a series of tricyclic benzimidazoles (38) of 
which (38b), (38f) and (38g) were found to be strong potentiators of the cytotoxic 
activities of temozolomide and topotecan. AG14361 (38f) increased the delay of LoVo 
xenograft growth induced by irinotecan, irradiation or temozolomide by two- to three 
fold. A combination of AG14361 and temozolomide caused the complete regression of 
SW620 xenograft tumours.46 A potent new class of tricyclic lactam indole PARP-1 
inhibitors have been designed, represented by (39) and (40). Compounds (40a), (40c) 
and (40d) displays potent in vitro PARP-1 enzymatic inhibition and enhancement of 
cellular growth inhibition.135 
             
                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. PARP-1 inhibitory activity of benzimidazole-related compounds. 
Code R Ki (nM) 
(a) Ph 4.1 
(b) 4-Cl-Ph 5.7 
(c) 2-Cl-Ph 7.7 
(d) 1-naphthyl 4.9 
(e) 4-PhCH2OH 4.2 
(f) 
AG14361 N  
6.3 
(g) N
 
5.8 
Code R Ki (nM) 
39(a) H 38 
(b) CN 11 
(c) 1-naphthyl 5 
40(a) H 6 
(b) 4-CF3 5 
(c) 4-CH2NMe2 5 
(d) N
 
6 
3
4
NH
HN
1
2
O
R
(39)
3
4
NH
HN
1
2
O
(40)
R
N
N
O
H
N
R
(38)
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1.7.4.5 Quinazolin-4-ones 
 
During initial synthetic studies with benzoxazole-4-carboxamides, an unexpected 
rearrangement occurred to afford the 8-hydroxyquinazolin-4(3H)-one NU1025 (41d).119 
A series of 2-alkyl- and 2-aryl substituted 8-hydroxy-, 8-methyl -, and 8-methoxy 
quinazolin-4(3H)-ones were synthesized and evaluated for PARP inhibitory activity.136 
2-Phenylquinazolinones (42) were marginally less potent than the corresponding 2-
methylquinazolinones (41), but the introduction of an electron-withdrawing or electron-
donating 4-substituent on the 2-aryl ring invariably increased potency. The 8-
methylquinazolinone series (IC50 values 0.13-0.27 µM), were found to be the most 
potent PARP-1 inhibitors. NU1025 (41d) potentiated the cytotoxicity of the 
monomethylating agent 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) and of 
γ-radiation 3.5-and 1.4-fold, respectively.136 
 
Fujisawa synthesised several highly potent quinazolin-4(3H)-one derivatives (43) that 
are modified at the 2,5- and 2,8-positions.137,138 Compound (43b) FR247304 exerts its 
neuroprotective efficacy in in vitro and in vivo experimental models of cerebral 
ischaemia via potent PARP-1 inhibition.139 The 2,8-disubstituted derivative (43d) has a 
three-methylene unit and 4-(4-fluorophenyl)tetrahydropyridine substitution at the 
quinazolinone-2-position. This compound shows strong PARP-1 inhibition and in vivo 
neuroprotective activity. In a mouse model of Parkinson’s disease, this compound 
prevented the depletion of striatal dopamine and metabolites of dihydroxyphenylacetic 
acid and homovanillic acid.  
 
Quinazolinedione-based PARP inhibitor (44) linked with large substitution exhibits 
strong potency against PARP-1 with an IC50 of 60 nM.
137 Quinoxaline derivatives (45) 
were identified as potent and selective PARP-2 inhibitors in PARP enzyme assays 
using recombinant PARP-1 and PARP-2.137 Compound (45b) (FR261529) (2-(4-
chlorophenyl)-5- quinoxalinecarboxamide) was about 5-fold more potent for PARP-2 
(IC50 = 7 nM) than PARP-1 (IC50 = 33 nM) and protects against both ROS-induced cell 
injury in vitro and METH-induced dopaminergic neuronal damage in an in vivo 
Parkinson’s disease (PD) model.140 
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Table 7. PARP-1 inhibitory activity of quinazolin-4-ones and quinoxalines. 
Code X R IC50 (µM) 
42(a) OH H 1.06 
(b) OH NO2 0.23 
(c) OH OH 0.29 
(d) OH NH2 0.52 
(e) Me H 0.87 
(f) Me OH 0.22 
(g) Me NH2 0.44 
(h) Me CN 0.27 
(i) Me NO2 0.13 
(j) Me OMe 0.19 
(k) OMe H 4.2 
(l) OMe OMe 2.0 
(m) OMe NO2 0.85 
Code X R IC50 (µM) 
41(a) H H 9.50 
(b) OMe Me 0.78 
(c) Me Me 0.39 
(d) 
[NU1025] 
OH Me 0.40 
Code R 
PARP-1 
IC50(nM) 
PARP-2 
IC50(nM) 
45(a) H 131 14 
(b) 
Cl 
FR261529 
33 7 
(c) CN 101 8 
(d) CF3 118 11 
(e) OMe 71 8 
(f) NH2 87 9 
Code R X IC50 (nM) 
43(a) H H 21 
(b) 
Cl 
FR247304 
H 23 
(c) Cl CN 3 
(d) Cl F 13 
(e) 
Me 
FR257517 
F 16 
N
N
H
O
X
R
Quinazolin-4-ones (41)
N
N
H
O
X
2-Phenyl substituted quinazolin-4-ones (42)
R
H
N
O
H
N
N
R
Quinoxalines (45)
(43)
N
N
O
H
R
(CH2)3
N
X
(44)
N
N
O
H
F
(CH2)4
N
O
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1.7.4.6 Quinazolinone-related compounds 
 
Iconix claimed that (46a) showed selectivity for PARP-1 over PARP-2 with IC50 values 
of 5.5 and 41 µM, respectively. Of the thieno(3,4-d)pyrimidin-4(3)ones, (47a) and (47b) 
give 81% and 42% inhibition of PARP-1 (mouse) at a concentration of 10.8 and 8.8 µM 
respectively.116 Meiji Seika Kaisha reported the neuroprotective effects of DR2313 (48)  
in in vivo models of permanent and transient stroke in rats.141 DR2313 also showed 
excellent profiles in terms of water-solubility and CNS penetration. Pyrimidinones fused 
to a saturated heterocycle with additional keto group (49) were also reported.142 Uracil 
derivatives iodouracil (50a) and iodouridine (50b) reported by Banasik et al117 have 
weak inhibitory effects on PARP-1. 
 
N
N
H
O
S R N
N
H
O
S
R N
N
H
O
CH3
S
N
N
H
O
O
X
R
N
N
H
O
O
R
I
(46) (47) (48) (49) (50)  
 
 
 
 
 
 
 
 
Table 8. PARP-1 inhibitory activity of quinazolinone-related compounds. 
 
1.7.4.7 Phthalazinones 
 
KuDOS Pharmaceuticals, in collaboration with Maybridge, have identified a series of 4-
aryl-2H-phthalazinones as sub-micromolar PARP-1 inhibitors.143 Early SAR studies, 
suggested that structural elaboration around the meta position of the benzyl moiety 
could be potency enhancing. The enhancement of potency via the fluoro substituent 
ortho to the imide ring appeared quite general for this series as exemplified by 
compounds 51e-g. The substituted homopiperazine based amides (51i) were found to 
be most promising lead compounds.144 Further introduction of fluorine at the para 
position of the pendant benzene ring, aiming to block possible metabolism at this 
Code R IC50(µM) 
46(a) H 5.5 
47(a) Me 10.8 
47(b) Ph 8.8 
50(a) H 70 
50(b) ribofuran 43 
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position and extend half-life, resulted in a class of potent inhibitors with excellent 
cellular activity as indicated by (52e-j).  
 
Kamanaka et al reported the neuroprotective effects of the phthalazinone-based PARP 
inhibitor ONO-1924H (53). In a rat stroke model, ONO-1924H reduced the stroke 
volume and attenuated the development of neurological deficits. Structurally, ONO-
1924H is a 2H-phthalazin-1-one substituted in the 4-position with phenyl groups, and 
bearing amine-containing side chains to improve water solubility.145 Further variations 
include a series of tetracyclic benzopyrano(4,3,2-de)phthalazinones (54) and 
indeno(1,2,3-de) phthalazinones (55). Here the 4-phenyl group is held rigid by linking to 
the 5-position either via an oxygen or directly. 
 
1.7.4.8 Isoindolinones   
 
Isoindolinones are another class of PARP-1 inhibitors, which incorporate the requisite 
lactam in a 5-membered ring. The simple 5-substituted derivatives (56) have only poor 
potency (IC50 > 10 µM) but more elaborate side-chains improve activity. Guilford 
claimed the tetracyclic isoindolinones (57) for use in peripheral neuropathy caused by 
stroke trauma, spinal cord damage, ischaemia, reperfusion injury and 
neurodegeneration.142 Novartis patented a series of substituted derivatives of 
indoloquinazolinones as PARP inhibitors. The tetrazole-substituted compound (58) has 
an in vitro IC50 value of 12 nM and dose-dependently reduced infarct size by up to 60% 
in a rabbit myocardial infarction model.48 A series of novel pyrrolocarbazoles was 
synthesized as potential PARP-1 inhibitors. When an additional keto group is adjacent 
to the ring nitrogen to give the imide, the potency is enhanced. Pyrrolocarbazole (59c) 
was identified as a potent PARP-1 inhibitor.146,147 Cephalon evaluated the chemo-
potentiating capacity of CEP-6800 (59d), the novel 3-aminomethyl carbazole imide, in 
combination with three chemotherapeutic agents (temozolomide, irinotecan and 
cisplatin) against U251MG, glioblastoma, HT29 colon carcinoma, and Calu-6 non-small 
cell lung carcinoma xenografts and cell lines. This is an inhibitor of both PARP-1 and 
PARP-2, and has an inhibition constant (Ki) of 5 nM.
148 Compound (60) was reported to 
have an IC50 of 2 nM. 
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Table 9. PARP-1 inhibitory activity of phthalazinones. 
Code R X IC50 (nM) 
51(a) N
H
O
 
H 20 
(b) N
H
O
 
H 50 
(c) N
H
O
F
F
F
 
H 13 
(d) N
O
O  
H 13 
(e) N
O
O  
F 5 
(f) N
O
O  
F 3.8 
(g) N OO
 
F 4.1 
(h) NO
 
H 8 
(i) N NH
O
 
H 9 
Code R X IC50 (nM) 
52(a) Me H 23 
(b) Et H 15 
(c) nPr H 10 
(d) 
 
H 6 
(e) H F 7 
(f) Me F 9 
(g) Et F 7 
(h) nPr F 5 
(i) 
 
F 5 
(j) 
 
F 5 
Code R IC50 (nM) 
54(a) H 80 
54(b) NHCOMe 37 
55(a) H 140 
55(b) NHCOMe 69 
N
NH
O
R
X
Phthalazinones (51)
N
NH
O
X
O
N
N R
(52)
N
NH
O
N
H
O
(CH2)
N
O
(53)
N
NH
O
O
R
N
NH
O
R
(54) (55)
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Table 10. PARP-1 inhibitory activity of isoindolinones, indoloquinazolinones and 
pyrrolocarbazoles. 
 
1.7.4.9 Miscellaneous classes of compounds  
 
While much development has centered on the lactam/carboxamide pharmacophore, 
there are several groups of compounds that do not possess this functionality. Most of 
these are inhibitors of moderate potency compared to those discussed above and they 
have very different modes of action. For instance, 1,2-benzopyrone (61a) was reported 
as a non-competitive inhibitor of PARP and 6-nitrosobenzopyrone (61b) inhibits PARP 
by interacting with the DNA-binding Zn finger in the N-terminal domain of PARP.149 5-
Iodo-6-amino-1,2-benzopyrone (INH2B) (61c) inhibits PARP-1 by uniquely oxidising 
one of its two zinc fingers, resulting in zinc ion ejection and a concomitant inactivation 
of its activity. It has been shown to protect oxidatively damaged cells in vitro and exert 
beneficial effects in stroke, circulatory shock and autoimmune diabetes.149 Other 
examples include aryl carboxylic acids linked to a 4-t-butylbenzene-1,2-diol fragment 
(62) and coumalic acid derivatives (63).142 
 
The O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime (BGP-15) (64) belongs to 
the class of unsaturated hydroximic acid derivatives which are claimed to be PARP-1 
inhibitors, and protects the isolated heart from ischaemia–reperfusion injury, with an 
IC50 value of 120 µM.
61  
Code X R IC50 (nM) 
59(a) H H 56 
(b) H CN 18 
(c) O H 36 
(d) 
CEP-6800 
O CH2NH2 5 N NH
N OO
H
(60)
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Table 11. PARP-1 inhibitory activity of miscellaneous classes of compounds.  
 
Inotek has developed a series of PARP inhibitors derived from compound (65). The 
potent parenteral inhibitor, INO-1001 has an in vitro IC50 value of 1 nM and protective 
effects in stroke, myocardial infarction and chronic heart failure. This drug is now in 
clinical trials for the treatment of reperfusion injury induced by myocardial infarction, 
cardiopulmonary bypass and thoraco-abdominal aortic aneurysm surgery.48 
 
1.7.5 Bioreductive prodrugs of PARP-1 inhibitors  
 
Tissue selectivity is important for PARP-1 inhibitors to sensitise cancer cells towards 
chemotherapy and radiotherapy. Since PARP-1 inhibitors lack selectivity for cancer 
cells, the DNA repair process for rapidly dividing normal cells exposed to cytotoxic 
agents will also be impaired along with those of the tumour cells. This limits the 
effectiveness of inhibitors and gives rise to severe side effects. Use of a prodrug, 
which, in itself, is biologically inactive but could be selectively unmasked or activated by 
the tissues on which it is intended to act, could improve selectivity. Such systems make 
use of biochemical or physiological differences between the normal and tumour cells 
such as bioreductive prodrugs. It was observed that many disease states where PARP-
1 inhibition is therapeutically beneficial, such as cancer, inflammatory disorders and 
ischaemia-reperfusion injuries, are marked by acute or chronic tissue hypoxia. This 
physiological difference in the concentration of oxygen between normal and hypoxic 
tissues was exploited through the design of biologically inactive prodrug systems 
which, upon selective bioreduction in hypoxic tissue, would release PARP-1 inhibitors 
only in that tissue. Four different types of redox-sensitive triggers were designed and 
Code X R IC50(µM) 
61(a) H H - 
(b) NO H - 
(c) NH2 I 10 
62 - - 2.2 
63 - - <10 
N
N
NH2
O
OH
N
(64)
NH
O
(65)
 50 
the proposed mechanism for bioreductive release of PARP-1 inhibitors (DRUG) from 
nitroheterocyclylmethyl- and 4,7-dioxoindole-3-methyl- types are illustrated in schemes 
2 and 3, respectively.150-152  
 
Y
X NO2
DRUG
Y
X NHR
DRUG
Y
X NR
DRUG
Bioreduction
R = H or OH
a: X = O, Y = CH
b: X = MeN, Y = N
c: X = S, Y = CH  
 
Scheme 2. Demonstration of reductively triggered release of drugs from (a) 
5-nitrofuran-2-ylmethyl, (b) 1-methyl-2-nitroimidazole-5-ylmethyl and (c) 
5-nitrothien-2-ylmethoxy  prodrugs.150, 151 
O
O
MeO
N
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Me
OH
OH
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Me
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OH
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OH
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Scheme 3. Proposed mechanism of reductively triggered release of drugs from 
4,7-dioxoindole-3-methyl prodrugs.152 
 
The prodrug designed was made of a Trigger (a substrate for the endogenous or 
exogenous activating enzyme) and an Effector (the active drug to be released), joined 
by a Linker which releases the Effector in response to the Trigger.153 5-Iodo- and 
5-bromoisoquinolin-1(2H)-one were chosen as the DRUG for linkage to the Triggers.154 
Since the PARP-1 inhibitory activity of isoquinolin-1(2H)-ones depends critically on the 
carboxamide group, masking of the pharmacophore was achieved either by attaching 
the Trigger at oxygen (giving 1-alkoxyisoquinolinones) or at nitrogen (giving 
2-alkylisoquinolin-1-ones) as shown below.155 
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Figure 13. Representation of 1-alkoxyisoquinolinones and 2-alkylisoquinolin-1-ones triggers. 
 
In each case, the release of the isoquinolin-1-one Effector was initiated by chemical 
reduction of the Trigger, designed to mimic bioreduction in hypoxic tissues. Their 
release studies, resulted in a successful expulsion of 5-substituted isoquinolin-1-ones 
from 1-(5-nitrothien-2-ylmethoxy)isoquinolines and 2-(5-nitrofuran-2-ylmethyl) 
isoquinolines upon reductive triggering with a sodium borohydride / palladium / 
aqueous propan-2-ol system. Isoquinolin-1-ones were also found to be rapidly and 
quantitatively released from their 2-(1-methyl-2-nitroimidazole-5-ylmethyl)- and 
1-(4,7-dioxoindole-3-methoxy) derivatives by treatment with zinc / ammonium chloride 
and tin(II) chloride, respectively. It was also observed that reductively triggered release 
of the isoquinolin-1-ones only occurred from the O-linked prodrugs and not from N-
linked  ones.152 Another successful prodrug 4-iodo-3-nitrobenzamide was selectively 
retained and reduced to highly reactive and tumouricidal nitroso-compound, INOBA, in 
the presence of nitroreductase activity in malignant cells.156 In view of the preliminary 
success achieved in vitro with these prodrug systems, it is evident that use of tissue-
selective prodrugs would reduce their potential toxicity on normal tissues and reduce 
the dosage required for therapy. 
 
1.8 PARP Inhibitors in clinical trials 
 
Five PARP inhibitors are currently known to be in oncology clinical trials and two more 
are expected to enter clinical trials shortly; their current status is summarized in Table 
12. 
 
AG-014699 was the first PARP inhibitor to be evaluated in humans for cancer therapy. 
Preclinical data of this agent indicated that the combination of AG-014699 with 
irinotecan and with radiotherapy delayed xenograft tumor growth, and caused 
xenograft tumour regression with temozolomide. The Phase 1 study combined i.v. 
AG014699 with temozolomide in solid tumors, initially evaluating PARP activity in 
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peripheral blood lymphocytes with reduced doses of temozolomide until PARP 
inhibition was observed, and then increasing temozolomide to standard doses (200 
mg/m2) at a fixed AG-014699 dose. The recommended dose for the Phase 2 trial was 
12 mg/m2 AG-014699 with 200 mg/m2 temozolomide. In the Phase 2 trial, there was 
enhancement of temozolomide-related myelosuppression. 
 
Product Company 
Clinical 
status Indication 
INO-1001 Inotek/Genentech 
Phase 2 
Phase 1b 
Cardiovascular indications 
Malignant melanoma 
AGO14699 Pfizer Phase 2 
Advanced solid tumours in combination 
with temozolomide 
Metastatic malignant melanoma 
BS-201 BiPar Sciences Phase 1 Cancer 
BS-401 BiPar Sciences Preclinical Pancreatic cancer 
AZD2281 AstraZeneca Phase 1 Breast cancer 
KU59436 AstraZeneca/KuDOS Phase 2 
Advanced solid tumors 
BRCA1/2 mutant cancers 
In combination with DSB agents in HRD 
tumours 
MGI 
Pharma n/a Preclinical 
Radiation/chemotherapy sensitizer 
ABT-888 Abbott Laboratories Preclinical 
Refractory solid tumours 
and lymphoid malignancies 
 
Table 12. PARP-1 inhibitors in cancer therapy.157,33 
 
KU-0059436 is currently being evaluated in a Phase 1 trial in patients with advanced 
tumours. This study began with daily and twice a day dosing of the oral inhibitor for 14 
days of a 21-day cycle, and is now evaluating continuous twice a day dosing. Minimal 
toxicity has been reported. Pharmacodynamic studies showed dose-dependent 
inhibition of PARP activity in peripheral blood mononuclear cells.  
 
ABT-888 is an oral PARP inhibitor that is the first oncology agent to be studied in a 
Phase 0 clinical trial. In the Phase 0 study, participants with biopsiable tumour are 
given a single dose of ABT-888 to determine the dose range at which PARP is 
effectively inhibited in peripheral blood mononuclear cells and tumour cells. The study 
also aims to assess the pharmacokinetic characteristics of the agent and the time 
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course of PARP inhibition. Phase 1 combination studies will be with temozolomide, 
irinotecan, cyclophosphamide, and carboplatin. 
 
BiPAR Science’s lead compound BSI-201 is being tested as i.v. monotherapy in solid 
tumours, with the objective to determine a maximum tolerated dose and a 
pharmacokinetic profile. BiPAR also currently has another PARP inhibitor, BSI-401, in 
clinical oncology trials. 
 
Inotek’s INO-1001, an indenoisoquinolinone-based PARP inhibitor, is currently in 
Phase 2 trials for cardiovascular indications. It is also being studied in combination 
therapy in metastatic melanoma and glioma and as a single agent in cancer for 
BRCA1- and BRCA2-deficient tumours. A preliminary analysis of a Phase 1 trial 
evaluated INO-1001 in combination with temozolomide in unresectable stage III/IV 
melanoma. The investigators found that non-haematologic toxicities were mild and 
mostly related to temozolomide. 
 
MGI Pharma is developing GPI-21016, an orally available inhibitor of PARP-1 with a Ki 
of 50 nmol/L. Interestingly, GP-21016 ameliorated cisplatin induced neuropathy at the 
same time that antitumour efficacy was enhanced.  
 
AstraZeneca’s AZD2281 was studied in a range of tumour types in Phase I studies. 
Results showed that treatment with AZD2281 led to inhibition of PARP functional 
activity in both surrogate and tumour tissue and they have reported that strong signals 
were detected in hereditary ovarian cancer.  
 
1.9 Water-soluble PARP-1 inhibitors 
 
Most of the PARP-1 inhibitors reported to date are structurally based on the benzamide 
planar ring system, and are poorly water soluble. As a result, many potent inhibitors 
such as 5-hydroxydihydroisoquinolin-1-one (25d), DPQ (25f), PND (24), GPI-6150 (30) 
and INH2B (61c) suffer from poor water-solubility and this gives rise to poor 
pharmaceutical properties. Good water-solubility is a highly desirable property since it 
causes faster dissolution of the drug and thus, better bioavailability. DMSO is often 
used in place of water as a biocompatible vehicle for in vivo administration. However, it 
is a potent scavenger of hydroxyl radicals, and thus is able to reduce the organ injury 
and dysfunction in situations where the production of hydroxyl radicals is observed, 
such as haemorrhagic and endotoxic shock.158 In addition, it also inhibits PARP-1 
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activity weakly.159 This causes a great amount of ambiguity in the determination of the 
actual PARP-1 inhibitory activity.  
 
Our laboratory optimised a synthetic route for the known PARP-1 inhibitor 5-AIQ (29d) 
and then converted it to its highly water-soluble hydrochloride salt, 5-AIQHCl. 
(IC50 0.24 µM).
86 Investigation of pharmacological effects of 5-AIQ in a wide range of 
diseases, including animal models of myocardial infarction,73 ischaemia-reperfusion of 
the liver80,81 and kidney,82 heart transplantation84 and acute lung inflammation95 showed 
tremendous therapeutic potential. It also demonstrated protective effects on ischaemia-
reperfusion injury caused by severe haemorrhage and resuscitation in anaesthetized 
rats by abolishing multiple organ injury and dysfunction.86 Compared to the benchmark 
inhibitor 3-AB (5) (10 mg Kg-1 i.v.) only a remarkably low i.v. dose of 30 µg Kg-1 is 
required to confer similar protection. It is evident that 5-AIQ.HCl gains much of its 
advantage over other PARP-1 inhibitors through its excellent water-solubility, which 
conferred favourable pharmacokinetics, such as good absorption and biodistribution.  
 
Following the success of 5-AIQ our laboratory decided to build upon this lead and 
synthesised a series of 3-substituted 5-aminoisoquinolin-1-ones. In general, besides 
having a very good water-solubility profile, most of the 3-substituted isoquinolin-1(2H)-
ones exhibited excellent PARP-1 inhibitory potency with IC50 values in the low 
micromolar range (Table 13). It appeared that alkyl substituents confer slightly greater 
enhancement in PARP-1 inhibitory activities than an aryl moiety. This is especially 
evident with compounds 5-amino-3-methylisoquinolin-1-one (66a) and 
5-amino-3-pentylisoquinolin-1-one (66c) which are about 5- and 3-fold, respectively, 
more potent than the 3-phenyl substituted compound (67a) making them among the 
most potent members in this series. The presence of a para-substituent in the phenyl 
ring seemed to increase the activity, with inductive electron-withdrawing functionalities, 
such as trifluoromethyl (67d) and chloro (67e), appearing to confer slightly greater 
improvement in activity. It is also interesting to note that the introduction of a thiophene 
ring (66e) and a benzyl group (66f) at the 3-position resulted in a drastic loss of 
potency. 5-AIQ substituted, at the N5-position with an amidine group resulted in a 2.5-
fold reduction in activity (68) (IC50 4.04 µM). 
 55 
N
O
H
NH2
R
N
O
H
NH2 R
(66) (67)
N
O
NH+Cl-
NMe2
H
H
(68)
 
                 
 
 
 
 
 
 
 
 
 
 
Table 13. PARP-1 inhibitory activity of 3-substituted 5-aminoisoquinolin-1-ones. 
 
The strategy of building upon 5-AIQ could potentially be extended to the synthesis of 
another class of potential PARP-1 inhibitors, the 4-substituted isoquinolin-1(2H)-ones, 
and 3- and 4-substituted 5-aminoisoquinolin-1(2H)-ones. 
Code R IC50 (µM) 
5-AIQ 
29(d) 
H 1.60 
66(a) Me 0.23 
66(b) Et 0.49 
66(c) Pentyl 0.32 
66(d) isobutyl 1.17 
66(e) 
S  
5.61 
66(f) 
 
5.14 
Code R IC50 (µM) 
67(a) H 1.07 
67(b) OMe 0.90 
67(c) Me 0.88 
67(d) CF3 0.33 
67(e) Cl 0.57 
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2. Aims and Objectives 
 
2.1 Aim 
 
The aim of this research is to design, synthesise and evaluate potent and water-soluble 
DNA-repair (PARP-1) inhibitors using currently established SAR. 
 
2.2 Research proposal 
 
Following the success of 5-AIQ.HCl (29d) with highly encouraging activity in vivo, 
enzyme selectivity and very good water solubility, our laboratory decided to build upon 
this lead. Previous studies on the 5-substituted 3,4-dihydroisoquinolin-1-one and 5-
substituted isoquinolin-1-one classes of PARP-1 inhibitors centred around 
modifications at the 5, 6, 7 or 8-positions.118,154 Following the successful synthesis and 
demonstration of inhibitory activity of a series of 3-substituted 
5-aminoisoquinolin-1(2H)-ones,160 attention was directed to the synthesis of the 
4-substituted 5-aminoisoquinolin-1(2H)-ones. These were also of considerable interest 
as potential PARP-1 inhibitors, since an examination of the PARP-1 active site 
indicated that there is a relatively large binding pocket in the region corresponding to 
the 4-position of the isoquinolin-1(2H)-one ring which could potentially be exploited to 
enhance PARP-1 inhibitory potency. 
 
X-Ray crystallographic data on the PARP-1 structure with quinazolinones136 and 
phthalazinones121 bound seemed to suggest that benzyl groups were well tolerated in 
that region and that they generally improve inhibitory activity by binding to hydrophobic 
pockets.118 Identification of a novel series of meta-substituted 4-benzyl-2H-phthalazin-
1-ones as PARP-1 inhibitors with IC50 in the low nanomolar range also supported 4-
substitution.143,144 We therefore hypothesised that substitution in the four position of 5-
AIQ with lipophilic substituents may further improve its potency through an increased 
interaction with the active site. There is evidence to suggest putative water-mediated 
hydrogen-bond interactions between Glu988 of the active site and the amino group of 
4-amino-1,8-naphthalimide (22).121 This amino group corresponds, approximately, to 
the 5-position of 5-AIQ. The 5-amino group enables 5-AIQ to be easily converted into 
the water-soluble hydrochloride salt, consequently giving it excellent in vivo potency, 
and this will be retained in the design. This has, therefore, led to the investigation of a 
series of 4-substituted isoquinolin-1(2H)-one hydrochlorides. 
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The specific objectives are: 
1. To introduce small alkyl substituents, such as methyl and ethyl to the 4-position 
of 5-AIQ. 
2. To introduce bulkier groups like benzyl, 4-methylbenzyl 4-methoxybenzyl and 3-
succinimidobenzyl- to the 4-position of 5-AIQ. 
3. To study the modes of cyclisation of methyl 2-(substituted)alkynyl-3-
nitrobenzoates with different electrophiles (ICl, PhSeCl, HgSO4) to form 3-
substituted-5-nitroisocoumarins. 
4. To test these novel target compounds for their water solubility and in vitro 
PARP-1 inhibitory potency. 
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3.1 3-Substituted 5-aminoisoquinolin-1(2H)-ones  
 
3.1.1 Retrosynthetic analysis 
 
The first targets for chemical synthesis were 3-substituted 5-aminoisoquinolin-1-ones, 
which should be accessible through the corresponding 3-substituted-5-
nitroisocoumarins. A retrosynthetic analysis for the 3-substituted target is illustrated in 
Scheme 4. The retrosynthetic approach involved two functional group interconversions 
(FGI) on the target molecule. Both the conversions, i.e. reduction of the nitro group to 
amine (e.g. via catalytic hydrogenation or acid/metal reduction) and the conversion of 
isocoumarin to isoquinolin-1(2H)-one (e.g. via boiling with ammonia-saturated 
2-methoxyethanol), are reasonable and well-established reactions. 
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Scheme 4. Retrosynthetic analysis of the 3- substituted 5-aminoisoquinolin-1-ones. 
 
Disconnection at the C-O bond of the isocoumarin leads to 2-alkynylbenzoates (69) as 
starting materials. Synthesis of aryl alkynes is most reliably and conveniently achieved 
using organometallic approaches. A number of aryl-alkyne coupling methods have 
been developed over the past few decades. The Castro-Stephens reaction involves 
direct introduction of sp2 carbon to alkynes by the reaction of Cu acetylides with aryl 
and alkenyl halides to form arylalkynes and alkenylalkynes.161 Heck and Cassar 
reported direct coupling of terminal alkynes catalysed by a phosphine-Pd(0) complex in 
the presence of amines.162,163 Sonogashira coupling uses copper iodide as co-catalyst 
i.e. Pd(0)-CuI-catalysed reaction.164,165 Coupling reactions with metallated alkynes such 
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as zinc and tin acetylides, under palladium catalysis are known as Negishi and Stille 
reactions, respectively. Among this wide array of coupling reactions, the Sonogashira 
coupling reaction was chosen for the synthesis of the aryl alkyne, since it has been 
used in the synthesis of a wide range of heterocyclic compounds and is generally 
considered to be superior to other currently known protocols. It is also highly versatile, 
has great tolerance for nearly all types of functional groups and mild conditions are 
usually employed.166 The Sonogashira reaction cross-couples an aryl or vinyl halide 
(electrophile) with a terminal alkyne (nucleophile) under palladium catalysis. This 
catalytic process requires the use of a palladium(0) complex, and is performed in the 
presence of an aliphatic amine (base) and copper(I) iodide as a co-catalyst. (Scheme 
5) 
 
      
X
X = I, Br, Cl
OR X
Pd(0), CuI
alkylamine
R
R
OR
R
    
 
Scheme 5. Reaction conditions for the Sonogashira coupling reaction. 
 
The general order of reactivity of the organic halide is in line with the reactivity of the 
leaving group. Hence an iodoarene generally affords shorter reaction times and higher 
yield compared to its bromo or chloro counterparts.166 Based on these observations, a 
C-C disconnection of (69) (Scheme 4) led back to two starting materials: methyl 
2-iodo-3-nitrobenzoate (71) and the substituted ethyne (70). Sonogashira coupling 
suffers from two serious competitive side-reactions, namely homocoupling and 
decomposition of alkynes.166 The most direct route to the synthesis of arylalkyne (69) is 
to cross-couple the iodo-ester (71) with ethyne gas. However, the product (72), would 
be more acidic than ethyne itself, thus competing for coupling reaction with halide (71) 
and ultimately leading to the formation of 1,2-disubstituted alkyne (73) (Scheme 6). To 
overcome this difficulty, an indirect route involving protection and deprotection of the 
ethynyl group is, therefore, necessary. The trimethylsilyl (TMS) group is commonly 
used for this purpose. CuI and Pd(0) also catalyse oxidative homocoupling of terminal 
alkynes in an O2 atmosphere (Glaser reaction). Hence, carrying out the reaction in an 
atmosphere of N2 or argon is necessary. 
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Scheme 6. Potential Formation of 1,2-disubstituted alkyne from Sonogashira homocoupling 
reaction. 
 
3.1.2 Synthesis of methyl 2-iodo-3-nitrobenzoate 
 
The iodo-ester methyl 2-iodo-3-nitrobenzoate (71), starting material for the preparation 
of the target compounds, is not commercially available and the synthesis as shown in 
Scheme 7 is now well established. Culhane et al167 first described the synthesis of 
2-iodo-3-nitrobenzoic acid (76) by the decarboxylative iodination of 3-nitrophthalic acid. 
The starting material 3-nitrophthalic acid (74) has both the required carboxylic acid 
(1-position) and nitro functions (3-position) positioned meta to each other. The first 
stage in the synthesis was to decarboxylate 3-nitrophthalic acid with mercury(II) 
acetate, followed by electrophilic iodination with a mixture of iodine and potassium 
iodide. Interestingly, only the desired 2-iodo-acid (76) was formed without any of the 
possible by-products arising from iodination at the 1-position suggesting that 
mercuration has occurred regiospecifically at the 2-position. Presumably the reaction 
proceeded through a free radical mechanism via an aryl-mercury intermediate, 
2-hydroxymercuri-3-nitrobenzoic acid (75). The second stage involved 
H2SO4-catalysed esterification of the iodo-acid and this reaction proceeded smoothly 
affording the methyl ester (71) in excellent yield (95%). This compound serves as an 
important precursor for the Sonogashira coupling reaction. 
 
Scheme 7. Synthesis of methyl 2-iodo-3-nitrobenzoate. 
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3.1.3 Sonogashira coupling reaction 
 
Sonogashira coupling was performed between methyl 2-iodo-3-nitrobenzoate (71) and 
trimethylsilylacetylene (TMSA) (77), in the presence of a catalytic amount of 
bis(triphenylphosphine)palladium(II) chloride [(Ph3P)2PdCl2] (78) and copper(I) iodide in 
diisopropylamine (DIPA) and dry THF. The mixture was stirred at 45  oC for 72 h under 
argon. The catalyst, used in this reaction, (Ph3P)2PdCl2, was prepared separately by 
heating a mixture of palladium(II) chloride and two equivalents of triphenylphosphine in 
DMF at 80 oC for 24 h (Scheme 10). Although the coordinatively unsaturated Pd(0) is 
the catalytically active species, it is often more convenient to use Pd(II) derivatives, 
such as palladium(II) acetate [Pd(OAc)2] and bis(acetonitrile)palladium(II) chloride 
[(MeCN)2PdCl2]. Palladium(II) complexes are generally more stable than their 
palladium(0) counterparts. They are also generally more soluble in organic solvents. 
The copper(I) salt functions as an important co-catalyst that facilitates the substitution 
reaction. Coupling catalysed by Pd(0) and CuI proceeds via in situ generation of Cu 
acetylides. The aliphatic amine diisopropylamine serves as a reducing agent to 
generate Pd(0) from the Pd(II) precatalyst and is sometimes used as a solvent.166 
 
The reaction mechanism as proposed by Sonogashira166 suggests that the substitution 
reaction occurs via a catalytic cycle which consists of three main steps (Scheme 8): 
1. Oxidative addition 
2. Transmetallation  
3. Elimination 
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Scheme 8. Proposed mechanism for Sonogashira coupling between methyl 2-iodo-3-
nitrobenzoate (71) and trimethylsilylacetylene. 
 
Under the reaction conditions, (Ph3P)2PdCl2 was rapidly reduced in situ to give the 
catalytic species (Ph3P)2Pd(0). Oxidative addition of this Pd(0) complex with the methyl 
2-iodo-3-nitrobenzoate (71) gives a Pd(II) intermediate (78). It is speculated that an 
alkynylcopper species (79), is generated as a result of a pi-alkyne-copper complex 
formed in situ from a reaction between TMSA and the copper(I) iodide, thus making the 
alkyne proton more acidic for easier abstraction (Scheme 9). Finally coupling of the two 
organic ligands and reductive elimination gave the desired methyl 
3-nitro-2-(2-trimethylsilylethynyl) benzoate (80) in 28% yield. The reaction also gave 
methyl 3-nitrobenzoate (81) as a dehalogenated side product (14% yield). This was 
formed from decomposition of the intermediate arylpalladium, which had failed to 
couple with the alkyne, i.e. replacement of iodine with hydrogen during the coupling 
process.  
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Scheme 9. Formation of alkynyl copper species. 
 
The long reaction time (72 h), modest yield of the desired alkyne (80) (28%) and side 
product (81) (14%) could be associated with the use of sterically hindered halides (71) 
where both ortho positions were substituted with bulky groups. 
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Scheme 10. Sonogashira coupling of methyl 2-iodo-3-nitrobenzoate with TMSA and 
subsequent desilylation of methyl 3-nitro-2-(2-trimethylsilylethynyl)benzoate. 
 
Attempted desilylation of methyl 3-nitro-2-(2-trimethylsilylethynyl)benzoate (80) under a 
variety of basic conditions (e.g., potassium carbonate/methanol) caused extensive 
decomposition.160 The classical tetrabutylammonium fluoride (TBAF) ion-mediated 
desilylation gave only a maximum yield of 9% of desilylated product.160 Removal of 
trimethylsilyl protection from alkynes with silver(I) nitrate is widely reported to be 
efficient if cyanide ion is added to break up the initially formed alkynylsilver(I).168,169 
Orsini et al170 have recently developed a selective desilylation of 1-trimethylsilyl-2-
alkylalkynes with silver(I) triflate in a biphasic solvent system at room temperature. 
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Adapting this method to desilylate (80), prolonged heating with silver(I) triflate in a 
mixture of methanol, water and dichloromethane gave good yields (>70%) of the 
required alkyne (82). We attribute the need for the higher temperature and much longer 
reaction times to the highly electron-deficient nature of the starting trimethylsilylalkyne. 
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Scheme 11. Desilylation of methyl 3-nitro-2-(2-trimethylsilylethynyl)benzoate with silver(I) 
triflate. 
 
The first step in the mechanism is the formation of a pi-complex between the silver 
triflate and (80).171 This coordination activates the TMS group towards nucleophilic 
attack by either the counterion (-OTf) or a nucleophilic solvent which leads to cleavage 
of the C–Si bond and in situ formation of silver acetylide and a silyl-triflate species. In 
protic solvents, the latter is hydrolysed leading to a better proton source (HOTf), strong 
enough to hydrolyse the alkynyl silver species (83). Silver ion released completes the 
catalytic cycle (Scheme 11).  
 
Having successfully coupled TMSA to the iodo-ester, the corresponding reaction with 
phenylacetylene was investigated. The Sonogashira coupling reaction between (71) 
and phenylacetylene (84) (the least expensive and exceptionally reactive alkyne) under 
the same reaction conditions as with TMSA gave the coupling product, methyl 
3-nitro-2-(2-phenylethynyl)benzoate (85), in very good yield (51%) and the reaction 
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was completed in a much shorter period of time (48 h). As in the previous reaction, the 
dehalogenated side product (81) was also isolated (38%) (Scheme 12). The reaction 
also gave 1,4-diphenylbutadiyne (86) as a by-product, the product of Glaser-like 
homodimerisation of the starting alkyne. 
NO2
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Scheme 12. Sonogashira coupling of methyl 2-iodo-3-nitrobenzoate with phenylacetylene.  
 
3.1.4 Study of the modes of cyclisation of methyl 2-alkynyl-3-nitrobenzoates 
 
Several groups have reported the cyclisation of 2-alkynylbenzoic acids and 2-
alkynylbenzoate esters under electrophilic conditions, although no examples have a 
substituent at the 3-position of the benzoate. There is debate about whether the 
reaction goes 5-exo-dig (giving ylidenephthalides 88) or 6-endo-dig (giving 
isocoumarins 89), as shown in Scheme 13 (R3 = H); both are favoured under Baldwin’s 
Guidelines.172  
O
R1
R2R3
O
O
R2R
3
O
O
R3
R2
5-exo-dig 6-endo-dig
(87)
(89)(88)  
Scheme 13. Possible alternative cyclisation modes of 2-alkynylbenzoic acids (87) (R1 = OH) 
and 2-alkynylbenzoate esters (R1 = OMe) via 5-exo-dig (giving 88) and 6-endo-dig (giving 89) 
routes. R2 = alkyl, aryl. R3 = H. 
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Treatment of methyl 2-arylethynylbenzoates with Hg(II) under acidic conditions is 
reported to give intermediate mercurials, from which 3-arylisocoumarins can be 
isolated by reduction with NaBH4.
173,174 Similarly, reaction of the same starting 
materials with hydrogen iodide, electrophilic iodine reagents, bromine, sulfenyl 
chlorides and selenyl chlorides gave 3-arylisocoumarins and their 4-iodo, 4-bromo, 4-
arylthio and 4-arylselenyl derivatives, respectively.175-178 Dihydrofuroisocoumarins have 
also been synthesised by Ag(I)-promoted 6-endo-dig cyclisation of the corresponding 
arylalkynylbenzoate esters.179 In contrast, methyl 2-ethynylbenzoate undergoes 5-exo-
dig cyclisation with iodine178 and Ag(I)-mediated cyclisation of 2-alkynylbenzoic acids 
affords the corresponding ylidinephthalides.180 Under basic conditions (LiOH), methyl 2-
(pent-1-ynyl)benzoate undergoes exclusive 6-endo-dig cyclisation whereas methyl 2-
(3-hydroxypent-1-ynyl)benzoate gives a mixture of products from both cyclisation 
modes.181 Cherry et al.182 have shown very recently that treatment of 2-iodobenzoic 
acid with allenylstannanes under Pd-catalysed Stille conditions also gives 
isocoumarins, through 6-endo-dig cyclisation of the intermediate 2-(3-substituted-
allenyl)benzoic acids.  
 
3.1.5 Castro-Stephens coupling reaction 
 
Stephens and Castro,161 during the synthesis of arylalkynes from iodoarenes and CuI-
acetylides, claimed that treatment of 2-iodobenzoic acid (90) with Cu-C≡C-Ph gave 3-
phenylisocoumarin (91) by Cu-catalysed 6-endo-dig cyclisation of the intermediate 2-
phenylethynylbenzoic acid (Scheme 14). However this claim was later withdrawn184 
with the correction of the characterisation of the product to be the benzylidenephthalide 
(92) resulting from 5-exo-dig cyclisation. 
 
Woon et al160 carried out the reaction of 2-iodo-3-nitrobenzoic acid (76) with copper(I) 
phenylacetylide in boiling pyridine under nitrogen and characterised the only cyclisation 
product to be 5-nitro-3-phenylisocoumarin (93) (Scheme 15). It was firmly established 
that Cu-catalysed cyclisation of the 2-(arylalkynyl)-3-nitrobenzoic acids (76) followed 6-
endo-dig mode of cyclisation as (93) was the only product formed. It may be significant 
that the presence of a highly electron-withdrawing nitro group in the 
2-iodo-3-nitrobenzoic acid (76) might favour the formation of isocoumarin (93) rather 
than phthalide (94). 
 67 
                  
O
O
Ph
I
OH
O
O
O
H
Ph
pyridine
Cu Ph
6-endo-dig
5-exo-dig
(90)
(91)
(92)                                                                                                                                 
Scheme 14: Reaction of 2-iodobenzoic acid with copper(I)phenylacetylide to yield 3-
benzylidene phthalide instead of the isomeric 3-phenylisocoumarin.161,183 
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Scheme 15: Reaction of 2-iodo-3-nitrobenzoic acid with copper(I) phenylacetylide to yield 5-
nitro-3-phenylisocoumarin instead of 3-benzylidene-4-nitrophthalide.160 
 
3.1.6 Investigations into electrophile driven cyclisations of methyl 2-alkynyl–3-
nitrobenzoates 
 
Given the dichotomy of reports of the outcome of the 
cyclisations, in the Castro-Stephens tandem version, 
we initiated a short study on whether the mode of 
cyclisation would be influenced by the presence of the 
nitro group ortho to the alkyne. This strongly electron-
withdrawing group should influence the electron 
distribution in the alkyne and was predicted to favour 
6-endo-dig cyclisation by making the alkyne carbon 
further from the nitroarene more electrophilic (Figure 
R'
O
R"N
O O
Figure 14: Proposed influence
of the or tho nitro group on the
electron-distribution in the
alkyne in 2-alkynyl-3-nitro
benzoic acids and 2-alkynyl-3-
nitrobenzoate esters. R' = H or
alkyl, R'' = H, silyl, alkyl, aryl.
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14). Each of the three methyl 2-alkynyl-3-nitrobenzoates (85), (80) and (82) (carrying 
the diverse substituents Ph, SiMe3 and H, respectively) was treated with three different 
electrophiles (HgSO4/H2SO4, ICl and PhSeCl), to investigate whether or not cyclisation 
would occur and whether such cyclisation would be 5-exo or 6-endo (Scheme 18).  
 
3.1.6.1 Hg(II)-mediated cyclisations  
 
It was reported earlier that treatment of (85) with mercury(II) sulfate under acidic 
conditions afforded an almost quantitative yield of a single product, the isocoumarin 
(93), which was identical to the material prepared by the Castro–Stephens one-pot 
method.160 (Scheme 16) 
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Scheme 16: Mercury-mediated ring-closure of methyl 3-nitro-2-(2-phenylethynyl)benzoate. 
 
Similar treatment of the analogous trimethylsilylalkyne (80), however, gave only methyl 
2-acetyl-3-nitrobenzoate (95), in modest yield after chromatography. The same ketone 
was also isolated from the reaction of (82) with mercury(II) sulfate and acid; the NMR 
spectrum also indicated the presence of a trace of the isomeric pseudoester (96).184  
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Scheme 17: Proposed routes for the formation of (95) and (96) through 5-exo attack of the 
neighbouring ester carbonyl oxygen. 
 
The mechanism of the reaction involves the formation of 2-acetyl-3-nitrobenzoate (95) 
from both (80) and (82). This is achieved by attack of an oxygen nucleophile on the 
alkyne carbon nearest to the benzene ring, in contrast to the formation of 
5-nitro-3-phenylisocoumarin (93) from (85), which must arise from 6-endo attack of the 
ester carbonyl oxygen on the carbon remote from the substituted ring. The alkyne here 
is polarised in the opposite sense. Scheme 17 shows a mechanism for this change in 
reactivity. By analogy with the mechanism of the silver(I)-mediated desilylations,170,171 
we propose that transmetallation of (80) occurs to form an alkynylmercury species, 
such as (97). This intermediate could also be formed by direct metallation of (82). In 
intermediate (97) the polarisation of the alkyne is caused by coordination to mercury. It 
is likely that this is more than the opposite polarisation induced by the two ortho-
electron-withdrawing substituents (nitro, carbonyl) on the benzene ring. The ester 
carbonyl oxygen is located on the same side for 5-exo nucleophilic attack, giving 
intermediate (98). Hydrolysis would then afford the major product, the ketone (95). It is 
not clear whether the minor side-product (96) is formed from (95) or directly from 
intermediate (98). 
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Scheme 18:  Electrophile-driven cyclisations of methyl 2-alkynyl-3-nitrobenzoates. 
 
3.1.6.2 ICl- mediated cyclisations  
 
The set of three alkynes (80), (82) and (85) was also treated with the electrophilic 
iodine reagent iodine monochloride at ambient temperature in dichloromethane. Only 
the phenylalkyne (85) gave an identifiable product, affording 4-iodo-5-nitro-3-
phenylisocoumarin (99) in good yield (81%) (Scheme 18).  
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Scheme 19. Proposed mechanism for the putative formation of phthalide (103) and 4-iodo-5-
nitro-3-phenylisocoumarin (99). 
 
It was believed that heteroannulation proceeded via the mechanism outlined in 
Scheme 19. The first step presumably involves the formation of the bridged iodonium 
complex (100) via electrophilic addition of I+ to the alkyne. This was followed by 
nucleophilic attack by the oxygen of the carbonyl group. Finally facile removal of the 
methyl group via SN2 displacement by the chloride anion present in the reaction 
mixture generates the 4-iodo-5-nitro-3-phenylisocoumarin (99) and one molecule of 
MeCl. Theoretically, there are two possible ways in which cyclisation can occur. The 
carbonyl oxygen may either attack in a 5-exo-dig manner (Path A) to give a 
5-membered side product, 3-(iodo(phenyl)methylene)-4-nitrophthalide (103), or it may 
undergo 6-endo-dig ring closure (Path B) to give the desired 4-iodo-
5-nitro-3-phenylisocoumarin (99). According to Baldwin’s guidelines for ring closure,172 
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both reactions are favourable because both carbons of the acetylene have two pi* 
orbitals, one of which must always lie in the plane of the new ring, making it very easy 
for the lone pair on the carbonyl oxygen to overlap with. Hence a mixture of phthalide 
and isocoumarin was expected from the reaction.  
 
Only isocoumarin (99) was obtained from this iodocyclisation. No benzofuranone 
product was observed to arise by this process. Obviously, 6-endo cyclisation is more 
facile than 5-exo cyclisation. The presence of a neighbouring powerfully electron-
withdrawing nitro group possibly made carbon B more electron deficient compared to 
carbon A, thus greatly favouring 6-endo-dig over 5-exo-dig ring closure, and accounting 
for the lack of formation of any 5-membered phthalide product (103). The structure of 
(99) was confirmed as being the isocoumarin product of 6-endo cyclisation by two 
methods. 
• Firstly, the IR spectrum showed absorption at 1732 cm-1, which lies in the 
range 1730–1750 cm-1 for six-membered ring lactones but not in the 
corresponding range for five-membered ring lactones (1760–1780 cm-1). 
•  Secondly, palladium-catalysed reductive deiodination of (99) with triethyl 
ammonium formate (by the general method of Rossi et al.178) gave an excellent 
yield of 5-nitro-3-phenylisocoumarin (93), identical to samples prepared by the 
one-pot Castro–Stephens method and the Hg(II)-mediated cyclisation of (85).  
 
No isocoumarins or isobenzofuranones were identified in the NMR spectra of the crude 
mixtures of products formed from the treatment of ICl with trimethylsilylalkyne (80) or 
from the monosubstituted alkyne (82). An interesting feature of the iodocyclisation 
reaction is the fact that the iodoisocoumarins generated could be further elaborated by 
using various palladium-catalysed processes (Sonogashira, Heck or Suzuki coupling 
reactions) to introduce substituents at the 4-position of the isocoumarin. Hence this 
reaction could prove a useful tool for the synthesis of 3,4-disubstituted 
5-aminoisoquinolin-1(2H)-ones.  
 
3.1.6.3 PhSeCl-mediated cyclisations  
 
The reactions of the electrophile phenylselenyl chloride with the alkynes (80), (82) and 
(85) were investigated (Scheme 18). The monosubstituted alkyne (82) did not undergo 
cyclisation as no isocoumarins or isobenzofuranones could be identified as products of 
the reaction. However, the disubstituted alkynes (80) and (85) formed the 
corresponding 4-phenylselenylisocoumarins (104) and (105) in moderate-to-good 
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yields, through 6-endo cyclisation. Again, the IR spectra indicated 6-membered ring 
lactones, with bands at 1733 cm-1 for both isocoumarins. Since suitable methods for 
reductive removal of phenylselenyl group were lacking, we could not carry out the 
comparison with (93) synthesised previously by three independent routes. An X-ray 
crystal structure determination was carried out for 5-nitro-3-phenyl-4-
phenylselenylisocoumarin (105). Large bright orange-red crystals were formed from 
ethyl acetate. The structure and X-ray crystallographic numbering scheme are shown 
in Figure 15. 
 
The most striking observation in this crystal structure is the intermolecular and 
intramolecular pi-stacking of all three benzene rings in the molecule. Figure A shows 
four molecules in two parallel stacks, viewed from the axis of the stacking. The nature 
of the stacking is shown in the side view in Figure B, with the C–Ph and SePh rings 
stacked intramolecularly; these then stack intermolecularly with the carbocyclic ring of 
the isocoumarins. This isocoumarin also displays interesting conformational features 
within the molecule, as shown in Figure 16. 
 
 
Figure 15. The structure and X-ray crystal structure of 5-nitro-3-phenyl-4-
phenylselenylisocoumarin (105) with crystallographic numbering.  
 
The three adjacent substituents, phenyl, phenylselenyl and nitro, at the 3-, 4- and 5-
positions, respectively, occupy very crowded regions of space. In particular, there is a 
severe peri interaction between the nitro and phenylselenyl groups. The nitro group is 
twisted out of the plane–plane subtended by atoms C2–C8 and C10 of the 
isocoumarin, by 36.9 o. Because of the severe steric crowding the pyranone ring of the 
isocoumarin is forced out of the plane described above, such that C-1 lies some 0.19 Å 
above same. This effect is demonstrated even more clearly by the position of the 
O
O
SeNO2
(105)
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selenium atom at 0.93 Å above this mean plane, as depicted in Figure C (wherein the 
structure is viewed from the plane of the benzene ring) and in Figure D (in which the 
structure is viewed along the Se–C bond vector). The 3-phenyl substituent is twisted 
out of the isocoumarin mean plane by 36.5°. The presence of the adjacent bulky 
phenylselenyl is presumably responsible for this greater lack of coplanarity.  
 
The gross structure is dominated by interdigitating intra- and intermolecular stacking of 
the aromatic rings. The intermolecular centroid–centroid distance between the aromatic 
rings is 3.8 Å, while the comparable intermolecular aromatic–aromatic distances 
average 4.1 Å. This latter value reflects the fact that the pi-stacking is offset in the 
intermolecular case. 
 
 
 
Figure 16 A: Axial view of intermolecular and intramolecular pi-stacking in the crystal of (105). 
B: Side view of intermolecular and intramolecular pi-stacking of two molecules. C: View of single 
molecule of (105) in the plane of the isocoumarin carbocyclic ring. D: View of single molecule of 
(105) along the Se–C bond. Grey = C, white = H, blue = N, red = O and orange = Se. 
A B 
C D 
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3.1.7 Conclusions 
 
Cyclisations of methyl 2-alkynyl-3-nitrobenzoates with various electrophiles were 
studied. Cyclisations of methyl 3-nitro-2-phenylethynylbenzoate (85) with iodine 
monochloride and with phenylselenyl chloride followed the 6-endo route to give the 
isocoumarins (99) and (105), respectively, as did cyclisation of methyl 3-nitro-2-
trimethylsilylethynylbenzoate (80) with phenylselenyl chloride, affording the 
isocoumarins (104). This change in regiochemistry of cyclisation is presumably due to 
the nitro group inducing polarisation of the alkyne, making the remote sp-carbon more 
electrophilic (Figure 14). Similarly, Hg(II)-catalysed cyclisation of methyl 2-
phenylalkynyl-3-nitrobenzoate (85) was reported to proceed in the 6-endo mode to give 
2-nitro-3-phenylisocoumarin (93). This too demonstrates the directing influence of the 
electron-withdrawing nitro group on the electrophilicity of the alkyne. Thus the 
regiochemistry of these cyclisations is also likely to be under the control of the nitro 
group. In contrast, the formation of methyl 2-acetyl-3-nitrobenzoate (95) by treatment of 
(80) and (82) with Hg(II) suggests that a 5-exo cyclisation may have been driven by the 
change in electron-distribution caused by the formation of an intermediate 
alkynylmercury complex. 
 
These studies extend the understanding of electrophile-driven cyclisations of 2-
alkynylbenzoic acids and 2-alkynylbenzoate esters to the previously unreported cases 
where a powerful electron-withdrawing group is present, influencing the electron-
distribution of the alkyne. This understanding will be useful in predicting modes of 
cyclisation in the synthesis of more complex isocoumarins. 
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3.2 Route I: 4-Substituted 5-aminoisoquinolin-1(2H)-ones by reductive cyclisation 
of Phenylacetonitrile 
 
3.2.1 Retrosynthetic analysis 
 
The first series of target compounds investigated were the 4-substituted 
5-aminoisoquinolin-1(2H)-ones. In designing our synthetic strategies, efforts were 
made to ensure sufficient versatility to allow for a great variety of substituents (alkyl and 
aryl substituents of various electronic and steric nature) to be attached at the 4-position 
via a common synthetic route. Ideally; diversification should occur at a late stage of 
synthesis to avoid inefficient repetition of synthetic steps.  
 
Retrosynthetic analysis for the 4-substituted targets is illustrated in Scheme 20. We 
approached our retrosynthesis by first performing functional group interconversion 
(FGI) on the target molecule (106). Reduction of the nitro group to an amine via 
catalytic hydrogenation or acid/metal reduction is a highly efficient and reliable reaction. 
Though the nitro group, being highly electron-withdrawing, is likely to reduce the 
reactivity of the carbocyclic ring towards electrophilic attack and should, in most cases, 
be disconnected first, we reasoned that incorporation of nitro group at the beginning of 
synthesis will avoid the need for subsequent regioselective nitration of the 4-substituted 
isocoumarin or isoquinolin-1(2H)-one ring. Disconnection at the C-N bond of the ring of 
(107) focusses on the cyclisation between an imine and an ester. DIBAL-H, well known 
for its selectivity for reducing nitriles, is used to reduce the nitrile function to imine.185,186 
 
Disconnection at the C-C bond of (108) led to methyl 2-cyanomethyl-3-nitrobenzoate 
(109). At this point, the desired substituents could be introduced via alkylation of the 
methylene carbon of compound (109). This could be achieved quite simply, for 
instance via initial deprotonation with a hindered base such as lithium 
hexamethyldisilazide (LHMDS), followed by reaction with an appropriate alkylating 
agent such as iodomethane. The alkylation process is considered as a reliable and 
standard process to introduce appropriate substituents. Synthesis of (109) from (110) 
requires a functional group interconversion (FGI) and is achieved by nucleophilic 
substitution with tetraethylammonium cyanide. The precursor is formed from radical 
bromination of the ester (111) which, in turn, could be synthesised via acid-catalysed 
esterification of the carboxylic acid (112). 
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Scheme 20. Retrosynthetic analysis of the 4-substituted 5-aminoisoquinolin-1-ones via 
reduction of a phenylacetonitrile.  
 
In the project on PARP-1 inhibitors, new synthetic approaches to 5-aminoisoquinolin-1-
ones were investigated.160 In one of the synthetic routes to 5-aminoisoquinolin-1-one 
the 2-N and 3-C were introduced at a higher oxidation level, as a cyanide group.187 This 
route not only provides a novel, reliable and simple route for the preparation of 5-AIQ 
(Scheme 21) but also represents a promising synthetic strategy for the synthesis of the 
4-substituted 5-aminoisoquinolin-1-ones. This could be achieved by introducing the 
desired substituents via alkylation of the methylene carbon of compound (109) and 
subsequent ring closure of (108) with DIBAL-H to form the 4-substituted 5-
nitroisoquinolin-1(2H)-ones.  
 
2-Methyl 3-nitrobenzoic acid (112) was used as the precursor. The first step was 
esterification of the acid via an acid-catalysed esterification process. Radical 
bromination of the aryl methyl was achieved with bromine and dibenzoyl peroxide in 
boiling carbon tetrachloride under irradiation with a tungsten lamp. This gave the 
monobrominated product, methyl 2-bromomethyl-3-nitrobenzoate (110), in good yield. 
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Scheme 21. Synthesis of 5-aminoisoquinolin-1(2H)-one. 
 
Displacement of the bromo group with cyanide was carried out by nucleophilic 
substitution with Et4N
+CN- in acetonitrile at room temperature affording the nitrile (109) 
in good yield. The nitrile was then reduced selectively with DIBAL-H at -78°C, 
generating the intermediate imine (115) which cyclised to give 5-nitroisoquinolin-1-one 
(113) in moderate yield. Presumably, during aqueous acid work-up, the transitional 
imine (or the tautomeric enamine) underwent rapid intramolecular cyclisation to (113) 
before reduction of the neighbouring methyl ester could occur (Scheme 22). 
 
 
Scheme 22. Proposed mechanism for the reductive cyclisation of methyl 2-cyanomethyl-3- 
nitrobenzoate (109). 
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3.2.2 Investigations into reductive cyclisations catalysed by DIBAL-H 
 
The DIBAL-H reductions of two analogues of (114) with bulky substituents at either the 
ester or methylene position were studied to explore the generality of this route. The 
benzyl group was chosen to increase the steric bulk at the methylene position while an 
isopropyl ester was used instead of a methyl ester. The acidity of methylene protons 
adjacent to the nitrile group allowed introduction of the benzyl group. As these 
methylene protons were adjacent to the two electron-withdrawing groups, one of them 
could be removed using the non-nucleophilic base lithium hexamethyldisilazide 
(LHMDS). This, on quenching with benzyl bromide, afforded (116) (Scheme 23). 
Reduction with DIBAL-H at -78 °C, did not form 5-nitro-4-benzylisoquinolin-1(2H)-one 
(118) as predicted but afforded only the aldehyde 2-(2-formyl-6-nitrophenyl)-3-
phenylpropanenitrile (117), arising from reduction of the ester while leaving the nitrile 
unaltered. To form the desired product (118) DIBAL-H has to reduce the nitrile function 
first to an imine, which on subsequent intramolecular nucleophilic attack of the ester 
undergoes cyclisation. 
O
OMe
NO2
CN
LHMDS
BnBr
O
OMe
NO2
CN
DIBAL-H
O
H
NO2
CN
(109) (116)
O
N
NO2
(118)
H
(117)
 
 
Scheme 23. Formation of 2-(2-formyl-6-nitrophenyl)-3-phenylpropanenitrile (117). 
 
In compound (116) approach of the DIBAL-H to the nitrile is obstructed by the adjacent 
benzyl group, leading to reduction at the ester only, giving (117) via formation of the 
tetrahedral intermediate (119) which is stable even at -70°C (Scheme 24). This 
intermediate collapses to the aldehyde on aqueous work-up. 
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Scheme 24. Proposed mechanism for formation of 2-(2-formyl-6-nitrophenyl)-3-
phenylpropanenitrile (117). 
 
Studies using the isopropyl ester to increase steric bulk at the ester were conducted 
earlier in our laboratory.187 It was expected that steric bulk at the ester would slow 
down reduction of the ester, allowing the nitrile more time to react. The isopropyl 
ester188 was brominated and converted to the nitrile (120). Reduction with DIBAL-H, 
however, gave the isoquinoline (123) as the sole identifiable product, formed from 
reduction of both the ester and the nitrile. This indicates, surprisingly, that increasing 
the steric bulk of the ester makes it more prone to reduction. Careful examination of the 
mechanism reveals that for (120), step 1 is fast, giving (121) but approach of the 
nucleophile in step 2 is slowed by the steric bulk of the Pri, allowing time for reduction 
of the ester (step 3), leading to aldehyde (122) and cyclisation to 5-nitroisoquinoline 
(123) (scheme 25). 
 
O
OPri
NO2
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O
O
NO2
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H
NH
O
H
NO2 H
NH2
N
NO2
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N
O
NO2
H
(120) (121) (122) (123)
(113)  
Scheme 25. Proposed route for the formation of 5-nitroisoqunioline (123).187 
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This route could thus only be used for the synthesis of 5-AIQ (114) (scheme 21). The 
severe effects of steric bulk mitigate against the general utility of this reductive 
cyclisation using DIBAL-H. Since reductive cyclisation of nitrile is the most critical step 
in the proposed route, difficulties in this step called for alternative routes to be 
developed.  
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3.3 Route II: 4-Substituted 5-aminoisoquinolin-1(2H)-ones via Pd-catalysed 
couplings of 4-bromoisoquinolin-1-ones 
 
3.3.1 Retrosynthetic analysis 
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Scheme 26. Retrosynthetic analysis of the 4-substituted 5-aminoisoquinolin-1-ones via Pd-
catalysed couplings of 4-bromoisoquinolin-1-ones. 
 
Retrosynthetic analysis of our 4-substituted target (106) gave the pathway illustrated in 
Scheme 26. The target molecule could be synthesised by two routes. Route 1 requires 
the formation of 4-substituted 5-nitroisoquinolin-1-ones (107) achieved using 
organometallic approaches on 4-bromo-5-nitroisoquinolin-1-one (124). Route 2 
suggested synthesis of the target molecule directly by organometallic approaches 
using Pd(0) coupling reactions on 5-amino-4-bromoisoquinolin-1-one (125), followed by 
functional group interconversion to 4-bromo-5-nitroisoquinolin-1-one (124). In Route 2 
reduction of the nitro group to amine (via hydrogenolysis or acid/metal reduction) is 
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performed prior to Pd(0)-catalysed coupling reactions. This is done in order to minimise 
any steric hindrance that may be arising from sterically bulky groups like bromo and 
nitro placed adjacent to each other. The 4-bromo group is of great value in 
organometallic synthesis as a means through which a diverse range of substituents 
may be introduced at the 4-position via appropriate organometallic reagents, such as 
organoboranes (Suzuki coupling reaction), organostannanes (Stille coupling 
reaction) or organoacetylenes (Sonogashira coupling reaction). We believe that a 
series of 4-substituted targets are synthetically accessible through these pathways.  
 
Both the Routes (1 and 2) converge at this stage to 4-bromo-5-nitroisoquinolin-1-one 
(124), synthesis of which could be achieved by bromination of 5-nitroisoquinolin-1-one 
(113). Synthesis of the latter requires functional group interconversion of isocoumarin 
to isoquinolin-1(2H)-one (e.g. by treatment with boiling ammonia-saturated 
2-methoxyethanol). This is well-established reaction that is highly reliable and efficient. 
The challenge, then, was to devise a synthetic strategy for the construction of the 
isocoumarin (126). Disconnection at the C-O bond of the isocoumarin as shown, i.e. 
ring opening is rational because the reverse lactonisation process is a very fast 
reaction, easily accomplished, for instance, through the use of an acid catalyst. The 
synthesis of 5-nitroisocoumarin (126) (Scheme 27) is now well established,86 through 
condensation of methyl 2-methyl-3-nitrobenzoate (111) with dimethylformamide 
dimethylacetal (128), followed by hydrolysis of the intermediate methyl E-2-(2-
dimethylaminoethenyl)-3-nitrobenzoate (127) and cyclisation catalysed by wet silica. 
 
 
 
Scheme 27. Chemical synthesis of 5-nitroisocoumarin via condensation of compound (111) 
with DMFDMA. 
 
It was reported earlier that condensation of methyl 2-methyl-3-nitrobenzoate with, 
DMFDMA at high temperature (150 oC) gave the enamine methyl E-2-(2-
dimethylaminoethenyl)-3-nitrobenzoate (127) (Scheme 27).86 Immediate passage of 
this crude enamine through undried silica gel (column chromatography) not only 
provides sufficient acid catalysis to hydrolyse the enamine and to cyclise the 
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intermediate enol to 5-nitroisocoumarin, but also purifies the product, all in one elegant 
step. Alternatively (route 2) the enamine is hydrolysed to the aldehyde which later 
displaces the methoxy group to form (126). 
 
 
Scheme 28. Proposed mechanism for the condensation reaction between methyl 2-methyl-3-
nitrobenzoate (111) and DMFDMA (128). 
 
Heating with ammonia at high temperature154,150 is one of the simplest procedures 
reported in the literature for the conversion of isocoumarins to isoquinolin-1-ones. Thus 
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5-nitroisocoumarin (126) was treated with boiling ammonia-saturated 2-methoxyethanol 
and this afforded 5-nitroisoquinolin-1-one (113) in good yield (89%).  
 
3.3.2 Iodination / bromination at 4-position of 5-nitroisoquinolin-1-one  
 
The 4-position of 5-nitroisoquinolin-1-one (113) is believed to be more nucleophilic, 
compared to the 3-position, due to a mesomeric electron-donating effect of the ring 
nitrogen. Such a difference in 
nucleophilicity, and thus reactivity, 
towards electrophiles between the 3- 
and 4-position can be exploited to 
attach an electrophile selectively, such 
as iodine or bromine, at the 4-position. 
Alternatively, the pyridine ring of isoquinolin-1-one also act as N-acyl enamine thus 
contributing to the nucleophilicity of 4-position (Figure 17). 
 
The iodination of 5-nitroisoquinolin-1-one (113) with a solution of iodine in acetic acid 
was undertaken. However, the reaction mixture remained unchanged even after stirring 
for 24 h with heating to 100 oC. Employment of more electrophilic conditions, such as 
N-iodosuccinimide in acetic acid, also failed to effect halogenation. Treatment of 
5-nitroisoquinolin-1-one (113) with iodine in the presence of silver trifluoroacetate in 
Et2O/THF/CHCl3 also gave the starting material unchanged.
189,190 A switch to the use of 
brominating reagents (bromine being more reactive compared to iodine) was therefore 
considered. Bromination of 5-nitroisoquinolin-1-one (113) with N-bromosuccinimide in 
glacial acetic acid furnished a mixture of 4-bromo-5-nitroisoquinolin-1-one (124) and 4-
bromo-5-nitro-1-oxo-1,2,3,4-tetrahydroisoquinolin-3-yl acetate (129). The latter when 
heated to melt gave a mixture of 4-brominated (124) and debrominated (113) 
compounds in the ratio of 2:3. However, the low yield (30%) and lack of reproducibility 
of the reaction discouraged further attempts of bromination with N-bromosuccinimide. 
 
N
O
NO2
H
N
O
NO2
Figure 17: Pyridine ring of 4-nitroisoquinolin-1-one
as tautomeric enamine
H
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Scheme 29. Different chemical approaches for iodination / bromination at the 4-position of 
5-nitroisoquinolin-1-one. 
 
Horning et al191 described various electrophilic substitutions on N-alkylated isoquinolin-
1-ones and emphasised the fact that electrophilic attack of the hetero ring would be 
confined to one carbon atom i.e. to C-4. In this study, bromination of 2-methyl-5-
nitroisoquinolin-1-one (132) was carried out with the addition of one molecular 
equivalent of bromine in acetic acid to a solution of (132) in same solvent. This 
reaction, on aqueous work-up, gave a 1:1 mixture of two monobromo compounds: 4-
bromo-2-methyl-5-nitroisoquinolin-1-one (133) and 4-bromo-3-hydroxy-2-methyl-5-
nitro-3,4-dihydroisoquinolin-1-one (134) (Scheme 30). The bromohydrin compound 
(134) was converted to (133) when heated to its melting point. 
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Scheme 30. Bromination of 2-methyl-5-nitroisoquinolin-1-one (132) using bromine in acetic 
acid.191 
 
All of Horning’s reactions used N-alkylated isoquinolin-1-ones. However, we decided to 
use isoquinolin-1-one as such as required by our project. Accordingly, we carried out 
bromination of 5-nitroisoquinolin-1-one (113) using one molecular equivalent of 
bromine in acetic acid, which on aqueous work-up gave a 1:1 mixture of 4-bromo-5-
nitroisoquinolin-1-one (124) and 4-bromo-3-hydroxy-5-nitro-3,4-dihydroisoquinolin-1-
one (130). Analogously to the above mentioned reaction, the bromohydrin compound 
(130) was converted to the desired (124) when heated to its melting point (Scheme 29). 
The overall yield of the reaction was a moderate 53%. 
 
Attempts to brominate 5-nitroisocoumarin (126) in the same way gave a dibrominated 
compound, 3,4-dibromo-5-nitroisocoumarin (131). 
 
3.3.3 Sonogashira, Suzuki or Stille coupling reactions 
 
With the 4-bromo-5-nitroisoquinolin-1-one (124) in hand, a series of Pd(0)-catalysed 
cross-couplings were attempted to introduce substituents at the 4-position. The first 
reaction attempted was a Sonogashira coupling reaction performed between 4-bromo-
5-nitroisoquinolin-1-one (124) and phenylacetylene (84), in the presence of a catalytic 
amount of (Ph3P)2PdCl2 (78) and copper(I) iodide in diisopropylamine (DIPA) and dry 
THF (standard Sonogashira conditions). The mixture was stirred at 45 oC under argon 
for 24 hours. However, the expected coupling reaction did not occur. Only the 
debrominated material (113) was isolated. Use of a sterically hindered halide such as 
(124) (with nitro and bromo group peri to each other) could possibly account for the 
inability to undergo coupling with phenylacetylene (84). Buchwald et al.192 performed a 
series of Suzuki-Miyaura coupling reactions with very hindered aryl halides using 2-
(2′,6′-dimethoxybiphenyl)-dicyclohexylphosphine (SPhos) (135) as a ligand. Following 
this example, the coupling reaction of 4-bromo-5-nitroisoquinolin-1-one (124) was 
studied with phenylboronic acid in DMF using the combination of Pd(OAc)2 and SPhos 
as catalyst system in the presence of K3PO4 base. The mixture was stirred at 100
 oC 
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under argon for 24 h. Coupling failed to proceed and gave some unidentified complex 
mixture. Finally Stille cross-coupling reaction was attempted on 4-bromo-5-
nitroisoquinolin-1-one (124) to introduce a smaller methyl substituent. Reaction of (124) 
with tetramethyltin [(CH3)4Sn] in N-methylpyrrolidin-2-one (NMP) in the presence of 
tetrakis(triphenylphosphine)palladium [Pd(Ph3P)4] in an inert atmosphere was carried 
out at 80 oC for 20 h.193 The reaction failed to proceed. A switch to tetraethyltin 
[(C2H5)4Sn] and refluxing at a higher temperature (100
 oC) did not alter the outcome. 
    
Scheme 31. Different organometallic cross-coupling reactions for introduction of substituents at 
the 4- position of 5-nitroisoquinolin-1-one (124) and 5-aminoisoquinolin-1-one (125). 
 
It was reasoned that the presence of the bulkier nitro group at the 5-position of (124) 
was hindering 4-bromo-5-nitroisoquinolin-1-one (124) to participate in any of the Pd(0) 
catalysed cross-coupling reactions. To overcome this problem, it was decided to carry 
out the reduction of the nitro group to the more slender amino group first and then 
perform the organometallic cross-coupling reactions. Thus, 4-bromo-
5-nitroisoquinolin-1-one (124) was reduced with tin(II) chloride by heating at 70 oC in 
ethanol to give 4-bromo-5-aminoisoquinolin-1-one (125) in 54% yield.150 Tin(II) chloride 
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was used to avoid any reductive debromination of the C-Br bond observed on 
treatment with Pd/C hydrogenations.  
 
Analogously, the same set of reactions (Sonogashira and Stille) was repeated with 
(125). Sonogashira reaction performed under standard conditions gave a mixture of 
unidentifiable products. Since no starting material was isolated we could speculate that 
product formed may not be stable under the conditions of the reaction. The Stille 
reaction was attempted with tetraethyltin in NMP in the presence of Pd(PPh3)4 in an 
inert atmosphere at 100 oC for 20 h. Among the products isolated were unreacted 4-
bromo-5-aminoisoquinolin-1-one (124) and traces of debrominated compound (114).  
 
No apparent reasons could be concluded for the failure of 4-bromo-
5-aminoisoquinolin-1-one (125) to undergo Pd(0) catalysed cross-coupling reactions. 
The inability to perform the organometallic cross-coupling reactions with both 4-bromo-
5-nitroisoquinolin-1-one (124) and less hindered 4-bromo-5-aminoisoquinolin-1-one 
(125) meant that this route was no longer viable. 
 90 
3.4 Route III: 4-Substituted 5-aminoisoquinolin-1(2H)-ones via intramolecular 
Heck coupling 
 
3.4.1 Retrosynthesis 
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Scheme 32. Retrosynthetic analysis of the 4-substituted 5-aminoisoquinolin-1-ones.  
 
The retrosynthetic analysis for the target molecule (106) is illustrated in Scheme 32. As 
usual, retrosynthesis began by first performing functional group interconversion (FGI) 
on the target molecule and this led to the corresponding 5-nitroisoquinolin-1-one (107). 
This conversion, i.e. the reduction of the nitro group to amine (via hydrogenolysis or 
acid/metal reduction), is highly reliable and efficient. Formation of (107) involved 
removal of the protecting group G (allyl or benzhydryl) on nitrogen, which is introduced 
in order to facilitate the molecule adopting the correct reacting conformation about the 
amide C-N bond to allow cyclisation by intramolecular Heck coupling. Synthesis of 
(136) is achieved by an intramolecular Heck coupling / double bond migration of a 2-
iodo-3-nitro-N-(alk-2-enyl)benzamide (137) as the key C-C bond-forming step in 
assembling the isoquinolinone. The C-N amide bond disconnection of (137) led to 
secondary amine (138), with an N-protecting group and substitution at the alkene, and 
2-iodo-3-nitrobenzoyl chloride (139). The latter could be prepared from reaction of 2-
iodo-3-nitrobenzoic acid (76) with thionyl chloride catalysed by DMF. The synthesis of 
(76) is outlined in section 3.1.2. 
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3.4.2 Synthesis of 2-iodo-3-nitrobenzoyl chloride  
 
2-Iodo-3-nitrobenzoic acid (76) was converted into the acid chloride by treatment with 
thionyl chloride in the presence of catalytic DMF.  
 
Scheme 33. Proposed mechanism for the SOCl2-DMF-mediated synthesis of 2-iodo-3-
nitrobenzoyl chloride (139) 
 
The initial step in the mechanism is the formation of the reactive intermediate (140) by 
nucleophilic substitution of Cl− (formed from reaction between SOCl2 and DMF) at the 
carbonyl group (Scheme 33). The reactive intermediate is highly electrophilic and 
reacts rapidly with the carboxylic acid (76), producing another intermediate which 
intercepts Cl− to give the 2-iodo-3-nitrobenzoyl chloride (139) and regenerate DMF. 
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3.4.3 Formation of tertiary amides  
 
In a secondary amide, the lowest energy 
conformation is likely to be trans. As shown in 
Figure 18, in the case of N-allyl-2-iodo-3-nitro-
benzamide, the conformation required for 
intramolecular Heck coupling would thus be the 
higher energy cis-amide conformer (143). In the 
tertiary amide (141), with two N-allyl groups, one 
allyl group should always be in close proximity to the aryl ring. It was predicted that the 
other allyl group could be removed from the nitrogen later. 
 
Attempts to synthesise the tertiary amide (141) involved coupling reactions of 2-iodo-3-
nitrobenzoyl chloride (139) with the appropriate amine. With N,N-diallylamine in the 
presence of two equivalents of triethylamine, (139) afforded N,N-di(prop-2-enyl)-2-iodo-
3-nitrobenzamide (141) in good yield (75%) (Scheme 34). 
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Scheme 34. Preparation of N,N-di(prop-2-enyl)-2-iodo-3-nitrobenzamide (141). 
 
An MM2 energy minimisation for this compound (141), however, suggested that the 
amide carbonyl should be approximately orthogonal to the benzene ring (Figure 19), 
owing to steric interactions with the large adjacent iodine. This would make the 
molecule chiral, with the asymmetric centre located in the centre of the Ar-C bond. This 
chirality means that not only are the two allyl groups inequivalent (owing to restricted 
amide C-N bond rotation) but the two aliphatic methylenes are also each in chiral 
environments. This was evident in the 1H NMR spectrum, which showed different 
chemical shifts for the hydrogens of the two allyl side chains and that each CH2 proton 
was diastereotopic. 
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Figure 18: Different conformations of
N-allyl-2-iodo-3-nitrobenzamide (143).
 93 
 
 
 
 
 
 
 
Figure 19: MM2-energy minimized model of N,N-di(prop-2-enyl)-2-iodo-3-nitrobenzamide (141) 
 
 
 
Scheme 35. Synthesis of N-diphenylmethyl-2-iodo-3-nitro-N-(3-phenylprop-2-enyl) benzamide 
(148). 
 
While cyclisation of N,N-di(prop-2-enyl)-2-iodo-3-nitrobenzamide (141) was expected to 
afford a 4-methyl substituent, a parallel effort was also directed to introduce a benzyl 
group into the 4-position of 5-aminoisoquinolin-1(2H)-one. For this synthesis a 
benzhydryl group was selected (bulkiness and predicted ease of removal) to restrict the 
rotation around the C-N bond, and to have a ring forming allyl group in close vicinity to 
the 2-position of the arene. To prepare the required secondary amine, 
aminodiphenylmethane (144) was condensed with cinnamaldehyde (145) in toluene in 
a Dean-Stark apparatus until the calculated amount of water had separated.194 The 
product, (E)-diphenyl-N-(3-phenylprop-2-enylidene) methanamine (146) was formed in 
good yield (97%). Selective reduction of the imine of (146) with excess sodium 
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borohydride in MeOH also gave a good yield (95%) of the secondary amine (E)-N-
diphenylmethyl-3-phenylprop-2-en-1-amine (147). This, on coupling with 2-iodo-3-
nitrobenzoyl chloride (139), formed the Heck cyclisation precursor (E)-N-
diphenylmethyl-2-iodo-3-nitro-N-(3-phenylprop-2-enyl)benzamide (148) in moderate 
yield (54%) (Scheme 35).    
 
 
 
 
 
 
 
 
 
 
Figure 20. MM2-energy minimized models of (E)-N-diphenylmethyl-2-iodo-3-nitro-N-(3- 
phenylprop-2-enyl)benzamide (148).  
 
The structure of (148) was characterised by 1H NMR, 13C NMR, HMQC, HMBC, MS 
and CHN analyses. The MM2 molecular modelling studies of this compound (148) 
showed two low energy rotamers arising from rotation about C-N bond (Figure 20). 
Both rotamers are also chiral. Model A shows intramolecular stacking of 2-iodo-3-
nitrobenzyl ring and 3-phenylprop-2-enyl rings. Model B is the result of flipping over the 
3-phenylprop-2-enyl ring. The dihedral angle calculated C(15)-N(13)-C(7) was 175 Å. 
The 1H NMR spectra of (148) also indicated the presence of two rotamers resulting 
from different conformations of side chains in space. The NMR spectrum showed a 3:4 
mixture of rotamers α and β about the amide double bond and magnetic inequivalence 
of the diastereotopic CH2 protons in each rotamer. Figure 21 shows assignment of 
1H 
NMR signals for N-3-phenylprop-2-enyl chain of (148). It is evident that propenyl 2-H 
and 3-H were in trans configuration as shown by the coupling constant J = 16.0 Hz. 
Interestingly the chemical shift for CH2 protons of α rotamer was at δ 3.91, whereas for 
the β rotamer the chemical shifts were different for the geminal protons (multiplet at δ 
3.93 and double doublet at δ 4.81 with J value of 14.5 and 5.5). This was assigned with 
the help of two-dimensional HMQC (1H-13C COSY) spectrum (Figure 22). 
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I
 
 
Figure 21. Assignment of 1H NMR signals for N-3-phenylprop-2-enyl chain of (148) and its  
deuterated analogue (158). 
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Figure 22.
 1H-13C COSY spectrum of (E)-N-diphenylmethyl-2-iodo-3-nitro-N-(3-phenylprop-2-
enyl)benzamide (148) 
 
3.4.4 C=C Bond migration and intramolecular Heck cyclisations 
 
The Heck reaction has shown to be very useful for the preparation of especially 
disubstituted olefins. This is a versatile carbon-carbon bond-forming reaction which 
allows desirable functionalities to be attached across alkenes. In this palladium- 
catalysed reaction, the carbon–carbon bond is formed from a vinyl functionality and an 
aryl and (or) alkyl halide or triflate. The intramolecular Heck coupling reaction is also 
palladium-catalysed and couples an alkene with the halide in the same molecule to 
form a new cyclic alkene. This reaction has been well-established as a powerful tool for 
the construction of polycyclic structures and quarternary carbon stereocentres. The first 
intramolecular Heck reaction was reported by Mori and Ban in 1977.195 This reaction is 
catalysed by Pd(0) complexes of phosphines such as Pd(PPh3)4 and Pd(II) complexes 
like Pd2(dba)3 and Pd(OAc)2. The base used could be a mild one like Et3N, NaOAc or 
aqueous Na2CO3. Coordinating and polar solvents, such as DMF, MeCN, NMP and 
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DMSO are preferred.166 Palladium complexes are also known to catalyse the migration 
of C=C double bonds in allyl systems (e.g. removal of Alloc protecting groups). Thus it 
was planned that reaction of the N-allyl-2-iodobenzamides (141 and 148) with Pd 
catalysts would first allow migration of the double bond into conjugation with the amide 
nitrogen, and then Heck cyclisation to furnish 4-substituted 5-nitroisoquinolin-1-ones.  
 
Initial experiments used catalytic amounts (5 mol%) of Pd(PPh3)4 with Et3N in refluxing 
MeCN (80 oC) or EtCN (100 °C) (Scheme 36). Treatment of N,N-di(prop-2-enyl)-2-iodo-
3-nitro-benzamide (141) with Pd(PPh3)4 and Et3N in refluxing MeCN for 48 h gave the 
Heck-cyclised isomers 2-(prop-2-enyl)-4-methyl-5-nitroisoquinolin-1(2H)-one (149) and 
2-(prop-2-enyl)-4-methylene-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (150) in good 
total yield (79%). The former (required) isomer results from C=C migration followed by 
cyclisation, whereas the latter is formed by Heck coupling without prior C=C migration. 
These isomers were not separable by column chromatography. The 1H NMR spectrum 
of the mixture revealed that the populations of (149) and (150) were in the ratio of 1:2. 
The required isomer (149) was the minor product of this reaction and could not be 
isolated for further reactions (N-deallylation and reduction of the 5-nitro functional 
group) to synthesise 5-amino-4-methylisoquinolin-1(2H)-one. Figure 23 shows 1H-1H 
COSY spectrum of (149) and (150). The propenyl 2-H of both compounds formed cross 
peaks between propenyl 1-H and propenyl 3-H, thus making assignment of protons for 
the propenyl side chain possible.  
 
Scheme 36. Intramolecular Heck cyclisations of N,N-di(prop-2-enyl)-2-iodo-3-nitrobenzamide 
(141) and (E) N-diphenylmethyl-2-iodo-3-nitro-N-(3-phenylprop-2-enyl) benzamide (148). 
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Figure 23.
 1H-1H COSY spectrum of 1:2 mixture of 2-(prop-2-enyl)-4-methyl-5-nitroisoquinolin-
1(2H)-one and (149) and 2-(prop-2-enyl)-4-methylene-5-nitro-3,4-dihydroisoquinolin-1(2H)-one 
(150).  
 
Similarly, intramolecular Heck coupling of the other iodobenzamide aryl iodide, (E)-N-
diphenylmethyl-2-iodo-3-nitro-N-(3-phenylprop-2-enyl)benzamide (148) with Pd(PPh3)4 
and Et3N in refluxing EtCN for 48 h afforded the isomers 2-diphenylmethyl-5-nitro-4-
phenylmethylisoquinolin-1(2H)-one (151) and (Z)-4-benzylidene-2-diphenylmethyl-5-
nitro-3,4-dihydroisoquinolin-1(2H)-one (152) in moderate total yield (41%). Use of EtCN 
allows heating at higher temperature. i.e 100 oC. Again, these compounds could not be 
separated using column chromatography. A series of NMR experiments (NOESY, 
COSY, HMQC, HMBC) allowed the assignment of signals corresponding to each 
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isomer. These isomers were found to be present in the ratio of 1:3. As seen in the 
spectra in Figure 24, signals for protons on the two phenyl rings of benzhydryl group 
were overlapping and were difficult to assign. From the 1H-1H COSY spectrum, it was 
evident that there was ortho-coupling between 8-H and 7-H (adjacent protons on the 
ring) and between 6-H and 7-H in both the compounds. Cross peaks were observed 
due to long range coupling of 3-H and 4-CH2 protons in (151) and 3-H2 and 4-CH in 
(152). 
  
Surprisingly, when the cyclisations of (148) were repeated under the same conditions 
but for 2 h, the overall yield was unchanged but the ratio of isomers changed markedly 
as (152) was formed as the major product while desired (151) was formed only in 
traces. This observation suggested that Heck cyclisation may have preceded migration 
of the C=C in the formation of (151).  
 
The Heck reaction mechanism involves the following four steps196 (Scheme 37). 
1. oxidative addition 
2. carbopalladation 
3. β-hydride elimination or dehydropalladation 
4. reductive elimination 
Palladium (0) in Pd(PPh3)4 undergoes oxidative addition with suitable substrates such 
as halides resulting in the active catalytic unit, i.e. coordinatively unsaturated, 14-
electron species PdL2 palladium(II) complex. This would seem reasonable since PdL2 
is electron-rich and nucleophilic in character and has vacant sites so that the organic 
electrophile R1X can undergo oxidative addition to give the R1PdXL2 (153) intermediate 
in which the R group (aryl or vinyl) is σ-bonded to the Pd(II). The resulting σ alkyl bond 
in such complexes is very reactive, especially towards carbon-carbon pi bonds. Thus an 
alkene in the reacting system will lead to coordination followed by migratory insertion 
into the palladium-carbon σ bond. This process is called carbopalladation as carbon 
and palladium are attached to the ends of the alkene system. In this step, ligand 
dissociates to allow coordination of the alkene and associate to provide a stable 
product (154). Dehydropalladation or β-hydride elimination from this molecule results in 
the product alkene and catalytically inactive HPdXL2 species. A base then regenerates 
the palladium(0) catalyst by reductive elimination of HX. 
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Figure 24.
 1HNMR and 1H-1H COSY spectra of 1:3 mixture of 2-diphenylmethyl-5-nitro-4-
benzylisoquinolin-1(2H)-one (151) and (Z)-4-benzylidene-2-diphenylmethyl-5-nitro-3,4-
dihydroisoquinolin-1(2H)-one (152).
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Scheme 37. Proposed general mechanism for the Heck reaction 
 
The major problem observed in this intramolecular Heck cyclisation is the efficiency of 
the palladium-catalysed migration of the carbon-carbon double bond along the alkyl 
chain. In the mechanism proposed the order of the two steps (Heck cyclisation, C=C 
migration was unclear (Scheme 38). The reaction follows Route A if there is no double 
bond migration resulting in exocyclic 4-alkylidine-5-nitro-3,4-dihydroisoquinolin-1-one 
(155) as the product. In the case of double bond migration, the reaction proceeds 
according to Route B, thus forming the desired endocyclic 4-alkyl-5-nitroisoquinolin-1-
one (156). 
 
However, it is known that, in many cases, further reaction of the initial products, i.e. 
isomerisation of double bonds, occurs to form thermodynamically more favoured 
alkenes. To check if migration of the double bond may occur after Heck cyclisation a 
mixture of isomers 2-(prop-2-enyl)-4-methyl-5-nitroisoquinolin-1(2H)-one (149) and 2-
(prop-2-enyl)-4-methylene-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (150) in the ratio 
(1:2) was exposed to the initial reaction conditions. Examination of the products by 
NMR revealed that there was no change in the ratio of isomers, suggesting either that 
product isomers were not interconvertible or that the 1:2 ratio of compounds with 
endocyclic or exocyclic C=C was the ratio at equilibrium. 
 
 102 
N
O
G
R
NO2
I
N
O
G
R
NO2
Pd
I
N
O
G
R
NO2
Pd
I
N
O
G
NO2
Pd
L
RH
L2
IHL
N
O
G
NO2
RH
H
N
O
G
NO2
RH
H
Pd L2
I
N
O
G
NO2 CH2R
Route A
Route B
(155)
(156)
?
 
Scheme 38. Mechanism proposed for the formation of 4-alkyl-5-nitroisoquinolinones and 4-
alkylidine-5-nitro-3,4-dihydroisoquinolinones by intramolecular Heck cyclisation. 
 
3.4.5 Deuterium tracing study 
 
These contrasting observations prompted an isotopic labelling study to study the order 
of the two steps (Heck coupling, C=C migration) in the reaction. Deuterium was 
introduced in a NaBD4 reduction of (146) in MeOH. The resulting (E)-N-diphenylmethyl-
1-deutero-3-phenylprop-2-en-1-amine (157) was coupled with 2-iodo-3-nitrobenzoyl 
chloride (139) in CH2Cl2 in the presence of Et3N. (E)-N-Diphenylmethyl-2-iodo-3-nitro-
N-(1-deutero-3-phenylprop-2-enyl)benzamide (158) was formed in moderate yield 
(61%) (Scheme 39). Analogously to (148), the 1H NMR spectrum of (158) indicated the 
presence of two rotamers about the amide C-N bond (α:β 2:3). However, (158) is 
racemic with respect to the CHD centre, which was reflected in the spectrum (Figure 
21). 
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Scheme 39. Deuterium labelling reactions to give (E)-N-diphenylmethyl-2-iodo-3-nitro-N-(1-
deutero-3-phenylprop-2-enyl)benzamide (158). 
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Double bond migration / Heck reaction of (158) with Pd(Ph3P)4 and Et3N in refluxing 
MeCN for 2 h gave an equimolar mixture of isotopomers (162) and (151) (minor 
products) and a single isotopomer (161) (major product).  
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Scheme 40. Heck cyclisation of (E)-N-diphenylmethyl-2-iodo-3-nitro-N-(1-deutero-3-
phenylprop-2-enyl)benzamide. 
 
It was reasoned that a change of solvent to MeCN (b.p. 80 oC) might slow down the 
reaction and isolation of unreacted mono-D isotopomer would be possible to study 
probable double bond isomerisation and the isotopic composition of unreacted starting 
material (to help detect any kinetic deuterium isotope effect in the double bond 
migration). Reaction was stopped before completion and again the same trend 
(equimolar mixture of isotopomers (162) and (151) (minor products) and a single 
isotopomer (161) (major product)) of products was observed along with some 
unreacted starting material. All recovered starting material (158) carried one deuterium 
at the original position, showing that molecules were committed to cyclisation once they 
had reacted initially with Pd. All the 4-benzylidine-2,3-dihydroisoquinolone product 
contained one deuterium located at position-3 (161), with no material which either 
contained no deuterium or had migrated (which would have been located at PhCD=). 
Failure to isolate any of the double-bond migrated mono-D isotopomer (164) suggests 
that C=C migration in the starting material is slow relative to ring-closure under these 
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conditions. In the mechanism outlined in Scheme 40, (Z)-4-benzylidene-2-
diphenylmethyl-3-deutero-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (161) was formed 
following route A (no double bond migration). If the C=C migration takes place and the 
reaction follows route B, then there are three possible intermediates: (159) formed by 
migration of H, (160) formed by migration of D and (163) formed by loss of deuterium 
and introduction of “migrated” H from a different source were predicted. None of the 
above intermediates were isolated.  
 
Cyclisations of these intermediates were expected to give (162) (164) and (151), 
respectively. However, formation of an equimolar mixture of isotopomers 2-
diphenylmethyl-3-deutero-5-nitro-4-phenylmethylisoquinolin-1(2H)-one (162) and 2-
diphenylmethyl-5-nitro-4-phenylmethylisoquinolin-1(2H)-one (151) suggested that 
reaction proceeds via the intermediates (159) and (163) only. Thus deuterium does not 
appear to migrate, possibly owing to a large kinetic deuterium isotope effect. Formation 
of (151) from (163) indicates loss of deuterium during the process and introduction of H 
from a different source. Failure to form any of (164) rules out the migration of 
deuterium. 
 
One of the measures taken to slow down the Heck cyclisation is to replace iodine with 
the less reactive leaving group bromine. It was expected that replacement of iodine 
with bromine and use of MeCN as solvent will slow the reaction, and isolation of 
intermediates would be more straightforward. This approach may also allow more time 
for double bond migration to occur before cyclisation. The synthetic route for the 
preparation of the aryl bromide, (E)-2-bromo-N-diphenylmethyl-3-nitro-N-(1-deutero-3-
phenylprop-2-enyl) benzamide is presented in Scheme 41. 2-Bromo-3-nitrobenzoic 
acid (165) was satisfactorily synthesised through mercuration (mercury(II) acetate) and 
bromination (sodium bromide/bromine) of 3-nitrophthalic acid and this gave a white 
solid in good yield (66%). 2-Bromo-3-nitrobenzoyl chloride (166) was prepared from 
(165) by treatment with thionyl chloride in the presence of catalytic DMF. This, on 
coupling with (E)-N-diphenylmethyl-1-deutero-3-phenylprop-2-en-1-amine (157) in 
CH2Cl2 in the presence of Et3N, gave (E)-2-bromo-N-diphenylmethyl-3-nitro-N-(1-
deutero-3-phenylprop-2-enyl) benzamide (167) in moderate yield (54%). Again, the 
NMR spectrum showed a 2:3 mixture of rotamers α and β about the amide bond. 
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Scheme 41. Synthetic route for the preparation and double-bond migration / Heck cyclisation of 
(E)-2-bromo-N-diphenylmethyl-3-nitro-N-(1-deutero-3-phenylprop-2-enyl) benzamide (163). 
 
Intramolecular Heck reaction of (167) was carried out with Pd(Ph3P)4 and Et3N in 
refluxing MeCN. After 48 h, along with the unreacted starting material (167), an 
equimolar mixture of isotopomers (162) and (151) (minor products) and a single 
isotopomer (161) (major product) were isolated. The repeated failure to isolate the 
double-bond-migrated mono-D isotopomer intermediate despite the formation of 
double-bond-migrated products of cyclisation (151) / (162) was most puzzling. This 
observation is again consistent with the migration of the C=C after Heck cyclisation, i.e. 
the Br is not sufficiently slower in coupling to allow migration before coupling. Attempts 
to remove the benzhydryl group on nitrogen of (Z)-4-benzylidene-2-diphenylmethyl-5-
nitro-3,4-dihydroisoquinolin-1(2H)-one (152) using trifluoroacetic acid were 
unsuccessful.  
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3.4.6 Synthesis of secondary amides  
 
As explained in section 3.4.3 it was reasoned that secondary amides should be 
disfavoured for intramolecular Heck coupling. However, owing to the complications 
involved with removal of the protecting groups (allyl and benzhydryl) in tertiary amides, 
it was decided to investigate secondary amides instead of tertiary amides. Thus, the 
synthesis of secondary amides was undertaken. The first one to be synthesised was 2-
iodo-3-nitro-N-(prop-2-enyl)benzamide (143), which was prepared by coupling prop-2-
en-1-amine with 2-iodo-3-nitrobenzoyl chloride (139) in the presence of two equivalents 
of Et3N at room temperature for 2 h (Scheme 42). The product was isolated in good 
yield (71%). An interesting by-product 3-nitro-N-(prop-2-enyl)-2-(prop-2-
enylamino)benzamide (168) was also isolated (10%) from the reaction.  
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Scheme 42. Preparation of 2-iodo-3-nitro-N-(prop-2-enyl)benzamide (143). 
 
Compound (168) was formed as a result of SNAr (nucleophilic aromatic substitution) 
reaction of the very activated 2-iodo-3-nitro-N-(prop-2-enyl)benzamide (143). In this 
addition-elimination mechanism (Scheme 43), the electron-withdrawing nitro and 
carbonyl functional groups positioned ortho to the halide leaving group activate the ring 
towards nucleophilic attack. Prop-2-en-1-amine acts as a nucleophile and displaces 
iodine, a good leaving group, on the aromatic ring.  
 
NH
I
N H2N
O
OO
NH
N
O
O O
NH
I
NH
N
H
N
O
OO
(168)(143)
 
 
Scheme 43. SNAr addition-elimination mechanism proposed to form (168).  
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The 1H NMR spectrum of (168) showed broad singlets for each NH, one at δ 6.82 
corresponding to the NH attached to the benzene ring, and another further downfield at 
δ 7.72 for the NH of the carboxamide. The structure of (168) was confirmed by X-ray 
crystallographic analysis (Figure 25). Interestingly, despite the presence of 
neighbouring nitro and secondary amide groups, no intramolecular hydrogen-bonding 
interactions were observed from the amine N-H in the crystal structure of (168). 
Intermolecular hydrogen-bonding was observed between the carbonyl oxygen and 
carboxamide N-H of the neighbouring molecule. 
 
 
 
Figure 25. X-ray crystal structure of 3-nitro-N-(prop-2-enyl)-2-(prop-2-enylamino)benzamide 
(168) with crystallographic numbering. 
 
3.4.7 Alternative approach to 4-substituted 5-aminoisoquinolin-1-ones via a 
Pinner reaction  
 
With the secondary amide (143) in hand, slight modification of the synthetic approach 
to 4-substituted-5-aminoisoquinolin-1-ones was attempted. In this newly proposed 
route (Scheme 44), introduction of a methyl group on the carbonyl oxygen was 
attempted to avoid problems of rotation about the carboxamide bond. Once this was 
done, Heck cyclisation on (E)-methyl N-allyl-2-iodo-3-nitrobenzimidate (169) was 
expected to furnish 1-methoxy-4-methyl-5-nitroisoquinoline. Demethylation with HBr / 
HOAc or with trimethylsilyl iodide would give 4-substituted-5-nitro isoquinolin-1-one 
(107) which, on reduction with tin(II) chloride, would give the target (106).  
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Scheme 44. Proposed alternative synthetic approach to target (106) via a Pinner reaction. 
 
Methylation was attempted on the secondary amide (143) using the powerful 
methylating agent and hard electrophile methyl trifluoromethanesulfonate (MeOTf) in 
CH2Cl2. The reaction did not proceed as expected. Change of solvent to dioxane did 
not alter the outcome. In a further experiment the anion was generated with the strong 
non-nucleophilic base LHMDS but failed to react with the MeOTf. Attempts with 
trimethyloxonium tetrafluoroborate and TMSOTf followed the same outcome. The 
inability to synthesise (E)-methyl N-allyl-2-iodo-3-nitrobenzimidate (169) prompted us to 
look for alternative routes. This led us to explore the Pinner reaction where a nitrile is 
converted to the hydrochloric acid salt of an imino ester or an alkyl imidate, on reaction 
with alcohol under acid catalysis. To carry out this reaction, 2-iodo-3-nitrobenzonitrile 
(171) was needed. This was easily achieved in excellent yield from acid chloride (139), 
via dehydration of its corresponding amide (170), as shown in Scheme 44. The Pinner 
reaction is the partial solvolysis of a nitrile to yield an iminoether (Scheme 45). N-
Alkylation with 3-bromoprop-1-ene should furnish (E)-methyl N-allyl-2-iodo-3-
nitrobenzimidate (169).  
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Scheme 45. General mechanism proposed for Pinner reaction 
 
Surprisingly, treatment of the 2-iodo-3-nitrobenzonitrile (171) with gaseous HCl in 
anhydrous MeOH did not furnish the imidate salt as expected. Only the starting 
material was recovered from the reaction. Change of acid to stronger trifluoroacetic 
acid also gave the same result. Failure to synthesise (E)-methyl N-allyl-2-iodo-3-
nitrobenzimidate (169) meant that the route outlined in Scheme 44 was no longer 
viable. 
 
3.4.8 Synthesis and Heck cyclisations of prop-2-enyl-2-iodo-3-nitrobenzoate  
 
In our continuing efforts to optimise the reaction conditions for Heck cyclisation we 
decided to synthesise the ester prop-2-enyl-2-iodo-3-nitrobenzoate (173) and conduct 
the intramolecular cyclisation on this ester, which should not suffer from conformational 
problems. The ester (173) was easily synthesised by reaction of acid chloride (139) 
with prop-2-en-1-ol in CH2Cl2 in good yield (64%) (Scheme 46). Intramolecular Heck 
cyclisation under the initial conditions (Pd(Ph3P)4, Et3N in refluxing EtCN for 2 d gave 
the starting material unchanged. Change of solvent to DMF and base to N,N-diiso-
propylethylamine (DIPEA) and refluxing at 150  oC for 24 h resulted in formation of N,N-
dimethyl-3-nitrobenzamide (174) as sole product. DMF at high temperatures (150 oC) 
for a long time (24 h) breaks down to dimethylamine and carbon monoxide. Under such 
strong reducing conditions deiodination takes place and the dimethylamine displaces 
the ester thus forming (174). 
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Scheme 46. Synthesis and Heck cyclisations of prop-2-enyl-2-iodo-3-nitrobenzoate (173). 
 
3.4.9 Secondary amides and improved conditions for Heck cyclisations 
 
As discussed in section 3.4.6, synthesis of secondary amides was required to carry out 
the intramolecular Heck cyclisation. 2-Iodo-3-nitro-N-(prop-2-enyl)benzamide (143) was 
prepared by coupling prop-2-en-1-amine with 2-iodo-3-nitrobenzoyl chloride (139) in 
the presence of Et3N (Scheme 42). The Heck reaction of this secondary amide (143) 
with (Pd(Ph3P)4, Et3N, boiling EtCN, 24 h) gave the dehalogenated amide 3-nitro-N-
(prop-2-enyl)benzamide (175), the C=C migrated and dehalogenated amide (E)-3-nitro-
N-(prop-1-enyl)benzamide (176) and an inseparable mixture of the target 4-methyl-5-
nitroisoquinolin-1(2H)-one (177) and 4-methylene-5-nitro-3,4-dihydroisoquinolin-1(2H)-
one (178) in 1:1 ratio (Scheme 47). 
 
Larock et al197 reported the synthesis of various other nitrogen heterocycles via 
palladium-catalysed intramolecular Heck cyclisation and stated that 2% Pd(OAc)2 in the 
presence of Bu4NCl (phase-transfer catalyst), DMF and appropriate base (Na2CO3, 
NaOAc or Et3N) forms excellent catalytic systems. Keeping this finding in mind, in an 
alternative approach, Pd(Ph3P)4, Et3N and Bu4NCl were used in DMF at various 
temperatures to cyclise (143).  
• At 50 oC after 48 h, the reaction was not complete. However, (177) and (178) 
were formed in 1:1 ratio along with dehalogenated amide (175).  
• At 100 oC after 48 h, the ratio of (177) to (178) was the more favourable 2.5:1. 
The reaction was not complete as some of the starting material was also 
isolated along with dehalogenated amide (175). 
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• At 150 oC after 16 h, the reaction was complete, with target 4-methyl-5-
nitroisoquinolin-1(2H)-one (177) as the sole product in 66% yield. In this 
reaction, Pd(Ph3P)4, Et3N and Bu4NCl in DMF were mixed in the flask which 
was placed in a preheated oil bath at 150 oC. The compound to be cyclised 
(143) was added later. This was done since these reactions indicated that C=C 
migration required higher temperatures and that deiodination occurs even at 
low temperatures. 
 
 
Scheme 47. Various reaction conditions attempted for the synthesis of 4-Methyl-5-
nitroisoquinolin-1(2H)-one (177). Numbers on the arrows indicate the reaction conditions and 
temperatures used in individual reactions as entered in table 14. 
 
Table 14. Different reaction conditions employed for Heck cyclisation of (143). 
Entry Reaction conditions 
Temperature 
in 
 o
C 
Products 
Ratio of 
(172) to (173) 
1 
5 mol% Pd(Ph3P)4, EtCN,  Et3N 
(2 equiv.) 
100 
(175), (176), 
(177), (178) 
1:1 
2 
2 mol% Pd(Ph3P)4, DMF, Bu4NCl 
(1 equiv.) Et3N (2 equiv.) 
50 
(175), (177), 
(178) 
1:1 
3 
2 mol% Pd(Ph3P)4, DMF, Bu4NCl 
(1 equiv.) Et3N (2 equiv.) 
100 
(175), (177), 
(178) 
2.5:1 
4 
2 mol% Pd(Ph3P)4, DMF, Bu4NCl 
(1 equiv.) Et3N (2 equiv.) 
150 (fast 
heating) 
(177)  
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Dehalogenation to form (175) was a commonly observed phenomenon in Pd-catalysed 
couplings and is a result of decomposition of the intermediate aryl palladium, which had 
failed to undergo cyclisation and subsequent protonation.198 It was observed that 2 
mol% Pd(Ph3P)4, Bu4NCl (1 equiv.) and Et3N (2 equiv.) in DMF refluxing at 150
 oC is 
the best reaction condition, and it was decided to follow the same for further 
intramolecular Heck cyclisations.  
 
3.4.10 Double bond isomerisation study 
 
Recently, some ruthenium and rhodium complexes were reported to catalyse the 
isomerisation of N-allylamides to the corresponding 1-propenyl derivatives.199,200 
Following this protocol, double-bond isomerisation of 2-iodo-3-nitro-N-(prop-2-
enyl)benzamide (143) was carried out using 0.5% RuClH(CO)(PPh3)3 in benzene at 80
 
oC for 3 h. The double-bond-migrated product (E)-2-iodo-3-nitro-N-(prop-1-
enyl)benzamide (179) was formed in excellent yield (96%) (Scheme 48). The reaction 
could be described as being E-selective as the Z-enamide was detected only in traces. 
This is the result of a specific coordination of the metal atom by the substrates and 
products of double-bond migration.200  
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benzene, 80oC
RuClH(CO)(PPh3)3
O
NH
I
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Pd(Ph3P)4, Et3N
 DMF, Bu4NCl
NO2
NH
O
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NO2
NH2
O
(180)
NO2
NH
O
I
NH
O
CH3NO2
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Scheme 48. Double bond isomerisation of 2-iodo-3-nitro-N-(prop-2-enyl)benzamide (143) to 
(E)-2-iodo-3-nitro-N-(prop-1-enyl)benzamide (179) and attempted Heck cyclisation of (179). 
 
To test whether this prior C=C bond migration might enhance the formation of 4-
methyl-5-nitroisoquinolin-1(2H)-one (177), Heck cyclisation was carried out according 
to the modified conditions (2 mol% Pd(Ph3P)4, Bu4NCl (1 equiv.) and Et3N (2 equiv.) in 
DMF refluxing at 150 oC). Curiously, (179) failed to cyclise under Pd-catalysis; the 
dehalogenated amide (176) and 3-nitrobenzamide (180) were among the products 
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isolated (Scheme 48). The reaction when repeated at 100 oC, resulted in isolation of 
unreacted starting material along with (176) and (180). Formation of dehalogenated 
amide (176) could be explained as a result of decomposition of the intermediate aryl 
palladium, which had failed to undergo cyclisation and subsequent protonation. 
Compound 3-nitrobenzamide (180) might have formed by decomposition of amide 
(176). Interestingly, the much anticipated cyclised compound (177) was not formed. 
 
Now that optimum conditions for Heck cyclisation had been established, the tertiary 
amides (141) and (148) were investigated using the same protocol. The tertiary amides 
(141) and (148) also gave greater proportions of the desired 4-substituted isoquinolin-
1-one isomer under the modified conditions. Compound (141) gave (149) and (150) 
(8:1) and (148) gave (151) and (152) (3:1). 
 
Repetitions of Heck cyclisations of (143) in larger scales (0.25 g) under the modified 
conditions were found to give 78% of inseparable mixtures of 4-methyl-5-nitro-
isoquinolin-1(2H)-one (177) isomer along with the undesired, 4-methylene-5-nitro-3,4-
dihydroisoquinolin-1(2H)-one (178) in 5:1 ratio. The deiodinated amide (175) was 
formed in 19% yield. This led us to conclude that these tandem double bond migration / 
Heck cyclisations under the modified conditions may be scale-sensitive.  
 
Further exploring this reaction, we decided to introduce a Boc protecting group on the 
amide nitrogen of (143). This was done keeping in mind the bulky nature of Boc group 
in the tertiary imide which might direct the ring-forming allyl group to be in close vicinity 
to the 2-iodo group, thus increasing the rotamer population favoured for the Heck 
cyclisation. The Boc group should also improve solubility. This was accomplished by 
using (Boc)2O, and DMAP in the presence of Et3N in good yield (92%). The Heck 
cyclisation of tert-butyl N-prop-2-enyl-N-(2-iodo-3-nitrobenzoyl)carbamate (181) 
resulted in (177) and (178) in the ratio of 1:1 (Scheme 49). It was thought that thermal 
loss of N-Boc occurred only after cyclisation as the ratio of (177) and (178) was not 5:1 
as in the previous experiment, where the Boc group was absent. 
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Scheme 49. Introduction of N-Boc protection and Heck cyclisation of (181). 
 
Having successfully synthesised 4-methyl-5-nitroisoquinolin-1(2H)-one (177), attempts 
were then made to reduce selectively the nitro function via catalytic hydrogenation with 
10% palladium on charcoal (Pd/C) and hydrogen in the presence of few drops of conc. 
HCl in ethanol (Scheme 50). The product, 5-amino-4-methylisoquinolin-1(2H)-one 
hydrochloride (182) was isolated in excellent yield (70%) as buff crystals. Thus, the first 
4-substituted analogue of 5-AIQ had been synthesised. 
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Scheme 50. Reduction of nitro function of (177) to form 5-amino-4-methylisoquinolin-1(2H)-one 
hydrochloride (182).  
 
3.4.11 Synthesis of 5-amino-4-benzylisoquinolin-1(2H)-one 
 
Following the successful synthesis of 5-amino-4-methylisoquinolin-1(2H)-one 
hydrochloride (182), attention was now focussed towards introducing a benzyl group at 
the 4-position. For this, it was necessary to couple (E)-3-phenylprop-2-en-1-amine 
(185) with 2-iodo-3-nitrobenzoyl chloride (139). Since compound (185) was not 
commercially available, the preliminary aim was to synthesise this primary amine. 
Nucleophilic substitution of (E)-(3-bromoprop-1-enyl)benzene with the potassium salt of 
trifluoroacetamide which was prepared in situ from trifluoroacetamide and potassium t-
butoxide in dry THF, gave (E)-N-(3-phenylprop-2-enyl)2,2,2-trifluoroacetamide (184) 
(33%).201 A lower yield of (7%) highly lipophilic ion-pair of (E)-3-phenylprop-2-enylamine 
trifluoroacetate salt (183) was also isolated. The N-trifluoroacetyl (N-TFA) group was 
 115 
considered as it is easily removed by nucleophiles (ammonia, sodium carbonate) to 
generate the primary amines. The trifluoroacetamide (184) was cleaved either by 
ammonia in methanol or by reduction with sodium borohydride in ethanol to furnish (E)-
3-phenylprop-2-enylamine (185). This primary amine, on coupling with the acid chloride 
(139), afforded (E)-2-iodo-3-nitro-N-(3-phenylprop-2-enyl)benzamide (186) in good 
yield (74%) as yellow crystals (Scheme 51).  
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Scheme 51. Synthetic route to 4-benzyl-5-nitroisoquinolin-1(2H)-one (187). 
 
Double bond migration / Heck cyclisation of (186) was carried out under the previously 
optimised conditions (Pd(Ph3P)4, Et3N, Bu4NCl, DMF, 150
 oC quick heating) for 48 h. 
Products isolated included a separable mixture of isomers 4-benzyl-5-nitroisoquinolin-
1(2H)-one (187) (17%) and (Z)-4-benzylidene-5-nitro-3,4-dihydroisoquinolin-1(2H)-one 
(188) (14%), along with the dehalogenated products (E)-3-nitro-N-(3-phenylprop-2-
enyl)benzamide (189) (11%) and traces of 3-nitro benzamide (180). About 14% of (E)-
3-amino-2-chloro-N-(3-phenylprop-2-enyl)benzamide (190) was also isolated as yellow 
crystals (Scheme 51). It appears that chloride from Bu4NCl replaced the iodine by SNAr 
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reaction (Scheme 52) and reduction of the nitro group might have occurred under Pd-
catalysis. 
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Scheme 52. SNAr addition-elimination mechanism proposed to form (191).  
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Scheme 53. Reduction of nitro functional groups of (187) and (188) using (H2/Pd/C) catalyst. 
 
Attempts to carry out selective reduction of the nitro group of (187) using 10% 
palladium on charcoal (Pd/C) and hydrogen in the presence of few drops of conc. HCl 
in EtOH gave the desired amine (192) with some unidentified impurities. Repeated 
attempts at recrystallisation (EtOH) to purify the product (192) failed. It was speculated 
that use of HCl prompts the cyclisation between the 5-amino group and the methylene 
group at the 4-position thus forming a compound like (195) which was taken to be the 
impurity. Hence, the reduction of (187) was carried out without conc. HCl and gave the 
desired amine (192) in 51% yield as a buff powder (Scheme 53). It was found that 
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Pd/C/H2 catalytic system reduces the double bond at the 3,4 position of (192) along 
with the nitro group as traces of 5-amino-4-benzyl-3,4-dihydroisoquinolin-1(2H)-one 
(193) were also identified in 1H NMR spectra of (192). Interestingly, reduction of (188) 
with Pd/C/H2 furnished an inseparable mixture of (193) and (192) in 4:1 ratio and none 
of the anticipated compound (194) was isolated. Formation of (192) from (188) is 
possible only by the migration of the exocyclic double bond into the ring. It is not clear 
whether the double bond migration occurs before reduction of the nitro group or after. 
 
3.4.12 Attempted synthesis of 5-amino-4-ethylisoquinolin-1(2H)-one  
 
Following the success in synthesis of (192) it was decided to extend the same 
methodology to synthesise the 5-amino-4-ethylisoquinolin-1(2H)-one. Since the 
compound but-2-en-1-amine (200) was not commercially available we needed to 
synthesise the same. At first thepotassium salt of trifluoroacetamide, which was 
prepared in situ from trifluoroacetamide and potassium t-butoxide in dry THF, was 
made to react with 1-bromobut-2-ene (available as mixture of E- and Z- isomers (5:1)). 
A yield of 33% of inseparable E- and Z-isomers of N-(but-2-enyl)-2,2,2-
trifluoroacetamide was obtained in the ratio 3:1 and 6% of the disubstituted E- and Z-
isomers of N,N-di(but-2-enyl)-2,2,2-trifluoroacetamide (197) and (198) in 4:1 ratio along 
with traces of EZ-compound (199). The mixture of E- and Z-trifluoroacetamides (195) 
and (196) was hydrolysed using alkali (10% aq. NaOH) to give a mixture of (E) and (Z) 
but-2-en-1-amines (200) and (201). This compound was not isolated for analysis as its 
boiling point was too low. It was used in the coupling without further purification. This, 
on coupling with the acid chloride (139) furnished an inseparable mixture of E- and Z-
isomers of N-(but-2-enyl)-2-iodo-3-nitrobenzamide (202) and (203) in the ratio 5:1 
(72%) as yellow crystals.  
 
The mixture of E- and Z-isomers of (202) and (203) was subjected to Heck cyclisation 
under optimised conditions (Pd(Ph3P)4, Et3N, Bu4NCl, DMF, 150
 oC quick heating,) for 
48 h. Curiously, the above mixture failed to cyclise under Pd-catalysis as none of the 
anticipated product 5-nitro-4-ethylisoquinolin-1(2H)-one (208) or the isomer (209) were 
formed. However 21% of E- and Z-isomers of the dehalogenated amide (204) and 
(205) in 4:1 ratio and 15% of E- and Z-isomers of 3-amino-N-(but-2-enyl)-2-
chlorobenzamide (206) and (207) in 4:1 ratio were the only products isolated (Scheme 
52). Compound (206) is believed to be formed as a result of SNAr addition-elimination 
reaction and reduction of nitro group under Pd-catalysis. Again the order of these two 
reactions was not clear. To avoid the formation of this type of compound and to 
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optimise the yield of desired cyclised products it was decided at this stage to use Bu4NI 
as phase transfer catalyst, instead of Bu4NCl, so that the SNAr reaction would be futile. 
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Scheme 54. Attempted synthesis of 5-nitro-4-ethylisoquinolin-1(2H)-one (208) via Heck 
cyclisation  
 
Failure to cyclise E- and Z-isomers of (202) and (203) was puzzling since we were 
successful in introducing the analogous methyl and benzyl groups to the 4-position of 
5-aminoisoquinolin-1-one. 
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3.4.13 Synthesis of 5-amino-4-(4-methylbenzyl)isoquinolin-1(2H)-one and 5-
amino-4-(4-methoxybenzyl)isoquinolin-1(2H)-one 
 
One of the main aims of the project was to introduce benzyl and substituted benzyl 
groups into the 4-position of 5-aminoisoquinolin-1(2H)-one. We were successful in 
synthesising 5-amino-4-benzylisoquinolin-1(2H)-one (192). Now attention was turned 
towards synthesising 5-amino-4-(4-methylbenzyl)isoquinolin-1(2H)-one and 5-amino-4-
(4-methoxybenzyl)isoquinolin-1(2H)-one. 
 
To accomplish this, it was necessary to synthesise substituted cinnamylamines such as 
3-(4-methylphenyl)prop-2-en-1-amine and 3-(4-methoxyphenyl)prop-2-en-1-amine. Ar-
substituted 3-phenylprop-2-enylamines could be synthesised by Heck coupling of 
substituted aryl halides and 2-allylisoindoline-1,3-dione, and subsequent deprotection 
of the product with hydrazine hydrate to generate the amines.202 Keeping in view the 
diversity of the aromatic residues that could be used in this coupling this method was 
investigated for the synthesis of 3-(4-methylphenyl)prop-2-en-1-amine and 3-(4-
methoxyphenyl)prop-2-en-1-amines. In this Pd(OAc)2-catalysed reaction, 2-
allylisoindoline-1,3-dione was coupled to an aromatic halide in the presence of Et3N in 
acetonitrile. The amines were generated by refluxing with hydrazine hydrate in ethanol.  
 
Synthesis of the precursor 2-allylisoindoline-1,3-dione was necessary as it was not 
commercially unavailable. Boiling phthalic anhydride with prop-2-en-1-amine in acetic 
acid and aqueous work-up and recrystallisation (EtOAc) gave 87% of (210) as white 
needles. The aryl halides, 4-iodotoluene and 4-iodoanisole were used to introduce 4-
methylbenzyl and 4-methoxybenzyl substituents on 5-aminoisoquinolin-1-one, 
respectively. The next step involved Pd(OAc)2 (1 mol %)-catalysed Heck coupling of 
(210) to 4-iodotoluene and 1-iodo-4-methoxybenzene, respectively, with two 
equivalents of Et3N, which also served as solvent for 16 h.. The mechanism of this 
reaction is as shown in section 3.4.4 (Scheme 37). In both cases, the trans (E) 
stereoisomer was the only product detected and isolated. The resulting (E)-2-(3-(4-
methylphenyl)prop-2-enyl)isoindoline-1,3-dione (211) and (E)-2-(3-(4-methoxyphenyl) 
prop-2-enyl)isoindoline-1,3-dione (212) were refluxed with one equivalent of hydrazine 
hydrate in EtOH. Alkaline workup and extraction with Et2O and CH2Cl2 afforded the 
amines (213) (65%) and (214) (89%), respectively as yellow oils (Scheme 55). These 
primary amines, on coupling with the acid chloride (139), afforded (215) (82%) and 
(216) (75%), respectively, ready for attempts to carry out tandem double bond 
migration / intramolecular Heck coupling.  
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Scheme 55. Synthesis of 3-(4-methylphenyl)prop-2-en-1-amine (213) and 3-(4-
methoxyphenyl)prop-2-en-1-amine (214). 
 
As discussed earlier in Section 3.4.12, to avoid the formation of SNAr reaction product 
(chloride from Bu4NCl replacing the iodine) and to optimise the yield of desired cyclised 
products, it was decided to use Bu4NI as phase transfer-catalyst, instead of Bu4NCl. 
Double bond migration / Heck cyclisation of (215) and (216) was carried out under the 
previously optimised conditions (Pd(Ph3P)4, Et3N, Bu4NI, DMF, 150
 oC quick heating) 
for 48 h (Scheme 56). Products isolated from Heck cyclisation of (215) included an 
inseparable mixture of (217) and (218) in the ratio (3:1) (17 mg, 16%). Formation of 
dehalogenated amide (E)-N-(3-(4-methylphenyl)prop-2-enyl)-3-nitro benzamide (217) 
could be explained as a result of decomposition of the intermediate aryl palladium, 
which had failed to undergo cyclisation and subsequent protonation. However, 
reduction of double bond in the side chain to form N-(3-(4-methylphenyl)propyl)-3-
nitrobenzamide (218) might have occurred under Pd-catalysis. The reaction also 
yielded separable mixture of isomers 4-(4-methylbenzyl)-5-nitroisoquinolin-1(2H)-one 
(219) (15%) and (Z)-4-(4-methylbenzylidene)-5-nitro-3,4-dihydroisoquinolin-1(2H)-one 
4-benzyl-5-nitroisoquinolin-1(2H)-one (220) (13%) and traces of 3-nitrobenzamide 
(180).  
 
Selective reduction of the nitro group of (219) using 10% palladium on charcoal (Pd/C) 
and hydrogen in EtOH gave an inseparable mixture of the desired amine 5-amino-4-(4-
methylbenzyl)isoquinolin-1(2H)-one (221) and 5-amino-4-(4-methylbenzyl)-3,4-
dihydroisoquinolin-1(2H)-one (222) in the ratio 10:3 (51%). Reduction of the nitro group 
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of (220) under same conditions as above gave an inseparable mixture (222) and (221) 
in the ratio 11:9 (42%). 
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Scheme 56. Synthesis and Heck coupling of (E)-2-iodo-3-nitro-N-(3-(4-methylphenyl)prop-2-
enyl)benzamide (215) and (E)-2-iodo-N-(3-(4-methoxyphenyl)prop-2-enyl)-3-nitrobenzamide 
 (216). 
 
Products isolated from Heck cyclisation of (E)-2-iodo-N-(3-(4-methoxyphenyl)prop-2-
enyl)-3-nitrobenzamide (216) included an inseparable mixture of dehalogenated amide 
(223) and double-bond reduced dehalogenated amide (224) in the ratio 2:3 (19%). Also 
isolated were separable mixture of cyclised isomers 4-(4-methoxybenzyl)-5-
nitroisoquinolin-1(2H)-one (225) (17%) and (Z)-4-(4-methoxybenzylidene)-5-nitro-3,4-
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dihydroisoquinolin-1(2H)-one (226) (15%). Reduction of the nitro group of (225) using 
10% palladium on charcoal (Pd/C) and hydrogen in EtOH afforded an inseparable 
mixture of the desired amine 5-amino-4-(4-methoxybenzyl)isoquinolin-1(2H)-one (227) 
and 5-amino-4-(4-methoxybenzyl)-3,4-dihydroisoquinolin-1(2H)-one (228) in the ratio 
1:2 (53%). Reduction of the nitro group of (226) was not attempted, owing to shortage 
of material. 
 
3.4.14 Synthesis of 5-1-(3-((5-nitro-1-oxo-1,2-dihydroisoquinolin-4-
yl)methyl)phenyl)pyrrolidine-2,5-dione 
 
In the continuing quest to introduce substituted benzyl groups, it was decided to 
introduce the bulkier 3-succinimidobenzyl as a substituent into the 4-position of 5-
aminoisoquinolin-1(2H)-one. Initial experiments included synthesis of 1-(3-
iodophenyl)pyrrolidine-2,5-dione (230) from heating succinic anhydride and 3-
iodoaniline at 190 oC for 6 h. Experiment was carried out with slow increase of 
temperature. At 150 oC formation of 4-(3-iodophenylamino)-4-oxobutanoic acid (229) 
was identified. Further increase in temperature to 190 oC afforded (230) (74%) as buff 
crystals. In the Pd(OAc)2-catalysed  reaction, two equivalents of Et3N served as both 
base and solvent. 2-Allylisoindoline-1,3-dione was coupled to (230) in Et3N for 24 h to 
furnish (E)-2-(3-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)isoindoline-1,3-dione 
(231) (86%). However, the usual method of generating amines by refluxing with 
hydrazine hydrate in ethanol failed to occur as none of the amine (232) was formed as 
hydrazine attacked the succinimide ring (Scheme 57). 
 
In the process of synthesising (E)-1-(3-(3-aminoprop-1-enyl)phenyl)pyrrolidine-2,5-
dione (232), firstly tert-butyl N-(prop-2-enyl)carbamate (233) (83%) was prepared by 
coupling prop-2-en-1-amine with di(tert-butyl) dicarbonate in CH2Cl2 for 3 h. Heck 
coupling of substituted aryl halide (230) and (233) using Pd(OAc)2 (1 mol %) and two 
equivalents of Et3N, under nitrogen for 48 h gave an inseparable mixture of (234) and 
the undesired regioisomer (235) in 4:1 ratio (Scheme 58). 
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Scheme 57. Attempted synthesis of (E)-1-(3-(3-aminoprop-1-enyl)phenyl)pyrrolidine-2,5-dione 
(232)  
 
Removal of the Boc group using trifluoroacetic acid in CH2Cl2 did not give the 
anticipated amine but instead gave a mixture of unidentified products. Passage of dry 
HCl to the solution of (234) and (235) in CH2Cl2 generated the mixture of amines (236) 
and (237) as hydrochloride salts (detected by TLC). This compound was not isolated 
for analysis and in its crude form was coupled with acid chloride (139) to furnish an 
inseparable mixture of (E)-N-(3-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)-3-
nitrobenzamide (238) and N-(2-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)-3-
nitrobenzamide (239) (4:1) in 32% yield.  
 
Double bond migration / Heck cyclisation of mixture of (238) and (239) was carried out 
under the previously used conditions (Pd(Ph3P)4, Et3N, Bu4NI, DMF, 150
   oC quick 
heating) for 48 h. Products isolated included an inseparable mixture of dehalogenated 
amide (240) and the regioisomer (241) (4:1) (18%) along with inseparable mixture of 
cyclised 1-(3-((5-nitro-1-oxo-1,2-dihydroisoquinolin-4-yl)methyl)phenyl)pyrrolidine-2,5-
dione (242) and (Z)-1-(3-((5-nitro-1-oxo-2,3-dihydroisoquinolin-4(1H)ylidene)methyl)-
phenyl) pyrrolidine-2,5-dione (243) in 21% yield. Reduction of the nitro groups of (242) 
and (243) were not attempted, owing to shortage of material. 
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Scheme 58. Synthesis and Heck coupling of (E)-N-(3-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-
enyl)-3-nitrobenzamide (238)  
 
In conclusion, Pd-catalysed cyclisation of tertiary amides N,N-diallyl-2-iodo-3-
nitrobenzamide (141) and N-benzhydryl-N-cinnamyl-2-iodo-3-nitrobenzamide (148) 
gave two isomeric products, the 4-alkyl-5-nitroisoquinolin-1-ones (149) and (151) and 
the 4-alkyl-5-nitro-3,4-dihydroisoquinolin-1-ones (150) and (152). The corresponding 
secondary amide N-allyl-2-iodo-3-nitrobenzamide (143) cyclised efficiently to give (177) 
and (178). Pd-catalysed cyclisations of a series of secondary N-cinnamyl 2-iodo-3-
nitrobenzamides were also investigated. Catalytic hydrogenation was used to convert 
the 5-nitro groups of the 4-substituted isoquinolin-1-ones to provide the target 5-
aminoisoquinolin-1-ones.  
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4. Biological Evaluation 
 
4.1 PARP-1 inhibition assays  
 
The standard assay for monitoring PARP-1 activity involves the use of radiolabeled 
NAD+ (32P- or 3H).203,204 An ELISA assay uses an antibody to ADP-ribose205 and two 
recently described assays utilise206,207 biotinylated NAD+. The use of radioactive and/or 
specialized reagents (such as biotinylated NAD+ and antibodies) in these assays can 
make them expensive when screening large compound collections for PARP inhibition. 
In addition, these assays often involve either the separation of ADP-ribose polymer 
product from the NAD+ substrate or the addition of specialized streptavidin-conjugated 
scintillation proximity assay beads. Thus, the search for an inexpensive and convenient 
method for identifying PARP-1 inhibitors led us to a novel colorimetric PARP-1 assay 
developed by Trevigen Inc. (Gaithersburg, USA). The assay is non-radioactive and 
utilises 96- well plates for rapid screening for PARP inhibition. This assay is ideal for 
screening of PARP-1 inhibitors for in vitro activity.  
 
This assay is based on the fact that PARP-1 enzyme, during the heteromodification 
process, catalyses poly(ADP-ribosyl)ation of histone proteins in response to damaged 
DNA. At first the test inhibitor is pre-incubated with the PARP-1 enzyme on a 96 strip-
well plate coated with histone acceptor proteins for a brief period of time. A PARP-
cocktail reagent, containing biotinylated NAD+ (6-biotin-17-nicotinamide-adenine-
dinucleotide) (Figure 26) and activated DNA, is added to the wells to initiate the 
reaction. Upon activation, PARP-1 cleaves biotinylated NAD+ into nicotinamide and 
biotinylated (ADP-ribose) and synthesises biotinylated (ADP-ribose) polymers 
covalently attached to the acceptor histone proteins. The extent of biotin incorporation 
is measured using a conjugated streptavidin detection system. The PARP-1 inhibitory 
activity of the inhibitors is assessed on the basis of their inhibition of biotinyl-(ADP-
ribose) incorporation. The presence of biotinylated poly(ADP-ribose) generated by 
PARP-1 during the ribosylation of histone proteins coated on the 96-well plate was 
detected using streptavidin horseradish peroxidase (Strep-HRP) and TACS 
Sapphire™. The TACS Sapphire™ substrate generates a soluble blue colour in the 
presence of Strep-HRP with a maximum absorbance of 630 nm. The development of 
the colourimetric reaction was terminated by addition of 0.2 M hydrochloric acid, 
generating a yellow colour with an absorption maximum at 450 nm. 
 
 
 126 
 
 
Figure 26. Structure of biotinylated NAD+. 
 
4.1.1 PARP-1 calibration curve 
 
Firstly, a standard curve using different amounts of PARP-1 enzyme was prepared for 
the biotinylated poly(ADP-ribose) polymerisation reaction. As shown in Figure 27, a 
linear relationship exists between the absorbance at 450 nm and the concentration of 
the PARP-1 enzyme. From the standard curve, it was established that 0.8 units of 
PARP-1 enzyme was sufficient to give an absorbance reading in the range of 2.0-2.5 in 
the absence of any inhibitor. A negative control without PARP enzyme was included to 
determine the background absorbance.  
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Figure 27. PARP-1 calibration curve. Data are the mean of three replicants and are reported as 
mean ± standard error of the mean (SEM). 
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4.1.2 PARP-1 inhibitory activity of 4-substituted 5-aminoisoquinolin-1-ones 
 
Various 4-substituted 5-aminoisoquinolin-1(2H)-ones synthesised in this project were 
evaluated for in vitro activity using the colourimetric PARP assay system. 5-AIQ was 
used as the benchmark inhibitor and was evaluated in the assay for comparison 
purposes. In this evaluation, seven different concentrations (100, 30, 10, 3, 1, 0.3, 0.1 
µM) of each inhibitor, in a range surrounding the likely IC50 value, were used. Figure 28 
shows a colourimetric assay plate used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Colourimetric readout of PARP-1 activity assay with inhibitors 4-benzyl-5-
aminoisoquinolin-1(2H)-one (lane 1-3), 5-amino-4-benzyl-3,4-dihydroisoquinolin-1(2H)-one 
(lane 4-6), 4-bromo-5-aminoisoquinolin-1(2H)-one (lane 7-9), 5-AIQ (lane 10-12). Bottom row: 
wells 1-6 negative control without PARP enzyme, wells 7-12 positive control without PARP 
inhibitor.  
 
For each inhibitor, three determinations of activity were performed at each 
concentration. The IC50 value of the inhibitor was then estimated graphically from a plot 
of log10 [inhibitor] versus absorbance. These assays were highly sensitive and 
reproducible, with standard error of mean (SEM) of less than 20% for most compounds 
tested (Table 15). Figure 29 shows the PARP-1 inhibition curves of 4-methyl 
1 2 3 4 5 6 7 8 9 10 11 12 
100 µM 
30 µM 
10 µM 
3 µM 
1 µM 
0.3 µM 
0.1 µM 
negative control positive control 
5AIQ control Inhibitor 1 Inhibitor 2 Inhibitor 3 
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5-aminoisoquinolin-1(2H)-one (182). The complete results for the evaluation of 
4-substituted 5-aminoisoquinolin-1(2H)-ones are given in the Appendices. 
 
 Figure 29. PARP-1 inhibition curve for 4-methyl 5-aminoisoquinolin-1(2H)-one (182).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 15. The IC50 values of the various 4-substituted 5-aminoisoquinolin-1(2H)-ones. 
aData are 
the mean of three experiments and are reported as mean ± standard error of the mean (SEM). 
 
Compound 
number 
IC50 (µM) Log IC50 (µM)
a 
29d (5-AIQ) 
 
1.8 0.26 ± 0.14 
(182)  0.25 -0.6 ± 0.28 
 
(125)  1.0 -0.02 ± 0.06 
 
(192)  0.5 -0.34 ± 0.11 
 
(193)  2.8 0.45 ± 0.08 
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The inhibition calculated for 4-methyl 5-aminoisoquinolin-1(2H)-one (182) was 0.25 µM. 
It is evident from this result that (182) is an excellent PARP-1 inhibitor and is 7 times 
more potent than 5-AIQ (IC50=1.8 µM) under the colourimetric assay conditions. 
Similarly, 4-benzyl-5-aminoisoquinolin-1(2H)-one (192) also exhibited excellent PARP-
1 inhibitory activity with IC50= 0.5 µM. It is also interesting to note that 5-amino-4-
benzyl-3,4-dihydroisoquinolin-1(2H)-one (193) the saturated analogue of (192) was 
less potent with respect to 5-AIQ as demonstrated by its IC50 2.8 µM. 4-Bromo-5-
aminoisoquinolin-1(2H)-one (125), one of the intermediates in the synthesis also 
demonstrated good inhibitory properties with an IC50 value of 1.0 µM. 
 
It is proposed that the 4-substituted 5-aminoisoquinolin-1-one inhibitors bind to the 
nicotinamide sub-site of the NAD+-binding domain of PARP-1 (Figure 30). The 
carboxamide moiety of the inhibitor forms three important hydrogen bonds with the 
enzyme active site. The inhibitor carbonyl moiety accepts two hydrogen bonds, one 
from the amino-acid residue Ser904, and the other from the Gly863 N-H. The third 
hydrogen bond is formed between the Gly863 carbonyl oxygen and the carboxamide 
N-H. 
 
 
 
Figure 30. Proposed enzyme-inhibitor interactions between the PARP-1 active site and 4-
substituted 5-AIQs. 
 
In this study the effects of bulky aromatic substituents at the 4-position were 
investigated, which will interact with the hydrophobic residues in the binding pocket. 
The colourimetric PARP-1 assay identified four compounds with PARP-1 inhibitory 
activity equal or better than the lead compound 5-AIQ. In general, besides having a 
good water-solubility profile, most of the 4-substituted 5-aminoisoquinolin-1(2H)-ones 
exhibited excellent PARP-1 inhibitory potency with IC50 values in the low micromolar 
range. It appeared that the presence of a methyl substituent confers a slightly greater 
enhancement in PARP-1 inhibitory activity It is also interesting to note that the 
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introduction of a bromo group at the 4-position resulted in enhanced potency. This 
could be due to bromo being isosteric with methyl group. Bulky aryl substituents also 
enhanced the potency of the parent compound. Thus, compounds with bulky aromatic 
substituents at the 4-position were well tolerated.  
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5. Conclusions 
 
Various approaches to the synthesis of novel classes of PARP-1 inhibitor, 3-substituted 
and 4-substituted 5-aminoisoquinolin-1(2H) ones were investigated, building on the 
pharmacophore of 5-AIQ. One approach to the 3-substituted compounds was 
successful and a novel and versatile synthetic route has been developed to a series of 
water-soluble target compounds, bearing varying substituents at the 4-position. 
 
Initially cyclisations of methyl 2-alkynyl-3-nitrobenzoates with various electrophiles 
were studied. Cyclisations of methyl 3-nitro-2-phenylethynylbenzoate (85) with iodine 
monochloride and with phenylselenyl chloride followed the 6-endo route to give the 
isocoumarins (99) and (105) respectively. Similarly, cyclisation of methyl 3-nitro-2-
trimethylsilylethynylbenzoate (80) with phenylselenyl chloride afforded the isocoumarin 
(104). This isocoumarin is highly crowded, carrying a nitro group at the 5-position, a 
phenylselenyl group at the 4-position and a phenyl at the 3-position; this severe 
crowding was evident in an X-ray crystal structure, which showed significant out-of-
plane distortion of the heterocyclic ring and extensive intramolecular and intermolecular 
pi-stacking of the benzene rings. This demonstrates the directing influence of the 
electron-withdrawing nitro group on the electrophilicity of the alkyne. The observed 6-
endo regiochemistry could be due to the 3-nitro group inducing polarisation of the 
alkyne, making the remote sp-carbon remote from the aryl ring more electrophilic. 
However, the formation of methyl 2-acetyl-3-nitrobenzoate (95) by treatment of (80) 
and (82) with Hg(II) was exceptional and suggests that a 5-exo cyclisation took place 
by the change in electron-distribution caused by the formation of an intermediate 
alkynylmercury σ-complex. 4-Iodo-5-nitro-3-phenylisocoumarin (99), the product of 
iodocyclisation, could be exploited for the synthesis of 3- and 4-substituted 5-AIQs 
through various organometallic approaches. 
 
In the first route to the 4-substituted 5-AIQ analogues, efforts to introduce a benzyl 
group into the 4-position of 5-aminoisoquinolin-1(2H)-one were unsuccessful, as 
cyclisation of methyl 2-(1-cyano-2-phenylethyl)-3-nitrobenzoate (116), through selective 
reduction of the nitrile using DIBAL-H, failed to occur. Approach of DIBAL-H to the 
nitrile was sterically obstructed, leading to reduction of the ester to give 2-(2-formyl-6-
nitrophenyl)-3-phenylpropanenitrile (117). The second route relied on Pd-catalysed 
couplings of 4-bromoisoquinolin-1-one to synthesise the target molecule. Bromination 
of 5-nitroisoquinolin-1(2H)-one was achieved to give 4-bromo-5-nitroisoquinolin-1-one 
(124) but Pd-catalysed cross-couplings (Stille, Sonogashira, Suzuki-Miyaura) were 
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unsuccessful. Reduction of the hindering nitro group of (124) to amino furnished 5-
amino-4-bromoisoquinolin-1-one (125) which also failed to participate in any of the 
Pd(0) catalysed cross-coupling reactions.  
 
Much interesting chemistry was developed in the third route, which aimed at 
synthesising 4-substituted 5-aminoisoquinolin-1(2H)-ones via intramolecular Heck 
coupling of N-(alk-2-enyl)-2-iodo-3-nitrobenzamides. Pd-Catalysed cyclisation of 
tertiary amides N,N-diallyl-2-iodo-3-nitrobenzamide (141) and N-benzhydryl-N-
cinnamyl-2-iodo-3-nitrobenzamide (148) gave two isomeric products, the 4-alkyl-5-
nitroisoquinolin-1-ones (149) and (151) and the 4-alkyl-5-nitro-3,4-dihydroisoquinolin-1-
ones (150) and (152). The latter were derived from direct Heck cyclisation without prior 
C=C bond migration, while the former, required Pd-catalysed migration of the double 
bond into conjugation with the amide nitrogen before or after cyclisation. In deuterium 
labelling studies, failure to isolate any of the double-bond migrated mono-D isotopomer 
intermediate despite the formation of double-bond-migrated products of cyclisation 
(151) / (162) suggests that C=C migration occurs after Heck cyclisation, but the 
products were not interconvertable. The corresponding secondary amide N-allyl-2-iodo-
3-nitrobenzamide (143) cyclised efficiently to give (177) and (178). The ratios of the 
isomeric products varied with the reaction conditions. The optimum conditions for the 
reaction was found to be Pd(Ph3P)4, Et3N, Bu4NI, DMF with quick heating (150
 oC). 
Double-bond isomerisation of (143) was achieved by treatment with RuClH(CO)(PPh3)3 
giving the N-prop-1-enyl amide, which when subjected to the Pd-catalysed cyclisation 
conditions, gave only the uncyclised reductively deiodinated material (176). Pd-
catalysed cyclisations of a series of secondary N-cinnamyl 2-iodo-3-nitrobenzamides 
were also explored. The 4-unsubstituted cinnamylamine was prepared by displacement 
of the bromine of cinnamyl bromide with the anion derived from trifluoroacetamide, 
followed by cleavage of the amide by hydrolysis or reductively with sodium 
borohydride. The 4-substituted cinnamyl amines were synthesised by Heck coupling of 
a protected allylamine to the appropriate iodoarene to form the N-cinnamylphthalimides 
followed by hydrazinolysis. 3-Succimimidocinnamylamine (236) was prepared by Heck 
coupling of N-Boc-allylamine with N-(3-iodophenyl)succinimide (230), followed by 
deprotection. Pd-catalysed cyclisation of (186) afforded a chromatographically 
separable mixture of 4-benzyl-5-nitroisoquinolin-1-one (187) and the 4-benzylidene-5-
nitro-3,4-dihydroisoquinolin-1-one isomer (188). N-(substituted cinnamyl)benzamides 
(215), (216) and (238) also gave 4-(substituted benzyl)isoquinolin-1-ones (219), (225), 
(242) and the 4-(4-substituted benzylidene)-3,4-dihydroisoquinolin-1-ones (220), (226),. 
(243). Catalytic hydrogenation was used to convert the 5-nitro groups of the 4-
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substituted isoquinolin-1-ones to provide the target 5-aminoisoquinolin-1-ones. 5-
Amino-4-methylisoquinolin-1(2H)-one hydrochloride (182) was isolated in excellent 
yield. The 4-benzyl analogue (187), furnished the 5-amino-4-benzylisoquinolin-1-one 
(192) contaminated with a small trace of the over-reduced 5-amino-4-benzyl-3,4-
dihydroisoquinolin-1-one (193). Interestingly, 4-benzylidene-3,4-dihydroisoquinolin-1-
one gave (193) along with (192), suggesting possible C=C bond migration on the Pd 
metal surface. Unfortunately, it was not possible to reduce the nitro groups of (219), 
(220) and (225) cleanly, as product mixtures always comprised inseparable mixtures of 
the corresponding 5-aminoisoquinolin-1-ones and over-reduced products. 
 
Biochemical evaluation of this series of compounds showed excellent in vitro inhibitory 
activity against human recombinant PARP-1, with IC50 values in the low micromolar 
range. Most of the 4-substituents were well received by the active site and they 
resulted in a significant enhancement of PARP-1 inhibitory potency with respect to 5-
AIQ (IC50=1.8 µM). This was particularly evident for 5-amino-4-methylisoquinolin-1(2H)-
one hydrochloride (182) (IC50 = 0.25 µM), 4-benzyl-5-aminoisoquinolin-1(2H)-one (192) 
(IC50= 0.5 µM) and the intermediate 4-bromo-5-aminoisoquinolin-1(2H)-one (125) 
(IC50= 1.0 µM), which were among the most potent members of this series. 
 
Pd-catalysed cyclisation for the future preparation of a range of 4-substituted-5-
nitroisoquinolin-1-ones leading to analogues of the potent water-soluble PARP-1 
inhibitor, 5-AIQ was achieved. Future work would involve the synthesis of further 3- and 
4-substituted 5-AIQs. Greatly encouraged by promising biological data, our main focus 
is to evaluate the inhibitors for their in vivo activity in various disease models. 
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6. Experimental 
 
General Procedures 
 
Melting points were determined using a Reichert-Jung Thermo Galen Kofler block and 
are uncorrected. IR spectra were recorded on a Perkin-Elmer RXI FT-IR spectrometer, 
either as a KBr disc (KBr) or as a liquid (film). νmax values are given in cm
-1. Thin layer 
chromatography (TLC) was performed on silica gel 60 F254 -coated aluminium sheets 
(Merck) and visualised under UV light (365nm) or stained with phosphomolybdic acid 
or ninhydrin. Flash column chromatography was performed using silica gel 60 (0.040-
0.063 mm, Merck) as the stationary phase. NMR spectra were acquired on a Jeol-Delta 
GX 270 (270.05 MHz 1H; 67.80 MHz 13C) or Varian Mercury EX 400 (399.65 MHz 1H; 
100.4 MHz 13C; 376.05 MHz 19F) or Varian Unity Inova 600 MHz spectrometers. 
Chemical shifts are reported in parts per million (ppm) relative to tetramethylsilane for 
samples in CDCl3, (CD3)2SO, CD3OD and (CD3)2CO. Multiplicities are indicated by s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Where 
indicated, 2-D experiments were used to assign 13C NMR signals. Mass spectra were 
obtained by either Electron Impact (EI), Electrospray (ESI) or Fast Atom Bombardment 
(FAB) (with 3-nitrobenzyl alcohol as the matrix) at the University of Bath Mass 
Spectrometry Service using a VG 7070 Mass Spectrometer, the University of Bath 
Department of Pharmacy and Pharmacology High Resolution Mass Spectrometry 
Service using a Bruker microTOF spectrometer and the EPSRC Mass Spectrometry 
Service, Swansea. Microanalysis was carried out at the University of Bath 
Microanalysis Service and School of Pharmacy, University of London, Microanalysis 
Service. 
 
All reagents for chemical synthesis were purchased from Sigma-Aldrich and Alfa Aesar 
and were used without further purification. Experiments were conducted at ambient 
temperature, unless otherwise stated. Where experiments were repeated, only one 
description is provided. Solutions in organic solvents were dried using anhydrous 
MgSO4 and solvents were evaporated under reduced pressure using a Büchi rotary 
evaporator. THF was freshly distilled under nitrogen from sodium/benzophenone and 
diisopropylamine, Et3N, acetonitrile and propanenitrile were distilled from calcium 
hydride.  
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2-Hydroxymercuri-3-nitrobenzoic acid (75) 
2-Iodo-3-nitrobenzoic acid (76) 
 
NO2
O
Hg
O
O
NO2
I
OH
 
 
3-Nitrobenzene-1,2-dicarboxylic acid 74 (10.55 g, 50.0 mmol) in hot aq. NaOH (10%, 
40 mL) was added to Hg(OAc)2 (17.5 g, 55 mmol) in hot AcOH (2.5 mL) and H2O (35 
mL). The mixture was heated at 120 oC for 70 h, then filtered. The precipitate was 
washed (H2O, then EtOH) and dried to give 2-hydroxymercuri-3-nitrobenzoic acid 75 
(18.12 g, 99%) as a cream solid. To a refluxing solution of 75 (18.12 g, 50 mmol) in aq. 
NaOH (3.5%, 250 mL) was slowly added, with vigorous stirring, aq. HCl (2 M, 6 mL) 
and the solution was allowed to cool to room temperature. AcOH (3 mL) was then 
added. The precipitate dissolved upon addition of KI (9.5 g, 57 mmol) and I2 (14.5 g, 57 
mmol) in H2O (15 mL). The solution was boiled under reflux for 24 h, cooled and 
neutralised with aq. NaOH before being filtered and acidified with aq. HCl (9 M). The 
precipitate was filtered, dried and recrystallised (EtOH) to give 76 (7.69 g, 53%) as 
yellow crystals: Rf = 0.61 (CH2Cl2:MeOH:AcOH 9:1:0.1); mp 203-204
 oC (lit.160 mp 204-
205 oC); IR νmax (KBr) 1375 & 1540 (NO2), 1712 (C=O), 2520-3050 (OH) cm
-1; 1H NMR 
(CD3)2SO δ 7.66 (1 H, t, J = 7.8 Hz, 5-H), 7.79 (1 H, dd, J = 7.7, 1.5 Hz, 4-H), 7.92 (1 
H, dd, J = 7.9, 1.7 Hz, 6-H). 
 
Methyl 2-iodo-3-nitrobenzoate (71) 
 
OMe
O
I
NO2  
 
Compound 76 (4.0 g, 14 mmol) in MeOH (120 ml) and H2SO4 (3 ml) was boiled under 
reflux for 48 h, then poured into ice-H2O (300 ml). The precipitate formed was filtered, 
dried and recrystallised (MeOH) gave 71 (4.0 g, 95%) as yellow crystals. Rf = 0.33 
(hexane:EtOAc 4:1); mp 65-66°C (lit.160 mp 64-66°C); IR νmax (KBr) 1351 & 1533 (NO2), 
1705 (C=O); 1H NMR (CDCl3) δ 3.99 (3 H, s, CH3), 7.54 (1 H, t, J = 7.8 Hz, 5-H), 7.70 
(1 H, dd, J = 7.8, 1.7 Hz, 4-H), 7.77 (1 H, dd, J = 7.8, 1.7 Hz, 6-H). 
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Methyl 3-nitro-2-((trimethylsilyl)ethynyl)benzoate (80) 
Methyl 3-nitrobenzoate (81) 
 
 
 
The Pd catalyst (Ph3P)2PdCl2, used in this reaction was prepared as follows: A mixture 
of PPh3 (0.375 g, 1.4 mmol) and PdCl2 (0.13 g, 0.7 mmol) in DMF (20 mL) was heated 
at 80 oC for 24 h. Filtration and drying yielded (Ph3P)2PdCl2 (0.4 g, 80%) as a yellow 
powder. Methyl 2-iodo-3-nitrobenzoate 71 (3.0 g, 9.8 mmol) in dry THF (120 mL) was 
added to a suspension of (Ph3P)2PdCl2 (0.3 g, 0.4 mmol) and CuI (0.4 g, 2.1 mmol) in 
dry diisopropylamine (40 mL) and the mixture was stirred at 45 oC for 30 min under Ar. 
Trimethylsilylethyne (1.1 g, 11.0 mmol) was added during 30 min and the mixture was 
stirred for another 72 h at 45 oC. Filtration (Celite®), evaporation and chromatography 
(hexane:EtOAc 15:1) gave 80 (0.76 g, 28%) as reddish brown oil: Rf = 0.34 
(hexane:EtOAc 15:1); IR νmax (KBr) 1351 & 1532 (NO2), 1738 (C=O), 2219 (C≡C) cm
-1; 
1 H NMR (CDCl3) δ 0.21 (9 H, s, Si(CH3)3), 3.88 (3 H, s, CH3), 7.44 (1 H, t, J = 7.9 Hz, 
5-H), 7.90 (1 H, dd, J = 8.1, 1.5 Hz, 4-H), 7.97 (1 H, dd, J = 7.9, 1.5 Hz, 6-H).  
 
Also isolated by chromatography was 81 (0.24 g, 14%) as yellow crystals: Rf = 0.39 
(hexane:EtOAc 15:1); mp 76-78 oC (lit.160 mp 75-76 oC); IR νmax (KBr) 1352 & 1531 
(NO2), 1720 (C=O) cm
-1; 1H NMR (CDCl3) δ 3.94 (3 H, s, CH3), 7.62 (1 H, t, J = 8.0 Hz, 
5-H), 8.32 (1 H, dt, J = 7.6, 1.5, Hz, 4-H), 8.36 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 6-H), 
8.79 (1 H, t, J = 1.7 Hz, 2-H).  
 
Methyl 2-ethynyl-3-nitrobenzoate (82) 
 
HNO2
O
OMe
 
 
To 80 (0.25 g, 0.9 mmol) in acetone (6.5 mL), water (1.5 mL), and CH2Cl2 (11.5 mL) 
was added silver trifluoromethanesulfonate (23 mg, 0.09 mol). The mixture was stirred 
for 7 d. Saturated aq. NH4Cl (2 mL) was added and the mixture was extracted thrice 
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with CH2Cl2. The combined organic layers were dried and filtered. Evaporation and 
chromatography (hexane:EtOAc 6:1) gave 82 (0.13 g, 72%) as pale yellow crystals: Rf 
= 0.4 (hexane:EtOAc 4:1); mp 78-80 oC; IR νmax (KBr) 1351 & 1530 (NO2), 1720 (C=O), 
2112 (C≡C) cm-1; 1H NMR (CDCl3) δ 3.72 (1 H, s, C≡CH), 3.95 (3 H, s, CH3), 7.54 (1 H, 
t, J = 8.0 Hz, 5-H), 7.97 (1 H, dd, J = 8.2, 1.2 Hz, 4-H), 8.06 (1 H, dd, J = 7.9, 1.2 Hz, 6-
H). 
 
Methyl 3-nitro-2-(phenylethynyl)benzoate (85) 
1,4-Diphenylbuta-1,3-diyne (86) 
Methyl 3-nitrobenzoate (81) 
 
 
 
The Pd catalyst, (Ph3P)2PdCl2, used in this reaction was prepared as above. Methyl 2-
iodo-3-nitrobenzoate 71 (3.0 g, 9.8 mmol) in dry THF (120 mL) was added to a 
suspension of (Ph3P)2PdCl2 (0.3 g, 0.4 mmol) and CuI (0.4 g, 2.1 mmol) in dry 
diisopropylamine (40 mL) and the mixture was stirred at 45 oC for 30 min under Ar. 
Phenylacetylene (1.5 g, 15 mmol) was then added during 30 min and the mixture was 
stirred for another 48 h at 45 oC. Filtration (Celite), evaporation and chromatography 
(hexane:CH2Cl2 2:1) gave 85 (1.4 g, 51%) as reddish brown crystals: Rf = 0.78 
(hexane:EtOAc 4:1); mp 58-59 oC (lit.160 mp 59-60 oC); IR νmax (KBr) 1342 & 1526 
(NO2), 1738 (C=O), 2214 (C≡C) cm
-1; 1 H NMR  (CDCl3) δ 3.99 (3 H, s, CH3), 7.31-7.40 
(3 H, m, 3’,4’,5’-H3), 7.48 (1 H, t, J = 8.0 Hz, 5-H), 7.54-7.62 (2 H, m, 2’,6’-H2), 8.03 (1 
H, dd, J = 8.1, 1.5 Hz, 4-H), 8.10 (1 H, dd, J = 7.9, 1.5 Hz, 6-H). 
 
 Compound 86 (0.5 g, 25%) was isolated by chromatography: Rf =0.9 (hexane:EtOAc 
4:1); mp 85-86 oC (lit.160 mp 83-84 oC); IR νmax (KBr) 2147 (C≡C) cm
-1; 1H NMR (CDCl3) 
δ 7.32-7.41 (6 H, m, 2 x 3,4,5-H3), 7.56-7.53 (4 H, m, 2 x 2,6-H2). 
 
Also isolated by chromatography was 81 (0.67 g, 38%) as pale yellow crystals with 
data as above. 
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Methyl 2-acetyl–3-nitrobenzoate (95) 
 
NO2
O
OMe
O
Me
 
 
To 80 (0.11 g, 0.4 mmol) and HgSO4 (0.15 g, 0.5 mmol) in acetone (10 mL) and conc. 
H2SO4 (0.1 mL) were boiled under reflux for 48 h, then evaporated to yield a brown 
residue. Extraction (CHCl3), evaporation and chromatography (hexane:EtOAc 4:1) 
gave 95 (25 mg, 27%) as pale buff crystals: Rf = 0.2 (hexane:EtOAc 4:1); mp 81-82
 oC 
(lit.208 mp 81 oC); IR (KBr) νmax 1346 & 1539 (NO2), 1700 & 1732 (C=O) cm
-1; 1H NMR 
(CDCl3) δ 2.71 (3 H, s, COCH3), 3.93 (3 H, s, OCH3), 7.64 (1 H, t, J = 8.2 Hz, 5-H), 8.33 
(1 H, dd, J = 7.9, 1.2 Hz, 4-H), 8.37 (1 H, dd, J = 7.9, 1.2 Hz, 6-H). 
  
Methyl 2-acetyl-3-nitrobenzoate (95) 
(±)-3-Methoxy-3-methyl-4-nitro isobenzofuran-1(3H)-one (96) 
 
NO2
O
OMe
O
Me
O
O
Me
OMe
NO2  
 
Compound 82 (0.10 g, 0.48 mmol) and HgSO4 (0.17 g, 0.6 mmol) in acetone (10 mL) 
and conc. H2SO4 (0.1 mL) was boiled under reflux for 48 h, then evaporated to yield a 
brown residue. Extraction (CHCl3) and evaporation gave 95 (27 mg, 28%) as buff 
crystals with properties as above. Also identified in trace amounts in the NMR spectrum 
was 96: 1H NMR (CDCl3) δ 2.05 (3 H, s, CH3), 3.22 (3 H, s, OCH3) 7.5-8.5 (3 H, m, Ar 
5,6,7-H3). 
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4-Iodo-5-nitro-3-phenylisocoumarin (99)  
 
O
NO2
O
I
 
 
Compound 85 (0.114 g, 0.37 mmol) in dry CH2Cl2 (4 mL) was stirred with ICl (0.09 g, 
0.55 mmol) in dry CH2Cl2 (1 mL) for 2 h in the dark. The mixture was diluted with Et2O 
(50 mL), washed with aq. sodium thiosulfate solution and dried. Evaporation and 
chromatography (hexane:EtOAc 4:1) gave 99 (0.13 g, 81%) as pale yellow crystals. 
Recrystallisation (EtOAc:hexane) gave yellow powder: Rf = 0.6 (hexane:EtOAc 4:1); mp 
154-156 oC; IR νmax (KBr) 1354 & 1532 (NO2), 1636 (C=C), 1732 (C=O) cm
-1; 1H NMR 
(CDCl3) δ 7.46-7.52 (3 H, m, Ph 3’,4’,5’-H3), 7.65 (1 H, t, J = 7.8 Hz, 7-H), 7.70-7.74 (2 
H, m, Ph 2’,6’-H2), 8.07 (1 H, dd, J = 7.8, 1.5 Hz, 6-H), 8.54 (1 H, dd, J = 7.8, 1.5 Hz, 8-
H); 13C NMR δ 61.58 (4-C), 123.47 (9-C), 128.35 (3’,5’-C2), 128.63 (7-C), 130.46 (2’,6’-
C2), 130.92 (4’-C), 131.21 (6-C), 131.95 (10-C), 133.25 (8-C), 134.90 (1-C), 150.06 (5-
C), 158.95 (3-C), 159.55 (1-C); MS (EI) m/z 392 (M - H), 265 (M - HI); Anal. Calcd for 
C15H18INO4: C, 45.83; H, 2.05; N, 3.56; Found: C, 46.1; H, 2.15; N, 3.69.  
 
5-Nitro-3-phenylisocoumarin (93)  
 
 
 
Formic acid (98%) (30 mg, 0.66 mmol) was added to a degassed mixture of 99 (0.13 g, 
0.33 mol), Et3N (0.1 g, 1.0 mmol), Pd(OAc)2 (6.6 mg, 7 µmol) and Ph3P (13.2 mg, 13 
µmol) in dry DMF (10 mL). The mixture was stirred at 60 oC for 4.5 h under Ar before 
being poured into water (50 mL). Extraction (EtOAc), drying, evaporation and 
chromatography (hexane:EtOAc 9:1) gave 93 (69 mg, 78%) as bright yellow crystals: 
Rf = 0.43 (hexane:EtOAc 4:1); mp 141-142
 oC (lit.160 mp 142-143 oC); IR νmax (KBr) 1341 
& 1527 (NO2), 1629 (C=C), 1739 (C=O) cm
-1; 1H NMR (CDCl3) δ 7.47-7.51 (3 H, m, Ph 
3’,4’,5’-H3), 7.60 (1 H, t, J = 7.8 Hz, 7-H), 7.86 (1 H, s, 4-H), 7.90-7.95 (2 H, m, Ph 2’,6’-
H2), 8.48 (1 H, dd, J = 7.9,1.2 Hz, 6-H), 8.54 (1 H, dd, J = 7.8, 1.5 Hz, 8-H).  
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5-Nitro-4-(phenylselenyl)-3-(trimethylsilyl)isocoumarin (104) 
  
O
SiMe3
NO2
O
Se
 
 
Compound 80 (0.11 g, 0.4 mmol) was stirred with phenylselenyl chloride (0.11 g, 0.6 
mmol) in dry CH2Cl2 (3 mL) for 24 h under N2. The mixture was washed with aq. 
NaHCO3 and dried. Evaporation and chromatography (hexane:EtOAc 4:1) gave 104 
(0.14 g, 82%) as a yellow solid. Recrystallisation (toluene) gave yellow powder: Rf = 
0.62 (hexane:EtOAc 4:1); mp 105-107 oC; IR (KBr) νmax 1370 & 1533 (NO2), 1733 
(C=O) cm-1; 1H NMR (CDCl3) δ 0.34 (9 H, s, SiMe3) 7.00 (2 H, m, SePh 2’,6’-H2) 7.10-
7.17 (3 H, m, SePh 3’,4’,5’-H3), 7.58 (1 H, t, J = 7.8 Hz, 7-H), 7.8 (1 H, dd, J = 7.9, 1.5 
Hz, 6-H), 8.50 (1 H, dd, J = 7.8, 1.4 Hz, 8-H); 13C NMR δ 0.34 (CH3)3, 110.27 (4-C), 
124.04 (9-C), 126.67 (4’-C), 127.84 (2’,6’-C2), 128.83 (7-C), 129.36 (3’,5’,-C2), 130.15 
(6-C), 130.33 (10-C), 132.96 (8-C), 133.73 (1’-C), 147.48 (5-C), 160.47 (1-C), 175.22 
(3-C); MS (FAB+) m/z 419.0095 (M) (C18H17NO4
80Se28Si requires 419.0092), 418 (M - 
H); Anal. Calcd for C18H17NO4SeSi: C, 51.67; H, 4.10; N, 3.35; Found: C, 51.8; H, 4.15; 
N, 3.33.  
 
5-nitro-3-phenyl-4-(phenylselenyl)isocoumarin (105)  
 
7
6
5
8
4
3
O 2
1
1'
6'
5'
4'
3'
2'
NO2
O
Se
1''
2''
3''
5''
4''
6''
 
 
Compound 85 (0.10 g, 0.36 mmol) was stirred with phenylselenyl chloride (0.1 g, 0.53 
mmol) in dry CH2Cl2 (5 mL) for 4 h under N2. The mixture was washed with aq. 
NaHCO3 and dried. Evaporation and chromatography (hexane:EtOAc 7:1) gave 105 
(72 mg, 47%) as orange crystals: Recrystallisation (EtOAc) gave bright orange crystals. 
Rf = 0.8 (hexane:EtOAc 4:1); mp 188-190
 oC; IR (KBr) νmax
 1354 & 1533 (NO2), 1733 
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(C=O) cm-1; 1H NMR (CDCl3) δ 6.80 (2 H, m, SePh 2”,6”-H2), 6.95 (2 H, m, SePh 3”,5”-
H2) 7.06 (1 H, tt, J = 7.3, 1.2 Hz, SePh 4”-H), 7.32-7.37 (2 H, m, CPh 3’,5’-H2), 7.38 (1 
H, tt, J = 7.3, 1.5 Hz, CPh 4’-H), 7.58 (2 H, m, CPh 2’,6’-H2), 7.63 (1 H, t, J = 8.0 Hz, 7-
H), 8.14 (1 H, dd, J = 8.0, 1.5 Hz, 6-H), 8.55 (1 H, dd, J = 7.9, 1.5 Hz, 8-H); 
13C NMR δ 
102.24 (4-C), 123.12 (9-C), 127.61 (4”-C, SePh), 127.85 (3’,5’-C2Ph), 128.04 (7-C), 
128.90 (3”,5”-C2, SePh), 130.34 (2’,6’-C2Ph), 130.60 (4’-CPh), 131.05 (6-C), 131.70 (1’-
C, SePh), 132.18 (2”,6”-C2, SePh), 133.26 (1’-CPh), 133.68 (8-C), 134.38 (10-C), 
148.35 (5-C), 159.90 (1-C), 160.65 (3-C); MS (EI) m/z 422 (M), 266 (M – C6H5Se); 
Anal. Calcd for C21H13NO4Se: C, 59.73; H, 3.10; N, 3.32; Found: C, 59.8; H, 3.06; N, 
3.32.  
 
Methyl 2-methyl-3-nitrobenzoate (111) 
 
Me
NO2
OMe
O
 
 
2-Methyl-3-nitrobenzoic acid 112 (10.0 g, 55.2 mmol) in MeOH (200 mL) and conc. 
H2SO4 (1 mL) was boiled under reflux for 48 h, then poured into ice-H2O (300 mL). The 
precipitated ester was filtered, washed (H2O) and recrystallised (MeOH) to give 111 
(10.2 g, 94%) as yellow crystals: Rf = 0.48 (hexane:EtOAc 4:1); mp 63-64
 oC (lit.160 mp 
65-66 oC); IR νmax (KBr) 1363 & 1522 (NO2), 1724 (C=O) cm
-1; 1H NMR (CDCl3) δ 2.63 
(3 H, s, ArCH3), 3.94 (3 H, s, CO2CH3), 7.38 (1 H, t, J = 8.0 Hz, 5-H), 7.85 (1 H, d, J = 
7.9 Hz, 4-H), 7.99 (1 H, d, J = 7.7 Hz, 6-H). 
 
Methyl 2-bromomethyl-3-nitrobenzoate (110) 
 
NO2
OMe
O
Br
 
 
Br2 (5.9 g, 37 mmol) in CCl4 (15 mL) was added over 30 min to a boiling solution of 111 
(5.75 g, 29.5 mmol) and dibenzoyl peroxide (0.55 g, 2.25 mmol) in CCl4 (50 mL) under 
irradiation using a 150 W lamp. After 20 h, additional Br2 (1.39 g, 8.7 mmol) and 
dibenzoyl peroxide (0.12 g, 0.5 mmol) in CCl4 (5 mL) were added. Heating and 
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irradiation were continued for another 29 h. Evaporation and recrystallisation (MeOH) 
gave 110 (4.69 g, 58%) as pale brown crystals: Rf = 0.42 (hexane:EtOAc 4:1); mp 70-
71 oC (lit.160 mp 68-69 oC); IR νmax (KBr) 1350 & 1528 (NO2), 1722 (C=O) cm
-1; 1H NMR 
(CDCl3) δ 4.01 (3 H, s, CH3), 5.17 (2 H, s, CH2), 7.55 (1 H, t, J = 7.9 Hz, 5-H), 7.97 (1 
H, dd, J = 8.1, 1.2 Hz, 4-H), 8.12 (1 H, dd, J = 7.9, 1.5 Hz, 6-H). 
 
Methyl 2-cyanomethyl-3-nitrobenzoate (109) 
 
NO2
OMe
O
CN
 
 
To 110 (5.00 g, 18.21 mmol) in acetonitrile (70 mL) was added Et4N
+ -CN (3.4 g, 22 
mmol) and the mixture was stirred for 4 h. Evaporation and chromatography 
(Et2O:hexane 1:1) yielded 109 (2.77 g, 69%) as white crystals: Rf = 0.6 (hexane:EtOAc 
4:1); mp 94-95 oC (lit.160 mp 93-94 oC); IR νmax (KBr) 1350 & 1531 (NO2), 1708 (C=O), 
2366 (CN) cm-1; 1H NMR (CDCl3) δ 4.01 (3 H, s, CH3), 4.35 (2 H, s, CH2), 7.64 (1 H, t, J 
= 8.0 Hz, 5-H), 8.13 (1 H, dd, J = 8.1, 1.5 Hz, 4-H), 8.28 (1 H, dd, J = 7.9, 1.5 Hz, 6-H). 
 
Methyl (±)-2-(1-cyano-2-phenylethyl)-3-nitrobenzoate (116)  
 
NO2
OMe
O
CN
 
 
To 109 (1.00 g, 4.5 mmol) in dry THF (15 mL) was added lithium 
bis(trimethylsilyl)amide (5.6 mL, 5.6 mmol, 1.0 M in THF) and the mixture was stirred at 
–78 oC for 20 min under N2. Benzyl bromide (1.13 g, 6.5 mmol) was added and solution 
was allowed to warm to room temperature and stirred for further 4 h. Extraction 
(CH2Cl2), washing (5% aq. HCl, H2O), drying and chromatography (toluene) gave 116 
(930 mg, 67%) as a pale brown oil: Rf = 0.25 (toluene); IR (film) νmax 1355 & 1540 
(NO2), 1716 (C=O), 2264 (CN) cm
-1; 1H NMR (CDCl3) δ 3.42 (1 H, dd, J = 13.0, 5.4 Hz, 
PhCH), 3.75 (1 H, dd, J = 13.0, 10.2 Hz, PhCH), 4.00 (3 H, s, CH3), 5.07 (1 H, dd, J = 
10.2, 5.4 Hz, CH), 7.28-7.42 (5 H, m, 2’,3’,4’,5’,6’- H5) 7.56 (1 H, t, J = 8.1 Hz, 5-H), 
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7.97 (1 H, dd, J = 8.1, 1.5 Hz, 4-H), 8.08 (1 H, dd, J = 7.9, 1.5 Hz, 6-H); 13C NMR δ 
34.52 (CH), 39.49 (CH2), 53.38 (CH3), 117.88 (CN), 127.57 (4’-C), 128.27 (4-C), 
128.80(2’,6’-C2), 129.19 (2-C), 129.37 (3’,5’-C2), 133.10 (1-C), 134.93 (6-C), 136.56 (1’-
C), 150.71 (3-C), 166.20 (C=O); MS (FAB+) m/z 311.1046 (M + H) (C17H15N2O4 
requires 311.1031). 
 
(±)-2-(2-Formyl-6-nitrophenyl)-3-phenylpropanenitrile (117)  
 
NO2
H
O
CN
 
 
Compound 116 (100 mg, 0.322 mmol) was dissolved in dry CH2Cl2 (5 mL) and the 
solution was stirred at –78 oC for 30 min under N2. DIBAL-H (1.0 M, 0.5 mL, 0.5 mmol) 
was added dropwise and the mixture was stirred for 1 h at -78 oC. The solution was 
then allowed to warm to room temperature. Washing (H2O), drying and 
chromatography (hexane:EtOAc 4:1) gave 117 (40 mg, 44%) as buff crystals: Rf = 0.36 
(hexane:EtOAc); mp 124-125 oC; IR (KBr) νmax 1355 & 1530 (NO2), 1697 (C=O), 2264 
(CN) cm-1; 1H NMR (CDCl3) δ 3.30 (1 H, dd, J = 13.3, 5.5 Hz, PhCH), 3.59 (1 H, dd, J = 
10.1, 13.3 Hz, PhCH), 5.25 (1 H, dd, J = 9.4, 5.5 Hz, CH), 7.43-7.24 (5 H, m, 
2’,3’,4’,5’,6’-H5), 7.76 (1 H, t, J = 7.8, Hz, 5-H), 8.00 (1 H, dd, J = 8.2, 1.5 Hz, 4-H), 8.15 
(1 H, dd, J = 7.8, 1.5 Hz, 6-H), 10.28 (1 H, s, CHO); 13C NMR δ 32.70 (CH), 39.39 
(CH2), 117.65 (CN), 127.83 (4’-C), 128.92 (2’,6’-C2), 129.38 (3’,5’-C2), 129.81 (2-C), 
129.85 (4-C), 130.03 (5-C), 135.03 (1-C), 135.86 (1’-C), 138.32 (6-C), 150.10 (3-C), 
190.18 (C=O); MS (FAB+) m/z 280.0850 (M) (C16H12N2O3 requires 280.0847). 
 
5-Nitroisocoumarin (126) 
 
O
O
NO2  
 
The ester 111 (5.0 g, 25.6 mmol) was heated with dimethylformamide dimethyl acetal 
(2.5 g, 21 mmol) in DMF (30 mL) at 150 oC for 16 h. Evaporation, chromatography 
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(hexane:EtOAc 10:1) gave 126 (1.9 g, 39%) as yellow crystals: mp 170-172 oC (lit.160 
mp 171-172 oC);  Rf = 0.41 (hexane:EtOAc 4:1); IR (KBr) νmax 1332, 1518 (NO2), 1748 
(C=O) cm-1; 1H NMR (CDCl3) δ 7.35 (1 H, dd, J = 6.1, 0.5 Hz, 4-H), 7.43 (1 H, d, J = 6.0 
Hz, 3-H), 7.65 (1 H, t, J = 7.9 Hz, 7-H), 8.48 (1 H, dd, J = 8.2, 1.3 Hz, 6-H), 8.64 (1 H, 
ddd, J = 7.9, 1.5, 0.5 Hz, 8-H). 
 
5-Nitroisoquinolin-1(2H)-one (113) 
 
NH
O
NO2  
 
A solution of 126 (1.7 g, 8.86 mmol) in 2-methoxyethanol (30 mL) was saturated with 
NH3 and boiled under reflux for 2 h. Evaporation and recrystallisation (EtOH) gave 113 
(1.5 g, 89%) as yellow crystals: Rf = 0.29 (hexane:EtOAc 1:2); mp 248-249
 oC (lit.160 mp 
247-249 oC); 1H NMR ((CD3)2SO) δ 6.98 (1 H, dd, J = 7.7, 4-H), 7.45 (1 H, dd, J = 7.7, 
1.5 Hz, 3-H), 7.66 (1 H, t, J = 7.9 Hz, 7-H), 8.47 (1 H, dd, J = 7.9, 1.3 Hz, 6-H), 8.59 (1 
H, d, J = 8.0 Hz, 8-H), 11.79 (1 H, br s, NH). 
 
4-Bromo-5-nitroisoquinolin-1-one (124)  
4-Bromo-5-nitro-1-oxo-1,2,3,4-tetrahydroisoquinolin-3-yl acetate (129) 
 
 
 
To a solution of 113 (0.1 g, 0.5 mmol) in AcOH (5 mL) was added equimolar amount of 
N-bromosuccinimide (0.09 g, 0.5 mmol). After 30 min the mixture was poured into ice 
H2O (100 mL) stirred for 10 min. Extraction (EtOAc), washing (aq. NaHCO3, H2O) 
drying, evaporation and chromatography (hexane:EtOAc 4:1) yielded 129 (0.07 g, 
33%) as buff solid: mp 137°C; IR (KBr) νmax 1335 & 1534 (NO2), 1675 (C=O), 3462 
(NH) cm-1; 1H NMR ((CD3)2CO) δ 2.08 (3 H, s, CH3), 5.79 (1 H, d, J = 4.7 Hz, 4-H), 5.95 
(1 H, m, 3-H), 7.82 (1 H, t, J = 7.9 Hz, 7-H), 8.33 (1 H, dd, J = 8.2, 1.5 Hz, 6-H), 8.45 (1 
H, dd, J = 8.0, 1.2 Hz, 8-H).  
 145 
Also isolated was 124 (0.3 g, 21%) as orange crystals: mp 233-235°C; IR (KBr) νmax 
1368 & 1534 (NO2), 1674 (C=O), 3467 (NH) cm
-1; 1H NMR ((CD3)2CO) δ 7.73 (1 H, s, 
3-H), 7.77 (1 H, t, J = 7.8 Hz, 7-H), 8.10 (1 H, dd, J = 7.8, 1.6 Hz, 6-H), 8.61 (1 H, dd, J 
= 8.6, 1.9 Hz, 8-H); 13C NMR δ 90.40 (4-C), 127.98 (10-C), 128.25 (7-C), 129.46 (6-C), 
129.88 (9-C), 132.05 (8-C), 135.60 (3-C), 147.25 (5-C), 159.00 (1-C); MS (ESI +ve) 
m/z 267.9478 (M) (C9H5
79BrN2O3 requires 267.9484), 290.9376 (M + Na) 
(C9H5
79BrN2O3Na requires 290.9332), 292.9354 (M + Na) (C9H5
81BrN2O3Na requires 
292.9312), Anal. Calcd. for C9H5BrN2O3: C, 40.18; H, 1.87; N, 10.41; Found: C, 40.60; 
H, 1.61; N, 10.19. 
 
4-Bromo-5-nitroisoquinolin-1(2H)-one (124) 
4-Bromo-3-hydroxy-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (130) 
 
NH
O
BrNO2                
NH
O
BrNO2
OH
 
 
To a solution of 113 (1.5 g, 7.8 mmol) in AcOH (15 mL) was added equimolar amount 
of Br2 (0.21 g, 1.31 mmol) in AcOH (7 mL). After 2 h the mixture was poured into ice 
H2O (100 mL) stirred for 10 min. Extraction (CH2Cl2), drying, evaporation and 
chromatography (hexane:EtOAc 4:1) yielded 124 (0.7 g, 33%) as orange crystals with 
data as above. 
 
Also isolated was 130 (0.7 g, 33%) as buff solid: mp 175-177°C; IR (KBr) νmax 1338 & 
1534 (NO2), 1672 (C=O), 3460 (NH) cm
-1; 1H NMR ((CD3)2CO) δ 8.55 (1 H, br s, NH), 
8.30 (1 H, dd, J = 7.7, 1.5 Hz, 8-H), 8.0 (1 H, dd, J = 7.9, 1.5 Hz, 6-H), 7.82 (1 H, t, J = 
7.9 Hz, 7-H), 6.73 (1 H, d, J = 5.9 Hz, 4-H), 5.52 (1 H, t, J = 5.7, 1.2 Hz, 6-H). 13C NMR 
δ 85.87 (4-C), 91.21 (3-C), 128.99 (7-C), 130.21 (6-C), 130.87(9-C), 132.16 (10-C), 
132.79 (8-C), 136.37 (3-C), 151.69 (5-C), 162.16 (1-C). 
 
3,4-Dibromo-5-nitroisocoumarin (131) 
 
O
O
NO2 Br
Br
 
 146 
To a solution of 126 (0.25 g, 1.31 mmol) in AcOH (2.5 mL) was added equimolar 
amount of Br2 (0.21 g, 1.31 mmol) in AcOH (1 mL). After 2 h the mixture was poured 
into ice H2O (100 mL) stirred for 10 min. Extraction (CH2Cl2), drying, evaporation and 
chromatography (hexane:EtOAc 4:1) yielded 131 (0.24 g, 52%) as white crystals: mp 
116-118 oC; Rf = 0.7 (hexane:EtOAc 4:1); IR (KBr) νmax 1054 (C-O), 1346, 1528 (NO2), 
1761 (C=O) cm-1; 1H NMR (CDCl3) δ 6.32 (1 H, d, J = 1.7 Hz, 4-H), 6.90 (1 H, d, J = 1.7 
Hz, 3-H), 7.80 (1 H, t, J = 8.2 Hz, 7-H), 8.52 (1 H, s, 6-H), 8.64 (1 H, s, 8-H); 13C NMR δ 
38.41 (4-C), 78.21 (3-C), 125.07 (9-C), 130.90 (7-C), 131.31 (8-C), 133.02 (10-C), 
135.65 (6-C), 145.34 (5-C), 158.28 (1-C); MS (ESI +ve) m/z 349.8658 (M + H) 
(C9H6
79Br2NO4 requires 349.8664), 351.8647 (M + H) (C9H6
79Br81BrNO4 requires 
351.8642), 353.8621 (M + H) (C9H6
81Br2NO4 requires 353.8623), 373.8455 (M + Na)  
(C9H6
79Br81BrNO4Na requires 373.8463). 
 
5-Amino-4-bromoisoquinolin-1(2H)-one (125) 
 
NH
O
BrNH2  
 
A mixture of 124 (0.54 g, 2.0 mmol) and SnCl2 (1.21 g, 6.4 mmol) in EtOH (20 mL) was 
heated at 80°C for 4 h, then carefully poured into ice-H2O (75 mL). The resulting 
suspension was made alkaline with aq. NaOH and the precipitate was filtered. 
Extraction of the filtrate (EtOAc), evaporation and chromatography (EtOAc:hexane 4:1) 
gave 125 (0.25 mg, 54%) as brown powder: Rf = 0.33 (EtOAc:hexane 1:4); mp 210-
212°C; IR (KBr) νmax 1661, 1624 (C=O), 3443, 3321 (NH) cm
-1; 1H NMR ((CD3)2SO) δ 
5.92 (2 H, br s, NH2), 7.73 (1 H, s, 3-H), 7.02 (1 H, dd, J = 8.2, 1.6 Hz, 6-H), 7.22 (1 H, 
s, 3-H), 7.25 (1 H, t, J = 8.2 Hz, 7-H), 7.54 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 11.34 (1 H, br 
s, NH); 13C NMR δ 93.10 (4-C), 115.83 (8-C), 119.17 (6-C), 119.42 (10-C), 128.04 (3-
C), 128.44 (9-C), 128.56 (7-C), 144.72 (5-C), 160.83 (1-C); MS (ESI +ve) m/z 238.9815 
(M + H) (C9H8
79
 BrN2O requires 238.9820). 
 147 
2-Iodo-3-nitrobenzoyl chloride (139) 
 
NO2
O
I
Cl
 
 
To 76 (3.0 g, 10.2 mmol) and DMF (0.2 mL) was carefully added SOCl2 (30 mL) and 
the mixture was boiled under reflux for 24 h. Evaporation and recrystallisation (hexane) 
yielded 139 (3.0 g, 94%) as yellow crystals: Rf = 0.88 (EtOAc:hexane 1:4); mp 71-73
 oC 
(lit.160 mp 70-71 oC); IR νmax (KBr) 1348 & 1530 (NO2), 1758 (C=O) cm
-1; 1H NMR 
(CDCl3) δ 7.64 (1 H, t, J = 7.8 Hz, 5-H), 7.79 (1 H, dd, J = 7.8, 1.6 Hz, 4-H), 7.95 (1 H, 
dd, J = 7.8, 1.6 Hz, 6-H). 
 
N,N-Di(prop-2-enyl)-2-iodo-3-nitrobenzamide (141) 
 
NO2
O
I
N
 
 
To 2-iodo-3-nitrobenzoyl chloride 139 (1.0 g, 3.2 mmol) in CH2Cl2 (5 mL) was added di-
2-propenylamine (0.4 mL, 3.2 mmol) and Et3N (0.64 g, 6.4 mmol) and the mixture was 
stirred for 30 min. Washing (5% aq. HCl, 5% aq. NaHCO3), drying, evaporation and 
chromatography (CH2Cl2:EtOAc 20:1) gave 141 (0.89 g, 75%) as a buff semisolid: Rf = 
0.64 (CH2Cl2:EtOAc 20:1); IR (film) νmax 1360 & 1532 (NO2), 1733 (C=O) cm
-1; 1H NMR 
(CDCl3) δ 3.63 (1 H, dd, J = 16.3, 3.9 Hz, propenyl 1-H), 3.76 (2 H, m, 2 x propenyl 1-
H), 4.60 (1H, dd, J = 14.9, 4.3 Hz, propenyl 1-H), 5.12 (1 H, dq, J = 17.2, 1.6 Hz, 
propenyl 3-H), 5.20 (1 H, dq, J = 10.2, 1.2 Hz, propenyl 3-H), 5.30 (1 H, dq, J = 10.6, 
1.2 Hz, propenyl 3-H), 5.35 (1 H, dq, J = 17.2, 1.2 Hz, propenyl 3-H), 5.65 (1 H, m, 
propenyl 2-H), 5.95 (1 H, m, propenyl 2-H), 7.34 (1 H, dd, J = 7.6, 1.5 Hz, 6-H), 7.49 (1 
H, t, J = 7.8 Hz, 5-H), 7.68 (1 H, dd, J = 7.9, 1.5 Hz, 4-H); 13C NMR δ 46.76 (CH2), 
50.16 (CH2), 85.22 (2-C), 118.46 (=CH2), 119.06 (=CH2), 124.63 (4-C), 129.47 (5-C), 
129.75 (6-C), 131.78 (=CH), 131.95 (=CH), 145.88 (1-C), 154.34 (3-C), 169.13 (C=O); 
MS (EI) m/z 371.9958 (M) (C13H13IN2O3 requires 371.9970). 
 148 
(E)-Diphenyl-N-((E)-3-phenylprop-2-enylidene)methanamine (146)  
 
N
 
 
Diphenylmethylamine 144 (6.9 g, 38 mmol) and E-3-phenylpropenal 145 (5.0 g, 38 
mmol) were boiled in toluene (50 mL) in a Dean-Stark apparatus until the calculated 
amount of water had separated (0.7 mL). Evaporation and recrystallisation (Et2O) gave 
146 (11.0 g, 97%) as yellow crystals: mp 115-117 oC (lit.209 mp 116-118 oC); IR (KBr) 
νmax 1444 & 1489 (C=C), 1598 (C=C conjugated) cm
-1; 1H NMR (CDCl3) δ 5.48 (1 H, s, 
Ph2CH), 6.96 (1 H, d, J = 16.1 Hz, propene 3-H), 7.06 (1 H, dd, J = 16.0, 8.1 Hz, 
propene 2-H), 7.20-7.40 (13 H, m, 2 x Ph-H5 + Ph 3’,4’,5’-H3), 7.47 (2 H, dd, J = 9.4, 
1.7 Hz, Ph 2’,6’-H2), 8.18 (1 H, dd, J = 8.2, 0.8 Hz, propene 1-H).  
 
(E)-N-Diphenylmethyl-3-phenylprop-2-en-1-amine (147)  
 
N
31
2
H
 
 
To 146 (6.0 g, 20 mmol) in MeOH (250 mL) warmed to 45 oC was slowly added NaBH4 
(0.77 g, 20 mmol) during 20 min. After evaporation of the solvent the residue was taken 
up in Et2O, washed (5% aq. NaHCO3) and dried.  Evaporation gave 147 (5.8 g, 95%) 
as pale yellow semi-solid. IR (film) νmax 1451 & 1492 (C=C), 1598 (C=C conjugated), 
3332 (NH) cm-1; 1H NMR (CDCl3) δ 1.94 (1 H, br s, N-H), 3.52 (2 H, dd, J = 6.2, 1.0 Hz, 
CH2), 5.07 (1 H, s, Ph2CH), 6.47 (1 H, dt, J = 15.8, 6.0 Hz, propene 2-H), 6.65 (1 H, d, 
J = 15.8 Hz, propene 3-H), 7.34-7.61 (15 H, m, 3 x Ph-H5).  
 149 
(E) N-Diphenylmethyl-2-iodo-3-nitro-N-(3-phenylprop-2-enyl)benzamide (148) 
  
NO2
I
N
O
 
 
To 139 (1.5 g, 4.8 mmol) in CH2Cl2 (10 mL) was added 147 (1.43 g, 4.8 mmol) and 
Et3N (0.97 g, 9.6 mmol) and the mixture was stirred for 30 min. Washing (5% aq. HCl, 
5% aq. NaHCO3) drying, evaporation and chromatography (hexane:EtOAc 4:1) gave 
148 (1.49 g, 54%) as a buff solid: mp 134-136 oC; Rf = 0.38 (hexane:EtOAc 4:1); IR νmax 
(KBr) 1360 & 1530 (NO2), 1636 (C=O) cm
-1; The NMR spectra showed a 3:4 mixture of 
rotamers α & β about the amide double bond. 1H NMR α (CDCl3) δ 3.91-4.06 (2 H, m, 
CH2), 5.20 (1 H, dt, J = 15.5, 6.5 Hz, =CHCH2), 5.42 (1 H, d, J = 16.0 Hz, =CHPh), 7.31 
(1 H, s, Ph2CH), 6.9-7.65 (18 H, m, 3 x Ph-H5 + 4,5,6-H3); 
13C NMR δ 49.33 (CH2), 
61.21 (Ph2CH), 85.89 (2-C), 123.91 (=CHCH2), 124.34 (4-C), 126.03, 127.16, 127.32, 
127.66, 127.76, 128.26, 128.38, 128.54, 128.84, 129.25, 130.66, 132.73 (=CHPh), 
135.45 (q), 138.16 (q), 138.60 (q), 145.95 (1-C), 154.19 (3-C), 168.80 (C=O); 
 
1H NMR β (CDCl3) δ 3.93-4.05 (1 H, m, H-CH), 4.81 (1 H, dd, J = 14.5, 5.5 Hz, H-CH), 
5.83 (1 H, s, Ph2CH), 5.88 (1 H, d, J = 16.0 Hz =CHPh), 6.0 (1 H, dt, J = 16.0, 6.0 Hz, 
=CHCH2), 6.90-7.65 (18 H, m, 3 x Ph-H5 + 4,5,6-H3); 
13C NMR δ 46.72 (CH2), 66.63 
(Ph2CH), 85.18 (2-C), 123.42 (=CHCH2), 124.49 (4-C), 126.15, 127.08, 127.58, 127.68, 
127.72, 128.16, 128.24, 128.35, 128.63, 128.79, 129.22, 132.36 (=CHPh), 136.63 (q), 
137.51 (q), 139.25 (q), 145.17 (1-C), 154.26 (3-C), 169.42 (C=O); MS (EI) m/z 
575.0821 (M + H) (C29H24IN2O3) requires 575.0826. 
 
2-(prop-2-enyl)-4-methyl-5-nitroisoquinolin-1(2H)-one (149)  
2-(prop-2-enyl)-4-methylene-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (150) 
 
7
6
5
8
4
3
N
2
O
1
NO2 Me
7
6
5
8
4
3
N
21
O
NO2 CH2  
 150 
To 141 (0.31 g, 0.81 mmol) in dry MeCN (10 mL) was added (Ph3P)4Pd (40.3 mg, 
0.035 mmol) and dry Et3N (0.175 g, 1.72 mmol) and the mixture was heated to reflux 
for 48 h. After evaporation of the solvent the residue was taken in EtOAc, washed (5% 
aq. HCl, 5% aq. NaHCO3) and dried. Evaporation and chromatography (hexane:EtOAc 
4:1) yielded 149 and 150 (0.15 g, 79%) (1:2) as a buff oil. Rf = 0.35 (hexane:EtOAc 
4:1); IR (film) νmax 1365 & 1531 (NO2), 1658 (C=O) cm
-1; 1H NMR 149 (CDCl3) δ 2.10 (3 
H, d, J = 1.2 Hz, CH3), 4.60 (2 H, dt, J = 5.7, 1.5 Hz, propenyl 1-H), 5.19 (2 H, m, 
propenyl 3-H), 5.96 (1 H, m, propenyl 2-H), 6.93 (1 H, d, J =1.2 Hz, 3-H), 7.53 (1 H, t, J 
= 7.9 Hz, 7-H), 7.74 (1 H, dd, J = 7.8, 1.5 Hz, 6-H), 8.66 (1 H, dd, J = 7.8, 1.5 Hz, 8-H); 
13C NMR δ 15.81 (CH3), 50.67 (NCH2), 108.36 (4-C), 118.74 (=CH2), 125.95 (7-C), 
127.18 (6-C), 131.86 (8-C), 131.99 (=CH), 132.60 (10-C), 133.18 (3-C), 133.87 (9-C), 
147.33 (5-C), 159.87 (1-C). 
 
1H NMR 150 (CDCl3) δ 4.12 (2 H, s, 3-CH2), 4.20 (2 H, dt, J =5.9, 1.5 Hz, propenyl 1-
H), 5.26 (2 H, m, propenyl 3-H), 5.29 (1 H, s, H of 4=CH2), 5.45 (1 H, s, H of 4=CH2), 
5.81 (1 H, m, propenyl 2-H), 7.47 (1 H, t, J = 7.9 Hz, 7-H), 7.70 (1 H, dd, J = 8.1, 1.5 
Hz, 6-H), 8.31 (1 H, dd, J = 7.8, 1.3 Hz, 8-H); 13C NMR δ 49.33 (NCH2), 52.18 (3-C), 
118.12 (=CH2), 119.39 (4=CH2),, 126.60 (6-C), 128.69 (7-C), 129.13 (10-C), 130.68 (9-
C), 131.55 (4-C), 131.78 (8-C), 131.89 (=CH), 147.51 (5-C), 161.05 (1-C). MS (ESI 
+ve) m/z 245.0916 (M + H) (C13H13N2O3 requires 245.0926), 267.0737 (M + H) 
(C13H12N2NaO3 requires 267.0746). 
  
2-Diphenylmethyl-5-nitro-4-phenylmethylisoquinolin-1(2H)-one (151) 
(Z)-4-Benzylidene-2-diphenylmethyl-5-nitro-3,4-dihydroisoquinolin-1(2H)-one 
(152)  
 
NO2
N
O
NO2
N
O
 
 
To 148 (0.5 g, 0.87 mmol) in dry propanenitrile (15 mL) was added (Ph3P)4Pd (50.3 
mg, 0.044 mmol), dry Et3N (0.17 g, 1.7 mmol) and the mixture was boiled under reflux 
for 48 h. After evaporation of solvent residue was taken up in EtOAc, washed (5% aq. 
 151 
HCl, 5% aq. NaHCO3) and dried. Evaporation and chromatography (hexane:EtOAc 
4:1) yielded an inseparable mixture of 151 and 152 (0.16 g, 41%) (1:3) as yellow 
crystals: IR νmax (KBr) 1347 & 1524 (NO2), 1654 (C=O) cm
-1; Rf = 0.35 (hexane:EtOAc 
4:1); 1H NMR 151 (CDCl3) δ 3.75 (2 H, s, CH2), 6.54 (1 H, s, 3-H), 6.86-7.30 (15 H, m, 
3 x Ph-H5), 7.44 (1 H, s, Ph2CH), 7.52 (1 H, t, J = 7.8 Hz, 7-H), 7.79 (1 H, dd, J = 7.5, 
1.4 Hz, 6-H), 8.75 (1 H, dd, J = 8.2, 1.7 Hz, 8-H); 13C NMR δ 35.45 (CH2), 60.72 
(Ph2CH), 112.07 (4-C), 125.96 (7-C), 126.59 (6-C), 128.16, 128.39, 128.62, 128.69, 
129.05, 131.27, 132.76 (8-C), 133.47 (3-C), 133.38, 137.54 (q), 147.88 (5-C), 159.95 
(1-C). 
 
1H NMR 152 (CDCl3) δ 4.24 (2 H, d, J = 1.1 Hz, 3-CH2), 6.82 (1 H, s, =CH), 7.24 (1 H, 
s, Ph2CH), 6.86-7.30 (15 H, m, 3 x Ph-H5), 7.51 (1 H, t, J = 8.2 Hz, 7-H), 7.78 (1 H, dd, 
J = 7.8, 1.3 Hz, 6-H), 8.41 (1 H, dd, J = 7.8, 1.3 Hz, 8-H); 13C NMR δ 43.66 (CH2), 60.77 
(Ph2CH), 124.93 (4-C), 127.14 (6-C), 127.48, 127.56, 128.30 (7-C), 128.38, 128.42, 
128.44, 128.74, 131.15 (10-C), 131.33 (9-C), 134.63 (q), 134.75 (=CH), 137.95 (q), 
147.94 (5-C), 161.52 (1-C). MS (EI) m/z 447.1703 (M + H) (C29H23N2O3 requires 
447.1707.)  
 
(E)-N-Diphenylmethyl-1-deutero-3-phenylprop-2-en-1-amine (157)  
 
N
31
2
D
H
 
 
To 146 (2.0 g, 6.72 mmol) in MeOH (100 mL) warmed to 45 oC was slowly added 
NaBD4 (0.28 g, 6.72 mmol) during 20 min. After evaporation of the solvent the residue 
was taken up in Et2O, washed (5% aq. NaHCO3) and dried.  Evaporation gave 157 (2.0 
g, 99%) as yellow semi-solid: IR (film) νmax 1599 (C=C conjugated), 2248 (C-D), 3325 
(NH) cm-1; 1H NMR (CDCl3) δ 2.09 (1 H, br s, N-H), 3.61 (1 H, br d, J = 6.0 Hz, 1-H), 
5.19 (1 H, s, Ph2CH), 6.57 (1 H, dd, J = 15.8, 6.0 Hz, 2-H), 6.81 (1 H, d, J = 15.8 Hz, 3-
H), 7.41-7.81 (15 H, m, 3 x Ph-H5). 
13C NMR δ 49.61 (t, J = 20.70 Hz, DCH), 66.33 
(Ph2CH), 126.24, 127.04, 127.31, 128.08 (=CCHD), 128.24, 128.49, 130.04, 131.49, 
132.39 (=CPh), 137.05 (q), 137.52 (q), 143.66 (q). 
 152 
(E)-N-Diphenylmethyl-2-iodo-3-nitro-N-(1-deutero-3-phenylprop-2-enyl) 
benzamide (158)  
 
NO2
I
N
O
D
  
 
To 139 (1.5 g, 4.8 mmol) in CH2Cl2 (10 mL) was added 157 (1.44 g, 4.8 mmol) and 
Et3N (0.97 g, 9.6 mmol) and the mixture was stirred for 30 min. Washing (5% aq. HCl, 
5% aq. NaHCO3) drying, evaporation and chromatography (hexane:EtOAc 6:1) gave 
158 (1.69 g, 61%) as light yellow crystals: mp 135-137 oC; Rf = 0.43 (hexane:EtOAc 
6:1); IR νmax (KBr) 1339 & 1529 (NO2), 1634 (C=O) cm
-1; The NMR spectra showed a 
2:3 mixture of rotamers α & β about the amide double bond. 1H NMR α (CDCl3) δ 3.93 
(1 H, m, H-CD), 5.16 (1 H, dd, J = 16.0, 7.0 Hz, =CHCHD), 5.40 (1 H, d, J = 16.0 Hz, 
=CHPh), 7.29 (1 H, s, Ph2CH), 6.90-7.65 (18 H, m, 3 x Ph-H5 + 4,5,6-H3); 
13C NMR δ 
49.25 (t, J = 20.7 Hz, DCH), 61.34 (Ph2CH), 86.08 (2-C), 124.06 (=CHCH2), 124.56 (4-
C), 126.21, 127.24, 127.26, 127.87, 128.35, 128.46, 128.62, 128.82, 128.84, 129.47, 
132.64, 132.69 (=CHPh), 135.61 (q), 138.28 (q), 138.84 (q), 146.27 (1-C), 154.30 (3-
C), 168.66 (C=O);  
 
1H NMR β (CDCl3) δ 3.90 (1/2 H, m, H-CD), 4.8 (1/2 H, d, J = 5.4 Hz, H-CD), 5.78 (1 H, 
s, Ph2CH), 5.84 (1 H, dd, J = 16.0, 5.0 Hz, =CHPh), 5.96 (1 H, dd, J = 16.0, 7.5 Hz, 
=CHCHD), 6.9-7.65 (18 H, m, 3 x Ph-H5 + 4,5,6-H3); 
13C NMR δ 46.68 (t, J = 20.70 Hz, 
DCH), 66.84 (Ph2CH), 85.43 (2-C), 123.44 (=CHCH2), 124.69 (4-C), 126.21, 126.36, 
127.37, 127.89, 128.48, 128.54, 128.74, 128.89, 129.38, 130.91, 132.95 (=CHPh), 
136.83 (q), 137.68 (q), 139.53 (q), 145.45 (1-C), 154.48 (3-C), 170.03 (C=O); 
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2-Diphenylmethyl-3-deutero-5-nitro-4-phenylmethylisoquinolin-1(2H)-one 
(151)/(162) 
(Z)-4-Benzylidene-2-diphenylmethyl-3-deutero-5-nitro-3,4-dihydroisoquinolin-
1(2H)-one (161)  
 
NO2
N
O
NO2
N
O
D/H D
 
 
To 158 (0.5 g, 0.87 mmol) in dry propanenitrile (15 mL) was added (Ph3P)4Pd (50.3 
mg, 0.0435 mmol) and dry Et3N (0.17 g, 1.74 mmol) and the mixture was heated to 
reflux for 2 h. After evaporation of the solvent the residue was taken up in EtOAc, 
washed (5% aq. HCl, 5% aq. NaHCO3) and dried. Evaporation and chromatography 
(hexane:EtOAc 4:1) yielded a mixture of 151/162 and 161 (1:20) (0.33 g, 85%) as 
yellow crystals: Rf = 0.37 (hexane:EtOAc 4:1); IR νmax (KBr) 1347 & 1523 (NO2), 1654 
(C=O) cm-1; 1H NMR 151/162 (CDCl3) δ 3.73 (2 H, s, CH2), 6.53 (1 H, s, 3-H/D), 6.86-
7.30 (15 H, m, 3 x Ph-H5), 7.42 (1 H, s, Ph2CH), 7.53 (1 H, t, J = 7.9 Hz, 7-H), 7.81(1 H, 
dd, J = 7.7, 1.5 Hz, 6-H), 8.74 (1 H, dd, J = 7.9, 1.4 Hz, 8-H). 
 
1H NMR 161 (CDCl3) δ 4.19 (1 H, s, 3-H/D), 6.80 (1 H, s, =CH), 7.23 (1 H, s, Ph2CH), 
6.86-7.30 (15 H, m, 3 x Ph-H5), 7.52 (1 H, t, J = 8.0 Hz, 7-H), 7.77 (1 H, dd, J = 8.0, 1.2 
Hz, 6-H), 8.39 (1 H, dd, J = 7.9, 1.2 Hz, 8-H); 13C NMR δ 43.43 (t, J = 20.7 Hz, CHD), 
60.73 (Ph2CH), 124.87 (4-C), 127.11 (6-C), 127.52, 127.56, 128.28, 128.34, 128.36, 
128.41, 128.43, 128.64 (q), 128.81, 129.07 (q), 132.01 (8-C), 134.61 (q), 134.74 
(=CH),137.92 (q), 137.95 (q), 147.91 (5-C), 161.48 (1-C). MS (ESI +ve) m/z 470.1527 
(M + Na) (C29H21DN2NaO3 requires 470.1591). 
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2-Hydroxymercuri-3-nitrobenzoic acid (75) 
2-Bromo-3-nitrobenzoic acid (165) 
 
NO2
O
Hg
O
O
NO2
Br
OH
 
 
3-Nitrobenzene-1,2-dicarboxylic acid 74 (21.1 g, 100 mmol) in hot aq. NaOH (10%, 80 
mL) was added to Hg(OAc)2 (35.0 g, 110 mmol) in hot AcOH (5 mL) and H2O (70 mL). 
The mixture was heated at 120 oC for 70 h and then filtered. The precipitate was 
washed (H2O, then EtOH) and dried to give 2-hydroxymercuri-3-nitrobenzoic acid 75 
(30.7 g, 84%) as a cream solid. To a refluxing solution of 75 (30.7 g, 84 mmol) in aq. 
NaOH (3.5%, 500 mL) was slowly added, with vigorous stirring, aq. HCl (2 M, 12 mL) 
and the solution was allowed to cool to room temperature. AcOH (3 mL) was then 
added. The precipitate dissolved upon addition of NaBr (10.0 g, 100 mmol) and Br2 
(15.98 g, 100 mmol) in H2O (20 mL). The solution was boiled under reflux for 24 h, 
cooled and neutralised with aq. NaOH before being filtered and acidified with aq. HCl 
(9 M). The precipitate was filtered, dried and recrystallised (EtOH) to give 165 (13.7 g, 
66%) as buff crystals: Rf = 0.22 (CH2Cl2:MeOH:AcOH 9:1:0.1); mp 185-187
 oC (lit.160 
mp 186-188 oC); IR νmax (KBr) 1372 & 1543 (NO2), 1712 (C=O), 2515-3060 (OH) cm
-1; 
1H NMR (CD3)2SO δ 7.70 (1 H, t, J = 7.9 Hz, 5-H), 7.94 (1 H, dd, J = 7.9, 1.5 Hz, 4-H), 
8.07 (1 H, dd, J = 8.1, 1.7 Hz, 6-H). 
 
2-Bromo-3-nitrobenzoyl chloride (166) 
 
NO2
O
Br
Cl
 
 
To 165 (1.0 g, 4.5 mmol) and DMF (0.1 mL) was carefully added SOCl2 (10 mL) and 
the mixture was boiled under reflux for 24 h. Evaporation and recrystallisation (Et2O) 
yielded 166 (1.02 g, 86%) as white solid: mp 65-67 oC (lit.210 mp 66-66.5ºC); Rf = 0.13 
(EtOAc:hexane 1:4); IR νmax (KBr) 1345 & 1534 (NO2), 1756 (C=O) cm
-1; 1H NMR 
(CD3)2SO δ 7.62 (1 H, t, J = 7.9 Hz, 5-H), 7.87 (1 H, dd, J = 8.1, 1.7 Hz, 4-H), 8.03 (1 
H, dd, J = 8.0, 1.5 Hz, 6-H). 
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2-Bromo(E)-N-Diphenylmethyl-3-nitro-N-(1-deutero-3-phenylprop-2-enyl) 
benzamide (167) 
 
NO2
Br
N
O
D
 
 
To 2-bromo-3-nitrobenzoyl chloride 166 (0.48 g, 1.8 mmol) in CH2Cl2 (10 mL) was 
added 157 (0.54 g, 1.8 mmol) and Et3N (0.36 g, 3.6 mmol) and the mixture was stirred 
for 30 min. Washing (5% aq. HCl, 5% aq. NaHCO3), drying, evaporation and 
chromatography (hexane:EtOAc 4:1) gave 167 (1.49 g, 54%) as buff crystals: mp 114-
116 oC; Rf = 0.25 (hexane:EtOAc 4:1); IR νmax (KBr) 1359 & 1532 (NO2), 1638 (C=O) 
cm-1; The NMR spectra showed a 2:3 mixture of rotamers α & β about the amide 
double bond. 1H NMR α (CDCl3) δ 3.93 (1 H, m, H-CD), 5.10 (1 H, dd, J = 15.87, 6.76 
Hz, =CHCHD), 5.41 (1 H, d, J = 15.87 Hz, =CHPh), 7.29 (1 H, s, Ph2CH), 6.80-7.46 (17 
H, m, 3 x Ph-H5 + 5,6-H2), 7.74 (1 H, dd, J = 7.35, 2.1 Hz, 4-H); 
13C NMR δ 48.96 (t, J = 
22.2 Hz, DCH), 61.26 (Ph2CH), 111.79 (2-C), 124.00 (=CHCHD), 125.16 (4-C), 126.11, 
128.04, 128.12, 128.17, 128.44, 128.74, 128.84, 130.14 (6-C), 131.62, 132.60 
(=CHPh), 135.59 (q), 138.79 (q), 139.26 (q), 141.67 (1-C), 152.53 (3-C), 168.22 (C=O); 
 
1H NMR β (CDCl3) δ 3.91 (1/2 H, m, H-CD), 4.75 (1/2 H, d, J = 4.99 Hz, H-CD), 5.81 (1 
H, s, Ph2CH), 5.81-5.88 (2 H, m, =CHPh & =CHCHD), 6.9-7.65 (18 H, m, 3 x Ph-H5 + 
4,5-H2), 6.98 (1 H, dd, J = 8.2, 1.8 Hz, 4-H), 7.71 (1 H, dt, J = 7.9, 1.8 Hz, 6-H); 
13C 
NMR δ 46.33 (t, J = 22.2 Hz, DCH), 66.72 (Ph2CH), 111.49 (2-C), 123.42 (=CHCHD), 
125.29 (4-C), 126.35, 127.88, 128.30, 128.48, 128.57, 128.78, 129.16 (6-C), 130.57, 
132.85 (=CHPh), 136.75 (q), 137.59 (q), 138.24 (q), 141.01 (1-C), 150.61 (3-C), 167.77 
(C=O); MS (EI) m/z 527.0945 (M) (C29H22DN2O3
79Br requires 527.0949), 528.1028 (M + 
H) (C29H23DN2O3
79Br requires 528.1027). 
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2-Iodo-3-nitro-N-(prop-2-enyl)benzamide (143)  
3-Nitro-N-(prop-2-enyl)-2-(prop-2-enylamino)benzamide (168) 
 
O
NH
I
NO2
N
NO2
O
HN
H
 
 
To 139 (1.65 g, 5.3 mmol) in CH2Cl2 (20 mL) was added prop-2-en-1-amine (0.25 mL, 
5.3 mmol) and Et3N (1.07 g, 10.6 mmol) and the mixture was stirred for 1 h. Washing 
(5% aq. HCl, 5% aq. NaHCO3), drying, evaporation and chromatography 
(CH2Cl2:EtOAc 4:1) gave 143 (1.25 g, 71%) as yellow crystals: mp 108-110
 oC; Rf = 
0.20 (hexane:EtOAc 4:1); IR (KBr) νmax 1349 & 1529 (NO2), 1588 & 1643 (C=O), 3077 
& 3264 (NH) cm-1; 1H NMR (CDCl3) δ 3.95 (2 H, dt, J = 5.9, 1.5 Hz, CH2), 5.11 (1 H, dq, 
J = 10.4, 1.3 Hz, H of =CH2), 5.25 (1 H, dq, J = 17.1, 1.5 Hz, H of =CH2), 5.77-5.91 (1 
H, m, =CH), 6.28 (1 H, br s, NH), 7.41 (1 H, dd, J = 7.7, 1.8 Hz, 4-H), 7.49 (1 H, t, J = 
7.5 Hz, 5-H), 7.62 (1 H, dd, J = 7.7, 1.8 Hz, 6-H); 13C NMR δ 42.48 (CH2), 84.86 (2-C), 
117.42 (=CH2), 125.00 (6-C), 129.40 (5-C), 130.30 (4-C), 132.99 (=CH), 146.03 (1-C), 
154.75 (3-C), 168.24 (C=O); MS (FAB+) m/z 331.9677 (M) (C10H9IN2O3 requires 
371.9657); Anal. Calcd for C10H9IN2O3: C, 36.17; H, 2.73; N, 8.44; Found: C, 36.6; H, 
2.85; N, 8.36.  
 
Also isolated by chromatography was 168 (0.14 g, 10%) as bright yellow crystals: mp 
54-57 oC; Rf = 0.45 (hexane:EtOAc 4:1); IR (KBr) νmax 1345 & 1516 (NO2), 1578 & 1639 
(C=O), 3334 & 3468 (NH) cm-1; 1H NMR δ (CDCl3) 3.75 (2 H, s, CH2), 4.01 (2 H, tt, J = 
6.0, 1.4 Hz, CH2), 5.13-5.25 (4 H, m, 2 x =CH2), 5.78-5.92 (2 H, m, 2 × H-C=C), 6.77 (1 
H, t, J = 8.2 Hz, 5-H), 6.82 (1 H, br s, NH), 7.66 (1 H, dd, J = 7.4, 1.7 Hz, 4-H), 7.72 (1 
H, br s, NH), 8.10 (1 H, dd, J = 8.2, 1.7 Hz, 6-H); 13C NMR δ 42.41 (O=CNCH2), 50.24 
(NCH2), 117.21 (5-C), 117.31 (=CH2), 117.40 (=CH2), 126.31 (2-C), 128.63 (6-C), 
133.30 (=CH), 133.72 (=CH), 136.30 (4-C), 137.23 (1-C), 143.58 (3-C), 167.37 (C=O). 
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2-Iodo-3-nitrobenzamide (170) 
 
NO2
I
NH2
O
 
 
A solution of ethereal NH3 was produced by slow addition of K2CO3 to mixture of Et2O 
(200 mL) and conc. aq. NH3 (20 mL). The top ethereal layer was then carefully 
transferred to 139 (3.0 g, 9.6 mmol) in Et2O (10 mL). The mixture was stirred at room 
temperature for 1 h, then evaporated to yield 170 (2.6 g, 93%) as yellow crystals: mp 
221-223 oC (lit.160 mp 220-221 oC); Rf = 0..38 (hexane:EtOAc 1:4); IR νmax (KBr) 1365 & 
1524 (NO2), 1628 & 1653 (C=O), 3178 & 3359 (NH2) cm
-1; 1H NMR ((CD3)2SO) δ 7.53 
(1 H, dd, J = 7.9, 1.8 Hz, 6-H), 7.61 (1 H, t, J = 7.9 Hz, 5-H), 7.72 (1 H, br s, NH), 7.84 
(1 H, dd, J = 7.9, 1.8 Hz, 4-H), 8.00 (1 H, br s, NH). 
 
2-Iodo-3-nitrobenzonitrile (171) 
 
NO2
I
CN
 
 
To 170 (3.0 g, 10.3 mmol) in THF (50 mL) was carefully added SOCl2 (17 mL) and 
refluxed for 24 h. Ice H2O (100 mL) was then added and the mixture made alkaline with 
cold aq. NaOH (10%, 100 mL). Extraction (CHCl3), washing (saturated NaHCO3, then 
H2O), drying and evaporation gave 171 (1.65 g, 59%) as yellow crystals: mp 145-147
 
oC (lit.160 mp 147-148 oC); Rf = 0.92 (hexane:EtOAc 1:4); IR νmax (KBr) 1358 & 1530 
(NO2), 2233 (CN) cm
-1; 1H NMR ((CD3)2SO) δ 7.80 (1 H, t, J = 8.0 Hz, 5-H), 8.12 (1 H, 
dd, J = 7.2, 1.5 Hz, 6-H), 8.18 (1 H, dd, J = 8.1, 1.6 Hz, 4-H). 
 
Prop-2-enyl-2-iodo-3-nitrobenzoate (173) 
 
O
O
I
NO2  
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To 139 (1.51 g, 4.8 mmol) in CH2Cl2 (10 mL) was added prop-2-en-1-ol (0.33 mL, 4.8 
mmol) and Et3N (0.97 g, 9.6 mmol) and the mixture was stirred for 2 h. Washing (5% 
aq. HCl, 5% aq. NaHCO3), drying, evaporation and chromatography (Petroleum 
ether:EtOAc 4:1) gave 173 (1.02 g, 64%) as brown liquid: Rf = 0.59 (Petroleum 
ether:EtOAc 4:1); IR (film) νmax 1359 & 1533 (NO2), 1588 & 1731 (C=O) cm
-1; 1H NMR 
CDCl3 δ 4.82 (2 H, dt, J = 6.0, 1.4 Hz, CH2), 5.27-5.31 (1 H, dq, J = 10.4, 1.3 Hz, H of 
=CH2), 5.38-5.43 (1 H, dq, J = 17.1, 1.4 Hz, H of =CH2), 5.95-6.04 (1 H, m, H-C=C), 
7.50 (1 H, t, J = 7.9 Hz, 5-H), 7.63 (1 H, dd, J = 7.9, 1.6 Hz, 4-H), 7.74 (1 H, dd, J = 7.9, 
1.6 Hz, 6-H); 13C NMR δ 66.85 (CH2), 85.22 (2-C), 119.49 (=CH2), 125.91 (5-C), 129.16 
(4-C), 130.98 (=CH), 132.07 (6-C), 139.97 (1-C), 155.81 (3-C), 165.77 (C=O); MS (EI) 
m/z 332.9497 (M) (C10H8INO4 requires 332.9498). 
 
4-Methyl-5-nitroisoquinolin-1(2H)-one (177) 
4-Methylene-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (178) 
3-Nitro-N-(prop-2-enyl)benzamide (175) 
 
NH
O
CH3NO2           
NH
O
CH2NO2             NO2
N
H
O
 
 
To 143 (200 mg, 0.6 mmol) in dry DMF (0.7 mL) was added (Ph3P)4Pd (14.0 mg, 2 
mol%), dry Et3N (0.2 mL, 1.5 mmol) and tetrabutylammonium chloride (170 mg, 0.6 
mmol) and the mixture was heated to 100 oC for 48 h. After evaporation of the solvent 
the residue was taken up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. 
Evaporation and chromatography (hexane:EtOAc 2:1) yielded 177 (40 mg, 33%) as 
buff powder: mp 209-211 oC; Rf = 0.15 (hexane:EtOAc 2:1); IR νmax (KBr) 1350 & 1529 
(NO2), 1639 (C=O), 3448 & 3173 (NH) cm
-1; 1H NMR (CDCl3) δ 2.16 (3 H, s, CH3), 7.05 
(1 H, s, 3-H), 7.52 (1 H, t, J = 7.9 Hz, 7-H), 7.82 (1 H, dd, J = 7.8, 1.4 Hz, 6-H), 8.68 (1 
H, dd, J = 7.8, 1.4 Hz, 8-H), 10.72 (1 H, br s, NH); 13C NMR δ 15.80 (CH3), 109.03 (4-
C), 126.08 (7-C), 127.79 (6-C), 127.87 (10-C), 129.47 (3-C), 129.74 (9-C), 131.37 (8-
C), 147.50 (5-C), 161.83 (1-C); MS (ESI +ve) m/z 205.0608 (M + H) (C10H9N2O3 
requires 205.0613). 
 
Also isolated from chromatography was an inseparable mixture of 177 & 178 (2.5:1) 
(30 mg, 25%) as brown semi-solid: Rf = 0.14 (hexane:EtOAc 2:1); 
1H NMR 178 (CDCl3) 
δ 4.22 (2 H, d, J = 1.2 Hz, CH2), 5.34 (1 H, s, =CH), 5.50 (1 H, s, =CH), 7.06 (1 H, br s, 
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NH), 7.52 (1 H, t, J = 8.2 Hz, 7-H), 7.76 (1 H, dd, J = 8.2, 1.4 Hz, 6-H), 8.32 (1 H, dd, J 
= 8.2, 1.4 Hz, 8-H); 13C NMR δ 47.45 (NCH2), 119.57 (=CH2), 127.19 (6-C), 128.81 (7-
C), 129.77 (10-C), 129.76 (9-C), 131.46 (8-C), 131.51 (4-C), 147.92 (5-C), 163.25 (1-
C). 
 
Compound 175 was also isolated (16 mg, 13%) as yellow semi-solid: Rf = 0.44 
(hexane:EtOAc 2:1); IR νmax (film) 1350 & 1528 (NO2), 1639 (C=O), 3349 & 3468 (NH) 
cm-1; 1H NMR (CDCl3) δ 4.09 (2 H, t, J = 5.9 Hz, CH2), 5.20 (1 H, dt, J = 10.1, 1.6 Hz, 
propenyl 3-H), 5.27 (1 H, dd, J = 17.2, 1.9 Hz, propenyl 3-H), 5.86-5.96 (1 H, m, 
propenyl 2-H), 6.73 (1 H, br s, NH), 7.62 (1 H, t, J = 8.2 Hz, 5-H), 8.15 (1 H, dd, J = 7.8, 
1.6 Hz, 6-H), 8.33 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 8.60 (1 H, t, J = 1.9 Hz, 2-H); 
13C NMR δ 42.70 (NCH2), 117.23 (=CH2), 121.77 (2-C), 126.04 (4-C), 129.82 (5-C), 
130.29 (6-C), 133.44 (=CH), 135.96 (1-C), 148.06 (3-C), 164.97 (C=O); MS (ESI +ve) 
m/z 207.077 (M + H) (C10H11N2O3 requires 207.0764). 
 
Reaction was repeated with 143 (200 mg, 0.6 mmol) in dry EtCN (5 mL), (Ph3P)4Pd 
(34.66 mg, 5 mol%) and dry Et3N (0.17 mL, 1.2 mmol) at 100
 oC for 24 h. After 
evaporation of the solvent the residue was taken up in CHCl3, washed (5% aq. HCl, 5% 
aq. NaHCO3) and dried. Evaporation and chromatography (hexane:EtOAc 4:1) yielded 
1:1 mixture of 177 & 178 (71 mg, 58%), 175 (32 mg, 23%) and traces of (176). 
 
Same reaction was repeated with 143 (200 mg, 0.6 mmol) in dry DMF (1.0 mL), 
(Ph3P)4Pd (14.0 mg, 2 mol%), dry DMF (1 mL) and tetrabutylammonium chloride (170 
mg, 0.6 mmol) at 50 oC for 48 h. After evaporation of the solvent the residue was taken 
up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. Evaporation and 
chromatography (hexane:EtOAc 2:1) yielded 1:1 mixture of 177 & 178 (40 mg, 54%) 
and 175 (20 mg, 27%).  
 
Reaction was repeated with 143 (100 mg, 0.3 mmol) in dry DMF (0.5 mL), (Ph3P)4Pd 
(7.0 mg, 2 mol%), dry Et3N (0.1 mL, 0.6 mmol) and tetrabutylammonium chloride (84 
mg, 0.6 mmol) at 150 oC for 16h. After evaporation of the solvent the residue was taken 
up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. Evaporation and 
chromatography (hexane:EtOAc 4:1) yielded 177 (40 mg, 65%) as buff powder with 
data as above. 
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(E)-2-Iodo-3-nitro-N-(prop-1-enyl)benzamide (179) 
 
O
NH
I
NO2  
 
Compound 143 (0.1 g, 0.3 mmol) in 0.2 mL of anhydrous benzene and 
[RuClH(CO)(PPh3)3] (1.42 mg, 0.5 %mol) were heated at 80
 oC for 3 h under Ar. After 
cooling to room temperature 25 mL of EtOAc is added and the mixture was cooled to 0 
oC. The precipitated ruthenium compounds and PPh3 were filtered off. Evaporation of 
the filterate and chromatography (hexane:EtOAc 4:1) gave 179 (0.96 g, 96%) as pale 
white coloured solid: mp 169-172 oC; IR (KBr) νmax 1349 & 1528 (NO2), 1586 & 1644 
(C=O), 3067 & 3245 (NH) cm-1;  1H NMR δ (CDCl3) 1.76 (3 H, dd, J = 6.76, 1.8 Hz, 
CH3), 5.37 (1 H, m, =CH-CH3), 6.83-6.92 (1 H, tq, J = 10.52, 1.8 Hz, =CH-NH), 7.20 (1 
H, br s, NH), 7.51-7.56 (2 H, m, 5,6-H2), 7.69 (1 H, m, 4-H); 
13C NMR δ 14.94 (CH3), 
84.89 (2-C), 110.99 (=C-CH3), 122.50 (=C-NH), 125.44 (4-C), 129.55 (6-C), 130.65 (5-
C), 130.83 (1-C), 154.99 (3-C), 164.91 (C=O); MS (EI) m/z 331.9672 (M) (C10H9IN2O3 
requires 331.9658). 
 
(E)-3-Nitro-N-(prop-1-enyl)benzamide (176) 
3-Nitrobenzamide (180) 
 
NO2
N
H
O
          NO2
NH2
O
 
 
To 179 (200 mg, 0.6 mmol) in dry DMF (1 mL) was added (Ph3P)4Pd (17.3 mg, 2 
mol%), dry Et3N (0.2 mL, 1.5 mmol) and tetrabutylammonium chloride (210 mg, 0.6 
mmol) and the mixture was heated to reflux for 7 d. After evaporation of the solvent the 
residue was taken up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. 
Evaporation and chromatography (hexane:EtOAc 2:1) yielded 176 (42 mg, 52%) as a 
buff semi-solid: Rf = 0.87 (hexane:EtOAc 2:1); IR νmax (film) 1350 & 1528 (NO2), 1638 & 
1654 (C=O), 3078 & 3306 (NH) cm-1; 1H NMR (CDCl3) δ 1.76 (3 H, dd, J = 6.6, 1.6 Hz, 
CH3), 5.36-5.45 (1 H, m, propenyl 2-H), 6.91-6.97 (1 H, m, propenyl 1-H), 7.66 (1 H, t, J 
 161 
= 8.2 Hz, 5-H), 7.70 (1 H, br s, NH), 8.17 (1 H, dt, J = 7.8, 1.2 Hz, 6-H), 8.36 (1 H, ddd, 
J = 8.2, 2.4, 1.2 Hz, 4-H), 8.60 (1 H, t, J = 1.9 Hz, 2-H); 13C NMR δ 14.99 (CH3), 110.47 
(C-CH3), 121.65 (2-C), 123.04 (C-NH), 126.35 (4-C), 130.04 (5-C), 133.33 (6-C), 
135.44 (1-C), 148.50 (3-C), 161.64 (C=O); MS (ESI +ve) m/z 229.0579 (M + Na) 
(C10H10N2O3Na requires 229.0589). 
 
Also identified in trace amounts in the NMR spectrum were 180. IR νmax (KBr) 1350 & 
1530 (NO2), 1624 & 1689 (C=O), 3178 & 3451 (NH2) cm
-1; 1H NMR (CDCl3) δ, 6.07 (1 
H, br s, NH), 6.34 (1 H, br s, NH), 7.68 (1 H, t, J = 7.9 Hz, 5-H), 8.18 (1 H, ddd, J = 7.9, 
2.7, 1.2 Hz, 4-H), 8.39 (1 H, ddd, J = 8.4, 2.4, 1.2 Hz, 6-H), 8.65 (1 H, t, J = 2.0 Hz, 2-
H). 
 
tert-Butyl N-prop-2-enyl(2-iodo-3-nitrobenzoyl)carbamate (181) 
 
O
N
I
NO2
O
O
CH3
CH3
CH3
 
 
Di(tert-butyl)dicarbonate (0.1 g, 0.45 mmol) was slowly added to an ice-cold solution of 
143 (0.1 g, 0.3 mmol). Et3N (0.062 mL, 0.45 mmol) and 4-(dimethyl amino)pyridine (7.4 
mg, 0.06 mmol) were added and the mixture was stirred for 3 h. Evaporation gave 181 
(0.12 g, 92%) as yellow semi-solid: Rf = 0.77 (hexane:EtOAc 4:1); IR (film) νmax 1347 & 
1535 (NO2), 1672 & 1739 (C=O), 1245 (C-O) cm
-1; 1H NMR (CDCl3) δ 1.19 (9 H, s, 
(CH3)3), 4.46 (2 H, d, J = 5.5 Hz, CH2), 5.11-5.23 (1 H, dd, J = 10.2, 1.4 Hz, H of =CH2), 
5.27-5.35 (1 H, dq, J = 17.1, 1.4 Hz, H of =CH2), 5.87-6.02 (1 H, m, =CH), 7.27 (1 H, 
dd, J = 7.4, 1.4 Hz, 4-H), 7.49 (1 H, t, J = 7.7 Hz, 5-H), 7.66 (1 H, dd, J = 8.0, 1.3 Hz, 6-
H); 13C NMR δ 27.46 (CH3)3, 46.66 (NCH2), 83.95 (2-C), 84.45 (C-CH3)3), 117.94 
(=CH2), 124.05 (4-C), 128.86 (6-C), 129.10 (5-C), 132.05 (=CH), 148.45 (1-C), 151.04 
(O-C=O), 154.16 (3-C), 169.64 (C=O); MS (ESI +ve) m/z 455.0048 (M+Na) 
(C15H17IN2NaO5 requires 455.0080). 
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5-Amino-4-methylisoquinolin-1(2H)-one hydrochloride (182) 
 
 
To a solution of 177 (58 mg, 0.28 mmol) in ethanol (5 mL) and conc. HCl (0.2 mL), a 
slurry of 10% palladium on charcoal (0.1 g) in ethanol (2 mL) was added. The mixture 
was stirred under H2 for 2 h. The suspension was then flltered through Celite
. The 
Celite pad and residue were suspended in water (100 mL) and heated. The hot 
suspension was filtered through a second Celite pad. Concentration of the filterate and 
drying gave 182 (42 mg, 70%) as buff crystals: mp 227-229 oC; IR νmax (KBr) 1654 
(C=O), 3421 (NH) cm-1; 1H NMR (D2O) δ 2.37 (3 H, s, CH3), 6.94 (1 H, s, 3-H), 7.42 (1 
H, t, J = 8.2 Hz, 7-H), 7.63 (1 H, d, J = 7.8 Hz, 6-H), 8.14 (1 H, d, J = 8.2 Hz, 8-H); 13C 
NMR δ 18.41 (CH3), 110.74 (4-C), 126.89 (5-C), 127.04 (9-C), 127.24 (7-C), 128.48 (8-
C), 128.64 (3-C), 129.55 (6-C), 132.52 (10-C), 162.72 (1-C); MS (ESI +ve) m/z 
175.0866 (M + H) (C10H11N2O1 requires 175.0871). 
 
(E)-N-(3-phenylprop-2-enyl)2,2,2-trifluoroacetamide (184) 
(E)-3-Phenylprop-2-enylamine triflouroacetate salt (183) 
 
N
H
CF3
O
NH3 CF3CO2
 
 
To 2,2,2-trifluoroacetamide (2.86 g, 25.4 mmol) in dry THF (25 mL), potassium t-
butoxide (2.84 g, 25.4 mmol) was added slowly. After 30 min, (E)-(3-bromoprop-1-
enyl)benzene (5.00g, 25.4 mmol) was added and the mixture was stirred for 2 h. After 
the evaporation of the solvent, the residue was taken up in CH2Cl2, washed (H2O) and 
dried. Evaporation and chromatography (hexane:EtOAc 4:1) yielded 184 (1.89 g, 33%) 
as white powder: mp 101-103 oC; (lit.212 mp 100-102 oC) Rf = 0.34 (hexane:EtOAc 4:1); 
IR (KBr) νmax 1179 (C-F), 1556 & 1704 (C=O), 3116 & 3299 (NH) cm
-1; 1H NMR (CDCl3) 
δ 4.13 (2 H, t, J = 6.5 Hz, CH2), 6.17 (1 H, dt, J = 15.4, 6.9 Hz, =CH-CH2), 6.52 (1 H, br 
s, NH), 6.60 (1 H, d, J = 15.4 Hz, =CH-Ph), 7.25-7.37 (5 H, m, 2’,3’,4’,5’,6’-H5);
 13C 
NMR δ 41.91 (CH2), 117.22 (CF3, q, J = 288.3 Hz), 122.62 (=C-CH2), 126.48 (2,6-C2), 
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128.24 (4-C), 128.68 (3,5-C2), 134.18 (=C-Ph), 135.78 (1-C), 157.23 (C=O, q, J = 37.6 
Hz); 19F NMR (CDCl3) δ -75.81 (3 F, s, CF3). 
 
Also isolated by chromatography was 183 (0.44 g, 7%) as yellow semisolid. Rf = 0.18 
(hexane:EtOAc 4:1); IR νmax (film) 1196 (C-F), 1674 & 1731 (C=O), 3197 & 3365 (NH) 
cm-1; 1H NMR (CDCl3) δ 4.32 (2 H, dd, J = 5.7, 1.4 Hz, CH2), 6.37 (1 H, dt, J = 15.9, 
5.7 Hz, =CH-CH2), 6.48 (3 H, br s, NH3), 6.57 (1 H, d, J = 16.1 Hz, =CH-Ph), 7.25-7.39 
(5 H, m, 2’,3’,4’,5’,6’-H5);
 19F NMR (CDCl3) δ -76.22 (3 F, s, CF3). 
 
(E)-3-phenylprop-2-enylamine (185) 
 
NH2
 
 
Method A: 
 
To 184 (1.2 g, 5.2 mmol) in EtOH (15 mL), was added conc. aq. NH3 (1 mL) and the 
mixture was stirred for 4 d. The evaporation residue, in CH2Cl2, was washed (H2O) and 
dried. Evaporation and chromatography (CH2Cl2:MeOH 10:1) yielded 185 (0.616 g, 
88%) as a pale yellow oil: Rf = 0.55 (CH2Cl2:MeOH 10:1); IR (film) νmax 1450 & 1494 
(C=C), 1598 (C=C conjugated), 3390 (NH) cm-1; 1H NMR (CDCl3) δ 3.47 (2 H, d, J = 6.7 
Hz, CH2), 6.10 (1 H, dt, J = 15.8, 6.9 Hz, =CH-CH2), 6.39 (2 H, br s, NH2), 6.54 (1 H, d, 
J = 15.8 Hz, =CH-Ph), 7.20-7.31 (5 H, m, 2’,3’,4’,5’,6’-H5); 
 
Method B: 
 
NaBH4 (1.06 g, 28.2 mmol) was added to 184 (0.81 g, 3.52 g) in EtOH (10 mL) and the 
mixture was stirred for 16 h. The evaporation residue, in CH2Cl2, was washed (H2O) 
and dried to give 185 (0.422 g, 90%) as a pale yellow oil with properties as above. 
 
(E)-2-iodo-3-nitro-N-(3-phenylprop-2-enyl)benzamide (186) 
 
NO2
I
N
H
O
 
 164 
To 139 (1.55 g, 5.0 mmol) in CH2Cl2 (20 mL) was added 185 (0.66 g, 5.0 mmol) and 
Et3N (1.4 mL, 10 mmol) and the mixture was stirred for 2 h. Washing (5% aq. HCl, 5% 
aq. NaHCO3), drying, evaporation and chromatography (hexane:EtOAc 4:1) gave 186 
(1.51 g, 74%) as yellow crystal:. mp 146-148 oC; Rf = 0.38 (hexane:EtOAc 2:1); IR 
(KBr) νmax 1377 & 1537 (NO2), 1645 (C=O), 3066 & 3263 (NH) cm
-1; 1H NMR (CDCl3) δ 
4.22 (2 H, t, J = 6.3 Hz, CH2), 6.08 (1 H, br s, NH), 6.26 (1 H, dt, J = 15.9, 6.3 Hz, =CH-
CH2), 6.64 (1 H, d, J = 15.6 Hz, =CH-Ph), 7.22-7.36 (5 H, m, 2’,3’,4’,5’,6’-H5), 7.42-7.50 
(2 H, m, 5,6-H2), 7.63 (1 H, m, 4-H);
 13C NMR δ 42.24 (CH2), 84.91 (2-C), 124.05 (=C-
CH2), 125.14 (4-C), 126.40 (2’,6’-C2), 127.97 (4’-C), 128.65 (3’,5’-C2), 129.46 (6-C), 
130.35 (5-C), 133.23 (=C-Ph), 136.15 (1’-C), 146.06 (1-C), 154.85 (3-C), 168.24 
(C=O); MS (ESI +ve) m/z 409.0035 (M + H) (C16H14IN2O3 requires 409.0049); Anal. 
Calcd for C16H13IN2O3: C, 47.08; H, 3.21; N, 6.86; Found: C, 47.58; H, 3.19; N, 6.93. 
 
4-Benzyl-5-nitroisoquinolin-1(2H)-one (187) 
(Z)-4-Benzylidene-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (188) 
(E)-3-nitro-N-(3-phenylprop-2-enyl)benzamide (189) 
3-Amino-2-chloro-N-(3-phenylprop-2-enyl)benzamide (190) 
         
 
 
To 186 (100 mg, 0.25 mmol) in dry DMF (0.5 mL) was added (Ph3P)4Pd (6.0 mg, 2 
mol%), dry Et3N (0.09 mL, 0.625 mmol) and tetrabutylammonium chloride (70 mg, 0.25 
mmol) and the mixture was heated to reflux for 48 h. After evaporation of the solvent 
the residue was taken up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. 
Evaporation and chromatography (hexane:EtOAc 2:1) yielded 187 (12 mg, 17%) as a 
yellow solid. mp 108-110°C; Rf = 0.63 (hexane:EtOAc 2:1); IR (KBr) νmax 1345 & 1530 
(NO2), 1638 (C=O), 3283 & 3468 (NH) cm
-1; 1H NMR (CDCl3) δ 4.24 (2 H, t, J = 6.7 Hz, 
CH2), 6.25 (1 H, dt, J = 15.6, 6.3 Hz, =CH-CH2), 6.57 (1 H, d, J = 16.0 Hz, =CH-Ph), 
7.06 (1 H, t, J = 5.5 Hz, NH), 7.20-7.33 (5 H, m, 2’,3’,4’,5’,6’-H5), 7.57 (1 H, t, J = 7.8 
Hz, 5-H), 8.20 (1 H, dd, J = 7.8, 1.6 Hz, 6-H), 8.29 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 
8.63 (1 H, t, J = 1.6 Hz, 2-H); 13C NMR δ 42.38 (CH2), 121.81 (2-C), 124.56 (=C-CH2), 
125.98 (4-C), 126.29 (2’,6’-C2), 127.84 (4’-C), 128.54 (3’,5’-C2), 129.73 (5-C), 132.78 
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(=C-Ph), 133.33 (6-C), 135.84 (1-C), 136.14 (1’-C), 147.98 (3-C), 165.00 (C=O); MS 
(ESI +ve) m/z 283.1077 (M + H) (C16H15N2O3 requires 283.1083). 
 
Also isolated from chromatography was 188 (10 mg, 14%) as yellow semisolid. Rf = 0.2 
(hexane:EtOAc 2:1); IR (film) νmax 1644 (C=O), 3061 & 3340 (NH) cm
-1; 1H NMR 
(CDCl3) δ 4.20 (2 H, s, NH2), 4.22-4.24 (2 H, m, CH2), 6.11 (1 H, br s, NH), 6.26 (1 H, 
dt, J = 15.7, 6.3 Hz, =CH-CH2), 6.58 (1 H, d, J = 16.0 Hz, =CH-Ph), 6.80 (1 H, dd, J = 
8.2, 1.6 Hz, 4-H), 6.88 (1 H, dd, J = 7.8, 1.6 Hz, 6-H), 7.07 (1 H, t, J = 7.8 Hz, 5-H), 
7.23-7.37 (5 H, m, 2’,3’,4’,5’,6’-H5); 
13C NMR δ 41.97 (CH2), 115.36 (2-C), 116.99 (4-C), 
118.28 (6-C), 124.95 (=CH-CH2), 126.38 (2’,6’-C2), 127.52 (4’-C), 127.76 (5-C), 128.58 
(3’,5’-C2), 132.44 (=CH-Ph), 136.37 (1-C), 136.42 (1’-C), 143.64 (3-C),  167.29 (C=O); 
MS (ESI +ve) m/z 287.0946 (M + H) (C16H16ClN2O requires 287.0951). 
 
Compound 189 (8 mg, 11%) was also isolated from above reaction as orange solid:. 
mp 210-212°C; Rf = 0.19 (hexane:EtOAc 2:1); IR (KBr) νmax 1354 & 1530 (NO2), 1636 
(C=O), 3287 & 3472 (NH) cm-1; 1H NMR (CDCl3) δ 3.88 (2 H, s, CH2), 6.75 (1 H, s, 3-
H), 7.11 (2 H, d, J = 7.0 Hz, 2’,6’-H2), 7.23-7.31 (3 H, m, 3’,4’,5’-H3), 7.56 (1 H, t, J = 
7.8 Hz, 7-H), 7.82 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.68 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 
11.07 (1 H, br s, NH); 13C NMR δ 35.45 (CH2), 113.27 (4-C), 126.11 (7-C), 126.94 (4’-
C), 127.94 (9-C), 128.71 (6-C) 128.81 (3’,5’-C2), 129.39 (2’,6’-C2), 129.59 (10-C), 
130.93 (3-C), 131.85 (8-C), 137.71 (1’-C), 147.65 (5-C), 161.89 (1-C); MS (ESI +ve) 
m/z 281.0921 (M + H) (C16H13N2O3 requires 281.0926). 
 
Compound 190 (10 mg, 14%) was also isolated from above reaction as yellow solid. 
mp 183-185°C; Rf = 0.17 (hexane:EtOAc 2:1); IR (KBr) νmax 1634 (C=O), 3270 & 3458 
(NH) cm-1; 1H NMR (CDCl3) δ 4.50 (2 H, q, J = 1.37 Hz, 3-CH2), 6.74 (1 H, br s, NH), 
6.79 (1 H, s, =CH), 7.18 (2 H, d, J = 7.2 Hz, 2’,6’-H2), 7.30-7.41 (3 H, m, 3’,4’,5’-H3), 
7.50 (1 H, t, J = 7.9 Hz, 7-H), 7.82 (1 H, dd, J = 8.2, 1.4 Hz, 6-H), 8.30 (1-H, dd, J = 
7.9, 1.4 Hz, 8-H);13C NMR δ 41.99 (3-C), 124.34 (4-C), 127.65 (6-C), 128.34 (7-C), 
128.58 (3’,4’,5’-C3), 129.14 (2’,6’-C2), 130.31 (9-C), 131.21 (8-C), 131.66 (10-C), 
134.72 (=CH), 134.80 (1’-C), 148.39 (5-C), 162.89 (1-C); Anal. Calcd for C16H12N2O3: 
C, 68.56; H, 4.32; N, 9.99; Found: C, 68.43; H, 4.07; N, 9.99. MS (ESI +ve) m/z 
287.0946 (M + H) (C16H16
35ClN2O requires 287.0951).  
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5-Amino-4-benzylisoquinolin-1(2H)-one (192) 
 
NH2
NH
O
 
 
To 187 (20 mg, 0.07 mmol) in EtOH (5 mL), a slurry of 10% palladium on charcoal (50 
mg) in EtOH (2 mL) was added. The mixture was stirred under H2 for 1 h. The 
suspension was then flltered through Celite. The Celite pad and residue were 
suspended in ethanol (100 mL) and heated. The hot suspension was filtered through a 
second Celite pad. Concentration of the filtrate and drying gave 192 (9 mg, 51%) as 
buff powder; mp 121-123°C; Rf = 0.3 (EtOAc:hexane 4:1); IR (KBr) νmax 1623 (C=O), 
3337 & 3407 (NH) cm-1; 1H NMR (CDCl3) δ 4.32 (2 H, s, CH2), 6.87 (1 H, d, J = 7.4 Hz, 
6-H), 6.9 (1 H, s, 3-H), 7.22 (1 H, t, J = 7.4 Hz, 7-H), 7.25-7.35 (5 H, m, 2’,3’,4’,5’,6’-H5), 
8.02 (1 H, d, J = 7.8 Hz, 8-H), 11.51 (1 H, br s, NH); 13C NMR δ 38.39 (CH2), 113.34 (4-
C), 119.11 (8-C), 120.92 (6-C), 126.64 (10-C), 126.93 (4’-C) 127.23 (3-C), 127.43 (7-
C), 128.09 (2’,6’-C2), 128.16 (9-C), 129.16 (3’,5’-C2), 140.05 (1’-C), 143.50 (5-C), 
163.99 (1-C); MS (ESI +ve) m/z 251.1179 (M + H) (C16H15N2O requires 251.1184). 
 
(±) 5-Amino-4-benzyl-3,4-dihydroisoquinolin-1(2H)-one (193) 
 
NH2
NH
O
 
 
To 188 (35 mg, 0.12 mmol) in EtOH (5 mL), a slurry of 10% palladium on charcoal (50 
mg) in EtOH (2 mL) was added. The mixture was stirred under H2 for 1 h. The 
suspension was then flltered through Celite. The Celite pad and residue were 
suspended in ethanol (100 mL) and heated. The hot suspension was filtered through a 
second Celite pad. Concentration of the filterate and drying gave 193 (24 mg, 68%) as 
a buff powder; mp 169-170°C; Rf = 0.6 (EtOAc:hexane 4:1); IR (film) νmax 1586 & 1660 
(C=O), 3238 & 3344 (NH) cm-1; 1H NMR (CDCl3) δ 2.92 (2 H, d, J = 3.52 Hz, PhCH2), 
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2.99 (1 H, dd, J = 9.4, 3.5 Hz, 4-H), 3.35 (1 H, ddd, J = 12.5, 5.1, 1.2 Hz, 3-H), 3.61 (1 
H, dd, J = 12.5, 3.9 Hz, 3-H), 6.64 (1 H, br s, NH), 6.82 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 
7.16 (2 H, d, J = 7.4 Hz, 2’,6’-H2), 7.18 (1 H, t, J = 7.8 Hz, 7-H), 7.20-7.35 (3 H, m, 
3’,4’,5’-H3), 7.62 (1 H, dd, J = 7.8, 1.2 Hz, 8-H); 
13C NMR δ 35.08 (4-C), 37.55 (CH2Ph), 
42.82 (3-C). 119.25 (8-C), 119.94 (6-C), 126.66 (4’-C), 127.71 (10-C), 127.61 (7-C) 
128.71 (9-C), 128.75 (3’,5’-C2), 129.03 (2’,6’-C2), 139.29 (1’-C), 142.81 (5-C), 166.67 
(1-C); MS (ESI +ve) m/z 253.1328 (M + H) (C16H17N2O requires 253.1335). 
 
(E)-N-(But-2-enyl)-2,2,2-trifluoroacetamide (195) 
(Z)-N-(But-2-enyl)-2,2,2-trifluoroacetamide (196) 
N,N-Di((E)-but-2-enyl)-2,2,2-trifluoroacetamide (197) 
N,N-Di((Z)-but-2-enyl)-2,2,2-trifluoroacetamide (198) 
 
N CF3
O
N CF3
O
N
H
CF3
O
N
H
CF3
O
 
 
To 2,2,2-trifluoroacetamide (2.06 g, 18.2 mmol) in dry THF (10 mL), tBuO-K+ (2.05 g, 
18.2 mmol) was added slowly. After 30 min, 1-bromobut-2-ene (mixture of E and Z 
isomers (5:1)) (2.5 g, 18.34 mmol) was added and the mixture was stirred for 2 h. After 
the evaporation of the solvent, the residue was taken up in EtOAc and washed (H2O) 
and dried. Evaporation and chromatography (hexane:EtOAc 10:1) yielded mixture of 
195 & 196 (3:1) (1.02 g, 33%) as colourless oil: Rf = 0.37 (hexane:EtOAc 10:1); IR 
(film) νmax 1179 (C-F), 1556 & 1704 (C=O), 3098 & 3306 (NH) cm
-1; 195 1H NMR 
(CDCl3) δ 1.65 (3 H, dd, J = 6.9, 1.5 Hz, CH3), 3.83 (2 H, m, CH2), 5.36-5.45 (1 H, m, J 
= CH-CH2), 5.62-5.70 (1 H, m, =CH-CH3), 7.07 (1 H, br s, NH);
 13C NMR δ 17.43 (CH3), 
41.67 (CH2), 117.24 (CF3, q, J = 287.5 Hz), 124.42 (=C-CH2), 130.24 (=C-CH3), 157.33 
(C=O, q, J = 36.8 Hz); 19F NMR (CDCl3) δ -76.15 (3 F, s, CF3); 
196 1H NMR (CDCl3) δ 1.65 (3 H, dd, J = 6.9, 1.5 Hz, CH2), 3.94 (2 H, t, J = 6.4 Hz 
CH2), 5.36-5.45 (1 H, m, =CH-CH2), 5.62-5.70 (1 H, m, =CH-CH3), 7.07 (1 H, br s, NH);
 
13C NMR δ 12.69 (CH3), 36.54 (CH2), 117.24 (CF3, q, J = 287.5 Hz), 123.62 (=C-CH2), 
129.29 (=C-CH3), 156.96 (C=O, q, J = 36.8 Hz); 
19F NMR (CDCl3) δ -76.17 (3 F, s, 
CF3). 
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Also isolated from chromatography was mixture of 197 & 198 (4:1) (0.23 g, 6%). Rf = 
0.75 (hexane:EtOAc 10:1) as colourless oil: IR (film) νmax 1142, 1203 (C-F), 1693 
(C=O) cm-1; 1H NMR 197 (CDCl3) δ 1.59-1.67 (3 H, m, CH3), 3.81-3.85 (2 H, m, CH2), 
5.25-5.36 (1 H, m, =CH-CH2), 5.55-5.68 (1 H, m, =CH-CH3);
 13C NMR δ 17.39 (2 x 
CH3), 46.89 (CH2), 48.02 (CH2), 117.91 (CF3, q, J = 288.3 Hz), 123.66 (=C-CH2), 
124.53 (=C-CH2), 130.54 (=C-CH3), 130.93 (=C-CH3), 156.03 (C=O, q, J = 35.27 Hz); 
19F NMR (CDCl3) δ -68.99 (3 F, s, CF3).  
 
198 (CDCl3) δ 1.59-1.67 (3 H, m, CH3), 3.93-3.98 (2 H, m, CH2), 5.25-5.36 (1 H, m, 
=CH-CH2), 5.55-5.68 (1 H, m, =CH-CH3);
 13C NMR δ 12.72 (2 x CH3), 41.69 (CH2), 
42.70 (CH2), 117.91 (CF3, q, J = 288.3 Hz), 123.35 (=C-CH2), 123.75 (=C-CH2), 129.08 
(=C-CH3), 129.11 (=C-CH3), 156.03 (C=O, q, J = 35.27 Hz); 
19F NMR (CDCl3) δ -68.95 
(3 F, s, CF3). 
 
(E)-But-2-en-1-amine (200) 
(Z)-But-2-en-1-amine (201) 
 
 
 
A mixture of 195 & 196 (0.83 g, 5.0 mmol) was stirred with 10% aq. NaOH (5 mL) for 3 
h. Extraction (Et2O) and drying (K2CO3) yielded mixture of 200 & 201 which was used 
in the next step without further purification. 
 
(E)-N-(But-2-enyl)-2-iodo-3-nitrobenzamide (202) 
(Z)-N-(But-2-enyl)-2-iodo-3-nitrobenzamide (203) 
 
NO2
I
N
H
O
 
 
To 139 (1.55 g, 5.0 mmol) in Et2O (20 mL) was added mixture of 200 & 201 (0.36 g, 5.0 
mmol) in Et2O and Et3N (1.4 mL, 10 mmol) and the mixture was stirred for 2 h. 
Washing (5% aq. HCl, 5% aq. NaHCO3), drying, evaporation and chromatography 
(hexane:EtOAc 3:2) gave mixture of 202 & 203 (5:1) (1.25 g, 72%) as yellow crystals: 
NO2
I
N
H
O
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Rf = 0.25 (hexane:EtOAc 2:1); IR (KBr) νmax 1348 & 1526 (NO2), 1589 & 1648 (C=O), 
3258 & 3467 (NH) cm-1; 1H NMR (CDCl3) δ 1.67 (3 H, dd, J = 6.5, 1.4 Hz, CH3), 3.81 (2 
H, tq, J = 5.64, 1.4 Hz, CH2), 5.53 (1 H, m, =CH-CH2), 5.67 (1 H, m, =CH-CH3),  7.51 (1 
H, dd, J = 7.6, 1.4 Hz, 6-H), 7.61 (1 H, t, J = 7.9 Hz, 5-H), 7.85 (1 H, dd, J = 7.9, 
1.4 Hz, 4-H), 8.67(1 H, t, J = 5.3 Hz, NH); 13C NMR δ 17.57 (CH2), 40.84 (CH3), 86.71 
(2-C), 123.89 (4-C), 126.73 (=C-CH2), 127.26 (=C-CH3), 129.68 (5-C), 130.21 (6-C), 
146.48 (1-C), 155.21 (3-C), 167.89 (C=O); MS (ESI +ve) m/z 346.9887 (M + H) 
(C11H12IN2O3 requires 346.9893). Anal. Calcd for C11H11IN2O3: C, 38.17; H, 3.20; N, 
8.09; Found: C, 38.50; H, 3.17; N, 8.16. 
 
1H NMR 203 (CDCl3) δ 1.67 (3 H, m, CH3), 3.89 (2 H, t, J = 5.4 Hz, CH2), 5.46-5.60 (1 
H, m, =CH-CH2),  5.62-5.72 (1 H, m, =CH-CH3),  7.65 (1 H, t, J = 7.6 Hz, 5-H), 7.71 (1 
H, dd, J = 7.6, 1.7 Hz, 6-H), 8.08 (1 H, dd, J = 7.9, 1.4 Hz, 4-H), 8.78 (1 H, m, NH); 13C 
NMR δ 12.94 (CH2), 36.19 (CH3), 79.21 (2-C), 125.37 (4-C), 126.27 (=C-CH2), 127.18 
(=C-CH3), 128.66 (5-C), 131.98 (6-C), 139.44 (1-C), 148.63 (3-C), 164.47 (C=O).  
 
(E)-N-(But-2-enyl)-3-nitrobenzamide (204) 
(Z)-N-(But-2-enyl)-3-nitrobenzamide (205) 
(E)-3-Amino-N-(but-2-enyl)-2-chlorobenzamide (206) 
(Z)-3-Amino-N-(but-2-enyl)-2-chlorobenzamide (207) 
 
 
 
To 202 & 203 (100 mg, 0.3 mmol) in dry DMF (0.5 mL) was added (Ph3P)4Pd (7 mg, 2 
mol%), dry Et3N (0.1 mL, 0.75 mmol) and tetrabutylammonium chloride (84 mg, 0.3 
mmol) and the mixture was heated to reflux for 48 h. After evaporation of the solvent, 
the residue was taken up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. 
Evaporation and chromatography (hexane:EtOAc 2:1) yielded mixture of 204 & 205 (14 
mg, 21%) as yellow semi-solid: Rf = 0.7 (hexane:EtOAc 2:1); IR νmax (film) 1349 & 1529 
(NO2), 1641 (C=O), 3306 (NH) cm
-1; 1H NMR 204 (CDCl3) δ 1.71 (3 H, d, J = 6.3 Hz, 
CH3), 4.01 (2 H, t, J = 6.7 Hz, CH2), 5.55 (1 H, m, =CH-CH2), 5.73 (1 H, m, =CH-CH3),  
6.28 (1 H, br s, NH), 7.63 (1 H, t, J = 7.8 Hz, 5-H), 8.14 (1 H, dd, J = 7.8, 1.4 Hz, 6-H), 
8.33 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 8.57 (1 H, t, J = 1.6 Hz, 2-H); 13C NMR δ 
17.73 (CH3), 42.29 (CH2), 121.63 (2-C), 125.08 (=C-CH3), 126.02 (4-C), 129.76 (=C-
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CH2), 129.86 (5-C), 133.27 (6-C), 136.14 (1-C), 148.11 (3-C), 164.72 (C=O); MS (ESI 
+ve) m/z 221.0921 (M + H) (C11H13N2O3 requires 221.0926). 
 
205 1H NMR (CDCl3) δ 1.71 (3 H, d, J = 6.3 Hz, CH3), 4.12 (2 H, t, J = 6.4 Hz, CH2), 
5.55 (1 H, m, =CH-CH2), 5.73 (1 H, m, =CH-CH3),  6.28 (1 H, br s, NH), 7.63 (1 H, t, J = 
7.8 Hz, 5-H), 8.14 (1 H, dd, J = 7.8, 1.4 Hz, 6-H), 8.33 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-
H), 8.57 (1 H, t, J = 1.6 Hz, 2-H); 13C NMR δ 17.73 (CH3), 36.79 (CH2), 121.63 (2-C), 
125.08 (=C-CH3), 126.02 (4-C), 129.76 (=C-CH2), 129.86 (5-C), 133.27 (6-C), 136.14 
(1-C), 148.11 (3-C), 164.72 (C=O). 
 
Also isolated from chromatography was mixture of 206 & 207 (10 mg, 15%) as brown 
powder: IR (film) νmax 1628 (C=O), 3232 & 3464 (NH) cm
-1; Rf = 0.25 (hexane:EtOAc 
2:1); 1H NMR 206 (CDCl3) δ 1.72 (3 H, dd, J = 6.3, 1.2 Hz, CH3), 3.99 (2 H, t, J = 6.3 
Hz, CH2), 4.17 (2 H, br s, NH2), 5.54 (1 H, m, =CH-CH2), 5.70 (1 H, m, =CH-CH3), 5.86 
(1 H, br s, NH), 6.80 (1 H, dd, J = 8.2, 1.6 Hz, 4-H), 6.88 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 
7.07 (1 H, t, J = 7.8 Hz, 5-H); 13C NMR δ 17.73 (CH3) 3 (CH2), 115.50 (2-C), 116.85 (4-
C), 118.32 (6-C), 126.36 (=CH-CH2), 127.48 (5-C), 128.93 (=CH-CH3), 136.63 (1-C), 
143.59 (3-C), 167.07 (C=O); MS (ESI +ve) m/z 225.0789 (M + H) (C11H14
35ClN2O 
requires 225.0795). 
 
207 1H NMR (CDCl3) δ 1.71 (3 H, d, J = 6.3 Hz, CH3), 4.09 (2 H, t, J = 6.3 Hz, CH2), 
5.55 (1 H, m, =CH-CH2), 5.73 (1 H, m, =CH-CH3),  6.28 (1 H, br s, NH), 7.63 (1 H, t, J = 
7.8 Hz, 5-H), 8.14 (1 H, dd, J = 7.8, 1.4 Hz, 6-H), 8.33 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-
H), 8.57 (1 H, t, J = 1.6 Hz, 2-H); 13C NMR δ 17.73 (CH3), 36.80 (CH2), 121.63 (2-C), 
125.08 (=C-CH3), 126.02 (4-C), 129.76 (=C-CH2), 129.86 (5-C), 133.27 (6-C), 136.14 
(1-C), 148.11 (3-C), 164.72 (C=O). 
 
N-Allylphthalimide (210) 
 
N
O
O  
To a solution of prop-2-en-1-amine (5.70 g, 100 mmol) in acetic acid (30 mL) phthalic 
anhydride (14.8 g, 100 mmol) was added with stirring, then the mixture was boiled 
under reflux for 2 h. It was poured to water (300 mL) and the precipitate formed was 
filtered and dried in vacuo over KOH pellets. Recrystallisation (EtOAc) afforded 210 
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(18.72 g, 87%) as white needles. mp 66-67 oC (lit.213 mp 68-69 oC); IR (KBr) νmax 1701 
(C=O) cm-1; 1H NMR δ 4.26-4.29 (2 H, dt, J = 5.5, 1.4 Hz, N-CH2), 5.15-5.19 (1 H, dq, J 
= 10.5, 1.1 Hz, H of =CH2) 5.19-5.27 (1 H, dq, J = 17.6, 1.1 Hz, H of =CH2), 5.8-5.94 (1 
H, ddt, J = 17.1, 10.2, 1.1 Hz =CH), 7.73-7.67 (2 H, m, 3,6-H2), 7.80-7.87 (2 H, m, 4,5-
H2);  
 
(E)-2-(3-(4-methylphenyl)prop-2-enyl)isoindoline-1,3-dione (211) 
 
N
O
O
CH3
 
To 210 (0.2 g, 1.06 mmol), 4-iodotoluene (0.22 g, 1.06 mmol) and Et3N (0.3 mL, 2.12 
mmol) in a flask Pd(OAc)2 (2.5 mg, 1 mol%) was added. Th e flask was flushed with 
nitrogen and the mixture was boiled under reflux at for 24 h. The solid residue was 
dissolved in EtOAc (20 mL). Washing (5% aq. HCl, 5% aq. NaHCO3), drying, 
evaporation and chromatography (hexane:EtOAc 2:1) gave 211 (0.24 g, 82%) as pale 
buff solid. Rf = 0.4 (hexane:EtOAc 4:1);
 mp 164-166 oC (lit.214 mp 165-166 oC); IR (KBr) 
νmax 1704 (C=O) cm
-1; 1H NMR δ 2.29 (3 H, s, CH3), 4.42 (2 H, dd, J = 6.6, 1.1 Hz, CH2) 
6.19 (1 H, dt, J = 16.0, 6.3 Hz, =CH-CH2), 6.64 (1 H, d, J = 16.0 Hz, =CH-Ph), 7.08 (2 
H, d, J = 8.0 Hz, 2,6-H2), 7.24 (2 H, d, J = 8.0 Hz, 3,5-H2), 7.68-7.72 (2 H, m, 3,6-H2), 
7.83-7.86 (2 H, m, 4,5-H2).  
 
(E)-2-(3-(4-methoxyphenyl)prop-2-enyl)isoindoline-1,3-dione (212) 
 
N
O
O
OCH3
 
 
Pd(OAc)2 (12.5 mg, 1 mol%) was added to 210 (1.0 g, 5.3 mmol), 1-iodo-4-
methoxybenzene (1.3 g, 5.3 mmol) and Et3N (1.5 mL, 10.6 mmol). The flask was 
flushed with nitrogen and the mixture was boiled under reflux for 16 h. The evaporation 
residue was dissolved in EtOAc (50 mL). Washing (5% aq. HCl, 5% aq. NaHCO3), 
drying, evaporation gave 212 (1.45 g, 94%) as yellow solid: mp 137-139 oC (lit.215 mp 
139-140 oC); Rf = 0.5 (hexane:EtOAc 2:1); IR (KBr) νmax 1704 (C=O) cm
-1; 1H NMR 
(CDCl3) δ 3.77 (3 H, s, CH3), 4.39 (2 H, dd, J = 6.6, 1.1 Hz, CH2) 6.13 (1 H, dt, J = 15.9, 
6.6 Hz, =CH-CH2), 6.56 (1 H, d, J = 16.0 Hz, =CH-Ph), 6.8 (2 H, d, J = 8.0 Hz, 3’,5’-H2), 
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7.28 (2 H, d, J = 8.0 Hz, 2’,6’-H2), 7.67-7.72 (2 H, m, 3,6-H2), 7.80-7.87 (2 H, m, 4,5-
H2). 
 
(E)-3-(4-methylphenyl)prop-2-en-1-amine (213) 
 
NH2
H3C  
Compound 211 (0.27 g, 1.0 mmol) and hydrazine hydrate (32.0 mg, 1.0 mmol) were 
boiled under reflux in EtOH (10 mL) for 3 h. The solid was filtered, washed with 
ethanol, and then suspended in water to which 1 mL of 50% aq. NaOH solution was 
added. The mixture was extracted with Et2O (2 x 10 mL) and CH2Cl2 (10 mL). Washing 
(H2O), drying (MgSO4) and evaporation yielded 213 (0.15 g, 65%) as yellow oil: Rf = 0.1 
(hexane:EtOAc 1:1); IR (film) νmax 3460 (NH) cm
-1; 1H NMR δ 2.32 (3 H, s, CH3), 3.43 (2 
H, d, J = 5.8 Hz, CH2) 6.19-6.29 (1 H, dt, J = 16.0, 6.0 Hz, =CH-CH2), 6.48 (1 H, d, J = 
15.9 Hz, =CH-Ph), 7.08 (2 H, d, J = 8.0 Hz, 2,6-H2), 7.24 (2 H, d, J = 7.9 Hz, 3,5-H2). 
 
(E)-3-(4-methoxyphenyl)prop-2-en-1-amine (214) 
 
NH2
H3CO  
Compound 212 (3.07 g, 10.5 mmol) and hydrazine hydrate (0.34 g, 10.5 mmol) were 
boiled under reflux in ethanol (25 mL) for 3 h. The solid was filtered, washed with 
ethanol, and then suspended in water to which 1 mL of 50% aq. NaOH was added. The 
mixture was extracted with Et2O (2 x 25 mL) and CH2Cl2 (25 mL). Washing (H2O), 
drying (MgSO4) and evaporation yielded 214 (1.5 g, 89%) as a yellow oil: Rf = 0.2 
(EtOAc:hexane 2:1); IR (film) νmax 1253, 1518 (C=C), 3460 (NH) cm
-1;  1H NMR (CDCl3) 
δ 1.35 (2 H, br s, NH2), 3.44 (2 H, dd, J = 5.8, 1.4 Hz, CH2), 3.79 (3 H, s, CH3), 6.16 (1 
H, dt, J = 16.0, 5.8 Hz, =CH-CH2), 6.45 (1 H, d, J = 15.7 Hz, =CH-Ph), 6.86 (2 H, d, J = 
8.8 Hz, 3,5-H2), 7.31 (2 H, d, J = 8.8 Hz, 2,6-H2). 
 
(E)-2-iodo-3-nitro-N-(3-(4-methylphenyl)prop-2-enyl)benzamide (215) 
 
NO2
I
N
H
O
CH3
 
 173 
To 139 (0.55 g, 1.8 mmol) in CH2Cl2 (10 mL) was added 213 (0.26 g, 1.8 mmol) and 
Et3N (0.5 mL, 3.6 mmol) and the mixture was stirred for 2 h. Washing (5% aq. HCl, 5% 
aq. NaHCO3), drying, evaporation and chromatography (hexane:EtOAc 4:1) gave 215 
(0.61 g, 82%) as yellow crystals: mp 159-162 oC; Rf = 0.4 (hexane:EtOAc 2:1); IR (KBr) 
νmax 1361 & 1530 (NO2), 1589 & 1644 (C=O), 3268 & 3468 (NH) cm
-1; 1H NMR δ 
(CDCl3) 2.34 (3 H, s, CH3), 4.23 (2 H, t, J = 5.9 Hz, CH2), 5.99 (1 H, br s, NH), 6.23 (1 
H, dt, J = 16.0, 6.6 Hz, =CH-CH2), 6.63 (1 H, d, J = 16.0 Hz, =CH-Ph), 7.14 (2 H, d, J = 
7.8 Hz, 3’,5’-H2), 7.27 (2 H, d, J = 7.8 Hz, 2’,6’-H2), 7.52 (2 H, m, 5,6-H5), 7.68 (1 H, m, 
4-H); 13C NMR δ 21.21 (CH3), 42.34 (CH2), 84.94 (2-C), 124.94 (=C-CH2), 125.15 (4-C), 
126.32 (2’,6’-C2), 129.35 (3’,5’-C2), 129.47 (5-C), 130.37 (6-C), 133.27 (=C-Ph), 133.36 
(1’-C), 137.93 (4’-C), 146.13 (1-C), 154.89 (3-C), 168.19 (C=O); Anal. Calcd for 
C17H15IN2O3: C, 48.36; H, 3.58; N, 6.63; Found: C, 47.84; H, 3.37; N, 6.54. 
 
(E)-2-iodo-N-(3-(4-methoxyphenyl)prop-2-enyl)-3-nitrobenzamide (216) 
 
NO2
I
N
H
O
OCH3
 
 
To 139 (3.12 g, 10.0 mmol) in CH2Cl2 (25 mL) was added 214 (1.65 g, 10.0 mmol) and 
Et3N (2.8 mL, 20 mmol) and the mixture was stirred for 4 h. Washing (5% aq. HCl, 5% 
aq. NaHCO3), drying, evaporation and chromatography (hexane:EtOAc 4:1) gave 216 
(3.3 g, 75%) as yellow crystals: mp 124-127 oC; Rf = 0.35 (hexane:EtOAc 2:1); IR (KBr) 
νmax 1348 & 1529 (NO2), 1588 & 1640 (C=O), 3259 & 3468 (NH) cm
-1; 1H NMR (CDCl3) 
δ 3.79 (3 H, s, CH3), 4.21 (2 H, t, J = 6.65 Hz, CH2), 6.01 (1 H, br s, NH), 6.11 (1 H, dt, 
J = 16.0, 6.6 Hz, =CH-CH2), 6.59 (1 H, d, J = 16.0 Hz, =CH-Ph), 6.83 (2 H, d, J = 8.6 
Hz, 3’,5’-H2), 7.28 (2 H, d, J = 8.9 Hz, 2’,6’-H2), 7.50 (2 H, m, 5,6-H2), 7.65 (1 H, m, 4-
H); 13C NMR δ 42.40 (CH2), 55.28 (CH3), 84.94 (C-2), 114.02 (3’,5’-C2), 121.68 (=C-
CH2), 125.13 (4-C), 127.62 (2’,6’-C2), 128.88 (1’-C),  129.45 (5-C), 130.36 (6-C), 
132.91 (=C-Ph), 146.12 (1-C), 154.86 (3-C), 159.44 (4’-C), 168.19 (C=O); Anal. Calcd 
for C17H15IN2O4: C, 46.59; H, 3.45; N, 6.39; Found: C, 46.48; H, 3.33; N, 6.31. 
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(E)-N-(3-(4-methylphenyl)prop-2-enyl)-3-nitro benzamide (217) 
N-(3-(4-methylphenyl)propyl)-3-nitro-benzamide (218) 
4-(4-Methylbenzyl)-5-nitroisoquinolin-1(2H)-one (219) 
(Z)-4-(4-Methylbenzylidene)-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (220) 
 
             
 
To 215 (150 mg, 0.35 mmol) in dry DMF (0.7 mL) was added (Ph3P)4Pd (8.2 mg, 2 
mol%), dry Et3N (0.09 mL, 0.89 mmol) and tetrabutylammonium chloride (99 mg, 0.35 
mmol) and the mixture was heated to reflux for 48 h. After evaporation of the solvent, 
the residue was taken up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. 
Evaporation and chromatography (hexane:EtOAc 2:1) yielded an inseparable mixture 
of 217 & 218 (3:1) (17 mg, 16%) as yellow semi-solid: Rf = 0.7 (hexane:EtOAc 2:1); IR 
(film) νmax 1350 & 1524 (NO2), 1641 (C=O), 3312 & 3467 (NH) cm
-1; 1H NMR 217 
(CDCl3) δ 2.33 (3 H, s, CH3), 4.23 (2 H, t, J = 6.3 Hz, CH2), 6.24 (1 H, dt, J = 15.6, 6.6 
Hz, =CH-CH2), 6.55 (1 H, d, J = 16.0 Hz, =CH-Ph), 6.6 (1 H, br s, NH), 7.10 (2 H, m, 
3’,5’-H2), 7.26 (2 H, d, J = 7.8 Hz, 2’,6’-H2), 7.64 (1 H, t, J = 8.2 Hz, 5-H), 8.18 (1 H, d, J 
= 8.2, 1.6 Hz, 6-H), 8.34 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 8.63 (1 H, t, J = 1.9 Hz, 2-
H); 13C NMR δ 21.18 (CH3), 42.50 (CH2), 121.75 (2-C), 123.38 (=C-CH2), 126.06 (4-C), 
126.28 (2’,6’-C2), 129.31 (3’,5’-C2), 129.85 (5-C), 133.11 (=C-Ph), 133.29 (6-C), 135.73 
(1’-C), 135.97 (1-C), 137.85 (4’-C), 148.10 (3-C), 164.86 (C=O); MS (ESI +ve) m/z 
297.1240 (M + H) (C17H17N2O3 requires 297.1239). 
 
218 1H NMR (CDCl3) δ 1.96 (2 H, q, J = 7.0 Hz, CH2CH2CH2), 2.29 (3 H, s, CH3), 2.71 
(2 H, t, J = 7.4 Hz, CH2Ph), 3.54 (2 H, q, J = 6.6 Hz, NCH2), 7.10 (2 H, m, 3’,5’-H2), 
7.26 (2 H, d, J = 8.2 Hz, 2’,6’-H2), 7.60 (1 H, t, J = 7.8 Hz, 5-H), 7.98 (1 H, dt, J = 7.4, 
1.9 Hz, 6-H), 8.30 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 8.44 (1 H, t, J = 1.9 Hz, 2-H), 
8.54 (1 H, br s, NH); 13C NMR δ 20.94 (CH3), 30.81 (CH2CH2CH2), 33.19 (CH2Ph), 
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40.26 (N-CH2), 121.54 (2-C), 125.88 (4-C), 126.28 (2’,6’-C2), 129.31 (3’,5’-C2), 129.68 
(5-C), 133.36 (6-C), 135.02 (1’-C), 136.11 (1-C), 138.14 (4’-C), 148.10 (3-C), 164.86 
(C=O); MS (ESI +ve) m/z 321.1207 (M + Na) (C17H18N2NaO3 requires 321.1215). 
 
Also isolated was 219 (16 mg, 15%) as an orange powder: mp 186-188 oC; Rf = 0.29 
(hexane:EtOAc 2:1); IR (KBr) νmax 1367 & 1526 (NO2), 1660 (C=O), 3118 & 3392 (NH) 
cm-1; 1H NMR (CDCl3) δ 2.33 (3 H, s, CH3), 3.82 (2 H, s, CH2), 6.75 (1 H, s, 3-H), 6.98 
(2 H, d, J = 7.9 Hz, 3’,5’-H2), 7.10 (2 H, d, J = 7.9 Hz, 2’,6’-H2), 7.54 (1 H, t, J = 7.9 Hz, 
7-H), 7.83 (1 H, dd, J = 7.9, 1.1 Hz, 6-H), 8.67 (1 H, d, J = 7.9, 1.1 Hz, 8-H), 11.32 (1 H, 
br s, NH); 13C NMR δ 21.07 (CH3), 34.98 (CH2), 113.56 (4-C), 126.01 (7-C), 127.85 (9-
C), 128.67 (6-C) 129.26 (3’,5’-C2), 129.49 (2’,6’-C2), 126.62 (10-C), 130.91 (3-C), 
131.77 (8-C), 134.54 (1’-C), 136.51 (4’-C), 147.63 (5-C), 162.03 (1-C); MS (ESI +ve) 
m/z 295.1077 (M + H) (C17H15N2O3 requires 295.1083). 
 
Compound 220 (14 mg, 13%) was also collected as a yellow solid: mp 152-154°C; Rf = 
0.25 (hexane:EtOAc 2:1); IR (KBr) νmax 1352 & 1529 (NO2), 1662 (C=O), 3042 (NH) 
cm-1 ; 1H NMR (CDCl3) δ 2.30 (1 H, s, CH3), 4.50 (2 H, d, J = 1.6 Hz, 3-CH2), 6.75 (1 H, 
s, =CH), 6.84 (1 H, br s, NH), 7.09 (2 H, d, J = 7.8 Hz, 2’,6’-H2), 7.20 (2 H, m, 3’,5’-H2), 
7.50 (1 H, t, J = 8.2 Hz, 7-H), 7.80 (1 H, dd, J = 8.1, 1.2 Hz, 6-H), 8.30 (1-H, dd, J = 
7.8, 1.2 Hz, 8-H); 13C NMR δ 21.32 (CH3),  42.04 (CH2), 123.51 (4-C), 127.64 (6-C), 
128.15 (7-C), 129.15 (2’,6’-C2), 129.25 (3’,5’-C2), 130.24 (9-C), 131.14 (8-C), 131.85 
(10-C), 132.01 (4’-C), 134.83 (=CH), 138.74 (1’-C), 148.41 (5-C), 162.96 (1-C); MS 
(ESI +ve) m/z 295.1066 (M + H) (C17H15N2O3 requires 295.1083). 
 
5-Amino-4-(4-methylbenzyl)isoquinolin-1(2H)-one (221) 
(±) 5-Amino-4-(4-methylbenzyl)-3,4-dihydroisoquinolin-1(2H)-one (222) 
 
NH2
NH
O
CH3            
NH2
NH
O
CH3  
 
To 219 (24 mg, 0.08 mmol) in EtOH (5 mL), a slurry of 10% palladium on charcoal (50 
mg) in EtOH (2 mL) was added. The mixture was stirred under H2 for 1 h. The 
suspension was then filtered through Celite. The Celite pad and residue were 
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suspended in ethanol (100 mL) and heated. The hot suspension was filtered through a 
second Celite pad. Concentration of the filtrate and drying gave an inseparable 
mixture of 221 & 222 (10:3) (11 mg, 51%) as a buff powder: Rf = 0.4 (EtOAc:hexane 
2:1); IR (KBr) νmax 1591 & 1654 (C=O), 3357 (NH) cm
-1; 221 1H NMR (CDCl3) δ 2.31 (3 
H, s, CH3), 4.25 (2 H, s, CH2), 6.82 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 6.86 (1 H, s, 3-H), 
7.05-7.14 (4 H, m, 2’,3’,5’,6’-H4), 7.28 (1 H, t, J = 7.8 Hz, 7-H), 7.97 (1 H, d, J = 7.0 Hz, 
8-H), 11.29 (1 H, br s, NH); 13C NMR δ 20.99 (CH3), 38.02 (CH2), 113.57 (4-C), 119.05 
(8-C), 120.83 (6-C), 126.61 (10-C), 127.02 (3-C), 127.40 (7-C), 127.96 (2’,6’-C2), 
128.16 (9-C), 129.85 (3’,5’-C2), 136.58 (4’-C), 136.89 (1’-C), 143.55 (5-C), 163.91 (1-
C); MS (ESI +ve) m/z 265.1334 (M + H) (C17H17N2O requires 265.1351). 
  
222 1H NMR (CDCl3) δ 2.32 (3 H, s, CH3), 2.89 (2 H, d, J = 6.26 Hz, PhCH2), 2.96 (1 H, 
m, 4-H), 3.35 (1 H, dd, J = 12.5, 4.3 Hz, 3-H), 3.61 (1 H, dd, J = 12.5, 3.9 Hz, 3-H), 
6.72 (1 H, br s, NH), 6.81 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.16 (2 H, d, J = 8.2 Hz, 2’,6’-
H2), 7.18 (1 H, t, J = 7.8 Hz, 7-H), 7.20-7.35 (3 H, m, 3’,4’,5’-H3), 7.59 (1 H, dd, J = 7.8, 
1.2 Hz, 8-H); 13C NMR δ 21.05 (CH3), 35.17 (4-C), 37.13 (CH2Ph), 42.84 (3-C). 119.29 
(8-C), 119.97 (6-C), 127.58 (7-C), 128.71 (10-C), 128.83 (9-C) 128.91 (2,6-C2), 129.44 
(3’,5’-C2), 136.17 (4’-C), 136.17 (1’-C), 142.81 (5-C), 167.00 (1-C); MS (ESI +ve) m/z 
289.1311 (M + Na), 267.1491 (M + H) (C17H19N2O requires 265.1492).  
 
Reaction was repeated with 220 (25 mg, 0.08 mmol) in EtOH (5 mL), gave an 
inseparable mixture of 222 & 221 (11:9) (10 mg, 42%) as a buff solid with properties as 
above. 
 
(E)-N-(3-(4-Methoxyphenyl)prop-2-enyl)-3-nitrobenzamide (223) 
N-(3-(4-Methoxyphenyl)propyl)-3-nitrobenzamide (224) 
4-(4-Methoxybenzyl)-5-nitroisoquinolin-1(2H)-one (225) 
(Z)-4-(4-Methoxybenzylidene)-5-nitro-3,4-dihydroisoquinolin-1(2H)-one (226) 
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To 216 (150 mg, 0.34 mmol) in dry DMF (0.7 mL) was added (Ph3P)4Pd (8.0 mg, 2 
mol%), dry Et3N (0.12 mL, 0.86 mmol) and tetrabutylammonium chloride (95.0 mg, 0.34 
mmol) and the mixture was heated to reflux for 48 h. After evaporation of the solvent, 
the residue was taken up in CHCl3, washed (5% aq. HCl, 5% aq. NaHCO3) and dried. 
Evaporation and chromatography (hexane:EtOAc 2:1) yielded an inseparable mixture 
of 223 & 224 (2:3) (20 mg, 19%) as a yellow semi-solid: Rf = 0.4 (hexane:EtOAc 2:1); 
IR (film) νmax 1357 & 1539 (NO2), 1637 (C=O), 3095 & 3300 (NH) cm
-1; 223 1H NMR 
(CDCl3) δ 3.76 (3 H, s, CH3), 4.17 (2 H, t, J = 6.7 Hz, CH2), 6.07 (1 H, dt, J = 16.0, 6.3 
Hz, =CH-CH2), 6.48 (1 H, d, J = 16.0 Hz, =CH-Ph), 6.79 (2 H, d, J = 8.6 Hz, 3’,5’-H2), 
7.21 (2 H, d, J = 9.0 Hz, 2’,6’-H2), 7.33 (1 H, br s, NH), 7.56 (1 H, t, J = 8.2 Hz, 5-H), 
8.18 (1 H, dt, J = 8.2, 1.6 Hz, 6-H), 8.27 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 8.64 (1 H, 
t, J = 1.9 Hz, 2-H); 13C NMR δ 42.44 (CH2), 55.14 (CH3), 113.88 (3’,5’-C2), 121.88 (2-C), 
122.24 (=C-CH2), 125.84 (4-C), 127.42 (2’,6’-C2), 128.88 (1’-C), 129.61 (5-C), 132.16 
(=C-Ph), 133.29 (6-C), 135.88 (1-C), 147.91 (3-C), 159.20 (4’-C), 164.99 (C=O); MS 
(ESI +ve) m/z 335.0996 (M + Na) (C17H16N2NaO4 requires 335.1008). 
 
224 Rf = 0.4 (hexane:EtOAc 2:1); 
1H NMR (CDCl3) δ 1.90 (2 H, q, J = 7.4 Hz, 
CH2CH2CH2), 2.63 (2 H, t, J = 7.4 Hz, CH2Ph), 3.48 (2 H, m, NCH2), 3.76 (3 H, s, CH3), 
6.90 (1 H, t, J = 5.4 Hz, NH), 6.79 (2 H, J = 8.6 Hz, 3’,5’-H2), 7.06 (2 H, d, J = 8.9 Hz, 
2’,6’-H2), 7.50 (1 H, t, J = 7.8 Hz, 5-H), 8.02 (1 H, dt, J = 7.8, 1.2 Hz, 6-H), 8.23 (1 H, 
ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 8.48 (1 H, t, J = 1.9 Hz, 2-H); 13C NMR δ 30.85 
(CH2CH2), 32.45 (CH2Ph), 40.09 (N-CH2), 55.08 (CH3), 113.78 (3’,5’-C2), 121.64 (2-C), 
125.70 (4-C), 129.10 (2’,6’-C2), 129.52 (5-C), 133.19 (1’-C), 133.11 (6-C), 136.03 (1-C), 
147.83 (3-C), 157.76 (4’-C), 165.05 (C=O); MS (ESI +ve) m/z 315.1320 (M + H) 
(C17H19N2O4 requires 315.1345), 337.1136 (M + Na). 
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Also isolated was 225 (18 mg, 17%) as an orange powder: mp 121-124 oC; IR (KBr) 
νmax 1367 & 1527 (NO2), 1604, 1661 (C=O), 3042 & 3119 (NH) cm
-1; 1H NMR (CDCl3) δ 
3.79 (3 H, s, CH3), 3.81 (2 H, s, CH2), 6.76 (1 H, s, 3-H), 6.82 (2 H, d, J = 8.6 Hz, 3’,5’-
H2), 7.02 (2 H, d, J = 8.6 Hz, 2’,6’-H2), 7.52 (1 H, t, J = 7.8 Hz, 7-H), 7.83 (1 H, dd, J = 
7.8, 1.2 Hz, 6-H), 8.65 (1 H, dd, J = 7.8, 1.6 Hz, 8-H), 11.68 (1 H, br s, NH); 13C NMR δ 
34.52 (CH3), 55.23 (CH2), 113.77 (4’-C), 114.18 (3’,5’-C2), 125.98 (7-C), 127.81 (9-C), 
128.66 (6-C) 129.52 (10-C), 129.60 (4-C), 130.41(2’,6’-C2), 130.93 (3-C), 131.75 (8-C), 
147.61 (5-C), 158.47 (1’-C), 162.21 (1-C); MS (ESI +ve) m/z 311.1026 (M + H) 
(C17H15N2O4 requires 311.1032). 
 
Compound 226 (16 mg, 15%) was also collected as a yellow solid: mp 203-204°C; 1H 
NMR (CDCl3) δ 3.83 (3 H, s, CH3), 4.52 (2 H, s, CH2), 6.24 (1 H, br s, NH), 6.72 (1 H, s, 
=CH), 6.92 (2 H, d, J = 8.9 Hz, 3’,5’-H2), 7.12 (2 H, d, J = 8.2 Hz, 2’,6’-H2), 7.52 (1 H, t, 
J = 8.2 Hz, 7-H), 7.80 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.31 (1 H, dd, J = 7.8, 1.2 Hz, 8-
H); 13C NMR δ 42.14 (CH2), 55.37 (CH3), 114.00 (3’,5’-C2), 122.58 (4-C), 127.48 (4’-C), 
127.67 (6-C), 128.02 (7-C) 130.15 (9-C), 130.73 (2’,6’-C2) 131.21 (8-C), 131.95 (10-C), 
134.56 (=CH), 148.43 (5-C), 159.83 (1’-C), 162.63 (1-C); MS (ESI +ve) m/z 311.1001 
(M + H) (C17H15N2O4 requires 311.1032). 
 
5-Amino-4-(4-methoxybenzyl)isoquinolin-1(2H)-one (227) 
(±) 5-Amino-4-(4-methoxybenzyl)-3,4-dihydroisoquinolin-1(2H)-one (228) 
 
NH2
NH
O
OCH3           
NH2
NH
O
OCH3  
 
To 225 (25 mg, 0.08 mmol) in EtOH (5 mL), a slurry of 10% palladium on charcoal (50 
mg) in EtOH (2 mL) was added. The mixture was stirred under H2 for 1 h. The 
suspension was then flltered through Celite. The Celite pad and residue were 
suspended in ethanol (100 mL) and heated. The hot suspension was filtered through a 
second Celite pad. Concentration of the filtrate and drying gave an inseparable 
mixture of 227 & 228 (1:2) (12 mg, 53%) as a buff powder: Rf = 0.42 (EtOAc:hexane 
2:1); 227 IR (KBr) νmax 1605, 1661 (C=O), 3357 (NH) cm
-1; 1H NMR (CDCl3) δ 3.78 (3 
H, s, CH3), 4.23 (2 H, s, CH2), 6.79 (1 H, s, 3-H), 6.82-7.15 (5 H, m, 2’,3’,5’,6’,6-H5), 
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7.30 (1 H, t, J = 7.8 Hz, 7-H), 8.00 (1 H, d, J = 7.4 Hz, 8-H), 10.6 (1 H, br s, NH); 13C 
NMR δ 35.11 (CH3), 36.81 (CH2), 113.65 (4-C), 114.54 (3’,5’-C2), 119.13, 126.47, 
126.47, 126.76, 127.32, 127.45, 129.11 (2’,6’-C2), 131.82, 131.82 (1’-C), 143.55 (5-C), 
158.56 (1-C); MS (ESI +ve) m/z (M + Na) 303.1094, 281.1270 (M + H) (C17H17N2O2 
requires 281.1290).  
  
228 1H NMR (CDCl3) δ 2.89 (2 H, m, PhCH2), 2.96 (1 H, m, 4-H), 3.37 (1 H, dd, J = 
12.5, 4.3 Hz, 3-H), 3.62 (1 H, dd, J = 12.5, 3.9 Hz, 3-H), 3.80 (3 H, s, CH3), 6.23 (1 H, 
br s, NH), 7.20-7.35 (5 H, m, 2’,3’,5’,6’,6-H5), 7.20 (1 H, t, J = 7.8 Hz, 7-H), 7.61 (1 H, d, 
J = 7.8 Hz, 8-H); 13C NMR δ 35.11 (4-C), 36.81 (CH2Ph), 42.98 (CH2), 55.28 (CH3), 
114.14 (3’,5’-C2), 119.98, 127.32, 127.59, 128.74, 129.11, 130.00 (2’,6’-C2), 131.26, 
142.85 (1’-C), 158.38 (5-C), 166.51 (1-C); MS (ESI +ve) m/z (M + Na) 305.1245, 
283.1418 (M + H) (C17H19N2O2 requires 283.1447).  
 
4-(3-Iodophenylamino)-4-oxobutanoic acid (229) 
 
O
OH
O
H
NI
 
 
Succinic anhydride (1.0 g, 10.0 mmol) and 3-iodoaniline (2.19 g, 10 mmol) were heated 
slowly to 190 oC. At 150 oC 229 was identified as a buff powder: mp 154-156 oC; Rf = 
0.12 (CH2Cl2:EtOAc 2:1); IR (KBr) νmax 1656 & 1696 (C=O), 3289 (NH), 3023 (OH) cm
-
1; 1H NMR ((CD3)2SO) δ 2.48-2.64 (4 H, m, 2 × CH2), 7.08 (1 H, t, J = 8.2 Hz, 5-H), 7.38 
(1 H, dd, J = 7.8, 1.6 Hz, 4-H), 7.48 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.10 (1 H, t, J = 1.9 
Hz, 2-H), 10.06 (1 H, s, OH), 12.15 (1 H, br s, NH); 13C NMR δ 28.68 (CH2CONH), 
31.05 (CH2COH), 94.67 (3-C), 118.06 (6-C), 127.07 (2-C), 130.82 (5-C), 131.48 (4-C), 
140.70 (1-C), 170.45 (C=ONH), 173.83 (C=O). 
 
1-(3-Iodophenyl)pyrrolidine-2,5-dione (230) 
 
I N
O
O
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Succinic anhydride (1.0 g, 10.0 mmol) and 3-iodoaniline (2.19 g, 10 mmol) were heated 
at 190 oC for 6 h. Recrystallisation (EtOAc) afforded 230 (2.23 g, 74%) as buff crystals: 
mp 167-169 oC; Rf = 0.7 (CH2Cl2:EtOAc 2:1); IR (KBr) νmax 1423 & 1473 (C=C), 1714 
(C=O) cm-1; 1H NMR (CDCl3) δ 2.82 (4 H, s, 2 × CH2), 7.19 (1 H, t, J = 8.2 Hz, 5-H), 
7.28 (1 H, dt, J = 7.8, 1.2 Hz, 6-H), 7.71 (1 H, t, J = 1.9 Hz, 2-H), 7.73 (1 H, dt, J = 7.8, 
1.6 Hz, 4-H); 13C NMR δ 28.35 (2 × CH2), 93.69 (3-C), 125.79 (6-C), 130.52 (5-C), 
132.84 (1-C), 135.23 (2-C), 137.65 (4-C), 175.70 (2 × C=O); MS (ESI +ve) m/z 
301.9658 (M + H) (C10H8NO2 requires 301.9678). 
 
(E)-2-(3-(3-(2,5-Dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)isoindoline-1,3-dione 
(231) 
 
N
O
O
N
O
O
 
 
To 210 (0.20 g, 1.1 mmol), 230 (0.32 g, 1.1 mmol) and Et3N (0.3 mL, 2.1 mmol), 
Pd(OAc)2 (2.5 mg, 1 mol%) was added. The flask was flushed with nitrogen and the 
mixture was boiled under reflux at 90 oC for 24 h. The solid residue was dissolved in 
EtOAc (20 mL). Washing (5% aq. HCl, 5% aq. NaHCO3), drying, evaporation gave 231 
(0.33 g, 86%) as a buff powder: mp 210-212°C; Rf = 0.2 (hexane:EtOAc 1:1);
 IR (KBr) 
νmax 1698 & 1711 (C=O) cm
-1; 1H NMR (CDCl3) δ 2.8 (4 H, s, 2 × CH2), 4.44 (2 H, d, J = 
6.3 Hz, CH2), 6.27 (1 H, dt, J = 16.0, 6.3 Hz, =CH-CH2), 6.66 (1 H, d, J = 15.7 Hz, =CH-
Ph), 7.12-7.41 (4 H, m, 2,4,5,6-H4), 7.71-7.74 (2 H, m, 3,6-H2), 7.83-7.87 (2 H, m, 4,5-
H2); 
13C NMR δ 28.36 (2 x CH2), 39.39 (CH2), 123.30 (3,6-C2), 124.16 (=CH-CH2), 
124.44 (2’-C), 125.72 (5’-C), 126.74 (6’-C), 129.31 (4’-C), 132.03 (3’-C), 132.13 (8,9-
C2), 132.48 (=CH-Ph), 133.99 (4,5-C2), 137.52 (1’-C), 167.84 (2 × C=O of Pth), 176.06 
(2 × C=O); MS (ESI +ve) m/z 361.1183 (M + H) (C21H17N2O4 requires 361.1188). 
 
tert-Butyl N-(prop-2-enyl)carbamate (233) 
 
O N
H
O
H3C
CH3
CH3  
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Prop-2-en-1-amine (0.75 mL, 10.0 mmol) was slowly added to an ice-cold solution of 
di(tert-butyl) dicarbonate (2.18 g, 10.0 mmol) in CH2Cl2 (5 mL) and the mixture was 
stirred for 3 h. Evaporation gave 233 (1.3 g, 83%) as colourless prisms: mp 33-35 oC 
(lit.9 mp 35-36 oC); Rf = 0.8 (hexane:EtOAc 1:1); IR (KBr) νmax 1169 (C-O), 1531 & 1684 
(C=O), 2980 & 3354 (NH) cm-1; 1H NMR (CDCl3) δ 1.42 (9 H, s, (CH3)3), 3.72 (2 H, t, J 
= 5.2 Hz, propenyl 1-H2), 4.60 (1 H, br s, NH), 5.05 (1 H, dq, J = 10.2, 1.6 Hz, propenyl 
3-H), 5.19 (1 H, dq, J = 17.1, 1.7 Hz, propenyl 3-H), 5.80 (1 H, m, propenyl 2-H).  
 
(E)-tert-Butyl 3-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enylcarbamate (234) 
tert-Butyl 2-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enylcarbamate (235) 
 
O N
H
O
N
O
O
H3C
CH3
CH3
           
O N
H
O
H3C
CH3
CH3
N
O
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To 233 (1.57 g, 10.0 mmol), 230 (3.0 g, 10.0 mmol) and Et3N (2.8 mL, 20 mmol), 
Pd(OAc)2 (22.5 mg, 1 mol%) was added. The flask was flushed with nitrogen and the 
mixture was boiled under reflux for 48 h. The solid residue was dissolved in CHCl3 (50 
mL). Washing (5% aq. HCl, 5% aq. NaHCO3), drying, evaporation gave an inseparable 
mixture of 234 & 235 (4:1) (1.2 g, 32%) as a buff semi-solid: Rf = 0.24 (CH2Cl2:EtOAc 
3:2); IR (film) νmax 1180 (C-O), 1709 (C=O), 3370, 2978 (NH) cm
-1; 234 1H NMR 
(CDCl3) δ 1.44 (9 H, s, (CH3)3), 2.87 (4 H, s, 2 x CH2), 3.88 (2 H, m, CH2), 4.71 (1 H, br 
s, NH), 6.22 (1 H, dt, J = 16.0, 5.9 Hz, =CH-CH2), 6.5 (1 H, d, J = 16.0 Hz, =CH-Ph), 
7.13 (1 H, dt, J = 7.4, 1.6 Hz, 6-H), 7.24 (1 H, s, 2-H), 7.36 (1 H, dd, J = 7.8, 1.6 Hz, 4-
H), 7.41 (1 H, t, J = 7.8 Hz, 5-H); 13C NMR δ 28.34 (2 x CH2), 28.37 (CH3)3, 42.47 
(CH2), 79.48 (C-CH3)3), 124.29 (2-C), 125.37 (4-C), 126.55 (6-C), 127.89 (=CHCH2), 
129.32 (5-C), 130.14 (=CHPh), 132.13 (3-C), 138.01 (1-C), 155.68 (C=O), 176.15 (2 x 
C=O); MS (ESI +ve) m/z 331.1652 (M + H) (C18H23N2O4 requires 331.1658). 
 
235 1H NMR (CDCl3) δ 1.43 (9 H, s, (CH3)3), 2.87 (4 H, s, 2 x CH2), 4.15 (2 H, d, J = 5.4 
Hz, CH2), 4.5 (1 H, br s, NH), 5.26 (1 H, s, =CH), 5.43 (1 H, s, =CH), 7.13-7.41 (4 H, m, 
2,4,5,6-H4); 
13C NMR δ 28.16 (2 x CH2), 28.22 (CH3)3, 44.14 (CH2), 79.48 (C-CH3)3), 
114.39 (=CH2), 124.38 (2-C), 125.88 (4-C), 126.36 (6-C), 129.40 (5-C), 129.46 
(C=CH2), 129.87 (3-C), 132.03 (1-C), 155.68 (C=O), 176.04 (2 x C=O). 
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(E)-1-(3-(3-aminoprop-1-enyl)phenyl)pyrrolidine-2,5-dione (236) 
1-(3-(3-aminoprop-1-en-2-yl)phenyl)pyrrolidine-2,5-dione (237) 
 
 
 
To the mixture 234 & 235 (1.2 g, 3.6 mmol) in CH2Cl2 (15 mL), dry HCl gas was passed 
for 30 min. The product mixture of 236 & 237 was used in the next step without further 
purification. 
 
(E)-N-(3-(3-(2,5-Dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)-2-iodo-3-nitrobenzamide 
(238) 
N-(2-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)-2-iodo-3-nitrobenzamide 
(239) 
 
NO2
I
N
H
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O
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To 139 (1.5 g, 5.0 mmol) in CH2Cl2 (15 mL) was added mixture of 236 & 237 (1.65 g, 
5.0 mmol) and Et3N (1.5 mL, 10 mmol) and the mixture was stirred for 6 h. Washing 
(5% aq. HCl, 5% aq. NaHCO3), drying, evaporation and chromatography 
(hexane:EtOAc 4:1) gave a mixture of 238 & 239 (0.8 g, 32%) as yellow crystals: IR 
(KBr) νmax 1391, 1534 (NO2), 1702, 1631 (C=O), 3467, 3313 (NH) cm
-1; 238 1H NMR 
((CD3)2SO) δ 2.78 (4 H, s, 2 x CH2), 4.06 (2 H, t, J = 5.5 Hz, CH2), 6.38 (1 H, dt, J = 
15.7, 5.87 Hz, =CH-CH2), 6.69 (1 H, d, J = 16.04 Hz, =CH-Ph), 7.12 (1 H, dt, J = 7.43, 
1.6 Hz, 6’-H), 7.33 (1 H, d, J = 1.6 Hz, 2’-H), 7.45 (1 H, t, J = 7.43 Hz, 5’-H), 7.49 (1 H, 
dt, J = 7.8, 1.6 Hz, 4’-H), 7.59 (1 H, dd, J = 7.8, 1.6 Hz, 4-H), 7.64 (1 H, t, J = 7.8 Hz, 5-
H), 7.85 (1 H, dd, J = 7.8, 1.6 Hz, 6-H), 8.88 (1 H, t, J = 5.5 Hz, NH); 13C NMR δ 28.55 
(2 x CH2), 40.89 (CH2), 86.77 (2-C), 124.03 (4-C), 124.83 (2’-C), 126.09 (6’-C), 126.21 
(4’-C), 127.42 (=CHCH2), 129.19 (5’-C), 129.57 (=CHPh), 129.77 (6-C), 130.34 (5-C), 
133.19 (1’-C), 137.44 (3’-C), 146.39 (1-C), 155.26 (3-C), 168.13 (C=O), 177.60 (2 x 
C=O); MS (ESI +ve) m/z 506.0207 (M + H) (C20H17IN3O5 requires 506.0213). 
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239 1H NMR ((CD3)2SO) δ 2.82 (4 H, s, 2 x CH2), 4.48 (2 H, d, J = 5.0 Hz, CH2), 5.38 (1 
H, s, =CH2), 5.40 (1 H, s, =CH2), 7.01-7.73 (5 H, m, 2’,4’,5’,6’,5-H5), 8.19 (1 H, m, 4-H), 
8.28 (1 H, m, 6-H).; 13C NMR δ 27.38 (2 x CH2), 51.63 (CH2), 121.02, 127.43, 129.47, 
129.54, 129.81, 131.99, 132.04, 132.14, 132.52, 133.37, 142.66 (q),149.00 (3-C), 
162.00 (C=O), 171.16 (2 x C=O). 
 
(E)-N-(3-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)-3-nitrobenzamide (240) 
N-(2-(3-(2,5-dioxopyrrolidin-1-yl)phenyl)prop-2-enyl)-3-nitrobenzamide (241) 
1-(3-((5-nitro-1-oxo-1,2-dihydroisoquinolin-4-yl)methyl)phenyl)pyrrolidine-2,5-
dione (242) 
(Z)-1-(3-((5-nitro-1-oxo-2,3-dihydroisoquinolin-4(1H)ylidene)methyl)phenyl) 
pyrrolidine-2,5-dione (243) 
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To mixture of 238 & 239 (100 mg, 0.2 mmol) in dry DMF (0.5 mL) was added 
(Ph3P)4Pd (4.6 mg, 2 mol%), dry Et3N (0.07 mL, 0.5 mmol) and tetrabutylammonium 
iodide (73.1 mg, 0.2 mmol) and the mixture was heated to reflux for 48 h. After 
evaporation of the solvent the residue was taken up in CHCl3, washed (5% aq. HCl, 5% 
aq. NaHCO3) and dried. Evaporation and chromatography (hexane:EtOAc 4:1) yielded 
an inseparable mixture of 240 & 241 (4:1) (14 mg, 18%) as yellow semi-solid: Rf = 0.5 
(hexane:EtOAc 2:1); IR (film) νmax 1350, 1528 (NO2), 1658, 1709 (C=O), 3078, 3351 
(NH) cm-1; 240 1H NMR (CDCl3) δ 2.87 (4 H, s, 2 x CH2), 4.17 (2 H, t, J = 6.3 Hz, CH2), 
6.20 (1 H, dt, J = 16.0, 6.26 Hz, =CH-CH2), 6.69 (1 H, d, J = 16.04 Hz, =CH-Ph), 7.10 
(1 H, dt, J = 8.2, 1.6 Hz, 6’-H), 7.19 (1 H, t, J = 1.9 Hz, 2’-H), 7.27 (1 H, d, J = 8.2 Hz, 
4’-H), 7.49 (1 H, dt, J = 7.8, 1.6 Hz, 5’-H), 7.59 (1 H, t, J = 7.8 Hz, 5-H), 8.20 (1 H, dt, J 
= 7.8, 1.6 Hz, 6-H), 8.29 (1 H, ddd, J = 8.2, 2.4, 1.2 Hz, 4-H), 8.66 (1 H, t, J = 1.9 Hz, 2-
H); 13C NMR δ 28.38 (2 x CH2), 42.20 (CH2), 121.92 (2’-C), 124.22 (4-C), 125.62 (2-C), 
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125.98 (6’-C), 126.36 (4’-C), 126.56 (=CHCH2), 129.35 (5’-C), 129.67 (=CHPh), 131.37 
(6-C), 131.89 (5-C), 133.51 (1’-C), 135.70 (3’-C), 137.60 (1-C), 147.99 (3-C), 164.96 
(C=O), 176.36 (2 x C=O); MS (ESI +ve) m/z 380.1246 (M + H) (C20H18N3O5 requires 
380.1240). 
 
241 1H NMR (CDCl3) δ 2.88 (4 H, s, 2 x CH2), 4.48 (2 H, d, J = 5. Hz, CH2), 5.36 (1 H, 
s, =CH2), 5.49 (1 H, s, =CH2), 7.08-7.63 (5 H, m, 2’,4’,5’,6’,5-H5), 8.19 (1 H, m, 6-H), 
8.28 (1 H, m, 4-H), 8.56 (1 H, s, 2-H); 13C NMR δ 28.38 (2 x CH2), 50.66 (CH2), 122.02, 
128.45, 128.57, 129.41, 129.61, 131.99, 132.04, 132.14, 132.52, 133.37, 142.66 
(q),149.00 (3-C), 165.00 (C=O), 171.26 (2 x C=O). 
 
Also isolated was an inseparable mixture of 242 & 243 (1:1) (16 mg, 21%). IR (film) 
νmax 1350, 1528 (NO2), 1658, 1709 (C=O), 3078, 3351 (NH) cm
-1; 1H NMR (CDCl3) δ 
2.85 (4 H, s, 2 x CH2), 4.48 (2 H, s, 4-CH2), 7.04 (1 H, s, 3-H),  7.15-7.43 (4 H, m, 
2’,4’,5’,6’,-H4), 7.53 (1 H, t, J = 7.8 Hz, 7-H), 7.81 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.65 (1 
H, dd, J = 7.8, 1.6 Hz, 8-H), 10.34 (1 H, br s, NH); 13C NMR δ 28.38 (CH3), 35.15 (CH2),  
60.39, 125.02, 126.19, 126.97, 128.64, 129.17, 129.60, 131.37, 132.22, 132.04, 
139.11, 148.27, 161.20 (C=O), 176.15 (2 x C=O). 
 
226 (16 mg, 15%) was also collected as a yellow solid: mp 203-204°C; 1H NMR 
(CDCl3) δ 2.91 (4 H, s, 2 x CH2), 4.49 (2 H, s, 3-CH2), 6.14 (1 H, br s, NH), 6.78 (1 H, s, 
4C=CH), 7.15 (1 H, m, 2’-H), 7.22 (1 H, m, 4’-H),7.32 (1 H, m, 6’-H), 7.51 (1 H, t, J = 
7.8 Hz, 5’-H), 7.54 (1 H, t, J = 7.8 Hz, 7-H), 7.83 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.33 (1 
H, dd, J = 7.8, 1.2 Hz, 8-H); 13C NMR δ 30.93 (CH2), 41.82 (CH3), 59.27, 125.91, 
126.29, 127.65, 128.69, 129.45, 129.72, 131.037, 131.97, 133.14, 135.78, 147.51, 
162.67 (C=O), 176.02 (2 x C=O). 
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Experimental Details for Chapter 4.0. 
 
PARP-1 Colourimetric Assay 
 
Materials and Method 
 
Inhibitor constants were determined using the Universal colourimetric PARP assay kit 
(Trevigen). The assays were performed in 96 strip-well plates pre-coated with histones. 
Firstly, PARP inhibitor stock solutions (50 mM) were prepared by dissolving them in 
DMSO. These were diluted with 1 x PARP buffer to seven different concentrations at 5 
x stock solution such that the final concentrations in the assay were 100, 30, 10, 3, 1, 
0.3, and 0.1 µM. The final concentration of DMSO in the assay was less than 0.2 % 
(v/v). A positive control (PARP enzyme with no inhibitor) and negative control (no 
PARP enzyme) were included in each assay. The PARP enzyme was diluted to 0.8 
units / 15 µl with 1 x PARP buffer. Diluted PARP inhibitor (40 µL) was mixed with 
diluted PARP enzyme (60 µL), centrifuged and incubated for 10 min at ambient 
temperature. Then 25 µL of each solution was distributed into wells in triplicate. To 
initiate the reaction 25 µL of PARP cocktail [(10 x PARP cocktail, 10 x Activated DNA, 1 
x PARP buffer (1:1:8) (v/v/v)] was added to each well using a multi-channel pipettor. In 
all cases the final reaction volume was 50 µL. The reaction was allowed to proceed for 
1 h at ambient temperature. Plates were washed four times with PBS + 0.1 % (v/v) 
triton X-100 (200 L). Then 50 L Strep-HRP (1000 fold with 1 x Strep dilutent) was 
added to each well with a multi-channel pipettor, and the plate was incubated for 30 
min at ambient temperature. . Plates were again washed four times with PBS + 0.1 % 
(v/v) triton X-100 (200 L). TACS Sapphire colourimetric substrate (50 L / well) was 
added with a multi-channel pipettor and the plates were incubated in the dark for 30 
min. Absorbance at 630 nm was measured using a Versamax microplate reader with 
SoftMax Pro 4.7.1 software. The colourimetric reaction was stopped by adding 0.2 M 
HCl (50 µL / well), and the absorbance was measured at 450 nm. 
 
Data were analysed using GraphPad Prism 2.01 software. The IC50 values were 
calculated by plotting log10 [inhibitor] versus absorbance for the three independent 
determinations. Quoted IC50 values are mean for the three replicant curves.  
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Appendices 
 
 
Appendix 1. Raw data for PARP-1 colourimetric activity assay 
 
 
5-Aminoisoquinolin-1(2H)-one (29d) 
 
 
 
4-Methyl 5-aminoisoquinolin-1(2H)-one (182)  
 
 
 
4-Benzyl-5-aminoisoquinolin-1(2H)-one (192) 
 
  
 
 
 
 
 
 
 
 
 
Absorbance reading (450nm) Log [µM] 
Data Set A Data Set B Data Set C Mean 
2.0 0.1410 0.1620 0.0900 0.131000 
1.5 0.3290 0.3060 0.2970 0.3106667 
1.0 0.5720 0.5490 0.4340 0.5183334 
0.5 1.0620 0.9940 1.0060 1.020667 
0.0 1.3340 1.3150 1.1480 1.265667 
-0.5 2.0220 2.0330 2.0100 2.021667 
-1.0 2.3310 1.9850 2.1020 2.139333 
Absorbance reading (450nm) Log [µM] 
Data Set A Data Set B Data Set C Mean 
2.0 0.066 0.063 0.062 0.063667 
1.5 0.134 0.138 0.137 0.136333 
1.0 0.381 0.396 0.331 0.369333 
0.5 0.699 0.367 0.705 0.590333 
0.0 0.39 0.389 0.356 0.378333 
-0.5 1.196 1.665 1.217 1.359333 
-1.0 1.79 2.11 1.745 1.881667 
Absorbance reading (450nm) Log [µM] 
Data Set A Data Set B Data Set C Mean 
2.0 0.1209 0.0886 0.112 0.107167 
1.5 0.159 0.1556 0.1487 0.154433 
1.0 0.3051 0.292 0.2789 0.292 
0.5 0.3207 0.4409 0.4444 0.402 
0.0 1.1391 0.7631 0.7179 0.873367 
-0.5 1.6657 1.2028 1.0851 1.317867 
-1.0 2.4658 2.2033 1.2307 1.9666 
5-Amino-4-benzyl-3,4-dihydroisoquinolin-1(2H)-one (193) 
 
 
 
4-Bromo-5-aminoisoquinolin-1(2H)-one (125) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Absorbance reading (450nm) Log [µM] 
Data Set A Data Set B Data Set C Mean 
2.0 0.1901 0.1843 0.1836 0.186 
1.5 0.455 0.2923 0.2938 0.347033 
1.0 0.5728 0.5934 0.4829 0.5497 
0.5 0.8076 0.9385 1.0543 0.933467 
0.0 1.2561 1.3833 1.5834 1.4076 
-0.5 1.6334 1.48 1.8916 1.668333 
-1.0 2.6138 1.4332 1.6171 1.888033 
Absorbance reading (450nm) Log [µM] 
Data Set A Data Set B Data Set C Mean 
2.0 0.1189 0.0852 0.0775 0.093867 
1.5 0.145 0.1611 0.1321 0.146067 
1.0 0.2206 0.1255 0.2134 0.1865 
0.5 0.3898 0.3184 0.3472 0.3518 
0.0 0.7252 0.7401 0.6362 0.7005 
-0.5 0.7256 1.3807 0.9798 1.0287 
-1.0 1.2314 1.2406 1.2098 1.227267 
Appendix 2. IC50 Data analysis for PARP-1 inhibitors 
5-Aminoisoquinolin-1(2H)-one (29d) 
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4-Methyl 5-aminoisoquinolin-1(2H)-one (182)  
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4-Benzyl-5-aminoisoquinolin-1(2H)-one (192) 
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5-Amino-4-benzyl-3,4-dihydroisoquinolin-1(2H)-one (193) 
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4-Bromo-5-aminoisoquinolin-1(2H)-one (125) 
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Appendix 3. X-ray crystallography data for compound 105 
Table 1.  Crystal data and structure refinement for 105 
                                                        
 Identification code Compound 105 
 Empirical formula C21 H13 N O4 Se 
 Formula weight 422.28 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/n 
 Unit cell dimensions a = 11.8050(1)Å α = 90o 
       b = 11.8550(1)Å β = 113.969(1)o 
       c = 13.3860(1)Å γ = 90o 
 Volume 1711.80(2) Å3 
 Z 4 
 Density (calculated) 1.639 Mg/m3 
 Absorption coefficient 2.222 mm-1 
 F(000) 848 
 Crystal size 0.50 x 0.30 x 0.10 mm 
 Theta range for data collection 3.54 to 27.54 o. 
 Index ranges -15<=h<=15; -15<=k<=15; -17<=l<=17 
 Reflections collected 28103 
 Independent reflections 3928 [R(int) = 0.0549] 
 Reflections observed (>2σ) 3671 
 Data Completeness 0.993 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.65 and 0.40 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 3928 / 0 / 245 
 Goodness-of-fit on F2 1.031 
 Final R indices [I>2σ(I)] R
1 = 0.0248   wR2 = 0.0627 
 R indices (all data) R1 = 0.0275  wR2 = 0.0643 
 Largest diff. peak and hole 0.380 and -0.568 eÅ-3 
 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2 x 103) for 105. 
                                                                                                                       
  Atom   x   y   z  U(eq) 
                                
Se(1) 8295(1) -649(1) 8838(1) 18(1) 
O(1) 6563(1) 1337(1) 6090(1) 19(1) 
O(2) 4653(1) 1413(1) 4823(1) 27(1) 
O(3) 6883(1) 308(1) 9881(1) 23(1) 
O(4) 5754(1) -1127(1) 9900(1) 32(1) 
N(1) 6041(1) -373(1) 9420(1) 20(1) 
C(1) 7099(1) 301(1) 7752(1) 16(1) 
C(2) 7433(1) 916(1) 7064(1) 17(1) 
C(3) 5325(2) 1116(1) 5737(1) 19(1) 
C(4) 4914(2) 569(1) 6513(1) 16(1) 
C(5) 3641(2) 417(1) 6193(1) 22(1) 
C(6) 3194(2) -79(2) 6890(1) 25(1) 
C(7) 4023(2) -376(1) 7938(1) 23(1) 
C(8) 5280(2) -207(1) 8252(1) 18(1) 
C(10) 5792(1) 220(1) 7541(1) 16(1) 
C(11) 9071(1) -1265(1) 7943(1) 17(1) 
C(12) 8385(2) -1708(1) 6908(1) 21(1) 
C(13) 9012(2) -2144(1) 6309(1) 26(1) 
C(14) 10295(2) -2163(1) 6740(2) 28(1) 
C(15) 10966(2) -1738(2) 7778(2) 27(1) 
C(16) 10360(2) -1276(1) 8381(1) 21(1) 
C(17) 8695(2) 1214(1) 7180(1) 18(1) 
C(18) 9017(2) 1128(1) 6289(1) 23(1) 
C(19) 10212(2) 1381(2) 6412(2) 29(1) 
C(20) 11086(2) 1742(2) 7414(2) 30(1) 
C(21) 10759(2) 1872(2) 8294(2) 28(1) 
C(22) 9568(2) 1608(1) 8178(1) 23(1) 
                                    
 
Table 3.   Bond lengths [Å] and angles [o] for 105. 
  
Se(1)-C(11) 1.9233(15) Se(1)-C(1) 1.9256(15) 
O(1)-C(3) 1.3663(19) O(1)-C(2) 1.3843(18) 
O(2)-C(3) 1.209(2) O(3)-N(1) 1.2333(19) 
O(4)-N(1) 1.2265(18) N(1)-C(8) 1.466(2) 
C(1)-C(2) 1.353(2) C(1)-C(10) 1.454(2) 
C(2)-C(17) 1.476(2) C(3)-C(4) 1.464(2) 
C(4)-C(5) 1.397(2) C(4)-C(10) 1.407(2) 
C(5)-C(6) 1.376(2) C(6)-C(7) 1.391(2) 
C(7)-C(8) 1.383(2) C(8)-C(10) 1.412(2) 
C(11)-C(16) 1.390(2) C(11)-C(12) 1.393(2) 
C(12)-C(13) 1.393(2) C(13)-C(14) 1.385(3) 
C(14)-C(15) 1.384(3) C(15)-C(16) 1.391(2) 
C(17)-C(18) 1.395(2) C(17)-C(22) 1.395(2) 
C(18)-C(19) 1.385(2) C(19)-C(20) 1.387(3) 
C(20)-C(21) 1.389(3) C(21)-C(22) 1.387(2) 
C(11)-Se(1)-C(1) 98.12(6) C(3)-O(1)-C(2) 122.51(12) 
O(4)-N(1)-O(3) 123.54(14) O(4)-N(1)-C(8) 118.48(14) 
O(3)-N(1)-C(8) 117.77(13) C(2)-C(1)-C(10) 118.90(14) 
C(2)-C(1)-Se(1) 120.10(12) C(10)-C(1)-Se(1) 120.17(11) 
C(1)-C(2)-O(1) 121.67(14) C(1)-C(2)-C(17) 128.22(14) 
O(1)-C(2)-C(17) 110.09(13) O(2)-C(3)-O(1) 117.62(14) 
O(2)-C(3)-C(4) 125.28(16) O(1)-C(3)-C(4) 117.07(13) 
C(5)-C(4)-C(10) 122.36(15) C(5)-C(4)-C(3) 117.67(15) 
C(10)-C(4)-C(3) 119.97(14) C(6)-C(5)-C(4) 120.55(16) 
C(5)-C(6)-C(7) 119.00(15) C(8)-C(7)-C(6) 119.92(15) 
C(7)-C(8)-C(10) 123.17(15) C(7)-C(8)-N(1) 114.93(14) 
C(10)-C(8)-N(1) 121.49(14) C(4)-C(10)-C(8) 114.69(14) 
C(4)-C(10)-C(1) 118.19(14) C(8)-C(10)-C(1) 127.10(14) 
C(16)-C(11)-C(12) 120.73(14) C(16)-C(11)-Se(1) 117.21(12) 
C(12)-C(11)-Se(1) 122.04(12) C(13)-C(12)-C(11) 118.83(16) 
C(14)-C(13)-C(12) 120.87(16) C(15)-C(14)-C(13) 119.69(16) 
C(14)-C(15)-C(16) 120.44(17) C(11)-C(16)-C(15) 119.42(15) 
C(18)-C(17)-C(22) 119.41(15) C(18)-C(17)-C(2) 120.47(15) 
C(22)-C(17)-C(2) 120.10(14) C(19)-C(18)-C(17) 120.04(16) 
C(18)-C(19)-C(20) 120.30(16) C(19)-C(20)-C(21) 119.99(16) 
C(22)-C(21)-C(20) 119.94(17) C(21)-C(22)-C(17) 120.25(16) 
                                                          
                                                            
 
 
Table 4.   Anisotropic displacement parameters (Å2 x 103) for 105.  
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                               
Se(1) 17(1) 23(1) 16(1) 4(1) 9(1) 5(1) 
O(1) 20(1) 19(1) 18(1) 4(1) 8(1) 2(1) 
O(2) 24(1) 32(1) 21(1) 8(1) 6(1) 5(1) 
O(3) 20(1) 31(1) 20(1) -4(1) 9(1) -3(1) 
O(4) 42(1) 33(1) 27(1) 7(1) 19(1) -6(1) 
N(1) 22(1) 23(1) 20(1) 0(1) 13(1) 0(1) 
C(1) 16(1) 16(1) 15(1) 0(1) 7(1) 2(1) 
C(2) 18(1) 16(1) 17(1) -1(1) 8(1) 2(1) 
C(3) 20(1) 18(1) 19(1) 0(1) 9(1) 3(1) 
C(4) 18(1) 16(1) 17(1) -1(1) 9(1) 2(1) 
C(5) 19(1) 23(1) 22(1) -2(1) 6(1) 2(1) 
C(6) 16(1) 28(1) 30(1) -5(1) 10(1) -2(1) 
C(7) 23(1) 25(1) 26(1) -4(1) 16(1) -5(1) 
C(8) 19(1) 18(1) 18(1) -2(1) 9(1) -1(1) 
C(10) 18(1) 14(1) 17(1) -2(1) 9(1) 0(1) 
C(11) 18(1) 15(1) 19(1) 2(1) 10(1) 2(1) 
C(12) 21(1) 18(1) 22(1) 1(1) 6(1) 0(1) 
C(13) 38(1) 19(1) 22(1) -2(1) 12(1) 0(1) 
C(14) 37(1) 22(1) 35(1) -2(1) 25(1) 3(1) 
C(15) 21(1) 26(1) 38(1) -2(1) 17(1) 1(1) 
C(16) 19(1) 22(1) 24(1) -3(1) 10(1) -1(1) 
C(17) 18(1) 15(1) 23(1) 2(1) 11(1) 0(1) 
C(18) 25(1) 26(1) 22(1) 1(1) 13(1) -1(1) 
C(19) 31(1) 32(1) 34(1) 4(1) 23(1) 0(1) 
C(20) 23(1) 28(1) 45(1) 4(1) 19(1) -4(1) 
C(21) 23(1) 25(1) 33(1) -2(1) 9(1) -7(1) 
C(22) 24(1) 22(1) 24(1) -2(1) 12(1) -2(1) 
  
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 
103) for 105. 
  Atom   x   y   z  U(eq) 
                                 
H(5) 3079 659 5489 27 
H(6) 2332 -217 6658 29 
H(7) 3727 -695 8437 27 
H(12) 7504 -1713 6615 25 
H(13) 8553 -2433 5595 31 
H(14) 10713 -2466 6325 33 
H(15) 11846 -1763 8079 32 
H(16) 10822 -972 9087 26 
H(18) 8416 897 5597 28 
H(19) 10433 1306 5808 35 
H(20) 11909 1901 7499 36 
H(21) 11350 2142 8974 33 
H(22) 9345 1696 8780 27 
 
Appendix 4. X-ray crystallography data for compound 168 
 
Table 1.  Crystal data and structure refinement for 168. 
                                                        
 Identification code Compound 168 
 Empirical formula C13 H14 N3 O3 
 Formula weight 260.27 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21 
 Unit cell dimensions a = 11.1000(5)Å α = 90o 
       b = 5.0730(2)Å β = 101.651(2)o 
       c = 11.9100(6)Å γ = 90o 
 Volume 656.84(5) Å3 
 Z 2 
 Density (calculated) 1.316 Mg/m3 
 Absorption coefficient 0.096 mm-1 
 F(000) 274 
 Crystal size 0.50 x 0.10 x 0.10 mm 
 Theta range for data collection 3.62 to 27.54o 
 Index ranges -14<=h<=14; -6<=k<=6; -15<=l<=15 
 Reflections collected 11607 
 Independent reflections 2887 [R(int) = 0.0555] 
 Reflections observed (>2σ) 2417 
 Data Completeness 0.996 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.99 and 0.90 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 2887 / 1 / 173 
 Goodness-of-fit on F2 1.059 
 Final R indices [I>2σ(I)] R1 = 0.0457   wR2 = 0.1019 
 R indices (all data) R1 = 0.0603  wR2 = 0.1092 
 Absolute structure parameter -1.1(13) 
 Largest diff. peak and hole 0.534 and -0.169 eÅ-3 
  
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2 x 103) for 168. 
                                                             
                                                             
  Atom   x   y   z  U(eq) 
                                
O(1) 5803(1) -4149(3) 5147(1) 33(1) 
N(1) 6298(2) -2443(3) 5838(2) 31(1) 
C(1) 7100(2) -482(4) 5484(2) 27(1) 
O(2) 6130(2) -2361(4) 6829(1) 49(1) 
N(2) 6550(2) -1728(3) 3462(1) 29(1) 
C(2) 7737(2) 1114(4) 6353(2) 32(1) 
O(3) 8761(1) -225(3) 2569(1) 34(1) 
N(3) 8638(2) 4209(3) 2535(2) 31(1) 
C(3) 8496(2) 3073(4) 6109(2) 34(1) 
C(4) 8639(2) 3395(4) 4984(2) 31(1) 
C(5) 8036(2) 1805(4) 4101(2) 26(1) 
C(6) 7199(2) -182(4) 4316(2) 26(1) 
C(7) 6101(2) -867(4) 2268(2) 31(1) 
C(8) 4924(2) -2297(4) 1816(2) 34(1) 
C(9) 4793(2) -4060(5) 997(2) 41(1) 
C(10) 8480(2) 1842(4) 2994(2) 28(1) 
C(11) 9218(2) 4443(5) 1544(2) 33(1) 
C(12) 8309(2) 4418(6) 432(2) 43(1) 
C(13) 8211(3) 6297(6) -333(2) 56(1) 
                                    
 
Table 3.   Bond lengths [Å] and angles [o] for 168. 
  
O(1)-N(1) 1.243(2) N(1)-O(2) 1.232(2) 
N(1)-C(1) 1.453(3) C(1)-C(2) 1.390(3) 
C(1)-C(6) 1.426(3) N(2)-C(6) 1.368(3) 
N(2)-C(7) 1.475(3) C(2)-C(3) 1.371(3) 
O(3)-C(10) 1.232(2) N(3)-C(10) 1.346(3) 
N(3)-C(11) 1.459(3) C(3)-C(4) 1.391(3) 
C(4)-C(5) 1.385(3) C(5)-C(6) 1.429(3) 
C(5)-C(10) 1.497(3) C(7)-C(8) 1.496(3) 
C(8)-C(9) 1.309(3) C(11)-C(12) 1.494(3) 
C(12)-C(13) 1.308(4)   
     
O(2)-N(1)-O(1) 121.73(17) O(2)-N(1)-C(1) 118.35(18) 
O(1)-N(1)-C(1) 119.92(17) C(2)-C(1)-C(6) 122.43(19) 
C(2)-C(1)-N(1) 115.63(18) C(6)-C(1)-N(1) 121.92(17) 
C(6)-N(2)-C(7) 124.86(17) C(3)-C(2)-C(1) 120.5(2) 
C(10)-N(3)-C(11) 121.10(16) C(2)-C(3)-C(4) 118.9(2) 
C(5)-C(4)-C(3) 122.14(19) C(4)-C(5)-C(6) 120.41(18) 
C(4)-C(5)-C(10) 117.83(17) C(6)-C(5)-C(10) 120.54(17) 
N(2)-C(6)-C(5) 122.34(18) N(2)-C(6)-C(1) 122.09(18) 
C(5)-C(6)-C(1) 115.56(17) N(2)-C(7)-C(8) 107.70(17) 
C(9)-C(8)-C(7) 123.9(2) O(3)-C(10)-N(3) 121.85(18) 
O(3)-C(10)-C(5) 120.46(18) N(3)-C(10)-C(5) 117.52(17) 
N(3)-C(11)-C(12) 112.76(18) C(13)-C(12)-C(11) 123.9(2) 
                                                       
 
                                                            
 
Table 4.   Anisotropic displacement parameters (Å2 x 103) for 168.  
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                 
O(1) 33(1) 28(1) 39(1) 3(1) 7(1) -4(1) 
N(1) 34(1) 26(1) 35(1) 5(1) 9(1) 3(1) 
C(1) 26(1) 24(1) 32(1) 4(1) 5(1) 4(1) 
O(2) 70(1) 46(1) 38(1) -2(1) 24(1) -14(1) 
N(2) 32(1) 25(1) 29(1) 3(1) 1(1) -2(1) 
C(2) 30(1) 33(1) 32(1) 1(1) 2(1) 3(1) 
O(3) 33(1) 19(1) 52(1) -3(1) 16(1) 1(1) 
N(3) 37(1) 20(1) 41(1) -2(1) 18(1) 2(1) 
C(3) 32(1) 30(1) 37(1) -4(1) -1(1) 2(1) 
C(4) 26(1) 23(1) 43(1) -1(1) 4(1) 0(1) 
C(5) 24(1) 20(1) 35(1) 2(1) 5(1) 4(1) 
C(6) 26(1) 18(1) 33(1) 0(1) 5(1) 4(1) 
C(7) 32(1) 30(1) 31(1) 3(1) 6(1) 1(1) 
C(8) 32(1) 36(1) 35(1) 0(1) 6(1) 0(1) 
C(9) 46(1) 37(1) 38(1) -2(1) 1(1) -5(1) 
C(10) 21(1) 24(1) 39(1) 0(1) 6(1) 0(1) 
C(11) 36(1) 25(1) 40(1) 2(1) 15(1) -1(1) 
C(12) 38(1) 51(2) 41(1) -10(1) 14(1) -7(1) 
C(13) 49(2) 74(2) 45(1) 8(1) 13(1) 7(1) 
    
  
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 
103) for 168. 
                                  
  
   
  Atom   x   y   z  U(eq) 
                                 
H(2) 7646 846 7121 39 
H(3) 8388 5640 2838 38 
H(3A) 8918 4191 6700 41 
H(4) 9166 4749 4815 37 
H(7A) 6716 -1285 1798 37 
H(7B) 5958 1060 2241 37 
H(8) 4232 -1902 2142 41 
H(9A) 5469 -4496 655 50 
H(9B) 4021 -4903 746 50 
H(11A) 9803 2966 1552 39 
H(11B) 9694 6106 1605 39 
H(12) 7770 2951 272 51 
H(13A) 8737 7790 -197 67 
H(13B) 7613 6168 -1025 67 
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